979

U.S. Department of Justice
Drug Enforcement Administration
United States Department of Health and Human Services
National Institute on Drug Abuse

Project DAWN Annual Report-1979

NEWARK PUBL'C LIBRARY

OCT 29 1980

U. S. GOVT. PUBS.
DEPOSITORY 376



J24.19/2:

READEX MICRO best copy available

DRUG ABUSE WARNING NETWORK

1979 DAWN ANNUAL REPORT

DEA Contract No. 79-15

Submitted by:

IMS America, Ltd.
Ambler, PA 19002

Submitted to:

Drug Enforcement Administration

National Institute on Drug Abuse

For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402

TABLE OF CONTENTS

Chapter		Page
1.	General Introduction to DAWN	1
	Purpose of the Study	1
	Historical Development	1
	Definitions of Drug Abuse	2
	Survey Design	2
	Geographic Distribution of SMSA Facilities	3
	Data Collection	5
	Drug Episodes and Drug Mentions	8
	Definition of DAWN Drug Vocabulary	9
	Most Frequently Mentioned Drugs	9
	Drug Profiles	9
	Ranks of Leading Drugs of Abuse	11
	Standard Notation Ranking Procedure	11
	System Caveats	11
2.	Emergency Room and Medical Examiner Reports	13
	I. Introduction	13
	II. Drug Mentions	13
	III. Sex, Age, Race Characteristics	13
	IV. Motivation for Use of Drugs Associated with Emergency Room Drug Abuse Episodes	13
	V. Source of Drugs (Emergency Room Data Only)	14
	VI. Top 20 Drugs: Sex, Race, Age (Emergency Room and Medical Examiner Episodes)	14
	A. Sex	14
	B. Race	14
	C. Age	15
	VII. Drug-Induced Deaths and Drug-Related Deaths	15
	VIII. Ranking of Top 20 Drugs for the DAWN SMSAs	15
3.	Drug Profiles	29
	Tranquilizers	32
	Diazepam	34
	Chlordiazepoxide	36

	Page
Chlorpromazine	38
Thioridazine	40
Meprobamate	42
Clorazepate	44
Oxazepam	46
Barbiturate Sedatives	48
Secobarbital	50
Secobarbital/Amobarbital	52
Phenobarbital	54
Pentobarbital	56
Amobarbital	58
Butabarbital	60
Non-Barbiturate Sedatives	62
Flurazepam	64
Methaqualone	66
Glutethimide	68
Ethchlorvynol	70
Over-the-Counter Sleep Aids	72
Alcohol-in-Combination	74
Narcotic Analgesics	76
Heroin/Morphine	78
Methadone	80
Codeine	82
Meperidine HCl	84
Hydromorphone	86
Oxycodone	88
Non-Narcotic Analgesics	90
Aspirin	92
d-Propoxyphene	94
Pentazocine	96
Acetaminophen	98
Amphetamines	100
Amphetamine	102
d-Amphetamine	104
Methamphetamine	106
Speed	108
Cocaine	110
Psychostimulants	112
Methylphenidate	114
Amitriptyline	116
Amitriptyline Combinations	118
Cannabis	120
Marijuana	122
Hashish	124

Page

Hallucinogens 126
LSD. 128
PCP/PCP Combinations 130

Anticonvulsants/Antinauseants 132
Hydantoin. 134

Codeine Combinations. 136

Inhalants/Solvents/Aerosols 138

CHAPTER 1

GENERAL INTRODUCTION TO DAWN

PURPOSE OF THE STUDY

Project DAWN is a nationwide program co-sponsored by the Drug Enforcement Administration and the National Institute on Drug Abuse, and conducted under contract by IMS America, Ltd.

The general goal of Project DAWN is to gather, interpret, and disseminate data on drug abuse from selected locations within the continental United States. The Drug Enforcement Administration uses this information in its enforcement, compliance, scheduling, and research programs; the National Institute on Drug Abuse applies the information in its forecasting, education, prevention, treatment, and rehabilitation programs.

The more specific objectives of the project are:

1. To identify drugs currently being abused and/or associated with harm to the individual and to society.

2. To the extent feasible, to determine existing patterns of drug abuse and to monitor changing trends, including the detection of new abuse entities and new combinations.

3. To provide current drug abuse data which can be used in appropriate cases to assess the relative hazards to health and the relative potentials for abuse of different chemical substances.

4. To provide data needed for the rational control and scheduling of both presently existing and new substances of potential abuse.

HISTORICAL DEVELOPMENT

For purposes of clarification and evaluation of data generated through this system, the overall program is represented in terms of the following phases:

Phase I: The initial Project DAWN, covering the time interval of September 1972 through April 1973. This phase is covered in the "DAWN I Analysis" on file with the National Technical Information Service, Department of Commerce, Washington, D.C.

Phase II: A modified and expanded Project DAWN covering the time interval of July 1973 through March 1974. This phase is covered in the "DAWN II Analysis" on file with the Drug Enforcement Administration, U.S. Department of Justice, Washington, D.C.

Phase III: A continuation of Phase II covering the time interval of April 1974 through April 1975. This phase is covered in "Project DAWN III" on file with the Drug Enforcement Administration, U.S. Department of Justice, and the National Institute on Drug Abuse, U.S. Department of Health, Education and Welfare, Washington, D.C.

Phase IV: A continuation of Phase III covering the time interval of May 1975 through April 1976. This phase is covered in "Project DAWN IV" on file with the Drug Enforcement Administration, U.S. Department of Justice, and the National Institute on Drug Abuse, U.S. Department of Health, Education and Welfare, Washington, D.C.

Phase V: A continuation of Phase IV covering the time interval of May 1976 through April 1977. This phase is covered in "Project DAWN V" on file with the Drug Enforcement Administration, U.S. Department of Justice, and the National Institute on Drug Abuse, U.S. Department of Health, Education and Welfare, Washington, D.C.

Phase VI: A continuation of Phase V covering the time interval of May 1977 through April 1978. This phase is covered in "Project DAWN VI" on file with the Drug Enforcement Administration, U.S. Department of Justice, and the National Institute on Drug Abuse, U.S. Department of Health, Education and Welfare, Washington, D.C.

Phase VII: A continuation of Phase VI covering the time interval of May 1978 through April 1979. The "Project DAWN Annual Report - 1978" overlaps part of Phase VI and VII in summarizing data for calendar year 1978 and is on file with the Drug Enforcement Administration, U.S. Department of Justice, and the National Institute on Drug Abuse, U.S. Department of Health and Human Services.

Phase VIII: A continuation of Phase VII covering the time interval of May 1979 through April 1980. This Project DAWN Annual Report - 1979 overlaps part of Phase VII and VIII in summarizing data for calendar year 1979.

DEFINITIONS OF DRUG ABUSE

The following definitions were adopted for use in the DAWN program.

Drug Abuse is defined as the non-medical use of a substance for any of the following reasons: psychic effects, dependence, or self-destruction (suicide attempt or gesture), i.e., the use of:

a) Prescription drugs in a manner inconsistent with accepted medical practice, or

b) Over-the-counter (OTC) drugs contrary to approved labeling, or

c) Any other substance (heroin, marijuana, glue, aerosols, etc.) for psychic effects, dependence, or self-destruction (suicide attempt or gesture).

A drug-involved death is defined as either:

a) Drug-caused, involving a drug "overdose" where evidence of a lethal level of the substance(s) is found or suspected, or

b) Drug-related, where the drug usage is a contributory factor but not the sole cause, i.e., accidents, diseased state, withdrawal syndrome, etc.

Drug abuse reports for episodes involving children under six years of age are not collected; it is generally held that those which occur by children under six are primarily accidental poisoning incidents rather than actual drug abuse.

SAMPLE SELECTION

Initially, the DAWN network was to represent the drug-abusing population as reported by hospital emergency room and in-patient facilities, student health crisis and emergency room centers, medical examiners and crisis centers. Hospital in-patient units reported to DAWN from September 1972 through April 1975. Student health crisis centers and emergency rooms in colleges and universities participated in the DAWN network from September 1972 through March 1973. Starting in May 1978, only data from hospital emergency rooms and medical examiners were maintained as the most appropriate sources for studying drug abuse trends and drug abuse demographic profiles. Consequently, the collection of data from crisis centers was discontinued. The hospital emergency rooms which have been selected to participate in DAWN since September 1972, have had to meet certain specific criteria:

1. Open 24 hours a day

2. Located in non-federal short-term hospitals

3. At least 1,000 emergency visits of all kinds were made to the hospital in a year

Specialty hospitals, hospital units of institutions, and pediatric hospitals are excluded. Medical examiner information is gathered from both medical examiner and coroner facilities located in the 26 Standard Metropolitan Statistical Areas shown on page 4, Table 1.1.

During 1979, the DAWN reporting panel was composed as follows:

1. Twenty-six SMSAs (Standard Metropolitan Statistical Areas),[1] twenty-three of which were in DAWN II and III. Kansas City SMSA was in the study since DAWN I but did not become a saturated SMSA[2] until DAWN IV. San Diego replaced Omaha between DAWN III and DAWN IV; Norfolk SMSA replaced Raleigh SMSA between DAWN IV and DAWN V. As of May 1977, the start of DAWN VI, only emergency room facilities within San Francisco County were continued in the DAWN panel; facilities from other counties in the San Francisco SMSA were discontinued at that time. Facilities in the Baltimore and St. Louis SMSAs were recruited into the system in January 1979 and began reporting in March 1979.

---

1 Standard Metropolitan Statistical Areas are statistical units composed of a relatively large core city or cities and the immediately adjacent geographic areas. Conceptually, SMSAs are integrated economic and social units with a large population nucleus. Present DAWN SMSAs were originally defined by the Bureau of Census in 1972; see: U.S. Department of Commerce, Bureau of the Census, Statistical Abstracts of the States, 1972 (Washington, D.C.: U.S. Government Printing Office, 1972).

2 Strictly defined, saturation means enlistment of and reporting by every eligible facility in each specified SMSA. Recognizing the realities of data collection in a voluntary reporting system such as DAWN the co-sponsoring agencies define a "saturated" SMSA as one in which the contractor makes a best effort to contact and recruit each eligible emergency room within the SMSA and negotiates a reporting arrangement. (For results of this effort, see Table 1.1.)

For the New York, Chicago and Los Angeles SMSAs, the size of the region precluded saturation reporting. Therefore, in 1973 (for DAWN II) a sample of approximately forty hospitals for each of the three SMSAs was randomly drawn.[1] By agreement with DEA and NIDA, this sample was later extended to increase DAWN coverage to a minimum of 50% of total emergency room visits possible among eligible hospitals within each SMSA; the method of achieving this increased participation was by adding selected and geographically distributed large hospitals to the DAWN reporting panel. In addition, since DAWN II, a small percentage of the original facilities has dropped out, and has been replaced by others. The facility samples for these three SMSAs cannot, therefore, be considered statistically random, but may be considered representative of the majority of facilities in the area.

2. In 1973, a national panel of 200 emergency rooms from areas outside the DAWN SMSAs was randomly selected from the universe of all facilities meeting DAWN criteria in the continental United States. Although some of the facilities in this original "National Panel" have been replaced by others, most (83%) still remain in the system. The panel presently consists of approximately 180 hospitals.

3. As of May 1979, 32 of the 125 medical examiners previously reporting to DAWN from the SMSAs no longer report to the system. These medical examiners accounted for fewer than 20 drug-related deaths during their last year of participation in DAWN. Eight "special panel" medical examiners from outside the SMSAs were also dropped in May 1979.

GEOGRAPHIC DISTRIBUTION OF SMSA FACILITIES

The numbers of each type of facility in each SMSA and in the total DAWN system as of December 1979 are shown in Table 1.1.

In each case, the named city is the central city in a Standard Metropolitan Statistical Area (SMSA) as defined by the United States Bureau of the Census in 1972. The geographic boundary of each sampling point is therefore the boundary of the SMSA instead of that of the central city. For example, Philadelphia SMSA includes five Pennsylvania counties (Bucks, Chester, Delaware, Montgomery and Philadelphia) and three New Jersey counties (Burlington, Camden and Gloucester).

As previously stated, the goal of "saturation" was to enlist in the DAWN reporting system every eligible hospital located within the 22 "saturated" SMSAs, all emergency rooms within San Francisco County and a representative sample of emergency rooms in the New York, Chicago and Los Angeles SMSAs. Table 1.1 also shows the degrees of saturation and coverage (ratio of DAWN emergency room visits to total SMSA emergency room visits) achieved for emergency rooms and the level of saturation for medical examiners.

When the term "total DAWN system" (TDS) is used in this report, it refers to the sum of data from all facilities in all SMSAs and in the National Panel that report to DAWN; it is not intended to be interpreted as representing the entire United States or truly national totals.

1979 U.S. Census - When this term is used in the text or in tables, it refers to the 1979 U.S. Bureau of the Census estimates[2] of the population of the entire country, not the total populations of the SMSAs in the DAWN system. Differences in demographic distributions in the population between the total DAWN system and the entire U.S. population are unlikely to be great since the DAWN SMSAs and National Panel include over one-third of the U.S. population.

---

1 Hospitals listed in the American Hospital Association: Guide to the Health Care Field (Chicago: American Hospital Association, 1973), were assigned numbers. Then a random number method was employed to select the numbers of the hospitals which would comprise the New York, Chicago and Los Angeles samples.

2 U.S. Bureau of the Census, Current Population Reports, Series P-25, No 870, "Estimates of the Population of the United States, by Age, Sex, and Race: 1976 to 1979" (Washington, D.C.: U.S. Government Printing Office, 1980).

TABLE 1.1

TOTAL DAWN SYSTEM
SATURATION RATE AND PERCENT OF COVERAGE
DAWN ANNUAL REPORT - JANUARY-DECEMBER 1979

		EMERGENCY ROOMS						MEDICAL EXAMINERS		
Saturated SMSAs	SMSA Population[a]	# ERs in SMSA	# ERs in DAWN[b]	Saturation Rate %	Total ER Visits in SMSA[c]	Total DAWN ER Visits	Percent of Coverage %	# Counties and Independent Cities in SMSA	# MEs in DAWN[b]	Saturation Rate %
Atlanta, GA	1,553,700	22	16	73	640,552	570,268	89	5	2	40
Baltimore, MD*	2,145,100	28	19	68	768,963	495,097	64	6	6	100
Boston, MA	2,697,212	39	33	85	1,213,942	1,058,568	87	5	5[d]	80
Buffalo, NY	1,302,900	19	19	100	466,236	466,236	100	2	5[e]	100
Cleveland, OH	1,938,900	33	27	82	760,863	602,451	79	4	1	25
Dallas, TX	1,798,000	35	23	66	558,776	436,292	78	6	1	17
Denver-Boulder, CO	1,480,000	19	17	89	489,879	450,912	92	5	5	100
Detroit, MI	4,093,400	52	45	87	1,379,931	1,147,671	83	3	3	100
Indianapolis, IN	1,156,100	14	11	79	410,473	349,105	85	8	2	25
Kansas City, MO/KS	1,305,200	27	23	85	410,827	397,135	97	6	2	33
Miami, FL	1,451,200	27	16	59	520,795	432,212	83	1	1	100
Minneapolis-St. Paul, MN	1,866,800	30	24	80	580,929	521,745	90	5	3	60
New Orleans, LA	1,141,100	21	18	86	543,620	475,552	87	4	2	50
Norfolk-Portsmouth-Virginia Beach, VA	742,600	9	8	89	251,087	231,083	92	4	3	75
Oklahoma City, OK	716,300	14	13	93	233,109	224,265	96	3	1	33
Philadelphia, PA/NJ	4,770,300	75	59	79	1,648,329	1,377,105	84	8	6	75
Phoenix, AZ	1,293,200	22	17	77	367,598	336,290	91	1	1	100
St. Louis, MO/IL*	2,335,600	38	17	45	826,580	363,761	44	7	7	100
San Antonio, TX	1,005,800	12	7	58	367,820	293,396	80	2	1	50
San Diego, CA	1,743,600	25	19	76	464,301	402,103	87	1	1	100
San Francisco-Oakland, CA	3,183,800	12[f]	8[f]	67[f]	271,821[f]	180,021[f]	66[f]	5	5	100
Seattle-Everett, WA	1,467,600	27	24	89	407,262	377,754	93	2	2	100
Washington, D.C./MD/VA	2,928,500	30	20	67	816,755	608,495	75	10	7[g]	90
Total	44,116,912	630	483	77	14,400,448	11,797,517	82	103	72[d,e,g]	68
Sampled SMSAs										
Chicago, IL	7,029,700	99	48	48	2,383,210	1,135,660	48	6	4	67
Los Angeles, CA	7,080,900	115	42	37	2,168,985	1,081,953	50	1	1	100
New York, NY	10,975,000	123	57	46	4,266,973	2,204,101	52	9	8	89
Total	25,085,600	337	147	44	8,819,168	4,421,714	50	16	13	81
SMSA Total	69,202,512	967	630	65	23,219,231	16,219,231	70	119	85[d,e,g]	70
National Panel	-	-	176	4[h]	-	-	7[h]	-	-	-

*See Introduction

[a]Population figures are the updated (1978) population estimates obtained from the U.S. Bureau of the Census, Current Population Reports, Population Estimates and Projections, Series P-25, No. 873, February 1980. Boston SMSA figures obtained from the U.S. Bureau of the Census, 1977 Population Estimates for Counties, Incorporated Places, and Minor Civil Divisions in Massachusetts, Series P-25, No. 834, November 1979.

[b]Facilities in DAWN as of December 1979.

[c]One year's total obtained from the 1978 Annual Survey of Hospitals tape, American Hospital Association, and DAWN reported visits for 1979, updated through April 30, 1980.

[d]Two medical examiners report from Suffolk County.

[e]Four medical examiners report from Niagara County.

[f]San Francisco County only

[g]One medical examiner reports for three areas: Fairfax County, VA; Fairfax City, VA; and Falls Church, VA.

[h]The percent is based upon total emergency rooms and emergency room visits obtained from the 1976 Annual Survey, American Hospital Association.

DATA COLLECTION

As each facility was recruited, a responsible reporter and an alternate were appointed by the facility administration. Four percent (4%) of the emergency room reporters had an administrative position in the hospital, 27% of the reporters were head nurses or nursing supervisors, 17% emergency room nurses, 36% trained emergency ward secretaries, 15% medical records specialists, and the other 1% was drawn from emergency room physicians, pharmacists, medical students and residents.

The total number of daily facility visits and total daily number of visits related to drug abuse are entered into a DAWN log for each reporting week; the details of each drug abuse episode are recorded on DAWN data forms designed by the co-sponsoring agencies. A technical assistance specialist who is a health services professional familiar with hospital data systems is responsible for personally training all facility personnel who retrieve and report DAWN data. This specialist also monitors the consistency and timeliness of DAWN reporting by each facility. When facility reporters have been sufficiently trained and tested, regular communication with the facility reporters is established and continued by a field monitor assigned to all facilities in that SMSA. This monitor is responsible for checking incoming data forms, contacting the reporter for missing data, answering questions, and working with reporters in stressing the importance of submitting data on time. Monitors routinely talk with each reporter at least once a month, more frequently if there are problems.

A copy of the form used by each facility type is displayed on pages 6 and 7 of this report.

AT NO TIME IS ANY INFORMATION GATHERED FROM THE FACILITIES WHICH CAN IDENTIFY AN INDIVIDUAL AND AT NO TIME ARE THE IDENTITIES OF PARTICIPATING FACILITIES RELEASED WITHOUT THEIR PERMISSION.

OMB No. 43-R-0545

Book Expiration Date April 30, 1980

HOSPITAL EMERGENCY ROOM

HOSPITAL	
DATE	TIME OF VISIT ☐ A.M. ☐ P.M.

(A) PATIENT INFORMATION

AGE	SEX	RACE
	☐ MALE ☐ FEMALE	☐ WHITE ☐ BLACK ☐ UNKNOWN ☐ OTHER

EMPLOYMENT STATUS ☐ STUDENT (ANY) ☐ UNEMPLOYED ☐ RETIRED WORKER ☐ UNKNOWN ☐ EMPLOYED ☐ HOMEMAKER ☐ OTHER

PATIENT CURRENTLY ENROLLED IN TREATMENT/REHABILITATION PROGRAM ☐ YES ☐ NO ☐ UNKNOWN → IF YES, CHECK TYPE ☐ METHADONE DETOXIFICATION ☐ METHADONE MAINTENANCE ☐ OTHER

REASON FOR TAKING SUBSTANCE(S)	REASON FOR PRESENT CONTACT	DISPOSITION
☐ PSYCHIC EFFECTS	☐ UNEXPECTED REACTION	☐ REFERRED TO ANOTHER AGENCY
☐ DEPENDENCE	☐ OVERDOSE	☐ TREATED AND REFERRED
☐ SUICIDE ATTEMPT OR GESTURE	☐ CHRONIC EFFECTS	☐ TREATED AND RELEASED
☐ UNKNOWN	☐ UNKNOWN	☐ ADMITTED TO HOSPITAL
☐ OTHER, SPECIFY_____	☐ OTHER, SPECIFY_____	☐ LEFT AGAINST MEDICAL ADVICE
_____	_____	☐ DIED
_____	_____	☐ UNKNOWN

(B) DRUG SUBSTANCE INFORMATION

LIST EACH SUBSTANCE NAME (CHEMICAL, GENERIC, TRADE OR STREET NAME) IN ONE OF THE NUMBERED SPACES BELOW		
1.	2.	3.

FOR EACH OF THE SUBSTANCES LISTED ABOVE, CHECK APPROPRIATE ANSWERS IN EACH RESPONSE FIELD BELOW.

FORM IN WHICH DRUG WAS ACQUIRED

	SUBSTANCE 1	2	3
TAB/CAP/PILL	☐	☐	☐
AEROSOL	☐	☐	☐
LIQUID	☐	☐	☐
POWDER	☐	☐	☐
PAPER	☐	☐	☐
INJECTABLE LIQUID	☐	☐	☐
CIGARETTE	☐	☐	☐
PLANT MATERIAL	☐	☐	☐
UNKNOWN	☐	☐	☐
OTHER, SPECIFY			

ROUTE OF ADMINISTRATION

	SUBSTANCE NUMBER 1	2	3
ORAL	☐	☐	☐
INJECTION (SPECIFY I.V., S.C., I.M.)	☐	☐	☐
INHALED (GAS, VOLATILE LIQUID, AEROSOL)	☐	☐	☐
SMOKED	☐	☐	☐
SNIFFED, SNORTED (e.g., COCAINE)	☐	☐	☐
UNKNOWN	☐	☐	☐
OTHER, SPECIFY_____			
_____			

SOURCE OF SUBSTANCE

	SUBSTANCE NUMBER 1	2	3
LEGAL RX	☐	☐	☐
FORGED RX	☐	☐	☐
STREET BUY	☐	☐	☐
O. T. C.	☐	☐	☐
STOLEN	☐	☐	☐
GIFT	☐	☐	☐
UNKNOWN	☐	☐	☐
OTHER, SPECIFY			

IDENTIFICATION OF SUBSTANCE (CHECK ALL THAT APPLY)

	SUBSTANCE NUMBER 1	2	3
Patient's statement of identification	☐	☐	☐
Doctor's statement of identification	☐	☐	☐
Positive clinical response to symptomatic treatment of drug	☐	☐	☐
Possession of commercial identifiable dosage form	☐	☐	☐
Statement of accompanying individual	☐	☐	☐
Identification of substance from blood sample	☐	☐	☐
Identification of substance from urine sample	☐	☐	☐
Identification of substance from other body fluid or tissue	☐	☐	☐

CLINICAL STATUS: ☐ CONSCIOUS → ☐ COHERENT ☐ INCOHERENT ☐ UNCONSCIOUS ☐ DEAD

OMB No. 43-R-0545

MEDICAL EXAMINERS

Book Expiration Date April 30, 1980

COUNTY & STATE	DATE OF DEATH
	☐ PRESUMED OR TO BE A DRUG-INVOLVED DEATH ☐ CONFIRMED

(A) INFORMATION ON DECEASED

AGE	SEX	RACE
	☐ MALE ☐ FEMALE	☐ WHITE ☐ BLACK ☐ UNKNOWN ☐ OTHER

EMPLOYMENT STATUS: ☐ STUDENT (ANY) ☐ UNEMPLOYED ☐ RETIRED WORKER ☐ UNKNOWN ☐ EMPLOYED ☐ HOMEMAKER ☐ OTHER

WAS DECEASED ENROLLED IN TREATMENT/REHABILITATION PROGRAM → IF YES, CHECK TYPE ☐ METHADONE DETOXIFICATION ☐ METHADONE MAINTENANCE ☐ OTHER _____

☐ YES ☐ NO ☐ UNKNOWN

CAUSE OF DEATH		MANNER OF DEATH (check one)			
		ACCIDENTAL/ UNEXPECTED	SUICIDE	HOMICIDE	UNKNOWN
DRUG INDUCED (Overdose or Drug Reaction)	A. *DIRECT – SINGLE DRUG CAUSE* (Overdose) (The single drug is named in Box #1 below.)	☐	☐	☐	☐
	B. *DIRECT – MULTIPLE DRUG CAUSE* (Cause not attributable specifically to any one drug, but to drug overdose.)	☐	☐	☐	☐
	C. *IDIOSYNCRATIC – UNEXPECTED EFFECT, ANAPHYLACTIC OR IMMUNE REACTION* (Drug Reaction)	☐			
DRUG RELATED (Contributory Factor)	D. *COMBINATION WITH PHYSIOLOGICAL CONDITION*	☐	☐	☐	☐
	E. *COMBINATION WITH EXTERNAL PHYSICAL EVENT*	☐	☐	☐	☐
	F. *COMBINATION WITH MEDICAL DISORDER PROBABLY DRUG CAUSED*	☐			☐

CAUSE OF DEATH DETERMINATION SUPPORTED BY:
(Check All that Apply)

- ☐ Toxicological Lab Report
- ☐ Autopsy
- ☐ Site Inspection
- ☐ External Physical Symptoms
- ☐ Statement of Family/Friends
- ☐ Other (specify) _____

PLEASE NOTE: (To be answered only in the case of *ACCIDENTAL/UNEXPECTED* manner of death.)
When the manner of death was accidental/unexpected (unintentional), was the decedent's use of drugs motivated either by a desire for psychic effects or dependence upon the drug which induced or contributed to the death?

☐ YES ☐ NO ☐ UNKNOWN

(B) DRUG SUBSTANCE INFORMATION

LIST EACH SUBSTANCE NAME (CHEMICAL, GENERIC, TRADE OR STREET NAME) IN ONE OF THE NUMBERED SPACES BELOW		
1.	2.	3.

FOR EACH OF THE SUBSTANCES LISTED ABOVE, CHECK APPROPRIATE ANSWERS IN EACH RESPONSE FIELD BELOW

FORM IN WHICH DRUG WAS FOUND	SUBSTANCE NUMBER 1	2	3
TAB/CAP/PILL	☐	☐	☐
AEROSOL	☐	☐	☐
LIQUID (ORAL)	☐	☐	☐
POWDER	☐	☐	☐
PAPER	☐	☐	☐
INJECTABLE LIQUID	☐	☐	☐
CIGARETTE	☐	☐	☐
PLANT MATERIAL	☐	☐	☐
UNKNOWN	☐	☐	☐
OTHER, SPECIFY_____	☐	☐	☐

ROUTE OF ADMINISTRATION	SUBSTANCE NUMBER 1	2	3
ORAL	☐	☐	☐
INJECTION (SPECIFY I.V., S.C., I.M.)	☐	☐	☐
INHALED (GAS, VOLATILE LIQUID, AEROSOL)	☐	☐	☐
SMOKED	☐	☐	☐
SNIFFED, SNORTED (e.g., COCAINE)	☐	☐	☐
UNKNOWN	☐	☐	☐
OTHER, SPECIFY_____	☐	☐	☐

LABORATORY TEST METHOD ORDERED TO IDENTIFY DRUGS

TEST METHOD	SPECIMEN	FINDING (in mg.% if available)

OTHER METHODS OF IDENTIFICATION (check all that apply)

	SUBSTANCE NUMBER 1	2	3
POLICE STATEMENT OF IDENTIFICATION	☐	☐	☐
DOCTOR'S STATEMENT OF IDENTIFICATION	☐	☐	☐
POSSESSION OF COMMERCIAL IDENTIFIABLE DOSAGE FORM	☐	☐	☐

(C) REMARKS

DRUG EPISODES AND DRUG MENTIONS

A patient contact (or abuse episode) represents a death or an emergency room visit to a DAWN facility as reported by that facility. In the DAWN context, visits are not synonymous with the number of individuals involved, since one person may make more than one visit to an emergency room, or to several emergency rooms, or have contact with more than one type of facility. Neither are numbers of visits synonymous with numbers of drug mentions, numbers of motivations for taking drugs or numbers of drug sources. Each patient will be recorded as one visit but may mention from one to several drugs with one or more motivations for each. Furthermore, a single drug may have been obtained from several sources. (For example, as a gift from a friend supplemented by the purchase of more from a "pusher".) Unique patients are in no way identified in DAWN to protect the confidentiality of patients and other patient rights.

An important consideration when using DAWN data is that the system only collects data concerning drug abuse episodes that have resulted in a crisis (emergency medical situation or death). The person involved in the reported abuse episode has typically sought emergency medical help (or died) and the incident has subsequently been reported by one of the two facility types (emergency room or medical examiner). The system reports only that portion of total drug abuse occurrences which result in such crises and which surface at one of the two DAWN facility types. Refer to page two for DAWN definition of drug abuse.

In certain situations, a drug abuse episode may be reported to DAWN some time after the episode occurred. This occurs primarily with medical examiners, who may wait until confirmation of the drug-relatedness of the death is ascertained and/or confirmed by completed lab tests, autopsy reports, etc. before filing a report. Thus, the data are continually being updated by the addition of these episodes, referred to as "back data." Of the episode reports submitted each month by emergency rooms, 90% are for the "current" month and the other 10% represent back data. Medical examiner data are 90% complete after six months.

Care must also be taken in analyzing information on motivation. The current DAWN forms report all the motivation responses given without reference to the drug involved. Hence, if motivation is associated with a specific drug (unless only one drug was used) erroneous conclusions could be reached. Because the present DAWN form provides for multiple-drug mentions but only a single motivation for taking the substances, caution must be observed in interpreting specific cross-tabulations of drug/motivation data.

Since DAWN accepts from one to six substances per episode (patient contact), the drug mentions (named substances) must be equal to or exceed the number of episodes. During the period January-December 1979, each episode from emergency rooms generated an average of 1.57 drug mentions, as compared with 2.00 mentions per episode for medical examiner cases.

This report contains the narrative description of DAWN data collected during the period January through December 1979.

TABLE 1.2

TOTAL DAWN SYSTEM
DRUG ABUSE EPISODES AND DRUG MENTIONS
BY FACILITY TYPE
JANUARY - DECEMBER 1979

	Medical Examiners	Emergency Rooms
Number of Facilities	85	806
Drug Abuse Episodes	3,626	117,949
Drug Mentions	7,237	185,270
Average Episodes per Facility	43	146
Average Mentions per Facility	85	230
Average Mentions per Episode	2.00	1.57

Deaths reported by medical examiners are frequently the direct consequence of an overdose of several drugs.

The reader should note that the drug(s) may or may not be the confirmed "cause" of the episode. When a single drug substance is reported, and a causal relationship seems apparent, allowance should still be made for missing reportable drugs.

Medical examiner data, on the other hand, are more definitive since cause and manner of death are requested (see Medical Examiner form). However, care must be taken to distinguish clearly between the terms "drug-related" and "drug-caused" (drug-induced) deaths.

DEFINITION OF DAWN DRUG VOCABULARY

The substances reported to DAWN are grouped into general categories, most of which are therapeutic classifications (TCs) such as tranquilizers, narcotic analgesics, non-narcotic analgesics, etc. for purposes of uniformity. The exceptions, hallucinogens, cannabis substances, alcohol-in-combination with other substances, cocaine, and substances abused by inhalation are grouped into separate classifications. A list of therapeutic classifications used in DAWN is given on page 10. These DAWN assignments are based primarily upon a pre-existing classification used in the National Drug and Therapeutic Index (IMS America, Ltd.).

Within each therapeutic class or category, drugs are grouped generically. Thus street names, trade names, or both, may be included in these generic groups. Street names are carried in DAWN due to the inability of some drug users to reliably identify the compound other than by its street name. Reference to substances such as speed may, therefore, appear in a table or in the text. Information obtained subsequently may confirm the street name as a known substance thereby updating the drug records for that substance, and providing more complete information in response to queries on drug substances in DAWN. The DAWN drug groupings are constantly reviewed in order to reflect the most recent changes in pharmaceutical classifications and drug legislation.

The term "drug unknown" is used in connection with approximately 6% of the drug mentions. "Drug unknown" may be recorded when the user did not know what had been taken or perhaps did not wish to reveal the truth (particularly if it were an illicit substance), or data were not available on the hospital records.

MOST FREQUENTLY MENTIONED DRUGS

Since its inception, the DAWN system has accumulated a vocabulary of approximately 4,000 substances mentioned in incidents of abuse. However, only 25 of these substances account for 63% of all drug mentions from emergency rooms. Thus, nearly two-thirds of all drug mentions are attributed to a very limited number of commonly-reported substances.

When reviewing this report the reader should note that DAWN does not gather data on episodes caused by the ingestion of only alcohol; alcohol is presently reported in DAWN when used concomitantly with another abused substance. Therefore, all alcohol mentions are combination mentions.

Some clarification regarding heroin and morphine is also in order. Although heroin may be the ingested drug, it is metabolized in the body to morphine. To prevent confusion, therefore, particularly with respect to attributions of cause of death, "heroin/morphine" is treated as a single drug, and the number of its mentions is the sum of the numbers of heroin and morphine mentions actually reported.

DRUG PROFILES

In Chapter 3, each drug and drug group is described in terms of the demographic characteristics of the drug abusers, whether the substance was taken alone or in combination with other substances, and (for emergency room patients) the source of and motivation for taking the drug. Emergency room data are broken down by SMSA in order to demonstrate variations in the patterns of drug abuse in different areas of the country. Comparisons between SMSAs should be tempered by considering the relative size of the cities, the absolute frequency of mentions, and the rank of the drug in the SMSAs.

For age data, two breakdowns are provided. The first grouping, used in other DAWN reports, provides a basis of continuity with previous DAWN publications. The second set of categories matches the grouping used by CODAP (Client Oriented Data Acquisition Process) a federal reporting system for drug abuse treatment programs and facilitates the use of both the DAWN and CODAP categories.

THERAPEUTIC CLASS ASSIGNMENTS USED IN DAWN

TC #	Therapeutic Class
01	Antacids without Antispasmodic Action
02	Antacids with Antispasmodic Action
03	Antidiarrheals, Intestinal Adsorbents
04	Antispasmodics, Anticholinergics
05	Bile Therapy
06	Laxatives
07	Ataractics, Tranquilizers — Tranquilizers
08	Oral Muscle Relaxants —
09	Surgical Muscle Relaxants
10	Hospital Solutions
11	Psychostimulants
12	A. Amphetamine Preparations B. Cocaine
13	All Other Antiobesity Preparations
14	Antihistamines
15	Bronchial Dilators
16	Cough Preparations
17	Cough, Cold Preparations
18	Oral Cold Preparations
19	Topical Nasal, Ophthalmic Decongestants
20	Diagnostic Aids
21	Broad, Medium Spectrum Antibiotics
22	Penicillin
23	Streptomycin, DHS, Combinations
24	Sulfonamides
25	Antibiotic-Sulfonamides
26	Penicillin-DHS Combinations
27	Other Topical Antibiotics
28	Urinary Antibacterials, Antiseptics
29	Solvents/Volatile Materials/Aerosols
30	Codeine Combinations
31	Amebicides, Trichomonacides
32	Antimalarials
33	Anthelmintics
34	Tuberculosis Preparations
35	A. Cannabis B. Drug Unknown
36	Topical Contraceptives
37	Vaginal Cleansers
38	General Antibacterials, Antiseptics
39	Hallucinogens
40	Narcotic Analgesics
41	Non-Narcotic Analgesics
42	Antiarthritics
43	Anesthetics, General Inhalants
44	Anesthetics, General Injectables
45	Anesthetics, Local Topical
46	Barbiturate Sedatives
47	Non-Barbiturate Sedatives
48	Anticonvulsants
49	Antinauseants
50	Corticoids, ACTH
51	Corticoids, Plain
52	Corticoids, Analgesic Combinations
53	Corticoids, Anti-Infective Combinations
54	Corticoids, Other Combinations
55	Thyroid Preparations
56	Antithyroid Preparations
57	Iodine Therapy
58	Diabetic Therapy
59	Anabolic Agents
60	Androgens
61	Estrogens
62	Androgen-Estrogen Combinations
63	Progestogen-Estrogen Combinations
64	Other Hormones
65	Lipotropics
66	Cholesterol Reducers
67	Digestants
68	Protein Lysates
69	Hyaluronidase
70	Rauwolfias
71	Other Hypotensives
72	Vasodilators, Coronary
73	Vasodilators, Peripheral
74	Digitalis Preparations
75	Xanthine Derivatives
76	Other Cardiovascular Preparations
77	Anticoagulants
78	Hemostatics
79	Diuretics
80	Pediatric Vitamins
81	Prenatal Vitamins
82	Other Multivitamins
83	Geriatric Vitamins
84	Vitamin B Complex with Vitamin C
85	Other Vitamins
86	Infant Formulas
87	Electrolytes, Miscellaneous Nutrients
88	Hematinics with/without Iron
89	Allergens
90	Biologicals
91	Antipruritics
92	Coal Tar, Sulfur, Resorcinol Preparations
93	Emollients, Protectives
94	Fungicides
95	All Other Dermatologicals
96	Hemorrhoidal Preparations
97	Oxytocics, Parasympathetic Agents
98	Miscellaneous
99	Miscellaneous

NOTE: The data on the underlined TC classes are given in this report.

RANKS OF LEADING DRUGS OF ABUSE

Various tables in this report display rankings by mention count of the leading drugs of abuse within each facility type (emergency rooms and medical examiners) for the total DAWN system and for each SMSA. The ranks of these drugs within individual SMSAs indicate the relative frequency of each drug to the given SMSA.

However, rank ordering presents data in a format which lends itself to misinterpretation. A difference in rank should be considered only as indicative of a difference in frequency among drugs reported to DAWN, no matter how small, and not as necessarily denoting a meaningful or significant difference. For example, a difference of one between ranks of drug mentions could mean a difference of one between the actual numbers (a trivial difference) or a difference of many, which would indicate a more significant difference.

STANDARD NOTATION RANKING PROCEDURE

The occurrence of equal values (ties) for two or more drugs listed in the ranking tables has been given in Standard Statistical Notation form starting with the DAWN IV Final Report.

The Standard Statistical Notation Procedure is best illustrated by the following table:

DRUG	SMSA # 1		SMSA # 2		SMSA # 3	
	# of Mentions	Rank	# of Mentions	Rank	# of Mentions	Rank
A	250	1	250	1	250	1
B	200	2	200	2.5	200	3
C	175	3	200	2.5	200	3
D	150	4	150	4	200	3
E	100	5	100	5	100	5

It will be noticed that when a drug is not tied, it retains the rank which it would have if there were no ties in the list (e.g., drugs D and E in SMSA #2, and E in SMSA #3). When two or more drugs are tied, the rank they have is the average of the ranks they would have had if not tied. Thus in SMSA #2, B and C fit into slots 2 and 3, whence their rank is $\frac{2 + 3}{2} = 2.5$. Similarly, in SMSA #3, drugs B, C, and D fit into slots 2, 3, and 4, whence $\frac{2 + 3 + 4}{3} = 3$ is the tied rank of all three drugs. In the case of ties, therefore, rankings may be denoted either by whole numbers or by fractions, and gaps will exist in the sequence of rank numbers.

SYSTEM CAVEATS

The 1979 DAWN Annual Report contains primarily unrefined data as received from the reporting facilities. That is, the data are uncorrected for various forms of interference such as changes in the facility clientele or elimination or replacement of facilities in the reporting panel. Consequently, certain apparently feasible conclusions and comparisons between 1979 and earlier years may be unjustified because of the absence of a uniform and continuous basis for such comparison.

Furthermore, changes in statistics such as percentage share or rank of a specific drug may occur not because of changes in the frequency of abuse episodes of that drug but through opposite changes in the abuse of other drugs.

Some of the more important of these potential misunderstandings are discussed here as a brief guide to the reader. Users of the 1979 DAWN Annual Report who are unfamiliar with the terminology, nomenclature, or conventions of the DAWN Project report series should carefully study the introductory material in this publication.

When all of the eligible facilities in a given Standard Metropolitan Statistical Area (SMSA) report to DAWN, termed "saturation" reporting, the data base will reflect maximum representation of the actual SMSA population. As a partial assistance to the reader, the rate of saturation of each SMSA in the DAWN system is listed in Table 1.1.

To avoid misinterpretation of the raw data, the reader should cross-reference drug profiles (Chapter 3) with leading drug ranks and facility profiles (Chapters 1 and 2).

Cross-checking of the tables in various chapters is advisable when interpreting data to ensure that the reference levels of the items being compared are identical or adequately adjustable. For example, the occurrence of ten mentions of abuse of drug X from region A may refer to a more, or a less, severe problem than the same number of mentions from region B. This can easily be seen if we imagine A to be a large city of 5,000,000 population and B a small city of only 5,000 population. In the former, an abuse level of ten mentions per month might be negligible; in the latter this might be a matter for serious concern.

For reasons such as those given in the preceding paragraphs, extreme caution should be exercised in comparing data from different SMSAs, or comparing the data from the same SMSA reported at different times. The 1979 DAWN Annual Report does not include any attempt at time series or trend analyses. Trend analysis for broad drug groupings is given in the DAWN Quarterly Reports (available from the National Clearinghouse on Drug Abuse Information, National Institute on Drug Abuse, or the Drug Enforcement Administration). The Quarterly Reports provide over two years of data for selected drugs for both the entire system and by individual DAWN SMSAs. In addition, summary analyses and graphs are presented for data reported from each SMSA during the current quarter.

The response rate for the large majority of the data cells on the DAWN reporting forms is quite satisfactory. However, there are others (motivation and source of substance) for which the proportion "unknown/no response" is high. This does not represent a lack of responsiveness, training or unwillingness on the part of personnel in participating facilities to report fully on all data cells. DAWN is a file review system. If an item does not occur on the emergency room admissions record, it can not be reported on the DAWN form. The following are some of the factors that may inhibit the inclusion of information in the emergency room admissions record:

1. As a matter of policy some hospitals do not ask questions regarding source and form of substance.

2. The attending physician did not supply data on his report relative to each cell on the DAWN form though he may have questioned patient and elicited a response. Consequently DAWN, which depends on a review of emergency room admission records, cannot capture the unrecorded elements of data.

3. Patient refused to supply information which would be carried in the hospital record containing data on the episode.

4. As a matter of state, city or county policy certain elements of data may not be collected.

5. In a few cases, data are collected by the hospital, but the administration refuses to divulge these data to any outside source, etc.

6. The data because of any of the above reasons 1-5 do not appear on any hospital record.

"Missing data" are included in the percentaging base of the tables throughout this report. It is, therefore, important that the reader be aware of the potential distortion in percentages of positive values in tables where the "unknown/no response" factor is significant. Interpretation of these data must always be tempered by recognition of the proportion of unknown (missing) data and the ways the findings could be affected.

Finally, the strength of DAWN data is in indicating the relative frequency of kinds of drug abuse. The number of patient episodes and drug mentions reported by DAWN should not be taken as an absolute measure of all drug abuse occurrences in a given SMSA. First, not all eligible facilities report to DAWN in many SMSAs, and second, drug abuse tends to be somewhat underreported. (Current efforts to improve DAWN data are designed to reduce underreporting.) A recent quality assurance study demonstrated that while underreporting varied by drug class, the relative ranking of drugs was unchanged with the inclusion of missing data. Therefore, figures reported in the 1979 DAWN Annual Report are representative of the SMSAs for indicator purposes. However, sophisticated statistical manipulation such as inference to larger populations, should be attempted with caution and knowledge of the idiosyncrasies of DAWN reporting.

CHAPTER 2

EMERGENCY ROOM AND MEDICAL EXAMINER REPORTS

I. Introduction

This chapter presents descriptive information concerning the salient aspects of drug abuse episodes reported by DAWN emergency rooms and medical examiners during the calendar year of 1979. Over this period there were 121,575 drug abuse episodes reported by DAWN facilities, 117,949 of which were from emergency rooms and 3,626 from medical examiners. These episodes combined account for 192,507 drug mentions representing an average of 1.57 drug mentions per episode for emergency rooms and 2.00 mentions per episode for medical examiners (Table 1.2).

II. Drug Mentions

The therapeutic class of tranquilizers (38,457 mentions) accounts for 20.8% of the 185,270 emergency room mentions (Table 2.1). Within this therapeutic class, mentions of diazepam constitute the largest percentage (48.3%). Tranquilizers, alcohol-in-combination, non-narcotic analgesics and non-barbiturate sedatives combined account for 51.9% of the total mentions.

Reports from medical examiners show that drugs of the therapeutic classes of barbiturate sedatives and narcotic analgesics are most frequently associated with drug deaths, with the combined mentions of these classes accounting for 35.4% of the total mentions. Heroin/morphine (619 mentions) and secobarbital (256 mentions) are the two predominant drugs within these two therapeutic classes. Alcohol-in-combination, with 993 mentions, is the leading substance of abuse reported by medical examiners during the January-December 1979 period.

III. Sex, Age, Race Characteristics

A. Sex

Table 2.2 compares the distribution of demographic characteristics associated with DAWN emergency room and medical examiner episodes with the 1979 United States Census and the 1977 National Death Rate. The distribution of males and females as reported from the DAWN system emergency rooms varies four percentage points from the corresponding distribution according to the 1979 census estimate. Females are overrepresented in DAWN and conversely, males are underrepresented.

When the distribution of males and females drug abuse episodes is broken down by age group, the difference between males and females changes with the age category (see top of Table 2.3). The most noticeable change occurs between the 10-19 age group, where females are represented by 4.1% more than males, and the 20-29 age group, which represents 47.2% of all male drug abuse episodes versus 39% of all female drug abuse episodes. Males in the 20-29 age group appear significantly more often than females in DAWN reports.

B. Age

The largest number of drug abusers represented in DAWN data falls into the 20-29 age category. This number is equal to 43.1% of total DAWN emergency room episodes for 1979, compared with 19.4% of the U.S. population (Table 2.2). Twenty to twenty-nine year olds are represented in 38.2% of DAWN medical examiner episodes versus 2.7% in the 1977 National Death Rate statistics. The percentage of 10-19 year olds who enter the DAWN-reporting facilities is similar to the U.S. population (22.1% in DAWN compared with 19.3% of the U.S. population).

C. Race

As displayed in Table 2.2 blacks account for 11.8% of the U.S. population, but 26.2% of the DAWN episodes. By contrast, 86.3% of the U.S. population is white, while only 69.2% of the DAWN emergency room population is represented by whites. The percentage of whites in DAWN data may be very slightly understated because people of Hispanic, Asian and American Indian descent are always classified as "Other Races" in DAWN whereas in the U.S. Census, respondents classify themselves.

IV. Motivations for Use of Drugs Associated with Emergency Room Drug Abuse Episodes

Almost forty percent (39.9%) of the motivation citations overall is suicide attempt/gesture (Table 2.5). Slightly more than one-half of the female citations is suicide attempt/gesture whereas only slightly more than one-fourth of the male citations is suicide attempt/gesture. Male motivation citations are more evenly dispersed among psychic effects, dependence and suicide attempt/gesture than are female motivation citations.

The examination of motivation by race reveals that motivation citations by white and other racial groups are concentrated in the suicide attempt/gesture category. Motivation citations by blacks, however, are more evenly distributed across psychic effects, dependence and suicide attempt/gesture categories.

With the exception of the 10-19 age group, Table 2.5 shows that the percentage of motivation citations for suicide attempt/gesture within each category increases with age. The percent of suicide attempt/gesture motivation citations for the 10-19 age group more closely resembles the 30-39 age group than the 20-29 age group. In contrast, beginning with the 10-19 age group, the percent of psychic effect motivations decreases with age.

Table 2.7 displays motivation citations associated with the top 20 most frequently used drugs. For two of these, PCP/PCP combinations and marijuana, psychic effects is the predominant citation with 54.1% for PCP and 53.9% for marijuana. Psychic effect motivations for methaqualone (38.3%) and cocaine (38.8%) are also remarkable. Dependence is the primary motivation cited in the use of heroin/morphine and methadone, 73.7% and 63.2% respectively. For each of the eight other drug groups, acetaminophen, amitriptyline, aspirin, chlordiazepoxide, diazepam, d-propoxyphene, flurazepam and over-the-counter (OTC) sleep aids, the major motivation cited in more than 50% of the total motivation citations, was suicide attempt/gesture.

V. Source of Drugs (Emergency Room Data Only)

Table 2.6 reveals that legal prescriptions are the predominant source of drugs for all age and sex categories. Whites are more likely than non-whites to secure drugs through a legal prescription. By contrast, non-whites are more likely than whites to secure drugs on the street. With the exception of the 6-9 age group, examination of the age distribution shows that the proportion of legal prescriptions as a source increases as the age increases.

Table 2.8 which displays the distribution of source mentions associated with the 20 most frequently abused drugs reveals a pattern of source mentions congruent with expectations. Aspirin, alcohol-in-combination, acetaminophen, and over-the-counter sleep aids are most likely obtained over-the-counter. Legal prescriptions are the main source for all prescription drugs listed with the exception of secobarbital/amobarbital and methaqualone which are primarily obtained on the street. Users of secobarbital/amobarbital and methaqualone are also likely not to mention source (52.1% and 38.9% of all source mentions respectively). Over 35% of the users of diazepam and PCP/PCP combinations also did not report source.

VI. Top 20 Drugs: Sex, Race, Age (Emergency Room and Medical Examiner Episodes)

A. Sex

There appears to be an association between the sex of the user and the preference for specific drugs. Table 2.9 shows that over 60% of all emergency room reports of heroin/morphine, PCP/PCP combinations, marijuana, methadone and cocaine are from males. By contrast, over 60% of all emergency room mentions of diazepam, aspirin, flurazepam, d-propoxyphene, amitriptyline, chlordiazepoxide, acetaminophen, and over-the-counter sleep aids are generated by females.

The drugs mentioned in medical examiner reports (Table 2.10) also show a relationship between sex and certain drugs. Males account for over 60% of the mentions of heroin/morphine, methadone, PCP/PCP combinations, methaqualone, cocaine and alcohol-in-combination. Drugs such as amitriptyline, phenobarbital, aspirin, and flurazepam tend to be associated with females. Mentions of the other ten of the top 20 drugs reported by medical examiners are more equally distributed between males and females.

B. Race

Table 2.9 reveals at least 60% of the mentions of 13 of the top 20 drugs are mentions by whites. The percentage of mentions by blacks exceeds the percentage of mentions by whites for only one drug - heroin/morphine.

The medical examiner data (Table 2.10) show that whites account for the majority of mentions of all top 20 drugs with heroin/morphine exhibiting the smallest share (54.8%). This share represents 339 deaths related to heroin/morphine abuse out of a total of 619 deaths which occurred during calendar year 1979. Drugs most reported in deaths of blacks were PCP/PCP combinations (40.2%), heroin/morphine (37.2%), methadone (22.6%), codeine (22%) and alcohol-in-combination (21.1%).

C. Age

As noted in preceding sections, the 20-29 age category is significant. Table 2.11 clearly shows the predominance of this age group with respect to involvement in episodes of abuse. The seven drugs for which the share of mentions in the 20-29 age category exceeds 50% are heroin/morphine, PCP/PCP combinations, secobarbital/amobarbital, methadone, methaqualone, amphetamine, and cocaine.

The 10-19 age group accounted for 21% of all emergency room episodes. In Table 2.11, mentions of eight drugs by 10-19 year olds exceeded this percentage: marijuana (37.5%), PCP/PCP combinations (34.3%), aspirin (40.8%), acetaminophen (36.4%), methaqualone (29.3%), d-propoxyphene (23.5%), over-the-counter sleep aids (27.7%) and amphetamine (23.6%). Medical examiner drug mentions for the 10-19 group (Table 2.12) tend to cluster around 5% with the exception of PCP/PCP combinations and methaqualone. For these substances, 10-19 year olds account for 12.0% and 23.0% respectively of the total medical examiner mentions.

Table 2.12 focuses on the top 20 drugs reported by medical examiners. The pattern of percentages in Table 2.12 differs primarily from the pattern displayed in Table 2.11 with respect to the 50 and over age category. For five drugs listed, secobarbital, phenobarbital, pentobarbital, aspirin, flurazepam, this age category is the dominant one; in the case of pentobarbital, mentions in this category comprise a 48.3% share of all mentions.

VII. Drug-Induced Deaths and Drug-Related Deaths

During 1979, DAWN medical examiners reported 3,626 deaths either drug-induced or drug-related. Eighty two percent (82%) of the deaths are listed as drug-induced (Table 2.13).

The drugs most frequently reported by medical examiners are barbiturate sedatives, narcotic analgesics and tranquilizers. These three therapeutic classes of drugs account for 47.5% of the total mentions. Alcohol-in-combination, heroin/morphine, amitriptyline, d-propoxyphene and methadone are the five most frequently-encountered substances associated with drug deaths.

Table 2.14 displays the manner of drug-induced deaths associated with drug mentions. Forty-three percent (43%) of all drug-induced deaths are attributed to suicidal overdose. Drugs of the therapeutic classes of barbiturate sedatives, tranquilizers and psychostimulants are the major ones used for suicidal overdose. Specific substances identified by medical examiners as most frequently used in cases of suicidal overdose are alcohol-in-combination, amitriptyline, d-propoxyphene, secobarbital and pentobarbital.

Accidental or unexpected overdose occurs in 30% of the cases of drug-induced deaths. Alcohol-in-combination, heroin/morphine, codeine, d-propoxyphene, diazepam, and methadone account for 52.3% of all drug mentions associated with deaths from accidental/unexpected overdoses.

VIII. Ranking of Top 20 Drugs for the DAWN SMSAs

Tables 2.15 and 2.16 display the ranking by frequency of mention of the top 20 drugs as reported by DAWN emergency rooms and medical examiners within the 26 SMSAs. Since the ranking of each drug is based on the number of times it was mentioned in connection with an abuse episode, its rank order is an indication of the relative importance of that drug within that SMSA. Differences in ranks across SMSAs may be trivial or significant depending on the absolute number of drug mentions. Slight differences in rankings of the drugs across the SMSAs should not be emphasized while large differences in the rank ordering of the drugs may suggest a variation that is in fact significant.

Methaqualone mentions demonstrate the tentative nature of inter-SMSA comparisons. In San Francisco (County), Washington, D.C., and Detroit methaqualone was ranked 11.5, 16, and 25.5, respectively (Table 2.15). However, in San Francisco, 63 methaqualone mentions were recorded as opposed to 62 in Washington, D.C. and 61 in Detroit. Within SMSA differences in rank tend to have greater face validity. For example, in Miami, methaqualone was ranked second (905 mentions) and phenobarbital was ranked eleventh (160 mentions).

TABLE 2.1

TOTAL DAWN SYSTEM
MENTIONS OF SELECTED LEADING DRUGS OF ABUSE
EMERGENCY ROOMS AND MEDICAL EXAMINERS
DAWN ANNUAL REPORT - JANUARY-DECEMBER 1979

Therapeutic Class and Drug Category	Commonly Encountered Brand and Generic Name Drugs	ER Mentions #	ER Mentions %	ME Mentions #	ME Mentions %
TRANQUILIZERS		38,457	20.8	876	12.1
Diazepam	VaTium	18,557	10.0	346	4.8
Chlordiazepoxide	Librium, Libritabs, SK Lygen	2,869	1.5	49	0.7
Chlorpromazine	Thorazine, Chlor-PZ, Promapar, Largactil	2,170	1.2	46	0.6
Thioridazine	Mellaril	1,840	1.0	66	0.9
Meprobamate	Equanil, Miltown, SK-Bamate, Kesso-Bamate	863	0.5	61	0.8
Clorazepate	Tranxene, Azene	1,736	0.9	7	0.1
Oxazepam	Serax	476	0.3	7	0.1
All Other Tranquilizers	. . .	9,946	5.4	294	4.1
BARBITURATE SEDATIVES		9,393	5.1	1,114	15.4
Secobarbital	SeconaT, Quinalbarbitone	1,589	0.9	256	3.5
Secobarbital/Amobarbital	Tuinal	2,516	1.4	211	2.9
Phenobarbital	Luminal, Barbita, Stental	2,799	1.5	249	3.4
Pentobarbital	Nembutal, Nebralin	564	0.3	203	2.8
Amobarbital	Amytal	222	0.1	109	1.5
Butabarbital	Butisol, Butazem, Butex, Soduben, Buticaps	179	0.1	15	0.2
All Other Barbiturate Sedatives	. . .	1,524	0.8	71	1.0
NON-BARBITURATE SEDATIVES		14,780	8.0	476	6.6
Flurazepam	DaTmane, Dalmadorm	4,666	2.5	105	1.5
Methaqualone	Quaalude, Sopor, Parest, Optimil, Somnafac	3,270	1.8	87	1.2
Glutethimide	Doriden	495	0.3	55	0.8
Ethchlorvynol	Placidyl	1,965	1.1	157	2.2
Over-The-Counter Sleep Aids	Sominex, Sleep-eze	2,260	1.2	5	0.1
All Other Non-Barb Sedatives	. . .	2,124	1.1	67	0.9
ALCOHOL-IN-COMBINATION		25,032	13.5	993	13.7
NARCOTIC ANALGESICS		13,525	7.3	1,445	20.0
Heroin/Morphine	. . .	6,822	3.7	619	8.6
Methadone	Dolophine, Amidone	2,415	1.3	353	5.0
Codeine	. . .	1,197	0.6	250	3.5
Meperidine HCl	Demerol, Pethidine	729	0.4	27	0.4
Hydromorphone	Dilaudid	485	0.3	20	0.3
Oxycodone	Percodan, Percocet-5, Tylox	1,226	0.7	5	0.1
All Other Narcotic Analgesics	. . .	651	0.4	161	2.2
NON-NARCOTIC ANALGESICS		17,921	9.7	659	9.1
Aspirin	. . .	6,682	3.6	120	1.7
d-Propoxyphene	Darvon, Dolene, SK-65, S-Pain-65	3,585	1.9	379	5.2
Pentazocine	Talwin, Fortral	1,640	0.9	29	0.4
Acetaminophen	Tylenol, Tempra, Datril, Capital	3,296	1.8	105	1.5
All Other Non-Narcotic Analgesics	. . .	2,718	1.5	26	0.4
AMPHETAMINES		3,726	2.0	60	0.8
Amphetamine	Benzedrine	1,996	1.1	32	0.4
d-Amphetamine	Dexedrine, Diphylets	203	0.1	-	-
Methamphetamine	Methedrine, Desoxyn	197	0.1	24	0.3
Speed	. . .	1,221	0.7	-	-
All Other Amphetamines	. . .	109	0.1	4	0.1
COCAINE		2,846	1.5	141	1.9
PSYCHOSTIMULANTS		7,647	4.1	623	8.6
Methylphenidate	RiTaTin	456	0.2	7	0.1
Amitriptyline	Elavil, Endep	3,297	1.8	407	5.6
Amitriptyline Combinations	Etrafon, Triavil, Limbitrol	1,842	1.0	3	*
All Other Psychostimulants	. . .	2,052	1.1	206	2.8
CANNABIS		5,369	2.9	23	0.3
Marijuana	. . .	4,555	2.5	20	0.3
Hashish	. . .	814	0.4	3	*
HALLUCINOGENS		8,379	4.5	119	1.6
LSD	. . .	1,828	1.0	1	*
PCP/PCP Combinations	. . .	6,002	3.2	117	1.6
All Other Hallucinogens	. . .	549	0.3	1	*
ANTICONVULSANTS/ANTINAUSEANTS		3,066	1.7	61	0.8
Hydantoin	DiTantin, Ekko	2,466	1.3	47	0.6
All Other Anticonvul/Antinaus	. . .	600	0.3	14	0.2
CODEINE COMBINATIONS		2,842	1.5	9	0.1
INHALANTS/SOLVENTS/AEROSOLS		743	0.4	55	0.8
ALL OTHER DRUGS		19,692	10.6	560	7.7
DRUG UNKNOWN		11,852	6.4	23	0.3
Total Drug Mentions		185,270	100	7,237	100
Total Drug Episodes		117,949		3,626	

NOTE: Percentages will not necessarily sum to 100.0 due to rounding and/or omission of values of less than 0.05%.

. . . Brand and/or generic name not applicable

*Less than 0.05%

- Denotes zero (0) drug mentions

TABLE 2.2

TOTAL DAWN SYSTEM
SEX, RACE, AND AGE COMPARISONS
ASSOCIATED WITH 1979 DAWN EMERGENCY ROOM AND MEDICAL EXAMINER EPISODES
1979 U.S. CENSUS AND 1977 NATIONAL DEATH RATE

	DAWN Emergency Room Episodes[a] %	1979 U.S. Census %	DAWN Medical Examiner Episodes[a] %	1977 National Death Rate[b] %
Sex				
Male	44.7	48.7	56.8	55.1
Female	55.3	51.3	43.2	44.9
Total	100	100	100	100
Race				
White	69.2	86.3	75.9	87.6
Black	26.2	11.8	19.7	12.1
Other	4.6	1.9	4.4	0.3
Total	100	100	100	100
Age[c]				
6 - 9	0.1	6.7	*	0.3
10 - 19	22.1	19.3	5.0	1.5
20 - 29	43.1	19.4	38.2	2.7
30 - 39	20.1	15.0	23.6	2.5
40 - 49	8.4	11.3	13.2	4.9
50 & Over	6.2	28.4	19.9	88.1
Total	100	100	100	100

NOTE: Percentages will not necessarily sum to 100.0 due to rounding and/or omission of values of less than 0.05%.

SOURCE: Census data obtained from U.S. Bureau of the Census, Current Population Reports, Series P-25, No. 870, "Estimates of the Population of the United States, by Age, Sex and Race: 1976 to 1979" U.S. Government Printing Office, Washington, D.C., 1980. Mortality data computed from 1977 mortality statistics and 1979 census estimates; mortality statistics collected by U.S. National Center for Health Statistics and reported in: Monthly Vital Statistics Report (Advance Report), Final Mortality Statistics, 1977, Vol. 28, No. 1, Supplement, May 11, 1979.

[a]Unknown/no response categories have been excluded from percentage calculations for DAWN data to permit meaningful comparisons with U.S. Census data and National Death Rate data.

[b]Deaths due to all causes.

[c]Distributions have been adjusted to reflect omission of data for cases/patients five years of age and under which are not collected in DAWN (see Introduction: Definitions of Drug Abuse).

*Less than 0.05%.

TABLE 2.3

TOTAL DAWN SYSTEM
AGE, RACE, AND SEX CHARACTERISTICS
ASSOCIATED WITH
1979 DAWN EMERGENCY ROOM EPISODES

	Total		Male		Female		Sex Not Reported	
	#	%	#	%	#	%	#	%
Total	117,949	100	52,633	100	65,104	100	212	100
6 - 9	147	0.1	86	0.2	60	0.1	1	0.5
10 - 19	25,810	21.9	10,300	19.6	15,455	23.7	55	25.9
20 - 29	50,324	42.7	24,854	47.2	25,403	39.0	67	31.6
30 - 39	23,478	19.9	10,715	20.4	12,723	19.5	40	18.9
40 - 49	9,811	8.3	3,554	6.8	6,240	9.6	17	8.0
50 & Over	7,293	6.2	2,542	4.8	4,743	7.3	8	3.8
Unknown/No Response	1,086	0.9	582	1.1	480	0.7	24	11.3
White	72,186	100	31,325	100	40,777	100	84	100
6 - 9	86	0.1	51	0.2	34	0.1	1	1.2
10 - 19	16,479	22.8	6,746	21.5	9,708	23.8	25	29.8
20 - 29	29,542	40.9	14,597	46.6	14,921	36.6	24	28.6
30 - 39	13,804	19.1	5,893	18.8	7,896	19.4	15	17.9
40 - 49	6,393	8.9	2,045	6.5	4,338	10.6	10	11.9
50 & Over	5,388	7.5	1,740	5.6	3,643	8.9	5	6.0
Unknown/No Response	494	0.7	253	0.8	237	0.6	4	4.8
Black	27,319	100	13,352	100	13,935	100	32	100
6 - 9	36	0.1	21	0.2	15	0.1	-	-
10 - 19	4,983	18.2	1,883	14.1	3,094	22.2	6	18.8
20 - 29	13,135	48.1	6,539	49.0	6,586	47.3	10	31.3
30 - 39	6,046	22.1	3,275	24.5	2,760	19.8	11	34.4
40 - 49	1,986	7.3	1,018	7.6	964	6.9	4	12.5
50 & Over	864	3.2	456	3.4	407	2.9	1	3.1
Unknown/No Response	269	1.0	160	1.2	109	0.8	-	-
Other	4,836	100	2,343	100	2,481	100	12	100
6 - 9	8	0.2	3	0.1	5	0.2	-	-
10 - 19	1,159	24.0	450	19.2	707	28.5	2	16.7
20 - 29	2,169	44.9	1,152	49.2	1,012	40.8	5	41.7
30 - 39	950	19.6	496	21.2	453	18.3	1	8.3
40 - 49	355	7.3	156	6.7	196	7.9	3	25.0
50 & Over	142	2.9	62	2.6	80	3.2	-	-
Unknown/No Response	53	1.1	24	1.0	28	1.1	1	8.3
Unknown/No Response	13,608	100	5,613	100	7,911	100	84	100
6 - 9	17	0.1	11	0.2	6	0.1	-	-
10 - 19	3,189	23.4	1,221	21.8	1,946	24.6	22	26.2
20 - 29	5,478	40.3	2.566	45.7	2,884	36.5	28	33.3
30 - 39	2,678	19.7	1,051	18.7	1,614	20.4	13	15.5
40 - 49	1,077	7.9	335	6.0	742	9.4	-	-
50 & Over	899	6.6	284	5.1	613	7.7	2	2.4
Unknown/No Response	270	2.0	145	2.6	106	1.3	19	22.6

NOTE: Percentages will not necessarily sum to 100.0 due to rounding and/or omission of values of less than 0.05%.

- Denotes zero (0) episodes

TABLE 2.4

TOTAL DAWN SYSTEM
AGE, RACE, AND SEX CHARACTERISTICS
ASSOCIATED WITH
1979 DAWN MEDICAL EXAMINER EPISODES

	Total		Male		Female	
	#	%	#	%	#	%
Total	3,626	100	2,060	100	1,566	100
6 - 9	1	*	-	-	1	0.1
10 - 19	182	5.0	109	5.3	73	4.7
20 - 29	1,382	38.1	947	46.0	435	27.8
30 - 39	855	23.6	513	24.9	342	21.8
40 - 49	478	13.2	233	11.3	245	15.6
50 & Over	722	19.9	256	12.4	466	29.8
Unknown/No Response	6	0.2	2	0.1	4	0.3
White	2,705	100	1,482	100	1,223	100
6 - 9	1	*	-	-	1	0.1
10 - 19	147	5.4	90	6.1	57	4.7
20 - 29	945	34.9	659	44.5	286	23.4
30 - 39	583	21.6	337	22.7	246	20.1
40 - 49	365	13.5	165	11.1	200	16.4
50 & Over	659	24.4	229	15.5	430	35.2
Unknown/No Response	5	0.2	2	0.1	3	0.2
Black	704	100	441	100	263	100
6 - 9	-	-	-	-	-	-
10 - 19	28	4.0	13	2.9	15	5.7
20 - 29	332	47.2	210	47.6	122	46.4
30 - 39	217	30.8	140	31.7	77	29.3
40 - 49	87	12.4	55	12.5	32	12.2
50 & Over	39	5.5	23	5.2	16	6.1
Unknown/No Response	1	0.1	-	-	1	0.4
Other	157	100	107	100	50	100
6 - 9	-	-	-	-	-	-
10 - 19	7	4.5	6	5.6	1	2.0
20 - 29	83	52.9	61	57.0	22	44.0
30 - 39	38	24.2	27	25.2	11	22.0
40 - 49	16	10.2	10	9.3	6	12.0
50 & Over	13	8.3	3	2.8	10	20.0
Unknown/No Response	-	-	-	-	-	-
Unknown/No Response	60	100	30	100	30	100
6 - 9	-	-	-	-	-	-
10 - 19	-	-	-	-	-	-
20 - 29	22	36.7	17	56.7	5	16.7
30 - 39	17	28.3	9	30.0	8	26.7
40 - 49	10	16.7	3	10.0	7	23.3
50 & Over	11	18.3	1	3.3	10	33.3
Unknown/No Response	-	-	-	-	-	-

NOTE: Percentages will not necessarily sum to 100.0 due to rounding and/or omission of values of less than 0.05%.

*Less than 0.05%

- Denotes zero (0) episodes

TABLE 2.5

TOTAL DAWN SYSTEM
AGE, RACE, SEX CHARACTERISTICS
ASSOCIATED WITH SPECIFIC MOTIVATION CITATIONS[a]
1979 DAWN EMERGENCY ROOM EPISODES

	Total Episodes	Total Motivation Citations	Psychic Effects	Dependence	Suicide Attempt/ Gesture	Other	Unknown/ No Response	Total
			Distribution of Citations					
	#	#	%	%	%	%	%	%
Sex								
Male	52,633	53,834	26.4	24.8	26.9	2.3	19.6	100
Female	65,104	65,902	17.7	11.0	50.5	2.5	18.4	100
Unk./No Resp.	212	215	14.4	20.0	36.7	4.7	24.2	100
Race								
White	72,186	73,121	20.9	13.5	44.9	2.3	18.4	100
Black	27,319	28,146	24.1	30.6	25.6	2.4	17.3	100
Other	4,836	4,936	21.2	18.8	41.4	1.9	16.7	100
Unk./No Resp.	13,608	13,748	20.5	9.1	41.6	2.9	26.0	100
Age								
6 - 9	147	148	15.5	0.7	23.0	25.0	35.8	100
10 - 19	25,810	26,083	29.4	6.0	41.4	2.5	20.7	100
20 - 29	50,324	51,268	23.1	20.5	35.8	2.1	18.4	100
30 - 39	23,478	23,968	16.7	23.1	40.9	1.9	17.3	100
40 - 49	9,811	9,990	13.7	17.8	48.2	2.5	17.8	100
50 & Over	7,293	7,398	11.2	14.5	49.9	4.4	20.0	100
Unk./No Resp.	1,086	1,096	17.7	13.4	28.1	2.0	38.8	100
Total	117,949	119,951	21.6	17.2	39.9	2.4	18.9	100

TABLE 2.6

TOTAL DAWN SYSTEM
AGE, RACE, SEX CHARACTERISTICS
ASSOCIATED WITH SPECIFIC SOURCE MENTIONS[b]
1979 DAWN EMERGENCY ROOM EPISODES

	Total Episodes	Total Source Mentions	Legal Rx	Forged Rx	Stolen	Street Buy	Over the Counter	Gift	Other	Unknown/ No Response	Total
			Distribution of Source Mentions								
	#	#	%	%	%	%	%	%	%	%	%
Sex											
Male	52,633	83,449	24.2	0.2	1.5	22.3	17.9	2.1	0.2	31.6	100
Female	65,104	101,912	37.4	0.1	2.0	8.5	18.7	2.1	0.1	31.0	100
Unk./No Resp.	212	306	25.2	-	2.9	12.4	18.3	0.7	-	40.5	100
Race											
White	72,186	116,440	35.0	0.1	1.9	12.4	13.6	2.0	0.2	29.7	100
Black	27,319	40,566	23.5	0.2	2.0	23.8	16.6	2.3	0.1	31.5	100
Other	4,836	7,285	27.3	0.1	2.6	18.5	20.5	2.2	0.2	28.7	100
Unk./No Resp.	13,608	21,376	28.4	0.1	0.9	8.7	19.3	2.2	0.2	40.2	100
Age											
6 - 9	147	174	28.2	-	19.0	2.9	16.7	2.3	3.4	27.6	100
10 - 19	25,810	38,493	20.4	0.1	5.6	14.8	19.7	4.0	0.3	35.1	100
20 - 29	50,324	78,284	27.7	0.2	1.0	19.2	17.4	1.9	0.2	32.6	100
30 - 39	23,478	38,397	37.2	0.2	0.6	13.3	18.2	1.4	0.1	29.0	100
40 - 49	9,811	16,620	46.1	0.1	0.6	6.3	20.3	1.4	0.1	25.2	100
50 & Over	7,293	12,122	53.8	*	0.4	2.5	19.0	0.7	0.1	23.5	100
Unk./No Resp.	1,086	1,577	23.2	-	0.3	11.7	14.0	2.4	0.2	48.2	100
Total	117,949	185,667	31.4	0.1	1.8	14.7	18.3	2.1	0.2	31.3	100

NOTE: Percentages may not necessarily sum to 100.0 due to rounding and/or omission of values of less than 0.05%.

[a]Number of motivation citations may exceed number of drug episodes given elsewhere in this report since multiple motivation citations are permissible for each drug episode. On the average, there were 1.02 motivations provided per drug episode.

[b]Number of source mentions may exceed number of drug mentions given elsewhere in this report since multiple source mentions are permissible for each drug mentioned. On the average, there were 1.57 sources provided per drug episode.

*Less than 0.05%

- Denotes zero (0) source mentions

TABLE 2.7

TOTAL DAWN SYSTEM
MOTIVATION CITATIONS[a]
ASSOCIATED WITH MENTIONS OF THE TOP TWENTY DRUGS
DAWN EMERGENCY ROOMS - JANUARY-DECEMBER 1979

Drug	Total Drug Mentions	Total Motivation Citations[a]	Psychic Effects	Dependence	Suicide Attempt/ Gesture	Other	Unk./ No Resp.	Total
	#	#	Distribution of Citations %					
Alcohol-in-Combination	25,032	25,658	25.7	19.9	36.3	2.1	16.1	100
Diazepam	18,557	18,838	16.4	13.2	51.6	1.6	17.2	100
Heroin/Morphine	6,822	7,138	14.1	73.7	3.3	0.7	8.1	100
Aspirin	6,682	6,727	11.8	1.3	67.9	3.4	15.6	100
PCP/PCP Combinations	6,002	6,081	54.1	10.0	4.0	1.3	30.6	100
Flurazepam	4,666	4,723	11.9	4.7	65.1	2.0	16.3	100
Marijuana	4,555	4,644	53.9	30.7	4.5	1.3	9.7	100
d-Propoxyphene	3,585	3,644	15.0	8.5	56.4	3.2	16.8	100
Amitriptyline	3,297	3,333	11.8	7.7	58.7	1.9	19.8	100
Acetaminophen	3,296	3,328	12.3	1.9	66.4	3.2	16.1	100
Methaqualone	3,270	3,318	38.3	17.7	28.0	1.5	14.5	100
Chlordiazepoxide	2,869	2,909	14.8	10.6	58.1	1.3	15.3	100
Cocaine	2,846	2,927	38.8	44.8	5.7	0.8	9.9	100
Phenobarbital	2,799	2,882	16.4	16.0	49.1	2.6	15.8	100
Secobarbital/Amobarbital	2,516	2,550	19.2	29.0	24.5	1.0	26.3	100
Hydantoin	2,466	2,571	17.7	28.7	37.3	3.2	13.1	100
Methadone	2,415	2,522	16.1	63.2	6.0	1.1	13.7	100
Over-the-Counter Sleep Aids	2,260	2,269	11.0	1.1	72.1	1.4	14.5	100
Chlorpromazine	2,170	2,186	14.4	21.1	46.7	2.3	15.5	100
Amphetamine	1,996	2,051	32.2	38.1	17.5	1.5	10.7	100

TABLE 2.8

TOTAL DAWN SYSTEM
SOURCE OF SUBSTANCE MENTIONS[b]
ASSOCIATED WITH MENTIONS OF THE TOP TWENTY DRUGS
DAWN EMERGENCY ROOMS - JANUARY-DECEMBER 1979

Drug	Total Drug Mentions	Total Source Mentions[b]	Legal Rx	Forged Rx	Stolen	Street Buy	Over the Counter	Gift	Other	Unk./ No Resp.	Total
	#	#	Distribution of Source Mentions %								
Alcohol-in-Combination	25,032	25,037	-	-	0.7	2.9	82.7	1.7	0.1	11.9	100
Diazepam	18,557	18,640	55.5	0.2	2.3	4.6	-	2.0	*	35.4	100
Heroin/Morphine	6,822	6,828	0.4	0.1	0.1	76.5	-	0.9	*	22.0	100
Aspirin	6,682	6,684	5.3	*	2.1	1.2	79.9	0.4	*	11.0	100
PCP/PCP Combinations	6,002	6,009	-	-	0.2	46.9	-	3.3	0.3	49.2	100
Flurazepam	4,666	4,671	63.2	0.1	1.9	1.2	-	1.2	0.1	32.3	100
Marijuana	4,555	4,558	-	-	0.2	70.5	-	6.9	0.2	22.2	100
d-Propoxyphene	3,585	3,593	58.9	0.2	3.2	1.6	-	1.7	0.1	34.3	100
Amitriptyline	3,297	3,309	62.9	0.2	2.5	2.5	-	1.2	0.1	30.6	100
Acetaminophen	3,296	3,296	9.6	-	2.4	1.5	67.3	0.5	0.1	18.7	100
Methaqualone	3,270	3,275	12.6	0.3	0.6	43.4	-	4.1	*	38.9	100
Chlordiazepoxide	2,869	2,873	64.2	0.2	1.7	1.3	-	1.8	0.1	30.6	100
Cocaine	2,846	2,849	-	-	0.2	72.6	-	2.0	0.1	25.1	100
Phenobarbital	2,799	2,811	65.3	0.5	2.9	2.2	-	1.3	0.1	27.7	100
Secobarbital/Amobarbital	2,516	2,523	18.3	0.2	1.0	27.1	-	1.3	0.1	52.1	100
Hydantoin	2,466	2,466	79.6	0.4	1.5	0.2	-	0.6	-	17.6	100
Methadone	2,415	2,447	48.9	0.3	0.8	24.4	-	0.9	1.1	23.5	100
Over-the-Counter Sleep Aids	2,260	2,262	2.6	-	0.6	1.9	85.1	0.3	-	9.5	100
Chlorpromazine	2,170	2,171	73.6	0.1	2.1	0.6	-	1.6	-	22.1	100
Amphetamine	1,996	2,005	8.7	0.2	0.3	55.0	-	4.1	0.1	31.6	100

NOTE: Percentages may not necessarily sum to 100.0 due to rounding and/or omission of values of less than 0.05%.

[a]Number of motivation citations may exceed number of drug mentions given elsewhere in this report since multiple motivation citations are permissible for each drug mentioned.

[b]Number of source mentions may exceed number of drug mentions given elsewhere in this report since multiple source mentions are permissible for each drug mentioned.

* Less than 0.05%

- Denotes zero (0) source mentions

TABLE 2.9

TOTAL DAWN SYSTEM
SEX AND RACE CHARACTERISTICS
ASSOCIATED WITH MENTIONS OF THE TOP TWENTY DRUGS
DAWN EMERGENCY ROOMS - JANUARY-DECEMBER 1979

Distribution of Mentions		Sex			Race				
Drug	Total Mentions #	Male %	Female %	Unknown/ No Response %	White %	Black %	Other %	Unknown/ No Response %	Total %
Alcohol-in-Combination	25,032	51.7	48.1	0.2	65.5	19.3	3.8	11.5	100
Diazepam	18,557	37.2	62.7	0.2	70.1	14.5	3.6	11.8	100
Heroin/Morphine	6,822	67.3	32.4	0.2	34.1	52.5	6.0	7.5	100
Aspirin	6,682	27.8	72.0	0.2	61.1	19.4	5.1	14.4	100
PCP/PCP Combinations	6,002	71.4	28.4	0.2	46.8	39.8	3.7	9.7	100
Flurazepam	4,666	30.0	69.8	0.2	71.8	10.8	3.5	14.0	100
Marijuana	4,555	68.3	31.6	0.1	50.4	35.3	5.2	9.1	100
d-Propoxyphene	3,585	31.3	68.5	0.3	65.5	18.8	4.0	11.7	100
Amitriptyline	3,297	30.2	69.6	0.2	71.1	14.0	3.7	11.3	100
Acetaminophen	3,296	26.8	73.1	0.1	59.1	23.9	3.8	13.2	100
Methaqualone	3,270	57.4	42.4	0.2	79.6	6.4	2.6	11.4	100
Chlordiazepoxide	2,869	36.4	63.5	0.1	70.0	15.2	2.6	12.2	100
Cocaine	2,846	66.8	33.0	0.2	43.1	40.4	5.5	10.9	100
Phenobarbital	2,799	41.4	58.4	0.1	65.0	22.2	2.9	9.9	100
Secobarbital/Amobarbital	2,516	51.3	48.4	0.3	71.7	13.6	3.9	10.8	100
Hydantoin	2,466	54.7	45.2	0.1	56.2	32.2	3.1	8.5	100
Methadone	2,415	65.7	34.1	0.2	55.9	26.5	7.6	10.0	100
Over-the-Counter Sleep Aids	2,260	33.8	66.1	0.1	67.8	13.5	3.8	14.9	100
Chlorpromazine	2,170	50.7	49.1	0.2	63.7	23.5	2.7	10.0	100
Amphetamine	1,996	58.1	41.7	0.2	72.3	18.3	2.0	7.4	100

TABLE 2.10

TOTAL DAWN SYSTEM
SEX AND RACE CHARACTERISTICS
ASSOCIATED WITH MENTIONS OF THE TOP TWENTY DRUGS
DAWN MEDICAL EXAMINERS - JANUARY-DECEMBER 1979

Distribution of Mentions		Sex		Race				
Drug	Total Mentions #	Male %	Female %	White %	Black %	Other %	Unknown/ No Response %	Total %
Alcohol-in-Combination	993	64.9	35.1	71.4	21.1	5.6	1.8	100
Heroin/Morphine	619	76.7	23.3	54.8	37.2	6.5	1.6	100
Amitriptyline	407	41.5	58.5	73.0	17.9	6.1	2.9	100
d-Propoxyphene	379	45.1	54.9	74.7	18.5	4.5	2.4	100
Methadone	363	73.0	27.0	64.2	22.6	12.1	1.1	100
Diazepam	346	59.5	40.5	84.1	12.1	2.3	1.4	100
Secobarbital	256	48.8	51.2	89.1	7.4	2.0	1.6	100
Codeine	250	48.0	52.0	74.4	22.0	3.6	-	100
Phenobarbital	249	44.6	55.4	80.3	16.5	2.4	0.8	100
Secobarbital/Amobarbital	211	54.5	45.5	84.4	11.4	3.3	0.9	100
Pentobarbital	203	46.3	53.7	90.6	3.9	3.9	1.5	100
Ethchlorvynol	157	54.1	45.9	86.0	10.8	3.2	-	100
Cocaine	141	68.1	31.9	80.1	17.0	2.1	0.7	100
Aspirin	120	40.0	60.0	77.5	18.3	1.7	2.5	100
PCP/PCP Combinations	117	82.9	17.1	55.6	40.2	4.3	-	100
Amobarbital	109	51.4	48.6	82.6	11.9	2.8	2.8	100
Flurazepam	105	44.8	55.2	88.6	5.7	4.8	1.0	100
Acetaminophen	105	49.5	50.5	81.0	16.2	1.9	1.0	100
Methaqualone	87	72.4	27.6	95.4	2.3	2.3	-	100
Thioridazine	66	45.5	54.5	81.8	16.7	1.5	-	100

NOTE: Percentages will not necessarily sum to 100.0 due to rounding and/or omission of values of less than 0.05%.

- Denotes zero (0) drug mentions

TABLE 2.11

TOTAL DAWN SYSTEM
AGE CHARACTERISTICS
ASSOCIATED WITH MENTIONS OF THE TOP TWENTY DRUGS
DAWN EMERGENCY ROOMS - JANUARY-DECEMBER 1979

Distribution of Mentions

Drug	Total Mentions #	6 - 9 %	10 - 19 %	20 - 29 %	30 - 39 %	40 - 49 %	50 & Over %	Unknown/ No Response %	Total %
Alcohol-in-Combination	25,032	*	17.0	39.9	22.9	11.7	7.7	0.8	100
Diazepam	18,557	*	15.0	40.2	23.9	11.6	8.6	0.7	100
Heroin/Morphine	6,822	*	4.0	59.1	28.2	6.0	1.5	1.2	100
Aspirin	6,682	0.2	40.8	32.9	15.0	5.8	4.8	0.5	100
PCP/PCP Combinations	6,002	*	34.3	53.4	8.9	1.5	0.4	1.4	100
Flurazepam	4,666	0.1	10.9	29.3	25.2	16.3	17.7	0.5	100
Marijuana	4,555	*	37.5	42.2	15.1	4.0	0.7	0.4	100
d-Propoxyphene	3,585	*	23.5	39.4	19.7	9.6	7.3	0.4	100
Amitriptyline	3,297	0.2	11.2	36.0	26.7	14.3	10.4	1.2	100
Acetaminophen	3,296	0.1	36.4	36.7	15.5	6.4	4.3	0.6	100
Methaqualone	3,270	*	29.3	56.4	11.4	1.4	0.9	0.5	100
Chlordiazepoxide	2,869	*	10.2	32.0	26.0	17.3	13.6	1.0	100
Cocaine	2,846	-	12.9	58.5	22.1	4.8	1.2	0.6	100
Phenobarbital	2,799	0.1	16.1	38.3	25.4	10.6	8.7	0.8	100
Secobarbital/Amobarbital	2,516	0.1	13.7	60.2	16.7	4.8	3.3	1.2	100
Hydantoin	2,466	0.4	11.7	33.3	28.0	15.0	10.9	0.6	100
Methadone	2,415	*	3.1	57.5	29.6	6.1	1.7	2.0	100
Over-the-Counter Sleep Aids	2,260	*	27.7	46.3	15.7	5.7	4.0	0.6	100
Chlorpromazine	2,170	*	11.9	42.4	24.0	13.1	8.2	0.4	100
Amphetamine	1,996	0.1	23.6	54.4	16.7	3.4	1.3	0.6	100

TABLE 2.12

TOTAL DAWN SYSTEM
AGE CHARACTERISTICS
ASSOCIATED WITH MENTIONS OF THE TOP TWENTY DRUGS
DAWN MEDICAL EXAMINERS - JANUARY-DECEMBER 1979

Distribution of Mentions

Drug	Total Mentions #	6 - 9 %	10 - 19 %	20 - 29 %	30 - 39 %	40 - 49 %	50 & Over %	Unknown/ No Response %	Total %
Alcohol-in-Combination	993	-	3.6	37.4	24.6	16.1	18.2	0.1	100
Heroin/Morphine	619	-	3.2	54.3	30.2	8.6	3.7	-	100
Amitriptyline	407	-	2.5	32.7	27.5	16.5	20.9	-	100
d-Propoxyphene	379	-	7.7	36.9	19.8	17.2	18.2	0.3	100
Methadone	363	-	2.5	60.3	27.8	6.3	3.0	-	100
Diazepam	346	-	3.5	42.8	28.3	10.7	14.7	-	100
Secobarbital	256	-	3.1	30.9	16.4	13.3	35.9	0.4	100
Codeine	250	-	2.8	31.2	28.4	20.4	16.8	0.4	100
Phenobarbital	249	-	3.6	27.3	24.9	16.1	28.1	-	100
Secobarbital/Amobarbital	211	-	4.3	43.6	24.6	10.9	15.6	0.9	100
Pentobarbital	203	-	2.0	24.1	14.3	11.3	48.3	-	100
Ethchlorvynol	157	-	5.7	36.9	29.3	11.5	16.6	-	100
Cocaine	141	-	7.1	58.2	27.0	5.7	1.4	0.7	100
Aspirin	120	0.8	5.0	20.0	22.5	16.7	35.0	-	100
PCP/PCP Combinations	117	-	12.0	65.8	14.5	5.1	2.6	-	100
Amobarbital	109	-	4.6	41.3	16.5	9.2	27.5	0.9	100
Flurazepam	105	-	2.9	23.8	11.4	21.0	41.0	-	100
Acetaminophen	105	-	3.8	38.1	14.3	18.1	25.7	-	100
Methaqualone	87	-	23.0	52.9	9.2	6.9	8.0	-	100
Thioridazine	66	-	-	24.2	30.3	22.7	22.7	-	100

NOTE: Percentages will not necessarily sum to 100.0 due to rounding and/or omission of values of less than 0.05%.

*Less than 0.05%

- Denotes zero (0) mentions

TABLE 2.13

TOTAL DAWN SYSTEM
DRUG-INDUCED AND DRUG-RELATED DEATHS
ASSOCIATED WITH SELECTED LEADING DRUGS
DAWN MEDICAL EXAMINER EPISODES AND MENTIONS
JANUARY-DECEMBER 1979

EPISODES	Total Cases	Total Drug-Induced[a] Deaths	Total Drug-Related[b] Deaths
Number of cases	3,626	2,985	641
Percent of total cases	100	82	18
Mentions per case	2.0	2.0	1.8

MENTIONS	Total Mentions #	Total Mentions %	Total Drug-Induced Mentions #	Total Drug-Induced Mentions %	Total Drug-Related Mentions #	Total Drug-Related Mentions %
TRANQUILIZERS	876	100	749	86	127	14
Diazepam	346	100	282	82	64	18
Chlordiazepoxide	49	100	45	92	4	8
Chlorpromazine	46	100	40	87	6	13
Thioridazine	66	100	57	86	9	14
Meprobamate	61	100	53	87	8	13
Clorazepate	7	100	4	57	3	43
Oxazepam	7	100	3	43	4	57
All Other Tranquilizers	294	100	265	90	29	10
BARBITURATE SEDATIVES	1,114	100	941	84	173	16
Secobarbital	256	100	228	89	28	11
Secobarbital/Amobarbital	211	100	186	88	25	12
Phenobarbital	249	100	185	74	64	26
Pentobarbital	203	100	182	90	21	10
Amobarbital	109	100	89	82	20	18
Butabarbital	15	100	12	80	3	20
All Other Barbiturate Sedatives	71	100	59	83	12	17
NON-BARBITURATE SEDATIVES	476	100	392	82	84	18
Flurazepam	105	100	92	88	13	12
Methaqualone	87	100	41	47	46	53
Glutethimide	55	100	53	96	2	4
Ethchlorvynol	157	100	138	88	19	12
Over-The-Counter Sleep Aids	5	100	4	80	1	20
All Other Non-Barb Sedatives	67	100	64	96	3	4
ALCOHOL-IN-COMBINATION	993	100	803	81	190	19
NARCOTIC ANALGESICS	1,445	100	1,228	85	217	15
Heroin/Morphine	619	100	535	86	84	14
Methadone	363	100	296	82	67	18
Codeine	250	100	217	87	33	13
Meperidine HCl	27	100	23	85	4	15
Hydromorphone	20	100	20	100	-	-
Oxycodone	5	100	3	60	2	40
All Other Narcotic Analgesics	161	100	134	83	27	17
NON-NARCOTIC ANALGESICS	659	100	598	91	61	9
Aspirin	120	100	102	85	18	15
d-Propoxyphene	379	100	353	93	26	7
Pentazocine	29	100	24	83	5	17
Acetaminophen	105	100	96	91	9	9
All Other Non-Narcotic Analgesics	26	100	23	88	3	12
AMPHETAMINES	60	100	40	67	20	33
Amphetamine	32	100	20	63	12	38
d-Amphetamine	-	-	-	-	-	-
Methamphetamine	24	100	16	67	8	33
Speed	-	-	-	-	-	-
All Other Amphetamines	4	100	4	100	-	-
COCAINE	141	100	106	75	35	25
PSYCHOSTIMULANTS	623	100	563	90	60	10
Methylphenidate	7	100	5	71	2	29
Amitriptyline	407	100	360	88	47	12
Amitriptyline Combinations	3	100	3	100	-	-
All Other Psychostimulants	206	100	195	95	11	5
CANNABIS	23	100	4	17	19	83
Marijuana	20	100	3	15	17	85
Hashish	3	100	1	33	2	67
HALLUCINOGENS	119	100	62	52	57	48
LSD	1	100	1	100	-	-
PCP/PCP Combinations	117	100	60	51	57	49
All Other Hallucinogens	1	100	1	100	-	-
ANTICONVULSANTS/ANTINAUSEANTS	61	100	48	79	13	21
Hydantoin	47	100	36	77	11	23
All Other Anticonvul/Antinaus	14	100	12	86	2	14
CODEINE COMBINATIONS	9	100	8	89	1	11
INHALANTS/SOLVENTS/AEROSOLS	55	100	35	64	20	36
ALL OTHER DRUGS	560	100	476	85	84	15
DRUG UNKNOWN	23	100	13	57	10	43
Total Drug Mentions	7,237	100	6,066	84	1,171	16

NOTE: Percentages will not necessarily sum to 100 due to rounding and/or omission of values of less than 0.5%.

[a]Death caused by a drug "overdose" where a toxic level is found or suspected, or a death caused by a drug reaction such as an immune reaction.

[b]Death in which a drug(s) is present and is a contributory factor, but not the sole cause of death.

*Less than 0.5%

- Denotes zero (0) drug mentions

TABLE 2.14

TOTAL DAWN SYSTEM
MANNER OF DRUG-INDUCED DEATHS
ASSOCIATED WITH SELECTED LEADING DRUGS
DAWN MEDICAL EXAMINER EPISODES AND MENTIONS
JANUARY-DECEMBER 1979

	Total Drug-Induced		Accidental/ Unexpected Overdose		Suicidal Overdose		Overdose Reason Unknown		Drug Reaction/ Hypersensitivity/ Unexpected Effect	
EPISODES										
Number of cases	2,985		898		1,274		799		14	
Percent of drug-induced cases	100		30		43		27		*	
Mentions per case	2.0		2.1		1.8		2.2		1.9	
MENTIONS	#	%	#	%	#	%	#	%	#	%
TRANQUILIZERS	749	100	191	26	395	53	159	21	4	1
Diazepam	282	100	106	38	109	39	66	23	1	*
Chlordiazepoxide	45	100	12	27	26	58	6	13	1	2
Chlorpromazine	40	100	8	20	22	55	10	25	-	-
Thioridazine	57	100	13	23	31	54	11	19	2	4
Meprobamate	53	100	17	32	31	58	5	9	-	-
Clorazepate	4	100	-	-	4	100	-	-	-	-
Oxazepam	3	100	-	-	3	100	-	-	-	-
All Other Tranquilizers	265	100	35	13	169	64	61	23	-	-
BARBITURATE SEDATIVES	941	100	226	24	539	57	175	18	1	*
Secobarbital	228	100	53	23	150	66	25	11	-	-
Secobarbital/Amobarbital	186	100	39	21	94	51	53	28	-	-
Phenobarbital	185	100	53	29	92	50	39	21	1	1
Pentobarbital	182	100	30	16	121	66	31	17	-	-
Amobarbital	89	100	28	31	49	55	12	13	-	-
Butabarbital	12	100	5	42	7	58	-	-	-	-
All Other Barbiturate Sedatives	59	100	18	31	26	44	15	25	-	-
NON-BARBITURATE SEDATIVES	392	100	105	27	219	56	68	17	-	-
Flurazepam	92	100	7	8	68	74	17	18	-	-
Methaqualone	41	100	13	32	18	44	10	24	-	-
Glutethimide	53	100	16	30	25	47	12	23	-	-
Ethchlorvynol	138	100	52	38	60	43	26	19	-	-
Over-The-Counter Sleep Aids	4	100	3	75	1	25	-	-	-	-
All Other Non-Barb Sedatives	64	100	14	22	47	73	3	5	-	-
ALCOHOL-IN-COMBINATION	803	100	238	36	277	34	234	29	4	*
NARCOTIC ANALGESICS	1,228	100	529	43	132	11	561	46	6	*
Heroin/Morphine	535	100	270	52	30	6	225	42	2	*
Methadone	296	100	100	34	17	6	178	60	1	*
Codeine	217	100	114	53	59	27	41	19	3	1
Meperidine HCl	23	100	11	48	4	17	8	35	-	-
Hydromorphone	20	100	15	75	2	10	3	15	-	-
Oxycodone	3	100	1	33	2	67	-	-	-	-
All Other Narcotic Analgesics	134	100	10	7	18	13	106	79	-	-
NON-NARCOTIC ANALGESICS	590	100	185	31	268	45	143	24	2	*
Aspirin	102	100	21	21	54	53	27	26	-	-
d-Propoxyphene	353	100	108	31	156	44	88	25	1	*
Pentazocine	24	100	10	42	8	33	5	21	1	4
Acetaminophen	96	100	41	43	35	36	20	21	-	-
All Other Non-Narcotic Analgesics	23	100	5	22	15	65	3	13	-	-
AMPHETAMINES	40	100	30	75	5	13	5	13	-	-
Amphetamine	20	100	15	75	2	10	3	15	-	-
d-Amphetamine	-	-	-	-	-	-	-	-	-	-
Methamphetamine	16	100	12	75	3	19	1	6	-	-
Speed	-	-	-	-	-	-	-	-	-	-
All Other Amphetamines	4	100	3	75	-	-	1	25	-	-
COCAINE	106	100	64	60	14	13	26	25	2	2
PSYCHOSTIMULANTS	563	100	92	16	320	57	149	26	2	*
Methylphenidate	5	100	2	40	2	40	1	20	-	-
Amitriptyline	360	100	60	17	176	49	123	34	1	*
Amitriptyline Combinations	3	100	-	-	3	100	-	-	-	-
All Other Psychostimulants	195	100	30	15	139	71	25	13	1	1
CANNABIS	4	100	2	50	2	50	-	-	-	-
Marijuana	3	100	2	67	1	33	-	-	-	-
Hashish	1	100	-	-	1	100	-	-	-	-
HALLUCINOGENS	62	100	46	74	4	6	12	19	-	-
LSD	1	100	1	100	-	-	-	-	-	-
PCP/PCP Combinations	60	100	44	73	4	7	12	20	-	-
All Other Hallucinogens	1	100	1	100	-	-	-	-	-	-
ANTICONVULSANTS/ANTINAUSEANTS	48	100	6	13	27	56	15	31	-	-
Hydantoin	36	100	5	14	16	44	15	42	-	-
All Other Anticonvul/Antinaus	12	100	1	8	11	92	-	-	-	-
CODEINE COMBINATIONS	8	100	2	25	5	63	1	13	-	-
INHALANTS/SOLVENTS/AEROSOLS	35	100	22	63	9	26	3	9	1	3
ALL OTHER DRUGS	476	100	108	23	129	27	236	50	3	1
DRUG UNKNOWN	13	100	3	23	4	31	4	31	2	15
Total Drug Mentions	6,066	100	1,899	31	2,349	39	1,791	30	27	*

NOTE: Percentages will not necessarily sum to 100 due to rounding and/or omission of values of less than 0.5%.

*Less than 0.5%

- Denotes zero (0) drug mentions

TABLE 2.15

RANK OF THE TOP TWENTY DRUGS OF ABUSE FROM EMERGENCY ROOMS
BY SMSA AND TOTAL DAWN SYSTEM
DAWN ANNUAL REPORT - JANUARY-DECEMBER 1979

	Total Drug Mentions	Total Drug Episodes	Alcohol-in-Combination	Diazepam	Heroin/Morphine	Aspirin	PCP/PCP Combinations	Pluranepam	Marijuana	d-Propoxyphene	Amitriptyline	Acetaminophen	Methaqualone	Chlordiazepoxide	Cocaine	Phenobarbital	Secobarbital/Amobarbital	Hydantoin	Methadone	Over-the-Counter Sleep Aids	Chlorpromazine	Amphetamine
Total DAWN System	185,270	117,949	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Atlanta	4,063	2,463	1	2	17.5	3	*	4	14	9.5	8	6	7	12	13	5	*	9.5	*	11	*	*
Baltimore**	3,748	2,352	1	2	3	6	5	12	4	7	8	14	10	12	12	15	*	17.5	16	20	*	*
Boston	7,450	4,333	1	2	3	4	*	6	11	5	8	15	18	9	10	12	*	7	16	14	19	*
Buffalo	4,539	2,829	1	2	*	4	3	7.5	5	6	11	10	*	9	*	14	*	*	*	19	12	*
Chicago	11,042	7,093	1	2	3	5	4	7	11	14	20	8	*	13	15	12	*	10	18	19	*	*
Cleveland	4,444	2,848	1	2	20	3	4	6	7	5	12	8	13	11	16	16	*	*	*	9	*	*
Dallas	2,817	1,879	2	1	*	3	*	4	20	7	5	6	17	11	*	9	*	12	*	10	*	14
Denver	5,106	3,267	1	2	18	3	*	5	15	6	14	4	17	12	13	8	*	11	*	7	*	*
Detroit	12,875	8,384	1	2	3	5	10	7	4	6	12.5	8	*	9	16	17	*	*	*	14	20.5[a]	*
Indianapolis	3,212	1,970	1	2	*	3	5	6	10.5	4	12	7	8	15	*	13.5	*	*	*	10.5	16	20.5[b]
Kansas City	3,149	1,914	1	2	*	3	13	4	17	6	5	7	15.5	8	23	11.5	*	20	*	9	18	19
Los Angeles	14,125	10,090	2	3	7	5	1	4	16	12	8	15	14	*	*	11	6	20.5[c]	*	17.5	17.5	*
Miami	10,235	6,486	1	3	10	9	7	8	4	*	18	*	2	*	5	11	13	6	12	*	15	*
Minneapolis	4,143	2,443	1	3	*	2	5	4	9	11	6	8	*	15	19	14	*	17	*	7	20.5[d]	13
New Orleans	3,387	2,206	5	1	3	7	4	14	15	11	16	12.5	8	10	18	12.5	*	*	9	*	20.5[e]	19
New York	30,326	19,163	1	2	3	13	8	17.5	5	*	14	*	10	20	7	19	6	12	4	*	11	9
Norfolk	1,429	952	2	1	*	3	*	6	*	5	7	4	12	9	19	10.5	*	15	*	8	16	*
Oklahoma City	1,529	968	2	1	*	4	6	3	*	10.5	8.5	10.5	17.5	7	*	12	*	13.5	*	16	20.5[f]	*
Philadelphia	10,999	7,244	2	1	19	4	10	3	11	5	12	15	6	9	*	16	13	*	*	*	17	8
Phoenix	4,653	2,743	1	2	6	3	11	4	*	5	10	7	17	13	19	9	*	19	*	8	*	16
St. Louis**	2,500	1,485	2	1	19	6	*	3	16.5	8	5	12	*	7	*	16.5	*	14	*	18	10	*
San Antonio	1,499	966	1.5	1.5	19.5	3	*	4.5	*	6	4.5	7	17	12	*	13	9.5	14	*	9.5	15.5	*
San Diego	4,990	3,011	1	2	3	4.5	6	4.5	8	9	7	13	14	10.5	17	10.5	*	19	*	15	20	18
San Francisco County	3,236	2,179	2	3	1	9.5	5	6	8	*	*	*	11.5	16.5	7	19	15	*	*	*	18	11.5
Seattle	4,486	2,562	1	2	15.5	3	17	4	12	11	9	6.5	*	8	18	6.5	*	*	*	5	*	*
Washington, D.C.	5,480	3,529	1	2	3	4	6	7	8	10	13	5	16	9	12	15	*	18	*	11	*	*
National Panel	19,808	12,570																				

NOTE: Ranks are based on numbers of mentions of drugs excluding Drug Unknown within SMSA.

*Below top 20 drugs

**See Introduction

[a] In the Detroit SMSA thioridazine and chlorpromazine each had 102 mentions and a rank of 20.5.

[b] In the Indianapolis SMSA meprobamate and amphetamine each had 26 mentions and a rank of 20.5.

[c] In the Los Angeles SMSA hydantoin and ethchlorvynol each had 128 mentions and a rank of 20.5.

[d] In the Minneapolis SMSA clorazepate and chlorpromazine each had 35 mentions and a rank of 20.5.

[e] In the New Orleans SMSA secobarbital and chlorpromazine each had 45 mentions and a rank of 20.5.

[f] In the Oklahoma City SMSA chlorpromazine and secobarbital each had 16 mentions and a rank of 20.5.

TABLE 2.16

RANK OF THE TOP TWENTY DRUGS OF ABUSE FROM MEDICAL EXAMINERS
BY SMSA AND TOTAL DAWN SYSTEM
DAWN ANNUAL REPORT - JANUARY-DECEMBER 1979

	Total Drug Mentions	Total Drug Episodes	Alcohol-in-Combination	Heroin/Morphine	Amitriptyline	d-Propoxyphene	Methadone	Diazepam	Secobarbital	Codeine	Phenobarbital	Secobarbital/Amobarbital	Pentobarbital	Ethchlorvynol	Cocaine	Aspirin	PCP/PCP Combinations	Amobarbital	Flurazepam	Acetaminophen	Methaqualone	Thioridazine
			1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17.5	17.5	19	20
Total DAWN System	7,237	3,626																				
Atlanta	58	37	1	3	8.5	3	18	8.5	8.5	18[a]	8.5	18	8.5	8.5	8.5	8.5	18	18	-	18	3	18
Baltimore**	128	81	6	1	3	4	2	6	13	20[a]	6	-	13	8.5	20[d]	-	20[a]	13	-	13	20[a]	20[a]
Boston	119	81	1	4	3	2	-	6.5	8	10.5	9	16.5	6.5	-	12.5	10.5	-	12.5	16.5	16.5	-	-
Buffalo	41	35	-	11.5	2	1	11.5	3.5	-	3.5	6	-	6	-	11.5	11.5	11.5	11.5	-	11.5	-	6
Chicago	481	214	1	2	8	5	4	3	10	6.5	9	*	13	6.5	18.5	18.5	11	12	15	18.5	*	15
Cleveland	169	73	1	14.5	8.5	3	*	2	8.5	14.5	8.5	*	11	5.5	*	5.5	18.5	8.5	*	4	*	14.5
Dallas	129	82	4	6	1	2	-	6	8.5	8.5	16.5	-	11.5	6	*	11.5	-	*	3	*	11.5	16.5
Denver	109	47	1	-	10.5	3	12.5	4	5.5	8	5.5	-	8	-	2	10.5	-	12.5	19	8	19	19
Detroit	415	187	1	2	5	4	13	3	11	6.5	11	-	9	8	20.5[b]	11	*	18	14	6.5	-	20.5[b]
Indianapolis	42	23	12	-	5.5	1	-	2	5.5	12	-	12	12	3	12	-	-	12	5.5	12	-	-
Kansas City	41	23	4	4	1.5	1.5	12.5	-	-	6.5	12.5	-	12.5	-	6.5	-	4	-	12.5	12.5	-	-
Los Angeles	1,350	742	1	3	6	10	13	12	7	2	4	5	8	11	16.5	16.5	9	14[d]	*	18.5	18.5	20.5[c]
Miami	387	174	1	-	14	8.5	14	2	10	-	14	6	11.5	5	4	8.5	17	20[d]	17	11.5	3	*
Minneapolis	75	42	1	15.5	2.5	4	7	2.5	15.5	7	7	15.5	15.5	15.5	15.5	15.5	-	-	7	-	-	-
New Orleans	34	23	2.5	1	6	6	6	-	-	6	-	6	-	-	-	11	11	-	-	-	-	-
New York	1,784	781	1	3	4	6	2	7	8	18	10	5	9	18	11	12	14	15	13	18	20	*
Norfolk	39	19	2	9.5	-	1	9.5	4	-	9.5	9.5	9.5	-	9.5	-	-	-	-	3	-	-	5
Oklahoma City	5	3	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Philadelphia	269	117	1	3	4.5	2	7.5	9.5	6	12	16	19.5	*	11	*	19.5	13.5	9.5	16	19.5	13.5	16
Phoenix	78	56	1.5	3.5	3.5	1.5	7.5	10.5	10.5	15.5	10.5	-	5.5	-	10.5	7.5	-	-	5.5	15.5	15.5	-
St. Louis**	101	58	2	19	2	11.5	19	7	7	2	19	11.5	19	11.5	4	11.5	-	15	11.5	11.5	-	-
San Antonio	57	31	1	14.5	4.5	3	14.5	14.5	7	14.5	14.5	7	-	14.5	-	14.5	4.5	-	-	-	-	2
San Diego	267	143	1	2	3	4.5	15	4.5	7.5	6	7.5	13	9	13	11	*	*	20[e]	20[e]	13	*	20[e]
San Francisco County	593	302	1	2	8	6	12.5	4	7	9	5	11	3	18.5	15.5	18.5	*	12.5	10	15.5	*	*
Seattle	92	60	1	16.5	16.5	5	-	7.5	2	16.5	3	-	7[f,5]	-	7.5	4[f]	-	11	11	11	-	16.5
Washington, D.C.	242	116	2	1	5.5	3	16.5	13	8.5	5.5	8.5	-	23[f]	13	8.5	23[f]	11	13	8.5	16.5	-	23[f]
National Panel***	132	76																				

NOTE: Ranks are based on numbers of mentions of drugs excluding Drug Unknown within SMSA.

*Below top 20 drugs

**See Introduction

***See page 3, no. 3

[a]In the Baltimore SMSA thioridazine, amphetamine, cocaine, methaqualone, codeine, PCP/PCP combinations and marijuana each had 1 mention and a rank of 20.

[b]In the Detroit SMSA cocaine and thioridazine each had 4 mentions and a rank of 20.5.

[c]In the Los Angeles SMSA glutethimide and thioridazine each had 11 mentions and a rank of 20.5.

[d]In the Miami SMSA oxycodone, amobarbital and clorazepate each had 4 mentions and a rank of 20.

[e]In the San Diego SMSA thioridazine, amobarbital, methamphetamine, flurazepam and pentazocine each had 2 mentions and a rank of 20.

[f]In the Washington, D.C. SMSA aspirin, pentobarbital, meprobamate, meperidine HCl, glutethimide, thioridazine and chlordiazepoxide each had 1 mention and a rank of 23.

CHAPTER 3

DRUG PROFILES

Presented in this chapter is comprehensive information on 42 drugs and 12 therapeutic classes each profiled on a separate table. These 54 tables display the following data for emergency rooms: the number of mentions, proportion of alone usage mentions, drug rank and distribution of demographic variables by SMSA and the total DAWN system. The information included on drugs and drug classes reported by medical examiners is similar to that for emergency rooms but is displayed for the total DAWN system only. In addition, supplementary information concerning the pharmacological aspects of use is given for each drug and drug class profiled.

This material is presented in this way to offer the reader an overall view of the demographic characteristics of the individuals involved in the abuse episodes, to display the sources and other information pertinent to the drug itself, and to provide a display of these data across the 26 DAWN SMSAs.

The reader should note that since only one mention can logically be reported for each drug, mentions and episodes are equal in number when the basis of comparison is the drug. When, however, the basis of comparison is the drug user, numbers of mentions will generally exceed numbers of episodes since each user may take, and hence mention, more than one drug. Furthermore, when sources and motivations are provided the numbers of source and motivation citations may also exceed the number of episodes: a user may have obtained a drug through more than one channel or have taken a drug for more than one reason.

It has been noted earlier in the introduction that the response rate for the large majority of the data cells on the DAWN reporting forms is quite satisfactory. On the succeeding profiles the reader will be aware, however, there are others (motivation and source of substance) for which the proportion "unknown/no response" is high. This does not represent a lack of responsiveness, training or unwillingness on the part of personnel in participating facilities to report fully on all data cells. It is rather indicative of one or many of a set of circumstances peculiar to individual hospitals such as:

1. As a matter of policy some hospitals do not ask questions regarding source and form of substance.

2. The attending physician did not supply data on his report relative to each cell on the DAWN form though he may have questioned patient and elicited a response. Consequently DAWN, which depends on a review of emergency room admission records, cannot capture the unrecorded elements of data.

3. Patient refused to supply information which would be carried in the hospital record containing data on the episode.

4. As a matter of state, city or county policy certain elements of data may not be collected.

5. In a few cases, data are collected by the hospital, but the administration refuses to divulge these data to any outside source, etc.

6. The data because of any of the above reasons 1-5 do not appear on any hospital record.

However, since the inclusion of missing data in the percentaging base of the tables throughout this report is a mandatory specification of the report format, it is important that the reader be aware of the potential distortion of determinate categories' percentages (i.e., percentage of responses in categories such as psychic effects or overdose) in tables where the "unknown/no response" factor is significant. Interpretation of these data must always be tempered by recognition of the proportion of unknowns (missing data) and the ways the findings could be affected.

THERAPEUTIC CLASS ASSIGNMENTS USED IN DAWN

TC #	Therapeutic Class
01	Antacids without Antispasmodic Action
02	Antacids with Antispasmodic Action
03	Antidiarrheals, Intestinal Adsorbents
04	Antispasmodics, Anticholinergics
05	Bile Therapy
06	Laxatives
07	Ataractics, Tranquilizers — Tranquilizers
08	Oral Muscle Relaxants —
09	Surgical Muscle Relaxants
10	Hospital Solutions
11	Psychostimulants
12	A. Amphetamine Preparations B. Cocaine
13	All Other Antiobesity Preparations
14	Antihistamines
15	Bronchial Dilators
16	Cough Preparations
17	Cough, Cold Preparations
18	Oral Cold Preparations
19	Topical Nasal, Ophthalmic Decongestants
20	Diagnostic Aids
21	Broad, Medium Spectrum Antibiotics
22	Penicillin
23	Streptomycin, DHS, Combinations
24	Sulfonamides
25	Antibiotic-Sulfonamides
26	Penicillin-DHS Combinations
27	Other Topical Antibiotics
28	Urinary Antibacterials, Antiseptics
29	Solvents/Volatile Materials/Aerosols
30	Codeine Combinations
31	Amebicides, Trichomonacides
32	Antimalarials
33	Anthelmintics
34	Tuberculosis Preparations
35	A. Cannabis B. Drug Unknown
36	Topical Contraceptives
37	Vaginal Cleansers
38	General Antibacterials, Antiseptics
39	Hallucinogens
40	Narcotic Analgesics
41	Non-Narcotic Analgesics
42	Antiarthritics
43	Anesthetics, General Inhalants
44	Anesthetics, General Injectables
45	Anesthetics, Local Topical
46	Barbiturate Sedatives
47	Non-Barbiturate Sedatives
48	Anticonvulsants
49	Antinauseants
50	Corticoids, ACTH
51	Corticoids, Plain
52	Corticoids, Analgesic Combinations
53	Corticoids, Anti-Infective Combinations
54	Corticoids, Other Combinations
55	Thyroid Preparations
56	Antithyroid Preparations
57	Iodine Therapy
58	Diabetic Therapy
59	Anabolic Agents
60	Androgens
61	Estrogens
62	Androgen-Estrogen Combinations
63	Progestogen-Estrogen Combinations
64	Other Hormones
65	Lipotropics
66	Cholesterol Reducers
67	Digestants
68	Protein Lysates
69	Hyaluronidase
70	Rauwolfias
71	Other Hypotensives
72	Vasodilators, Coronary
73	Vasodilators, Peripheral
74	Digitalis Preparations
75	Xanthine Derivatives
76	Other Cardiovascular Preparations
77	Anticoagulants
78	Hemostatics
79	Diuretics
80	Pediatric Vitamins
81	Prenatal Vitamins
82	Other Multivitamins
83	Geriatric Vitamins
84	Vitamin B Complex with Vitamin C
85	Other Vitamins
86	Infant Formulas
87	Electrolytes, Miscellaneous Nutrients
88	Hematinics with/without Iron
89	Allergens
90	Biologicals
91	Antipruritics
92	Coal Tar, Sulfur, Resorcinol Preparations
93	Emollients, Protectives
94	Fungicides
95	All Other Dermatologicals
96	Hemorrhoidal Preparations
97	Oxytocics, Parasympathetic Agents
98	Miscellaneous
99	Miscellaneous

NOTE: The data on the underlined TC classes are given in this report.

TABLE 3.01 THERAPEUTIC CLASS - TRANQUILIZERS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	38,457	808	857	1,751	1,093	1,931	952	749	1,017	2,564	632	771	2,587	1,868	740
Alone (%)	38	34	41	32	39	40	39	43	40	35	37	38	41	41	29
Rank in TDS/SMSA	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Source (%)															
Legal RX	61	66	59	46	53	54	57	49	69	66	49	54	46	82	77
Forged RX	+	-	+	1	+	+	-	-	+	+	-	-	+	-	-
Stolen	2	2	3	2	2	1	3	2	1	2	3	2	2	2	3
Street buy	3	+	10	5	3	2	1	+	+	2	1	4	+	2	1
Over-the-counter	+	-	-	-	-	+	+	+	+	+	+	+	+	+	-
Gift	2	2	2	2	2	2	2	2	1	3	3	4	2	4	2
Other	+	-	-	+	-	-	+	+	-	+	+	+	-	-	-
Unk./No resp.	32	30	26	45	40	41	36	47	28	27	45	38	51	10	17
Motivation (%)															
Psychic effects	17	20	27	13	15	14	16	29	12	16	23	14	12	44	13
Dependence	12	5	12	13	8	8	3	3	4	12	3	4	3	8	4
Suic.att./gest.	54	55	49	55	59	48	56	56	74	56	52	61	56	43	72
Unknow./Unwill.	+	-	+	+	-	-	+	-	-	-	-	-	+	-	-
Other	2	3	3	3	4	3	3	2	2	2	3	2	1	1	1
Unk./No resp.	17	19	13	18	16	30	24	11	8	17	20	20	28	4	9
Age (%) DAWN Grouping															
6-9	+	+	+	+	-	+	-	+	-	-	+	-	-	+	-
10-19	14	16	21	15	18	19	17	17	11	13	17	17	11	13	14
20-29	40	34	42	46	35	39	37	40	40	41	38	41	37	43	45
30-39	24	27	20	22	25	24	22	26	27	26	21	21	27	23	21
40-49	12	15	10	9	13	10	14	9	12	11	14	12	14	12	11
50 & Over	9	8	7	7	9	7	10	6	9	7	8	8	11	8	8
Unk./No resp.	1	1	+	1	+	1	1	1	1	1	+	1	1	+	1
Age (%) CODAP Grouping															
6-9	+	+	+	+	-	+	-	+	-	-	+	-	-	+	-
10-17	8	11	12	7	9	11	9	12	6	7	12	11	6	7	6
18-20	10	8	11	11	11	11	11	10	8	10	9	10	7	8	11
21-25	21	17	24	25	19	20	21	22	18	21	19	22	19	21	25
26-30	19	16	18	21	16	19	16	17	22	20	18	18	19	22	20
31-44	27	33	23	25	28	26	28	28	31	29	27	25	31	28	24
45 & Over	14	13	11	10	15	11	14	11	14	12	14	13	17	13	12
Unk./No resp.	1	1	+	1	+	1	1	1	1	1	+	1	1	+	1
Race (%)															
White	69	71	70	84	74	59	64	79	45	61	80	67	64	59	73
Black	16	16	27	8	15	22	22	14	4	26	12	13	14	22	2
Other	3	+	+	1	1	6	+	5	7	+	+	1	4	6	1
Unk./No resp.	12	13	3	7	9	12	14	3	44	13	8	19	18	14	23
Sex (%)															
Male	38	33	42	43	38	37	33	30	34	34	33	32	34	41	34
Female	62	67	58	57	62	63	67	70	66	66	67	68	66	59	66
Unk./No resp.	+	-	-	+	+	+	+	-	+	+	-	+	+	+	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

876

Rank in TDS

3

Concomitance	N	%
Alone	165	19
In Comb.	711	81

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	395	45	38	4
Accid./Unexp.	195	22	66	8
Unk./No resp.	159	18	23	3

Age	N	%		N	%
6-9	-	-	40-49	141	16
10-19	24	3	50 & Over	194	22
20-29	286	33	Unk./No resp.	-	-
30-39	231	26			

Race	N	%
White	729	83
Black	111	13
Other	21	2
Unk./No resp.	15	2

Sex	N	%
Male	465	53
Female	411	47

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.01 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	38,457	759	5,667	384	381	2,530	965	638	343	1,051	611	998	1,039	4,771
Alone (%)	38	56	36	42	39	43	29	36	36	31	34	29	36	41
Rank in TDS/SMSA	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Source (%)														
Legal RX	61	64	64	77	50	50	70	62	70	69	66	55	54	69
Forged RX	+	3	+	-	-	+	+	1	+	+	+	+	-	+
Stolen	2	2	3	3	1	1	5	4	3	3	+	2	3	2
Street buy	3	7	7	+	+	2	7	1	2	3	7	2	1	1
Over-the-counter	+	-	+	+	+	+	+	+	-	-	-	+	+	+
Gift	2	5	1	1	3	3	4	5	2	4	3	2	1	1
Other	+	-	+	-	-	+	+	-	-	-	+	+	+	+
Unk./No resp.	32	21	25	20	45	43	15	27	22	22	24	40	40	27
Motivation (%)														
Psychic effects	17	44	8	17	11	18	19	17	8	15	14	14	13	15
Dependence	12	7	47	1	2	5	11	9	1	7	4	7	9	3
Suic.att./gest.	54	41	34	64	59	48	60	51	67	58	74	68	69	64
Unknow./Unwill.	+	-	+	-	-	+	-	-	-	+	+	+	+	+
Other	2	2	1	2	2	2	2	2	1	5	3	3	1	2
Unk./No resp.	17	8	11	16	26	29	10	22	24	17	7	10	9	17
Age (%) DAWN Grouping														
6-9	+	-	+	-	+	+	-	+	-	-	-	+	-	+
10-19	14	18	11	15	21	17	14	21	16	12	5	14	15	16
20-29	40	45	43	39	41	40	37	37	41	39	49	38	36	38
30-39	24	20	25	27	22	21	25	21	19	25	29	24	23	23
40-49	12	10	11	11	9	12	13	14	16	12	8	14	15	13
50 & Over	9	6	9	8	6	9	12	6	6	11	8	10	10	9
Unk./No resp.	1	+	1	1	1	1	+	+	2	1	1	1	1	+
Age (%) CODAP Grouping														
6-9	+	-	+	-	+	+	-	+	-	-	-	+	-	+
10-17	8	11	6	10	15	10	7	11	11	8	1	6	9	9
18-20	10	11	8	10	9	11	10	14	9	8	7	12	8	10
21-25	21	26	22	19	21	22	18	20	23	19	21	18	21	19
26-30	19	20	22	17	20	18	19	16	16	20	31	19	17	18
31-44	27	22	27	29	24	24	28	25	25	28	27	29	28	28
45 & Over	14	11	14	13	10	15	17	13	13	16	12	16	16	14
Unk./No resp.	1	+	1	1	1	1	+	+	2	1	1	1	1	+
Race (%)														
White	69	62	68	77	77	72	84	67	62	70	63	75	56	80
Black	16	33	19	22	6	19	4	19	9	9	15	9	32	8
Other	3	1	6	+	2	3	7	1	25	4	8	2	1	1
Unk./No resp.	12	4	7	1	15	6	5	13	5	17	15	14	12	11
Sex (%)														
Male	38	42	48	26	23	39	34	41	29	33	55	37	34	33
Female	62	57	52	74	77	60	66	59	70	67	45	63	66	67
Unk./No resp.	+	+	+	+	-	+	-	-	1	+	-	+	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

As classified in DAWN, tranquilizers are those drugs promoted primarily for anxiety neuroses and psychoses and/or products used for producing relaxation of skeletal muscles. Tranquilizers have a depressant effect on the central nervous system. They are usually classified both pharmacologically and chemically as "antipsychotic agents" or "antianxiety agents".

TABLE 3.011 - DIAZEPAM

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	18,557	322	462	1,130	602	1,021	482	394	471	1,288	251	348	1,447	767	243
Alone (%)	35	37	37	29	37	37	38	37	34	33	31	33	40	36	22
Rank in TDS/SMSA	2	2	2	2	2	2	2	1	2	2	2	2	3	3	3
Source (%)															
Legal RX	56	68	50	40	44	52	53	47	72	61	40	53	47	80	72
Forged RX	+	-	+	1	-	+	-	-	-	+	-	-	+	-	-
Stolen	2	3	4	2	2	1	3	1	-	3	4	2	1	2	2
Street buy	5	-	17	6	5	4	1	-	1	4	1	2	+	3	2
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	2	2	3	2	2	2	2	1	1	3	4	3	1	2	2
Other	+	-	-	+	-	-	-	-	-	+	-	+	-	-	-
Unk./No resp.	36	27	27	49	47	41	40	51	26	30	53	40	50	14	21
Motivation (%)															
Psychic effects	17	18	32	13	16	17	15	31	15	17	25	13	13	36	19
Dependence	13	6	17	15	11	9	3	3	4	13	4	4	3	15	8
Suic.att./gest.	52	60	41	53	57	47	57	53	72	53	48	60	55	43	62
Unknow./Unwill.	+	-	+	+	-	-	+	-	-	-	-	-	+	-	-
Other	2	3	2	3	2	2	3	1	3	2	2	2	1	1	2
Unk./No resp.	17	17	13	18	16	28	24	11	7	17	23	21	28	5	10
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	+	-	-	-	-	-	+	-
10-19	15	16	22	16	19	20	16	17	11	15	20	17	10	12	14
20-29	40	33	44	49	36	38	36	40	37	42	39	41	36	44	40
30-39	24	25	19	21	23	23	23	27	28	24	20	20	27	23	17
40-49	12	17	7	8	13	11	14	10	14	11	15	13	15	11	11
50 & Over	9	8	7	6	7	7	11	6	10	7	6	8	12	9	6
Unk./No resp.	1	1	-	1	1	1	+	1	1	1	+	1	1	+	2
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	+	-	-	-	-	-	+	-
10-17	9	11	14	8	12	11	9	11	5	9	14	11	5	7	5
18-20	10	8	11	12	10	12	10	10	8	10	9	8	7	7	14
21-25	21	18	29	26	21	21	19	23	17	22	21	20	19	22	24
26-30	19	15	17	22	16	19	17	17	21	20	19	20	18	23	23
31-44	27	32	20	22	26	26	29	28	34	27	24	24	32	27	20
45 & Over	14	15	10	9	14	11	15	11	14	12	13	15	19	16	12
Unk./No resp.	1	1	-	1	1	1	+	1	1	1	+	1	1	+	2
Race (%)															
White	70	77	68	84	72	62	62	77	46	60	80	70	65	68	71
Black	14	13	30	7	16	20	20	16	4	24	14	12	14	13	1
Other	4	-	+	2	1	5	1	4	7	+	-	1	4	6	2
Unk./No resp.	12	10	2	7	10	12	17	3	42	15	7	17	17	14	26
Sex (%)															
Male	37	32	45	44	39	38	30	29	34	34	34	33	31	37	33
Female	63	68	55	56	61	62	70	71	65	66	66	67	69	63	67
Unk./No resp.	+	-	-	+	+	+	+	-	+	+	-	1	+	+	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

346

Rank in TDS

6

Concomitance	N	%
Alone	14	4
In Comb.	332	96

Cause/Manner of Death	Drug-Induced Deaths		Drug-Related Deaths	
	N	%	N	%
Suicide	109	32	17	5
Accid./Unexp.	107	31	34	10
Unk./No resp.	66	19	13	4

Age	N	%		N	%
6-9	-	-	40-49	37	11
10-19	12	3	50 & Over	51	15
20-29	148	43	Unk./No resp.	-	-
30-39	98	28			

Race	N	%
White	291	84
Black	42	12
Other	8	2
Unk./No resp.	5	1

Sex	N	%
Male	206	60
Female	140	40

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.011 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	18,557	328	2,906	166	174	1,112	389	271	167	472	301	374	554	2,115
Alone (%)	35	52	30	42	41	40	24	39	32	25	23	24	34	41
Rank in TDS/SMSA	2	1	2	1	1	1	2	1	1.5	2	3	2	2	2
Source (%)														
Legal RX	56	55	51	77	47	45	61	59	71	66	67	49	52	69
Forged RX	+	2	+	-	-	+	1	2	-	+	-	+	-	+
Stolen	2	1	3	4	1	1	6	6	3	2	-	1	3	2
Street buy	5	13	11	1	1	4	13	2	3	4	5	2	1	1
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	2	3	1	1	4	3	5	4	3	3	1	2	2	1
Other	+	-	-	-	-	+	+	-	-	-	-	-	+	-
Unk./No resp.	36	26	34	17	48	47	17	27	21	26	27	46	42	26
Motivation (%)														
Psychic effects	17	36	9	20	14	18	24	19	12	15	10	17	13	16
Dependence	13	13	41	2	4	7	14	10	1	9	5	9	9	4
Suic.att./gest.	52	42	35	60	55	45	53	50	64	61	80	66	68	63
Unknow./Unwill.	+	-	+	-	-	-	-	-	-	+	+	+	+	-
Other	2	2	+	2	1	2	1	1	1	3	2	2	2	1
Unk./No resp.	17	9	14	16	26	31	10	22	23	14	6	9	9	17
Age (%) DAWN Grouping														
6-9	+	-	+	-	-	+	-	+	-	-	-	-	-	+
10-19	15	18	11	17	24	20	15	20	18	11	5	14	18	15
20-29	40	49	42	37	38	40	35	39	39	39	52	37	32	38
30-39	24	19	26	26	25	21	26	24	18	24	26	23	25	25
40-49	12	9	11	11	10	11	11	10	16	13	7	14	14	12
50 & Over	9	5	9	8	2	7	13	6	7	12	10	10	11	9
Unk./No resp.	1	-	1	-	1	1	-	1	2	1	1	1	1	+
Age (%) CODAP Grouping														
6-9	+	-	+	-	-	+	-	+	-	-	-	-	-	+
10-17	9	11	6	10	15	12	8	8	12	7	2	6	11	10
18-20	10	11	9	13	13	11	10	15	9	6	8	11	8	10
21-25	21	26	21	22	18	23	17	20	21	20	21	19	18	19
26-30	19	23	21	13	17	17	20	18	19	22	33	19	15	18
31-44	27	19	27	29	26	24	29	26	22	28	23	28	29	29
45 & Over	14	9	14	14	9	12	17	11	14	17	13	16	17	14
Unk./No resp.	1	-	1	-	1	1	-	1	2	1	1	1	1	+
Race (%)														
White	70	70	67	74	76	75	83	71	57	70	65	75	58	82
Black	14	26	16	24	6	17	4	15	7	8	12	9	30	6
Other	4	1	8	-	2	3	8	1	31	3	8	3	+	1
Unk./No resp.	12	4	9	2	16	5	5	13	5	18	15	13	12	11
Sex (%)														
Male	37	43	46	28	26	39	37	40	32	32	49	37	34	32
Female	63	56	54	71	74	61	63	60	67	68	51	63	66	68
Unk./No resp.	+	1	+	1	-	+	-	-	1	+	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Diazepam, an antianxiety agent, is the most commonly employed psychotherapeutic agent of all drugs in the United States today. In general, it is well tolerated and has low toxicity. Side effects may be encountered particularly in emotionally unstable individuals. Along with chlordiazepoxide, it is considered the agent of choice in alcoholic psychotherapeutic rehabilitation.

Alcohol markedly increases the absorption of diazepam and severely increased motor impairment will be evidenced. Dryness of the mouth, gastric discomfort, nausea and gastrointestinal disturbances are often observed.

TABLE 3.012 - CHLORDIAZEPOXIDE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	2,869	63	70	140	91	163	73	42	74	236	46	67	127	88	41
Alone (%)	29	21	37	21	33	33	30	48	32	28	35	28	29	24	20
Rank in TDS/SMSA	12	12	12	9	9	13	11	11	12	9	15	8	22	22	15
Source (%)															
Legal RX	64	54	77	54	46	56	55	57	70	75	54	55	48	84	78
Forged RX	+	-	-	1	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	-	3	1	1	1	-	2	-	-	2	1	1	5	2
Street buy	1	-	4	4	1	2	-	-	-	-	-	1	1	1	-
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	2	2	1	2	1	2	3	-	1	2	7	-	-	5	5
Other	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unk./No resp.	31	44	16	39	51	39	42	40	28	22	37	42	51	6	15
Motivation (%)															
Psychic effects	15	8	34	13	10	9	15	24	18	14	22	10	15	42	15
Dependence	11	11	10	15	5	6	1	2	3	9	4	1	2	9	5
Suic.att./gest.	59	60	49	59	69	55	59	69	70	62	67	64	63	44	76
Unknow./Unwill.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	1	3	3	1	3	3	1	2	1	-	2	1	-	1	-
Unk./No resp.	16	19	10	15	13	31	23	2	9	17	9	22	20	3	5
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-19	10	8	7	7	15	15	10	19	5	6	13	10	9	15	2
20-29	32	32	37	28	25	34	33	24	32	36	35	42	31	24	44
30-39	26	29	14	31	35	22	21	29	23	31	26	22	27	28	32
40-49	17	19	26	21	10	17	19	14	19	17	17	16	14	15	5
50 & Over	14	6	16	12	14	10	16	14	20	8	9	7	19	18	12
Unk./No resp.	1	6	-	1	-	1	1	-	-	1	-	1	1	-	5
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-17	6	8	4	3	8	9	4	14	3	2	7	7	8	9	2
18-20	7	3	4	5	11	12	10	7	3	7	11	7	1	8	-
21-25	16	11	23	13	11	17	22	19	15	19	17	27	14	14	10
26-30	16	19	14	16	15	13	8	5	19	19	13	15	18	11	39
31-44	33	38	27	43	35	31	30	31	30	39	37	24	33	32	29
45 & Over	21	14	27	20	20	17	25	24	31	14	15	18	25	26	15
Unk./No resp.	1	6	-	1	-	1	1	-	-	1	-	1	1	-	5
Race (%)															
White	70	67	73	78	80	56	66	93	42	68	91	69	64	70	85
Black	15	17	24	11	10	24	15	2	7	23	7	7	13	15	-
Other	3	-	-	1	-	7	-	2	5	-	-	-	2	2	-
Unk./No resp.	12	16	3	11	10	13	19	2	46	9	2	24	20	13	15
Sex (%)															
Male	36	30	46	43	32	29	23	17	36	34	39	24	39	50	32
Female	64	70	54	57	68	71	77	83	64	66	61	76	61	50	68
Unk./No resp.	+	-	-	-	-	1	-	-	-	-	-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

49

Rank in TDS

23

Concomitance	N	%
Alone	3	6
In Comb.	46	94

Cause/Manner of Death	Drug-Induced Deaths		Drug-Related Deaths	
	N	%	N	%
Suicide	26	53	3	6
Accid./Unexp.	13	27	1	2
Unk./No resp.	6	12	-	-

Age	N	%		N	%
6-9	-	-	40-49	8	16
10-19	-	-	50 & Over	12	24
20-29	15	31	Unk./No resp.	-	-
30-39	14	29			

Race	N	%
White	38	78
Black	11	22
Other	-	-
Unk./No resp.	-	-

Sex	N	%
Male	27	55
Female	22	45

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.012 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	2,869	67	364	36	30	218	71	68	20	79	46	82	102	365
Alone (%)	29	61	24	39	27	36	28	25	30	28	28	15	24	33
Rank in TDS/SMSA	12	10	20	9	7	9	13	7	12	10.5	16.5	8	9	9
Source (%)														
Legal RX	64	76	68	75	40	54	73	60	70	72	76	50	62	73
Forged RX	+	7	+	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	1	4	3	-	1	3	4	-	4	-	2	1	1
Street buy	1	-	2	-	-	-	8	1	-	1	7	-	1	1
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	2	4	1	-	3	1	3	4	-	-	2	2	2	1
Other	+	-	+	-	-	+	-	-	-	-	-	-	-	-
Unk./No resp.	31	10	25	22	57	43	14	29	30	23	15	45	34	23
Motivation (%)														
Psychic effects	15	58	7	6	7	20	18	19	5	9	4	10	7	14
Dependence	11	1	40	-	3	4	13	12	-	6	9	6	10	4
Suic.att./gest.	59	33	43	89	53	52	62	47	70	62	85	73	75	64
Unknow./Unwill.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	1	-	+	-	-	2	-	1	-	4	-	4	1	2
Unk./No resp.	16	9	9	6	37	24	10	21	25	20	4	10	8	17
Age (%) DAWN Grouping														
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	+
10-19	10	12	8	8	7	12	13	22	15	14	2	6	7	12
20-29	32	40	32	33	33	33	27	34	40	20	43	33	28	30
30-39	26	27	26	36	20	23	27	16	20	29	30	24	25	24
40-49	17	12	17	8	23	17	18	22	15	15	13	23	24	18
50 & Over	14	9	16	14	13	14	15	4	10	19	11	13	16	15
Unk./No resp.	1	-	1	-	3	1	-	1	-	3	-	-	-	1
Age (%) CODAP Grouping														
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	+
10-17	6	9	6	6	3	8	6	16	10	10	-	-	3	6
18-20	7	6	6	3	3	6	7	9	10	5	2	7	7	10
21-25	16	25	17	25	27	17	14	15	25	6	9	12	15	15
26-30	16	13	13	14	10	16	14	18	10	13	37	23	14	14
31-44	33	33	32	33	37	30	35	25	35	35	35	30	32	32
45 & Over	21	13	24	19	17	21	24	16	10	28	17	27	29	23
Unk./No resp.	1	-	1	-	3	1	-	1	-	3	-	-	-	1
Race (%)														
White	70	57	64	81	73	73	76	63	75	68	63	83	60	80
Black	15	37	21	17	3	21	7	19	-	4	11	1	24	8
Other	3	1	7	3	-	2	6	1	15	5	9	4	1	1
Unk./No resp.	12	4	8	-	23	4	11	16	10	23	17	12	16	11
Sex (%)														
Male	36	49	45	25	13	33	24	50	10	38	65	40	31	35
Female	64	51	55	75	87	67	76	50	90	62	35	60	69	65
Unk./No resp.	+	-	-	-	-	+	-	-	-	-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Chlordiazepoxide is an antianxiety agent. It was the first of the benzodiazepines to be introduced in the 1960's and is widely used in antianxiety and neuroses therapy. It is more slowly absorbed than diazepam and has a shorter action time in the body. Withdrawal reactions, occasionally of a severe convulsive nature, may follow abrupt termination of drug usage by those who have developed a tolerance or dependence. Side effects of dryness of the mouth, dizziness, ataxia, headaches and confusion are frequently encountered.

TABLE 3.013 - CHLORPROMAZINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	2,170	32	21	83	81	77	39	16**	40	102	36	37	141	143	35
Alone (%)	48	44	57	46	49	44	49	44	45	46	58	41	59	44	40
Rank in TDS/SMSA	19	24	27	19	12	21	22.5	25	22.5	20.5	16	18	17.5	15	20.5
Source (%)															
Legal RX	74	75	81	63	83	69	87		60	75	64	51	41	93	89
Forged RX	+	-	-	1	-	-	-		-	-	-	-	-	-	-
Stolen	2	-	5	2	1	-	3		5	2	-	-	2	-	3
Street buy	1	-	-	1	-	-	-		-	1	3	-	-	2	-
Over-the-counter	-	-	-	-	-	-	-		-	-	-	-	-	-	-
Gift	2	-	-	-	-	1	3		-	3	6	3	2	3	-
Other	-	-	-	-	-	-	-		-	-	-	-	-	-	-
Unk./No resp.	22	25	14	33	16	30	8		35	20	28	46	55	2	9
Motivation (%)															
Psychic effects	15	22	33	8	7	10	13		20	12	22	11	12	62	9
Dependence	21	9	5	4	5	17	8		3	12	6	5	2	3	9
Suic.att./gest.	47	47	57	63	62	43	54		70	59	39	70	52	35	63
Unknow./Unwill.	+	-	-	-	-	-	-		-	-	-	-	-	-	-
Other	2	3	5	2	7	4	5		-	2	3	-	1	-	3
Unk./No resp.	16	25	5	23	20	30	21		10	18	31	16	33	1	17
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-		-	-	-	-	-	-	-
10-19	12	16	19	14	11	22	8		10	11	14	24	16	8	3
20-29	42	34	52	52	35	34	41		55	37	53	32	38	47	43
30-39	24	22	14	17	28	29	21		15	30	14	19	23	26	23
40-49	13	19	5	11	12	6	23		10	16	11	16	12	15	11
50 & Over	8	9	10	5	14	9	3		8	6	8	8	10	5	20
Unk./No resp.	+	-	-	1	-	-	5		3	-	-	-	1	-	-
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-		-	-	-	-	-	-	-
10-17	6	9	5	5	2	18	5		8	5	11	16	12	1	-
18-20	9	6	29	12	14	4	3		10	9	6	8	7	10	6
21-25	21	16	19	24	15	19	21		23	19	33	16	14	19	34
26-30	21	22	19	25	17	17	21		30	25	19	16	26	27	9
31-44	28	28	14	24	33	27	38		13	29	17	30	27	30	26
45 & Over	14	19	14	8	19	14	8		15	14	14	14	13	13	26
Unk./No resp.	+	-	-	1	-	-	5		3	-	-	-	1	-	-
Race (%)															
White	64	63	57	82	77	55	54		63	55	58	78	60	47	77
Black	24	22	38	7	21	26	36		3	38	31	-	20	36	3
Other	3	-	-	1	-	3	-		8	2	-	-	4	3	3
Unk./No resp.	10	16	5	10	2	17	10		28	5	11	22	16	13	17
Sex (%)															
Male	51	59	71	49	44	56	46		40	43	47	41	46	54	37
Female	49	41	29	51	54	44	54		60	57	53	59	53	46	63
Unk./No resp.	+	-	-	-	1	-	-		-	-	-	-	1	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions
46

Rank in TDS
25

Concomitance	N	%
Alone	16	35
In Comb.	30	65

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	22	48	3	7
Accid./Unexp.	8	17	1	2
Unk./No resp.	10	22	2	4

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	10	22	White	36	78	Male	27	59
10-19	2	4	50 & Over	12	26	Black	7	15	Female	19	41
20-29	11	24	Unk./No resp.	-	-	Other	2	4			
30-39	11	24				Unk./No resp.	1	2			

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.013 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	2,170	45	611	16**	16**	155	24	48	15**	47	45	34	40	191
Alone (%)	48	71	50	38	38	47	29	38	47	32	47	44	53	51
Rank in TDS/SMSA	19	20.5	11	16	20.5	17	32	10	15.5	20	18	25	21	15
Source (%)														
Legal RX	74	78	84			59	88	71		74	82	68	55	71
Forged RX	+	2	-			-	-	-		-	-	-	-	-
Stolen	2	2	2			3	4	2		4	-	-	8	3
Street buy	1	2	+			-	-	-		2	2	3	-	1
Over-the-counter	-	-	-			-	-	-		-	-	-	-	-
Gift	2	7	1			3	-	4		2	-	3	-	1
Other	-	-	-			-	-	-		-	-	-	-	-
Unk./No resp.	22	9	13			35	8	23		17	16	26	38	25
Motivation (%)														
Psychic effects	15	58	4			17	8	13		13	13	15	8	9
Dependence	21	2	62			1	8	8		4	4	3	20	3
Suic.att./gest.	47	38	28			52	71	46		51	73	62	60	65
Unknow./Unwill.	+	-	-			1	-	-		-	-	-	-	-
Other	2	-	1			2	4	2		4	2	6	3	5
Unk./No resp.	16	2	5			26	13	31		30	7	15	10	18
Age (%) DAWN Grouping														
6-9	+	-	+			-	-	-		-	-	-	-	-
10-19	12	16	8			14	13	19		13	4	6	13	15
20-29	42	42	44			41	29	38		38	44	38	50	40
30-39	24	22	26			19	25	23		30	42	35	13	21
40-49	13	16	14			14	13	15		9	7	12	15	14
50 & Over	8	4	8			11	21	6		11	2	9	5	9
Unk./No resp.	+	-	+			1	-	-		-	-	-	5	-
Age (%) CODAP Grouping														
6-9	+	-	+			-	-	-		-	-	-	-	-
10-17	6	11	4			6	8	10		9	-	-	8	10
18-20	9	4	8			12	4	10		6	4	6	5	9
21-25	21	31	21			23	8	21		19	24	18	33	26
26-30	21	18	22			14	25	23		23	24	24	25	13
31-44	28	20	31			25	25	23		28	42	38	20	27
45 & Over	14	16	13			19	29	13		15	4	15	5	15
Unk./No resp.	+	-	+			1	-	-		-	-	-	5	-
Race (%)														
White	64	36	67			64	83	63		66	56	68	45	68
Black	24	62	25			26	4	29		11	20	12	40	15
Other	3	-	3			3	4	-		4	7	3	-	3
Unk./No resp.	10	2	5			7	8	8		19	18	18	15	15
Sex (%)														
Male	51	47	57			48	54	54		49	58	50	48	45
Female	49	53	43			52	46	46		51	42	50	53	54
Unk./No resp.	+	-	-			-	-	-		-	-	-	-	1

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Chlorpromazine, a derivative of phenothiazine, is an antipsychotic agent used for the management of psychotic disorders. This agent is most likely to be used in the treatment of schizophrenic and psychotic individuals. Its principal pharmacological actions are psychotropic, sedative, and antiemetic. Like other phenothiazines, chlorpromazine is not known to cause psychic dependence and does not produce tolerance or addiction. Drowsiness, fatigue, lethargy and apathy are commonly encountered side effects. Drug-induced non-epileptic seizures have occurred in non-epileptic individuals. Chlorpromazine may be potentiated by alcohol and should not be used simultaneously with other central nervous system depressants.

TABLE 3.014 - THIORIDAZINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,840	41	36	52	49	55	54	26	46	102	33	51	134	82	40
Alone (%)	46	32	50	52	43	49	50	46	59	45	55	53	40	40	30
Rank in TDS/SMSA	23	19	21.5	22	17	26	16	18	19	20.5	17	10	19	24	17
Source (%)															
Legal RX	71	80	64	69	61	60	72	58	61	81	52	65	43	84	85
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	2	6	-	2	-	4	-	2	1	3	-	1	1	8
Street buy	+	-	3	-	-	-	-	-	-	-	-	2	-	1	-
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	1	-	-	2	4	2	2	-	2	1	-	-	2	4	-
Other	+	-	-	-	-	-	-	-	-	-	3	-	-	-	-
Unk./No resp.	25	17	28	29	33	38	22	42	35	17	42	33	54	10	8
Motivation (%)															
Psychic effects	14	24	8	23	8	7	20	27	9	15	21	12	10	49	15
Dependence	12	-	-	4	4	4	2	-	2	9	3	2	1	4	-
Suic.att./gest.	57	59	75	56	71	51	54	65	74	57	45	67	57	44	75
Unknow./Unwill.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	3	-	11	6	4	2	6	-	4	4	3	4	1	-	3
Unk./No resp.	15	20	6	17	14	40	19	8	13	17	30	18	30	4	8
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-19	15	29	33	4	20	16	22	4	20	15	15	27	9	11	8
20-29	41	44	36	56	33	40	30	62	41	41	45	27	39	49	40
30-39	23	5	14	29	24	18	30	23	35	24	15	25	31	20	28
40-49	11	7	17	4	14	7	15	-	2	13	15	8	12	11	13
50 & Over	9	12	-	6	8	15	2	12	2	8	9	12	7	10	13
Unk./No resp.	1	2	-	2	-	4	2	-	-	-	-	-	2	-	-
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-17	9	20	25	4	10	11	9	-	15	12	12	14	4	5	3
18-20	10	10	11	6	10	7	15	12	9	6	15	20	7	6	5
21-25	21	24	11	31	18	22	19	38	20	18	18	16	17	30	25
26-30	19	20	28	29	16	20	9	15	20	25	15	10	22	20	18
31-44	27	7	14	21	33	18	41	23	33	29	30	25	37	27	35
45 & Over	13	17	11	8	12	18	6	12	4	11	9	16	9	12	15
Unk./No resp.	1	2	-	2	-	4	2	-	-	-	-	-	2	-	-
Race (%)															
White	70	68	83	85	76	58	72	77	59	75	73	63	68	55	75
Black	17	22	17	8	14	18	22	19	-	16	9	10	17	30	5
Other	3	-	-	-	-	11	-	4	7	-	-	-	1	4	3
Unk./No resp.	10	10	-	8	10	13	6	-	35	9	18	27	13	11	18
Sex (%)															
Male	40	27	44	31	47	38	43	38	33	40	30	45	39	44	30
Female	60	73	56	69	53	62	56	62	67	60	70	55	60	56	70
Unk./No resp.	+	-	-	-	-	-	2	-	-	-	-	-	1	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

66

Rank in TDS

20

Concomitance	N	%
Alone	24	36
In Comb.	42	64

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	31	47	-	-
Accid./Unexp.	15	23	8	12
Unk./No resp.	11	17	1	2

Age	N	%		N	%
6-9	-	-	40-49	15	23
10-19	-	-	50 & Over	15	23
20-29	16	24	Unk./No resp.	-	-
30-39	20	30			

Race	N	%
White	54	82
Black	11	17
Other	1	2
Unk./No resp.	-	-

Sex	N	%
Male	30	45
Female	36	55

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.014 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,840	33	323	23	17**	150	45	31	15**	59	20	43	53	227
Alone (%)	46	76	52	52	41	47	38	26	53	41	40	28	47	43
Rank in TDS/SMSA	23	26	22	10.5	19	18	22	15	15.5	16	28	20	19	14
Source (%)														
Legal RX	71	91	80	83		63	87	81		75	80	65	66	74
Forged RX	-	-	-	-		-	-	-		-	-	-	-	-
Stolen	2	-	4	-		1	2	3		3	-	-	2	2
Street buy	+	-	2	-		-	-	-		2	-	-	-	-
Over-the-counter	-	-	-	-		-	-	-		-	-	-	-	-
Gift	1	3	1	-		2	-	-		2	10	-	-	1
Other	+	-	-	-		-	-	-		-	-	-	-	+
Unk./No resp.	25	6	14	17		33	11	16		19	10	35	32	22
Motivation (%)														
Psychic effects	14	58	4	4		12	2	23		12	-	7	15	17
Dependence	12	6	55	4		3	2	6		5	-	-	8	2
Suic.att./gest.	57	39	33	74		60	82	48		66	80	88	72	68
Unknow./Unwill.	-	-	-	-		-	-	-		-	-	-	-	-
Other	3	-	1	-		2	11	6		5	5	-	-	4
Unk./No resp.	15	-	8	17		26	2	16		12	15	5	6	11
Age (%) DAWN Grouping														
6-9	+	-	-	-		-	-	-		-	-	-	-	+
10-19	15	30	8	35		16	18	13		12	-	19	15	18
20-29	41	36	46	43		39	33	42		39	35	33	45	38
30-39	23	12	24	9		22	20	23		27	35	21	19	25
40-49	11	15	10	4		10	18	16		10	20	16	15	12
50 & Over	9	6	11	4		13	11	6		12	5	12	4	6
Unk./No resp.	1	-	+	4		1	-	-		-	5	-	2	+
Age (%) CODAP Grouping														
6-9	+	-	-	-		-	-	-		-	-	-	-	+
10-17	9	12	5	30		12	7	10		10	-	7	4	8
18-20	10	21	7	17		6	20	6		7	5	23	13	15
21-25	21	27	25	9		15	18	19		20	15	7	32	22
26-30	19	9	22	22		26	9	19		17	20	16	13	15
31-44	27	15	27	13		22	24	29		27	40	26	30	29
45 & Over	13	15	13	4		18	22	16		19	15	21	6	11
Unk./No resp.	1	-	+	4		1	-	-		-	5	-	2	+
Race (%)														
White	70	36	72	48		77	87	61		64	70	72	45	78
Black	17	61	20	52		17	2	26		15	5	16	38	10
Other	3	-	4	-		3	7	-		3	5	2	-	2
Unk./No resp.	10	3	5	-		4	4	13		17	20	9	17	10
Sex (%)														
Male	40	64	48	9		45	40	39		27	60	42	36	34
Female	60	36	52	91		54	60	61		73	40	58	64	66
Unk./No resp.	+	-	-	-		1	-	-		-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Thioridazine, a tranquilizer of the phenothiazine family, is effective in the management of manifestations of psychotic disorders. It is not considered to be addicting, and the euphoriant property that seems to be necessary for the development of psychological dependence is lacking. In common with other phenothiazines, thioridazine is contraindicated in severe central nervous system depression.

TABLE 3.015 - MEPROBAMATE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapo'is
No. of Mentions	863	16**	14**	31	12**	24	14**	34	26	32	26	25	58	32	23
Alone (%)	42	38	21	32	58	25	43	59	35	44	27	60	50	53	43
Rank in TDS/SMSA	31	28	33	30.5	33	32	34	13	24.5	34	20.5	21.5	28.5	33	24.5
Source (%)															
Legal RX	60			52		54		62	54	78	54	60	48	81	70
Forged RX	+			-		-		-	-	-	-	-	-	-	-
Stolen	3			10		-		-	8	-	-	-	-	3	9
Street buy	1			-		-		-	-	-	-	4	-	-	-
Over-the-counter	-			-		-		-	-	-	-	-	-	-	-
Gift	2			-		-		-	4	3	-	8	-	-	4
Other	+			-		-		-	-	-	-	-	-	-	-
Unk./No resp.	33			39		46		38	35	19	46	28	52	16	17
Motivation (%)															
Psychic effects	14			13		13		29	8	3	19	16	9	3	9
Dependence	7			10		25		-	4	9	8	4	3	6	13
Suic.att./gest.	60			58		50		56	77	72	46	56	55	81	78
Unknow./Unwill.	-			-		-		-	-	-	-	-	-	-	-
Other	2			6		4		3	8	-	4	-	2	-	-
Unk./No resp.	18			13		17		12	12	16	23	24	31	9	-
Age (%) DAWN Grouping															
6-9	+			-		-		-	-	-	-	-	-	-	-
10-19	12			13		13		26	15	9	4	4	7	13	26
20-29	32			26		33		32	38	28	31	40	24	25	26
30-39	23			23		25		26	15	41	31	16	24	16	22
40-49	15			13		8		3	8	9	23	24	28	16	13
50 & Over	17			26		21		12	23	13	12	16	17	31	13
Unk./No resp.	1			-		-		-	-	-	-	-	-	-	-
Age (%) CODAP Grouping															
6-9	+			-		-		-	-	-	-	-	-	-	-
10-17	8			3		4		21	12	3	4	-	5	9	26
18-20	6			13		13		12	8	6	8	8	2	3	-
21-25	17			10		4		18	23	22	8	20	9	16	17
26-30	15			13		29		12	15	6	19	24	17	9	9
31-44	28			26		25		24	15	44	31	20	33	22	30
45 & Over	24			35		25		15	27	19	31	28	34	41	17
Unk./No resp.	1			-		-		-	-	-	-	-	-	-	-
Race (%)															
White	81			97		54		91	38	81	92	76	69	78	87
Black	5			-		13		6	-	9	-	-	2	9	-
Other	2			-		17		3	8	-	-	-	2	9	-
Unk./No resp.	12			3		17		-	54	9	8	24	28	3	13
Sex (%)															
Male	24			16		38		18	31	38	23	20	19	31	22
Female	76			84		63		82	69	63	77	80	79	69	78
Unk./No resp.	+			-		-		-	-	-	-	-	2	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

61

Rank in TDS

21

Concomitance	N	%
Alone	14	23
In Comb.	47	77

Cause/Manner of Death

	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	31	51	1	2
Accid./Unexp.	17	28	7	11
Unk./No resp.	5	8	-	-

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	13	21	White	56	92	Male	22	36
10-19	1	2	50 & Over	28	46	Black	4	7	Female	39	64
20-29	9	15	Unk./No resp.	-	-	Other	1	2			
30-39	10	16				Unk./No resp.	-	-			

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.015 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	863	36	54	10**	20	57	30	6**	8**	39	7**	75	18**	136
Alone (%)	42	67	48	60	40	51	23	33	63	38	14	27	17	43
Rank in TDS/SMSA	31	24	33	19	15	35	31	34.5	23	23	36	10	31.5	22.5
Source (%)														
Legal RX	60	78	52		65	54	60			74		52		57
Forged RX	+	-	-		-	2	-			-		-		1
Stolen	3	3	9		5	-	3			5		3		3
Street buy	1	-	6		-	-	10			3		-		1
Over-the-counter	-	-	-		-	-	-			-		-		-
Gift	2	-	-		5	9	7			3		-		2
Other	+	-	-		-	-	-			-		-		1
Unk./No resp.	33	19	33		25	35	23			15		45		35
Motivation (%)														
Psychic effects	14	50	7		10	21	13			15		11		14
Dependence	7	3	11		-	5	17			13		13		4
Suic.att./gest.	60	36	69		60	53	53			54		65		61
Unknow./Unwill.	-	-	-		-	-	-			-		-		-
Other	2	-	2		5	2	7			3		3		1
Unk./No resp.	18	11	11		25	21	17			23		11		21
Age (%) DAWN Grouping														
6-9	+	-	-		5	-	-			-		-		-
10-19	12	3	17		15	12	7			8		7		13
20-29	32	53	28		40	42	30			26		43		26
30-39	23	11	26		15	19	27			36		23		23
40-49	15	8	9		-	14	13			21		15		19
50 & Over	17	25	19		25	9	23			10		13		18
Unk./No resp.	1	-	2		-	4	-			-		-		1
Age (%) CODAP Grouping														
6-9	+	-	-		5	-	-			-		-		-
10-17	8	-	9		10	11	3			5		5		7
18-20	6	3	11		5	7	7			5		3		6
21-25	17	25	15		15	21	13			10		23		17
26-30	15	28	15		25	16	20			15		21		10
31-44	23	14	24		15	25	30			49		25		32
45 & Over	24	31	24		25	18	27			15		23		26
Unk./No resp.	1	-	2		-	4	-			-		-		1
Race (%)														
White	81	89	80		95	82	90			90		80		88
Black	5	8	7		-	12	-			3		1		2
Other	2	3	2		-	2	3			-		1		-
Unk./No resp.	12	-	11		5	4	7			8		17		10
Sex (%)														
Male	24	25	28		10	26	20			26		20		23
Female	76	75	72		90	74	80			74		79		77
Unk./No resp.	+	-	-		-	-	-			-		1		-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Meprobamate is considered an antianxiety agent and muscle relaxant, which acts as a depressant on the central nervous system. Meprobamate shows similar effects to the barbiturates with respect to tolerance, physical dependence, psychic dependence, and ability to be potentiated by alcohol and other central nervous system depressants.

TABLE 3.016 - CLORAZEPATE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,736	33	46	25	46	128	55	28	86	158	25	43	53	138	35
Alone (%)	41	24	48	28	46	45	40	46	47	37	64	28	42	42	23
Rank in TDS/SMSA	25	23	17.5	34	18	17	14	16	9	12.5	22	14	30.5	16	20.5
Source (%)															
Legal RX	68	76	76	60	57	55	64	64	84	75	60	74	57	79	77
Forged RX	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	3	-	8	-	-	2	-	-	3	8	-	4	5	3
Street buy	1	-	-	-	2	1	-	-	-	-	-	-	-	-	-
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	2	-	-	-	2	3	-	4	-	4	4	5	2	1	-
Other	+	-	-	-	-	-	-	-	-	-	-	2	-	-	-
Unk./No resp.	27	21	24	32	39	41	35	32	16	20	28	21	38	15	20
Motivation (%)															
Psychic effects	14	24	13	8	13	13	9	21	5	12	16	12	4	29	6
Dependence	4	-	2	8	2	1	2	-	5	5	-	-	8	2	6
Suic.att./gest.	66	67	76	68	63	53	56	71	86	69	68	70	75	60	83
Unknow./Unwill.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	1	-	-	4	2	2	5	-	1	1	4	5	-	1	-
Unk./No resp.	16	9	9	16	22	32	27	7	3	15	16	14	15	8	6
Age (%) DAWN Grouping															
6-9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-19	12	12	7	12	13	16	15	11	9	9	20	12	6	17	9
20-29	37	27	30	40	24	37	31	39	31	39	40	42	25	35	43
30-39	29	52	46	32	39	24	25	36	35	34	20	28	32	22	37
40-49	14	9	11	16	20	13	15	7	20	13	12	9	25	17	6
50 & Over	7	-	7	-	4	9	15	7	5	5	8	9	13	9	3
Unk./No resp.	1	-	-	-	-	1	-	-	-	-	-	-	-	-	3
Age (%) CODAP Grouping															
6-9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-17	7	3	4	8	9	9	7	7	5	4	12	7	4	11	3
18-20	7	9	2	12	11	13	9	4	5	7	8	9	2	9	14
21-25	19	6	26	12	13	13	20	14	14	22	16	21	15	15	20
26-30	19	27	11	20	13	20	15	25	21	19	24	21	13	17	17
31-44	34	45	48	44	46	30	27	43	40	39	28	30	42	33	34
45 & Over	13	9	9	4	9	15	22	7	16	9	12	12	25	14	9
Unk./No resp.	1	-	-	-	-	1	-	-	-	-	-	-	-	-	3
Race (%)															
White	72	73	80	88	72	58	75	82	53	74	88	72	74	64	77
Black	11	3	13	4	11	21	13	7	3	18	4	12	4	7	3
Other	4	3	-	-	-	8	-	11	6	1	-	2	2	10	-
Unk./No resp.	13	21	7	8	17	13	13	-	37	8	8	14	21	18	20
Sex (%)															
Male	24	21	13	32	22	27	20	25	27	19	24	19	23	23	23
Female	75	79	87	68	78	73	80	75	73	81	76	81	77	77	77
Unk./No resp.	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

7**

Rank in TDS

34

Concomitance	N	%
Alone	-	-
In Comb.	7	100

Cause/Manner of Death

	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%		N	%
6-9			40-49		
10-19			50 & Over		
20-29			Unk./No resp.		
30-39					

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.016 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,736	29	92	18**	21	142	78	55	23	18**	8**	40	34	279
Alone (%)	41	41	48	44	43	51	24	47	48	33	25	25	38	42
Rank in TDS/SMSA	25	29	28	13.5	13.5	21	12	9	9.5	32	35	23	25	12
Source (%)														
Legal RX	68	72	62		67	49	73	67	78			63	68	72
Forged RX	+	3	-		-	-	-	-	4			-	-	-
Stolen	2	3	9		-	-	3	4	-			3	-	+
Street buy	1	-	3		-	1	3	-	4			-	-	-
Over-the-counter	-	-	-		-	-	-	-	-			-	-	-
Gift	2	3	1		5	3	4	4	-			-	-	1
Other	+	-	-		-	-	-	-	-			3	-	-
Unk./No resp.	27	21	25		29	48	18	27	22			33	32	27
Motivation (%)														
Psychic effects	14	28	17		5	21	14	11	-			8	15	13
Dependence	4	7	22		-	1	4	2	-			-	-	1
Suic.att./gest.	66	55	53		62	50	68	76	65			75	82	68
Unknow./Unwill.	-	-	-		-	-	-	-	-			-	-	-
Other	1	7	-		-	1	-	4	-			3	-	2
Unk./No resp.	16	3	9		33	29	15	9	35			15	3	17
Age (%) DAWN Grouping														
6-9	-	-	-		-	-	-	-	-			-	-	-
10-19	12	14	21		24	12	9	20	9			10	6	11
20-29	37	41	37		43	35	41	36	57			33	32	40
30-39	29	17	18		24	25	24	18	17			43	41	27
40-49	14	14	12		-	18	18	22	13			13	12	13
50 & Over	7	14	11		10	9	6	4	4			3	6	8
Unk./No resp.	1	-	1		-	2	1	-	-			-	3	1
Age (%) CODAP Grouping														
6-9	-	-	-		-	-	-	-	-			-	-	-
10-17	7	7	14		19	6	5	15	9			3	6	7
18-20	7	7	9		10	8	5	9	4			10	-	6
21-25	19	28	21		14	23	21	20	48			15	18	22
26-30	19	17	20		38	14	21	15	9			20	21	20
31-44	34	17	20		10	32	33	31	26			45	44	31
45 & Over	13	24	16		10	15	14	11	4			8	9	13
Unk./No resp.	1	-	1		-	2	1	-	-			-	3	1
Race (%)														
White	72	69	63		71	73	85	82	57			90	56	79
Black	11	24	17		-	17	-	5	30			3	32	6
Other	4	-	12		-	4	5	-	13			-	-	1
Unk./No resp.	13	7	8		29	7	10	13	-			8	12	14
Sex (%)														
Male	24	24	29		24	33	36	20	35			25	24	21
Female	75	76	71		76	67	64	80	65			75	76	79
Unk./No resp.	+	-	-		-	-	-	-	-			-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Clorazepate is a relatively new sedative - antianxiety agent that is more active than diazepam. It is chemically similar to chlordiazepoxide and diazepam, exerting a depressant action on the central nervous system. Tolerance effects, although less severe than those of the barbiturates, have been noted. Once tolerance has been established, psychological and physiological dependence may follow.

TABLE 3.017 - OXAZEPAM

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	476	12**	6**	21	13**	18**	11**	11**	6**	40	16**	11**	18**	11**	4**
Alone (%)	40	17	17	24	54	44	27	45	17	25	56	73	33	18	50
Rank in TDS/SMSA	37	32	38.5	35	32	33	36	31.5	36.5	31.5	28.5	30	34.5	38	38.5
Source (%)															
Legal RX	66			52						68					
Forged RX	+			-						-					
Stolen	2			5						3					
Street buy	1			-						-					
Over-the-counter	-			-						-					
Gift	1			-						3					
Other	-			-						-					
Unk./No resp.	31			43						28					
Motivation (%)															
Psychic effects	13			5						20					
Dependence	5			10						5					
Suic.att./gest.	66			62						70					
Unknow./Unwill.	-			-						-					
Other	1			-						-					
Unk./No resp.	16			24						13					
Age (%) DAWN Grouping															
6-9	+			5						-					
10-19	11			10						15					
20-29	39			43						25					
30-39	26			29						30					
40-49	13			-						10					
50 & Over	10			14						20					
Unk./No resp.	1			-						-					
Age (%) CODAP Grouping															
6-9	+			5						-					
10-17	7			-						13					
18-20	8			10						8					
21-25	24			29						15					
26-30	16			19						10					
31-44	30			24						33					
45 & Over	14			14						23					
Unk./No resp.	1			-						-					
Race (%)															
White	80			86						70					
Black	9			10						28					
Other	3			-						-					
Unk./No resp.	8			5						3					
Sex (%)															
Male	29			62						25					
Female	71			38						75					
Unk./No resp.	-			-						-					

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

7**

Rank in TDS

34

Concomitance	N	%
Alone	-	-
In Comb.	7	100

Cause/Manner of Death

	Drug-Induced Deaths		Drug-Related Deaths	
	N	%	N	%
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%		N	%
6-9			40-49		
10-19			50 & Over		
20-29			Unk./No resp.		
30-39					

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.017 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	476	6**	35	6**	5**	45	39	8**	7**	13**	3**	15**	15**	81
Alone (%)	40	67	40	33	80	53	46	13	57	31	33	40	40	40
Rank in TDS/SMSA	37	38.5	35	25	33.5	36	25	32	24	34	38	33	34	29
Source (%)														
Legal RX	66		69			51	90							72
Forged RX	+		-			-	-							-
Stolen	2		9			-	3							-
Street buy	1		6			-	-							-
Over-the-counter	-		-			-	-							-
Gift	1		-			2	-							1
Other	-		-			-	-							-
Unk./No resp.	31		20			47	8							27
Motivation (%)														
Psychic effects	13		6			24	18							14
Dependence	5		17			4	15							1
Suic.att./gest.	66		63			51	64							70
Unknow./Unwill.	-		-			-	-							-
Other	1		-			-	-							2
Unk./No resp.	16		14			22	8							14
Age (%) DAWN Grouping														
6-9	+		-			-	-							-
10-19	11		14			18	13							11
20-29	39		63			24	51							38
30-39	26		6			20	23							28
40-49	13		9			18	13							15
50 & Over	10		6			18	-							7
Unk./No resp.	1		3			2	-							-
Age (%) CODAP Grouping														
6-9	+		-			-	-							-
10-17	7		9			9	8							6
18-20	8		9			11	5							7
21-25	24		40			13	38							16
26-30	16		23			11	13							28
31-44	30		9			31	31							30
45 & Over	14		9			22	5							12
Unk./No resp.	1		3			2	-							-
Race (%)														
White	80		89			91	90							83
Black	9		9			4	5							10
Other	3		-			4	5							1
Unk./No resp.	8		3			-	-							6
Sex (%)														
Male	29		34			22	44							26
Female	71		66			78	56							74
Unk./No resp.	-		-			-	-							-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Oxazepam is a sedative - antianxiety agent, chemically similar to diazepam, that acts on the central nervous system. It is used medically in the control of anxiety, tension, agitation and in the treatment of alcohol withdrawal. Tolerance, psychic dependence and physiological dependence have been noted in cases of chronic oxazepam overdose. Alcohol, barbiturates and other central nervous system depressants may potentiate the effects of oxazepam.

TABLE 3.02 THERAPEUTIC CLASS - BARBITURATE SEDATIVES

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	9,393	160	162	301	209	348	164	109	164	421	122	92	1,007	509	125
Alone (%)	38	31	36	25	32	32	43	52	45	35	42	36	51	30	33
Rank in TDS/SMSA	5.	6	8	5	6	6	8	5	6	6	6	6	4	5	7
Source (%)															
Legal RX	38	60	49	37	41	49	42	39	48	49	35	42	24	59	69
Forged RX	+	-	1	+	-	+	-	-	-	-	-	-	-	-	-
Stolen	2	1	4	2	2	-	3	4	1	3	2	2	1	1	2
Street buy	17	4	10	10	9	6	15	2	5	10	3	8	2	22	4
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	2	2	2	2	2	2	5	2	1	2	6	4	2	1	4
Other	+	-	-	-	-	-	-	-	1	+	-	-	-	+	-
Unk./No resp.	41	33	34	50	46	43	35	53	45	35	53	43	71	17	21
Motivation (%)															
Psychic effects	19	17	25	13	14	29	20	29	15	13	31	18	11	45	13
Dependence	21	26	10	18	20	23	7	5	8	19	7	3	3	24	7
Suic.att./gest.	39	38	46	49	52	32	44	41	67	53	34	55	38	27	70
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	1	-	-	-	-
Other	2	4	2	3	3	2	5	5	2	1	5	3	2	1	2
Unk./No resp.	21	19	18	18	18	30	27	20	11	16	28	21	46	5	10
Age (%) DAWN Grouping															
6-9	+	-	1	-	-	-	-	-	-	+	1	-	+	-	-
10-19	15	20	22	11	15	17	24	25	13	16	25	32	10	11	17
20-29	48	28	38	49	45	44	48	47	52	44	36	33	47	48	38
30-39	20	26	20	19	19	22	7	16	18	21	22	15	23	23	22
40-49	8	14	9	10	11	9	8	6	10	10	5	8	11	8	14
50 & Over	8	12	10	11	8	7	12	7	6	8	10	10	7	9	9
Unk./No resp.	1	1	1	1	1	1	2	-	-	1	2	3	1	+	-
Age (%) CODAP Grouping															
6-9	+	-	1	-	-	-	-	-	-	+	1	-	+	-	-
10-17	8	13	14	7	7	9	15	14	8	7	16	16	4	7	11
18-20	12	10	11	9	11	14	13	13	10	16	11	18	11	8	11
21-25	27	16	22	26	27	24	26	30	25	19	20	21	24	27	19
26-30	21	13	20	20	19	16	18	16	26	22	16	11	22	22	15
31-44	22	32	19	23	25	23	11	18	21	23	22	18	27	24	27
45 & Over	11	16	13	14	10	13	15	9	11	11	11	12	12	13	16
Unk./No resp.	1	1	1	1	1	1	2	-	-	1	2	3	1	+	-
Race (%)															
White	70	68	80	87	69	54	68	71	48	65	88	66	57	70	67
Black	17	24	19	8	21	27	16	19	4	22	7	11	26	18	2
Other	3	1	-	+	1	5	-	3	9	-	-	1	4	2	1
Unk./No resp.	10	7	1	5	9	14	16	7	40	13	6	22	14	9	30
Sex (%)															
Male	47	53	45	50	37	56	40	33	40	37	48	42	35	53	40
Female	53	47	55	50	63	43	60	67	60	62	52	58	65	47	60
Unk./No resp.	+	-	-	-	-	+	1	-	1	+	-	-	+	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

1,114

Rank in TDS

2

Concomitance	N	%
Alone	325	29
In Comb.	789	71

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	539	48	46	4
Accid./Unexp.	227	20	106	10
Unk./No resp.	175	16	21	2

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	147	13	White	960	86	Male	536	48
10-19	39	4	50 & Over	349	31	Black	107	10	Female	578	52
20-29	353	32	Unk./No resp.	4	+	Other	32	3			
30-39	222	20				Unk./No resp.	15	1			

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.02 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	9,393	292	2,507	42	63	553	202	60	53	226	223	238	166	875
Alone (%)	38	27	37	60	52	45	39	32	38	33	40	33	42	37
Rank in TDS/SMSA	5	4	3	5	5	5	6	6	5	6	4	4	7	5
Source (%)														
Legal RX	38	30	24	62	37	33	49	52	55	45	46	35	40	59
Forged RX	+	9	+	-	2	+	-	-	-	+	-	-	-	-
Stolen	2	2	1	7	5	1	7	5	4	3	-	2	4	3
Street buy	17	39	36	-	8	9	20	7	19	11	20	6	5	4
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	2	4	+	5	8	2	8	5	-	2	+	2	1	2
Other	+	-	+	-	-	-	+	2	-	-	-	+	-	+
Unk./No resp.	41	17	39	26	43	55	17	30	26	40	33	55	51	33
Motivation (%)														
Psychic effects	19	67	12	14	13	22	27	17	9	15	11	19	16	17
Dependence	21	8	49	2	10	11	14	12	-	13	11	5	10	6
Suic.att./gest.	39	21	21	55	54	38	47	38	62	42	71	55	62	58
Unknow./Unwill.	+	-	-	-	-	+	-	-	-	-	-	-	1	+
Other	2	1	1	2	-	1	3	3	-	3	1	4	1	3
Unk./No resp.	21	4	17	29	24	33	11	30	28	29	10	18	14	17
Age (%) DAWN Grouping														
6-9	+	-	+	-	-	-	-	-	-	-	-	-	-	1
10-19	15	12	13	17	25	23	17	18	17	9	4	14	22	18
20-29	48	58	57	31	46	43	42	53	45	47	52	41	30	43
30-39	20	24	19	24	19	16	22	15	25	24	29	19	22	18
40-49	8	3	5	12	8	8	8	5	9	7	3	13	12	10
50 & Over	8	3	4	17	2	9	11	8	4	11	11	11	13	10
Unk./No resp.	1	+	1	-	-	1	-	-	-	2	+	1	1	1
Age (%) CODAP Grouping														
6-9	+	-	+	-	-	-	-	-	-	-	-	-	-	1
10-17	8	4	5	14	14	13	8	12	8	5	1	8	14	12
18-20	12	11	12	10	16	13	13	18	15	8	9	11	13	10
21-25	27	30	33	19	29	27	28	25	30	24	23	23	15	24
26-30	21	27	24	5	16	16	15	20	15	20	31	17	12	17
31-44	22	21	18	31	19	18	21	15	28	26	24	22	27	22
45 & Over	11	5	6	21	6	12	15	10	4	14	12	18	19	13
Unk./No resp.	1	+	1	-	-	1	-	-	-	2	+	1	1	1
Race (%)														
White	70	40	75	71	78	75	84	77	58	70	62	76	61	81
Black	17	59	11	29	6	20	4	15	19	12	16	9	25	7
Other	3	-	4	-	-	2	6	-	17	2	8	6	-	1
Unk./No resp.	10	1	9	-	16	3	5	8	6	16	14	9	14	11
Sex (%)														
Male	47	57	58	29	40	43	41	55	28	37	55	37	42	42
Female	53	43	42	71	60	57	59	45	72	63	45	63	58	58
Unk./No resp.	+	-	+	-	-	+	-	-	-	-	-	+	1	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Barbiturate sedatives are sedatives and hypnotics containing a barbituric acid derivative. Most of the modern sedative-hypnotic agents are general depressants in that they depress a wide range of cellular functions in many vital organ systems. The central nervous system is very sensitive to their action.

TABLE 3.021 - SECOBARBITAL

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,589	20	18**	58	64	38	35	18**	26	73	17**	16**	181	100	28
Alone (%)	34	50	22	22	33	37	37	56	38	25	24	38	46	30	29
Rank in TDS/SMSA	27	27	28	20	15	28	25	21.5	24.5	24	26.5	28	13	20	22
Source (%)															
Legal RX	34	35		24	27	24	40		42	52			24	42	64
Forged RX	-	-		-	-	-	-		-	-			-	-	-
Stolen	2	5		2	-	-	-		-	4			-	2	4
Street buy	18	10		12	14	11	11		8	15			4	33	4
Over-the-counter	-	-		-	-	-	-		-	-			-	-	-
Gift	2	5		3	5	3	11		4	1			2	-	4
Other	+	-		-	-	-	-		-	-			-	-	-
Unk./No resp.	44	45		59	55	63	37		46	27			70	23	25
Motivation (%)															
Psychic effects	17	25		16	22	32	23		12	11			8	31	18
Dependence	18	20		17	22	11	9		12	15			3	36	7
Suic.att./gest.	45	40		52	41	32	40		62	53			45	30	57
Unknow./Unwill.	+	-		-	-	-	-		-	-			-	-	-
Other	2	5		-	6	-	6		-	-			1	-	4
Unk./No resp.	20	10		16	22	26	29		15	23			43	5	14
Age (%) DAWN Grouping															
6-9	-	-		-	-	-	-		-	-			-	-	-
10-19	14	30		10	11	13	20		12	15			12	7	21
20-29	47	20		64	41	45	49		58	42			40	58	50
30-39	19	25		10	28	29	6		12	25			24	19	7
40-49	8	10		9	11	3	9		8	7			12	8	7
50 & Over	10	15		7	8	8	14		12	11			11	8	14
Unk./No resp.	1	-		-	2	3	3		-	-			2	-	-
Age (%) CODAP Grouping															
6-9	-	-		-	-	-	-		-	-			-	-	-
10-17	8	25		9	8	5	14		8	7			3	2	14
18-20	11	5		14	3	11	6		8	14			14	10	21
21-25	26	15		33	23	34	37		23	23			19	34	21
26-30	21	10		21	19	8	11		31	16			19	19	18
31-44	21	30		16	36	29	11		19	26			27	22	7
45 & Over	13	15		9	9	11	17		12	14			15	13	18
Unk./No resp.	1	-		-	2	3	3		-	-			2	-	-
Race (%)															
White	75	85		91	66	68	60		62	66			63	88	71
Black	14	5		2	25	11	14		4	19			22	4	4
Other	2	-		2	2	-	-		4	-			2	1	-
Unk./No resp.	10	10		5	8	21	26		31	15			14	7	25
Sex (%)															
Male	49	70		53	39	66	54		46	40			43	54	46
Female	51	30		47	61	34	46		54	60			57	46	54
Unk./No resp.	+	-		-	-	-	-		-	-			1	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

256

Rank in TDS

7

Concomitance	N	%
Alone	77	30
In Comb.	179	70

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	150	59	7	3
Accid./Unexp.	53	21	17	7
Unk./No resp.	25	10	4	2

Age	N	%		N	%
6-9	-	-	40-49	34	13
10-19	8	3	50 & Over	92	36
20-29	79	31	Unk./No resp.	1	+
30-39	42	16			

Race	N	%
White	228	89
Black	19	7
Other	5	2
Unk./No resp.	4	2

Sex	N	%
Male	125	49
Female	131	51

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.021 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,589	45	374	2**	16**	85	44	7**	4**	42	62	45	31	140
Alone (%)	34	33	30	-	63	44	23	14	50	36	34	33	42	37
Rank in TDS/SMSA	27	20.5	17.5	32.5	20.5	29	23.5	33	29	22	13	19	27	21
Source (%)														
Legal RX	34	27	26			31	41			33	45	27	39	53
Forged RX	-	-	-			-	-			-	-	-	-	-
Stolen	2	4	2			-	5			5	-	-	-	4
Street buy	18	24	34			11	25			19	13	4	19	9
Over-the-counter	-	-	-			-	-			-	-	-	-	-
Gift	2	4	1			1	7			-	-	2	-	2
Other	+	-	-			-	-			-	-	2	-	-
Unk./No resp.	44	40	37			59	23			43	42	64	42	32
Motivation (%)														
Psychic effects	17	38	9			22	27			24	11	20	29	19
Dependence	18	16	36			12	18			12	3	9	10	9
Suic.att./gest.	45	38	42			38	41			24	77	49	58	54
Unknow./Unwill.	+	-	-			1	-			-	-	-	-	-
Other	2	2	1			4	2			2	-	4	-	2
Unk./No resp.	20	9	13			29	14			40	13	20	6	16
Age (%) DAWN Grouping														
6-9	-	-	-			-	-			-	-	-	-	-
10-19	14	18	15			21	18			10	5	13	26	13
20-29	47	56	51			45	36			48	60	42	16	51
30-39	19	16	20			9	14			24	21	20	26	16
40-49	8	2	7			11	9			2	2	11	10	11
50 & Over	10	9	7			13	23			12	13	11	19	9
Unk./No resp.	1	-	1			1	-			5	-	2	3	1
Age (%) CODAP Grouping														
6-9	-	-	-			-	-			-	-	-	-	-
10-17	8	11	7			13	7			7	2	9	19	7
18-20	11	13	11			12	14			5	8	11	6	8
21-25	26	24	27			24	23			33	16	22	10	29
26-30	21	27	25			20	11			12	44	20	16	22
31-44	21	13	19			9	20			24	18	16	19	22
45 & Over	13	11	10			21	25			14	13	20	26	11
Unk./No resp.	1	-	1			1	-			5	-	2	3	1
Race (%)														
White	75	64	78			75	80			79	55	78	81	86
Black	14	33	11			20	5			10	27	11	13	5
Other	2	-	2			2	7			5	8	-	-	-
Unk./No resp.	10	2	9			2	9			7	10	11	6	9
Sex (%)														
Male	49	40	54			41	45			38	52	42	39	51
Female	51	60	46			59	55			62	48	58	61	49
Unk./No resp.	+	-	-			-	-			-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Secobarbital is a barbiturate sedative with a characteristic rapid onset and short duration. The suppression of mental activity by this agent may not be manifested immediately due to sleep-state but subtle distortion of mood and impairment of judgement can last for 10 to 22 hours. The results of overdose include: central nervous system depression, lowered body temperature and coma; death may result from respiratory arrest. Both tolerance effects and dependence are common with prolonged use. Furthermore, alcohol and other central nervous system depressants have the ability to potentiate secobarbital effects increasing the risk of toxicity and death.

TABLE 3.022 - SECOBARBITAL/AMOBARBITAL

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	2,516	11**	34	17**	35	51	14**	10**	8**	99	10**	5**	316	155	18**
Alone (%)	43	36	29	35	37	37	21	60	50	43	20	20	55	39	28
Rank in TDS/SMSA	15	34	23.5	37	23	27	34	33	33	22	31	36.5	6	13	26
Source (%)															
Legal RX	18		32		23	22				41			15	37	
Forged RX	+		3		-	-				-			-	-	
Stolen	1		3		-	-				1			-	1	
Street buy	27		15		9	14				11			2	39	
Over-the-counter	-		-		-	-				-			-	-	
Gift	1		3		3	2				-			2	1	
Other	+		-		-	-				-			-	-	
Unk./No resp.	52		44		66	63				46			81	22	
Motivation (%)															
Psychic effects	19		32		14	18				16			14	46	
Dependence	29		15		29	6				22			2	26	
Suic.att./gest.	25		35		40	29				47			34	23	
Unknow./Unwill.	-		-		-	-				-			-	-	
Other	1		3		-	4				2			1	1	
Unk./No resp.	27		18		17	47				13			50	4	
Age (%) DAWN Grouping															
6-9	+		-		-	-				1			+	-	
10-19	14		18		17	25				11			9	18	
20-29	60		53		63	51				55			57	59	
30-39	17		15		9	12				19			21	16	
40-49	5		6		6	6				6			8	2	
50 & Over	3		6		6	4				4			3	5	
Unk./No resp.	1		3		-	2				4			1	-	
Age (%) CODAP Grouping															
6-9	+		-		-	-				1			+	-	
10-17	5		6		3	10				5			3	12	
18-20	13		15		17	20				12			9	10	
21-25	34		24		43	25				21			31	36	
26-30	24		32		20	22				31			28	19	
31-44	16		9		9	14				20			22	15	
45 & Over	5		12		9	8				5			6	7	
Unk./No resp.	1		3		-	2				4			1	-	
Race (%)															
White	72		88		51	71				76			42	83	
Black	14		12		43	4				15			42	5	
Other	4		-		-	6				-			2	2	
Unk./No resp.	11		-		6	20				9			14	10	
Sex (%)															
Male	51		38		26	57				33			30	52	
Female	48		62		74	41				66			70	48	
Unk./No resp.	+		-		-	2				1			-	-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

211

Rank in TDS

10

Concomitance	N	%
Alone	71	34
In Comb.	140	66

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	94	45	8	4
Accid./Unexp.	39	18	15	7
Unk./No resp.	53	25	2	1

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	23	11	White	178	84	Male	115	55
10-19	9	4	50 & Over	33	16	Black	24	11	Female	96	45
20-29	92	44	Unk./No resp.	2	1	Other	7	3			
30-39	52	25				Unk./No resp.	2	1			

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.022 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	2,516	11**	1,294	1**	3**	186	16**	10**	23	37	48	20	18**	66
Alone (%)	43	27	44	100	33	42	38	20	39	27	29	25	44	32
Rank in TDS/SMSA	15	33.5	6	38	36.5	13	34	29	9.5	24	15	31	31.5	34
Source (%)														
Legal RX	18		8			22			35	32	56	15		56
Forged RX	+		+			-			-	-	-	-		-
Stolen	1		1			1			-	-	-	5		6
Street buy	27		41			11			30	11	4	15		9
Over-the-counter	-		-			-			-	-	-	-		-
Gift	1		+			3			-	8	2	-		2
Other	+		+			-			-	-	-	-		-
Unk./No resp.	52		50			64			35	49	38	70		27
Motivation (%)														
Psychic effects	19		16			28			17	19	10	40		35
Dependence	29		46			14			-	14	6	15		8
Suic.att./gest.	25		15			27			57	27	75	35		41
Unknow./Unwill.	-		-			-			-	-	-	-		-
Other	1		+			1			-	5	2	5		5
Unk./No resp.	27		24			37			26	41	8	10		12
Age (%) DAWN Grouping														
6-9	+		-			-			-	-	-	-		-
10-19	14		12			23			4	5	4	15		24
20-29	60		67			46			65	49	52	60		50
30-39	17		15			19			9	32	35	10		9
40-49	5		3			6			17	8	4	5		8
50 & Over	3		1			5			4	3	4	10		9
Unk./No resp.	1		1			1			-	3	-	-		-
Age (%) CODAP Grouping														
6-9	+		-			-			-	-	-	-		-
10-17	5		4			10			-	3	2	-		17
18-20	13		14			19			13	8	6	35		15
21-25	34		40			30			43	19	27	10		32
26-30	24		26			13			17	24	27	30		14
31-44	16		13			21			22	38	33	10		9
45 & Over	5		2			6			4	5	4	15		14
Unk./No resp.	1		1			1			-	3	-	-		-
Race (%)														
White	72		76			69			43	73	60	70		91
Black	14		7			26			26	19	10	15		2
Other	4		5			3			26	3	10	15		3
Unk./No resp.	11		12			2			4	5	19	-		5
Sex (%)														
Male	51		60			51			26	43	63	25		50
Female	48		40			49			74	57	38	75		50
Unk./No resp.	+		+			1			-	-	-	-		-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Secobarbital/amobarbital is a short-to-intermediate acting barbiturate sedative containing equal amounts of amobarbital sodium and secobarbital sodium. Its pharmacological action is similar to that of secobarbital and amobarbital with prolonged use resulting in tolerance effects, psychological dependence and physical dependence.

TABLE 3.023 - PHENOBARBITAL

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	2,799	97	62	129	65	189	54	55	90	130	49	46	202	160	44
Alone (%)	34	23	24	25	29	24	41	51	48	32	51	39	47	18	34
Rank in TDS/SMSA	14	5	15	12	14	12	16	9	8	17	13.5	11.5	11	11	14
Source (%)															
Legal RX	66	75	66	49	68	72	69	47	54	66	51	59	45	94	84
Forged RX	1	-	-	-	-	1	-	-	-	-	-	-	-	-	-
Stolen	3	-	5	2	3	-	6	5	1	5	2	2	1	1	2
Street buy	2	2	2	6	-	2	2	2	1	2	-	4	2	-	-
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	1	-	-	2	-	1	-	-	1	2	2	2	1	1	-
Other	+	-	-	-	-	-	-	-	1	1	-	-	-	-	-
Unk./No resp.	28	23	27	42	29	24	24	45	41	25	45	33	50	4	14
Motivation (%)															
Psychic effects	17	12	23	7	9	37	22	25	7	12	22	20	8	61	9
Dependence	17	33	6	22	11	37	-	4	6	12	2	-	4	10	5
Suic.att./gest.	51	36	58	52	69	30	50	45	78	66	47	65	50	27	77
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	3	3	2	5	2	2	9	5	4	2	6	4	3	1	-
Unk./No resp.	16	19	11	16	12	22	19	20	9	12	24	13	34	2	11
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-19	16	16	26	10	18	15	13	29	13	19	20	26	14	8	16
20-29	38	25	26	38	37	37	48	49	50	37	33	37	37	28	39
30-39	25	27	27	25	22	26	17	18	24	23	27	20	30	35	34
40-49	11	16	10	14	15	13	11	2	8	13	6	7	10	16	9
50 & Over	9	13	11	12	8	7	9	2	4	7	12	9	9	13	2
Unk./No resp.	1	2	-	2	-	1	2	-	-	1	2	2	+	1	-
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-17	9	9	21	6	6	9	9	15	8	8	6	20	6	6	7
18-20	11	8	10	5	20	12	11	16	9	18	20	13	11	4	11
21-25	20	15	13	17	22	19	19	38	28	13	12	26	21	12	25
26-30	17	10	15	22	14	16	22	11	23	24	16	9	16	23	11
31-44	28	36	29	32	28	29	24	18	24	22	29	22	32	35	39
45 & Over	13	19	13	16	11	15	13	2	8	14	14	9	13	21	7
Unk./No resp.	1	2	-	2	-	1	2	-	-	1	2	2	+	1	-
Race (%)															
White	65	59	73	82	80	41	59	71	46	58	82	67	57	44	61
Black	22	34	26	15	12	44	31	18	6	31	12	11	20	44	-
Other	3	-	-	-	2	4	-	2	10	-	-	-	7	3	2
Unk./No resp.	10	7	2	3	6	11	9	9	39	12	6	22	16	8	36
Sex (%)															
Male	41	54	34	43	40	59	31	33	34	35	39	30	32	54	27
Female	58	46	66	57	60	41	69	67	66	65	61	70	68	46	73
Unk./No resp.	+	-	-	-	-	-	-	-	-	-	-	-	+	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

249

Rank in TDS

9

Concomitance	N	%
Alone	53	21
In Comb.	196	79

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	92	37	11	4
Accid./Unexp.	54	22	44	18
Unk./No resp.	39	16	9	4

Age	N	%		N	%
6-9	-	-	40-49	40	16
10-19	9	4	50 & Over	70	28
20-29	68	27	Unk./No resp.	-	-
30-39	62	25			

Race	N	%
White	200	80
Black	41	16
Other	6	2
Unk./No resp.	2	1

Sex	N	%
Male	111	45
Female	138	55

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.023 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	2,799	63	366	23	25	160	89	30	19**	79	41	93	67	372
Alone (%)	34	56	19	65	44	50	43	37	37	33	41	39	39	38
Rank in TDS/SMSA	14	12.5	19	10.5	12	16	9	16.5	13	10.5	19	6.5	15	8
Source (%)														
Legal RX	66	59	79	65	68	52	61	57		66	56	53	49	72
Forged RX	1	17	-	-	-	1	-	-		1	-	-	-	-
Stolen	3	3	3	9	8	3	9	10		5	-	3	6	2
Street buy	2	2	3	-	-	1	11	7		3	10	1	-	1
Over-the-counter	-	-	-	-	-	-	-	-		-	-	-	-	-
Gift	1	6	-	9	8	2	9	-		1	-	2	-	+
Other	+	-	-	-	-	-	1	3		-	-	-	-	-
Unk./No resp.	28	16	15	17	20	43	11	23		27	34	41	45	25
Motivation (%)														
Psychic effects	17	57	5	4	-	13	25	20		8	5	9	4	15
Dependence	17	2	58	-	4	6	10	13		9	10	3	13	3
Suic.att./gest.	51	38	29	65	76	52	56	37		57	73	69	76	62
Unknow./Unwill.	+	-	-	-	-	-	-	-		-	-	-	1	-
Other	3	-	1	4	-	-	6	3		4	-	4	-	3
Unk./No resp.	16	5	7	26	20	31	6	27		24	15	16	6	18
Age (%) DAWN Grouping														
6-9	+	-	+	-	-	-	-	-		-	-	-	-	1
10-19	16	5	11	22	20	24	22	20		10	7	14	25	19
20-29	38	49	38	22	44	42	33	57		48	51	38	33	42
30-39	25	33	29	30	16	18	35	20		20	29	18	22	21
40-49	11	6	11	9	16	9	8	-		6	-	17	13	9
50 & Over	9	5	9	17	4	7	2	3		14	12	12	6	9
Unk./No resp.	1	2	1	-	-	1	-	-		1	-	1	-	1
Age (%) CODAP Grouping														
6-9	+	-	+	-	-	-	-	-		-	-	-	-	1
10-17	9	2	7	22	12	16	11	13		4	-	8	16	12
18-20	11	3	7	13	16	9	15	17		10	15	10	15	12
21-25	20	25	18	9	24	26	24	27		28	24	22	19	23
26-30	17	27	20	-	16	18	15	27		16	22	13	7	16
31-44	28	33	32	35	16	21	28	13		25	27	26	28	25
45 & Over	13	8	14	22	16	8	8	3		15	12	22	13	12
Unk./No resp.	1	2	1	-	-	1	-	-		1	-	1	-	1
Race (%)														
White	65	49	64	65	84	78	84	73		66	59	77	46	81
Black	22	49	28	35	8	17	3	20		11	10	8	37	10
Other	3	-	3	-	-	3	9	-		1	7	5	-	2
Unk./No resp.	10	2	5	-	8	3	3	7		22	24	10	16	7
Sex (%)														
Male	41	51	52	17	20	33	36	53		27	61	35	37	39
Female	58	49	48	83	80	67	64	47		73	39	65	61	61
Unk./No resp.	+	-	+	-	-	-	-	-		-	-	-	1	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Phenobarbital is a long-acting barbiturate sedative with a duration time of up to 24 hours. It has been prescribed medically as a hypnotic sedative and anticonvulsant. Because of its slow rate of metabolism (and therefore onset of action), phenobarbital is not used for episodic intoxication as frequently as other barbiturates.

TABLE 3.024 - PENTOBARBITAL

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	564	11**	15**	37	15**	14**	22	11**	7**	31	13**	8**	53	23	10**
Alone (%)	44	36	40	35	27	29	50	36	57	45	54	63	51	35	40
Rank in TDS/SMSA	34	34	31.5	28	30.5	34	31	31.5	34	35	30	33.5	30.5	34	31.5
Source (%)															
Legal RX	45			32			32			61			40	65	
Forged RX	-			-			-			-			-	-	
Stolen	2			-			-			6			4	-	
Street buy	9			11			36			6			2	13	
Over-the-counter	-			-			-			-			-	-	
Gift	2			3			9			-			4	-	
Other	-			-			-			-			-	-	
Unk./No resp.	42			54			23			26			51	22	
Motivation (%)															
Psychic effects	18			16			14			16			13	30	
Dependence	9			8			5			-			2	13	
Suic.att./gest.	51			43			55			55			45	43	
Unknow./Unwill.	+			-			-			-			-	-	
Other	3			3			9			-			4	4	
Unk./No resp.	22			30			18			29			36	9	
Age (%) DAWN Grouping															
6-9	+			-			-			-			-	-	
10-19	13			8			27			19			8	-	
20-29	42			51			45			32			42	43	
30-39	17			14			-			16			15	26	
40-49	12			5			-			19			25	17	
50 & Over	16			22			27			13			11	13	
Unk./No resp.	1			-			-			-			-	-	
Age (%) CODAP Grouping															
6-9	+			-			-			-			-	-	
10-17	9			5			18			16			8	-	
18-20	6			5			14			10			4	-	
21-25	24			30			23			16			17	26	
26-30	19			24			18			10			21	30	
31-44	20			14			-			29			28	26	
45 & Over	21			22			27			19			23	17	
Unk./No resp.	1			-			-			-			-	-	
Race (%)															
White	76			95			68			81			66	65	
Black	7			-			5			3			9	9	
Other	2			-			-			-			8	-	
Unk./No resp.	15			5			27			16			17	26	
Sex (%)															
Male	45			46			41			35			34	52	
Female	55			54			55			65			66	48	
Unk./No resp.	+			-			5			-			-	-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

203

Rank in TDS

11

Concomitance	N	%
Alone	94	46
In Comb.	109	54

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	121	60	5	2
Accid./Unexp.	30	15	14	7
Unk./No resp.	31	15	2	1

Age	N	%		N	%
6-9	-	-	40-49	23	11
10-19	4	2	50 & Over	98	48
20-29	49	24	Unk./No resp.	-	-
30-39	29	14			

Race	N	%
White	184	91
Black	8	4
Other	8	4
Unk./No resp.	3	1

Sex	N	%
Male	94	46
Female	109	54

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.024 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	564	6**	47	3**	10**	29	13**	3**	4**	27	35	22	16**	79
Alone (%)	44	50	38	33	70	48	46	67	50	41	54	27	69	43
Rank in TDS/SMSA	34	38.5	34	29	27	38	35	37.5	29	29	20	30	33	30
Source (%)														
Legal RX	45		43			38				33	60	32		47
Forged RX	-		-			-				-	-	-		-
Stolen	2		-			-				4	-	-		3
Street buy	9		17			14				15	14	9		4
Over-the-counter	-		-			-				-	-	-		-
Gift	2		-			3				-	-	-		1
Other	-		-			-				-	-	-		-
Unk./No resp.	42		40			45				48	26	59		46
Motivation (%)														
Psychic effects	18		15			10				22	11	18		15
Dependence	9		15			-				15	17	5		8
Suic.att./gest.	51		49			45				33	69	68		62
Unknow./Unwill.	+		-			-				-	-	-		1
Other	3		4			7				4	3	5		1
Unk./No resp.	22		17			38				30	6	5		14
Age (%) DAWN Grouping														
6-9	+		-			-				-	-	-		-
10-19	13		4			21				11	6	-		14
20-29	42		34			38				37	49	50		35
30-39	17		17			17				30	23	14		23
40-49	12		6			7				4	9	27		10
50 & Over	16		32			14				19	14	9		18
Unk./No resp.	1		6			3				-	-	-		-
Age (%) CODAP Grouping														
6-9	+		-			-				-	-	-		-
10-17	9		4			14				7	3	-		9
18-20	6		2			7				11	11	-		6
21-25	24		23			28				7	26	36		22
26-30	19		17			14				30	26	14		14
31-44	20		13			17				22	17	27		27
45 & Over	21		34			17				22	17	23		23
Unk./No resp.	1		6			3				-	-	-		-
Race (%)														
White	76		77			83				59	69	77		82
Black	7		11			7				7	14	5		4
Other	2		2			-				4	9	9		1
Unk./No resp.	15		11			10				30	9	9		13
Sex (%)														
Male	45		40			38				52	49	41		49
Female	55		57			62				48	51	59		51
Unk./No resp.	+		2			-				-	-	-		-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Pentobarbital is a short-to-intermediate acting barbiturate sedative which depresses the central nervous system to produce drowsiness and sleep. Pentobarbital is similar to the other barbiturates in that it has a very high potential for physiological dependence, and its withdrawal syndrome can be more dangerous than that of heroin. As with other barbiturates, tolerance to pentobarbital's sedative effects can occur rapidly.

TABLE 3.025 - AMOBARBITAL

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	222	3**	1**	7**	1**	3**	1**	1**	-	11**	2**	1**	3**	3**	4**
Alone (%)	15	67	-	29	-	-	-	-	-	18	50	-	33	33	75
Rank in TDS/SMSA	39	41	42	39	41	40	42	42	-	40	40.5	42	42	42	38.5
Source (%)															
Legal RX	20														
Forged RX	6														
Stolen	2														
Street buy	49														
Over-the-counter	-														
Gift	2														
Other	-														
Unk./No resp.	22														
Motivation (%)															
Psychic effects	63														
Dependence	9														
Suic.att./gest.	21														
Unknow./Unwill.	-														
Other	-														
Unk./No resp.	8														
Age (%) DAWN Grouping															
6-9	-														
10-19	13														
20-29	59														
30-39	17														
40-49	4														
50 & Over	7														
Unk./No resp.	1														
Age (%) CODAP Grouping															
6-9	-														
10-17	5														
18-20	12														
21-25	31														
26-30	25														
31-44	17														
45 & Over	9														
Unk./No resp.	1														
Race (%)															
White	39														
Black	55														
Other	+														
Unk./No resp.	5														
Sex (%)															
Male	64														
Female	36														
Unk./No resp.	-														

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

109

Rank in TDS

16

Concomitance	N	%
Alone	10	9
In Comb.	99	91

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	49	45	7	6
Accid./Unexp.	28	26	10	9
Unk./No resp.	12	11	3	3

Age	N	%		N	%
6-9	-	-	40-49	10	9
10-19	5	5	50 & Over	30	28
20-29	45	41	Unk./No resp.	1	1
30-39	18	17			

Race	N	%
White	90	83
Black	13	12
Other	3	3
Unk./No resp.	3	3

Sex	N	%
Male	56	51
Female	53	49

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.025 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	222	132	9**	-	2**	15**	1**	2**	1**	4**	2**	-	-	13**
Alone (%)	15	6	22	-	50	13	100	50	-	-	-	-	-	46
Rank in TDS/SMSA	39	6	38	-	38.5	41	41	39.5	38	40	39.5	-	-	42
Source (%)														
Legal RX	20	10												
Forged RX	6	9												
Stolen	2	-												
Street buy	49	74												
Over-the-counter	-	-												
Gift	2	2												
Other	-	-												
Unk./No resp.	22	5												
Motivation (%)														
Psychic effects	63	89												
Dependence	9	8												
Suic.att./gest.	21	2												
Unknow./Unwill.	-	-												
Other	-	-												
Unk./No resp.	8	1												
Age (%) DAWN Grouping														
6-9	-	-												
10-19	13	11												
20-29	59	67												
30-39	17	19												
40-49	4	2												
50 & Over	7	-												
Unk./No resp.	1	-												
Age (%) CODAP Grouping														
6-9	-	-												
10-17	5	2												
18-20	12	14												
21-25	31	35												
26-30	25	29												
31-44	17	18												
45 & Over	9	2												
Unk./No resp.	1	-												
Race (%)														
White	39	17												
Black	55	83												
Other	+	-												
Unk./No resp.	5	-												
Sex (%)														
Male	64	77												
Female	36	23												
Unk./No resp.	-	-												

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Amobarbital is a short-to-intermediate acting barbiturate sedative which acts as a depressant on the central nervous system. Tolerance may develop after continual usage, requiring an increase in dosage to attain the results desired. Alcohol, another depressant of the central nervous system, can potentiate the action of a barbiturate, causing respiratory failure and death.

TABLE 3.026 - BUTABARBITAL

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	179	3**	9**	3**	7**	3**	2**	6**	4**	7**	4**	3**	11**	5**	1**
Alone (%)	49	33	89	100	29	33	100	67	50	-	75	67	64	20	-
Rank in TDS/SMSA	42	41	37	42	37	40	41	36.5	40.5	42	38.5	40	38	41	42
Source (%)															
Legal RX	61														
Forged RX	-														
Stolen	4														
Street buy	1														
Over-the-counter	-														
Gift	2														
Other	-														
Unk./No resp.	32														
Motivation (%)															
Psychic effects	16														
Dependence	3														
Suic.att./gest.	64														
Unknow./Unwill.	-														
Other	1														
Unk./No resp.	17														
Age (%) DAWN Grouping															
6-9	-														
10-19	15														
20-29	32														
30-39	23														
40-49	15														
50 & Over	15														
Unk./No resp.	1														
Age (%) CODAP Grouping															
6-9	-														
10-17	7														
18-20	9														
21-25	18														
26-30	16														
31-44	30														
45 & Over	20														
Unk./No resp.	1														
Race (%)															
White	83														
Black	8														
Other	2														
Unk./No resp.	8														
Sex (%)															
Male	20														
Female	80														
Unk./No resp.	-														

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

15**

Rank in TDS

32

Concomitance	N	%
Alone	1	7
In Comb.	14	93

Cause/Manner of Death

	Drug-Induced Deaths		Drug-Related Deaths	
	N	%	N	%
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%		N	%
6-9			40-49		
10-19			50 & Over		
20-29			Unk./No resp.		
30-39					

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.026 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	179	15**	7**	7**	2**	10**	1**	6**	-	5**	-	-	7**	51
Alone (%)	49	67	71	86	100	50	100	33	-	20	-	-	29	35
Rank in TDS/SMSA	42	32	40	23.5	38.5	42	41	34.5	-	39	-	-	37	36
Source (%)														
Legal RX	61													73
Forged RX	-													-
Stolen	4													2
Street buy	1													-
Over-the-counter	-													-
Gift	2													-
Other	-													-
Unk./No resp.	32													25
Motivation (%)														
Psychic effects	16													8
Dependence	3													4
Suic.att./gest.	64													73
Unknow./Unwill.	-													-
Other	1													-
Unk./No resp.	17													16
Age (%) DAWN Grouping														
6-9	-													-
10-19	15													10
20-29	32													33
30-39	23													20
40-49	15													24
50 & Over	15													14
Unk./No resp.	1													-
Age (%) CODAP Grouping														
6-9	-													-
10-17	7													4
18-20	9													6
21-25	18													20
26-30	16													18
31-44	30													29
45 & Over	20													24
Unk./No resp.	1													-
Race (%)														
White	83													92
Black	8													4
Other	2													-
Unk./No resp.	8													4
Sex (%)														
Male	20													16
Female	80													84
Unk./No resp.	-													-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Butabarbital is a short-to-intermediate acting barbiturate. Its depressant action on the central nervous system makes the drug easily potentiated by other central nervous system depressants, especially alcohol. The tolerance effects of the barbiturates, which usually require larger doses to maintain the same results, may lead to both psychological and physical dependence.

TABLE 3.03 THERAPEUTIC CLASS - NON-BARBITURATE SEDATIVES

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	14,780	370	260	510	254	729	354	236	381	818	310	254	1,194	1,435	330
Alone (%)	40	41	40	37	41	41	44	53	44	41	35	42	45	38	39
Rank in TDS/SMSA	3	3	4	4	4	4	3	3	3	4	3	3	3	2	3
Source (%)															
Legal RX	34	32	37	33	37	35	38	41	44	44	24	40	31	25	47
Forged RX	+	+	+	+	-	-	-	-	-	+	-	-	-	-	-
Stolen	1	2	2	+	2	1	1	1	+	1	+	1	1	1	1
Street buy	15	6	14	8	2	6	5	2	2	5	5	6	2	47	3
Over-the-counter	14	18	14	19	17	10	19	18	24	16	19	19	11	5	31
Gift	2	2	1	2	1	2	2	2	2	2	2	4	1	3	1
Other	+	-	-	-	-	-	+	-	-	-	-	-	-	-	-
Unk./No resp.	34	40	32	37	41	46	35	37	29	32	50	30	54	18	17
Motivation (%)															
Psychic effects	19	19	19	13	13	18	12	24	13	14	31	12	13	48	12
Dependence	11	7	10	9	5	7	4	2	2	9	6	2	4	16	4
Suic.att./gest.	51	53	56	63	66	46	58	56	71	60	46	67	53	30	76
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	+	-	-	+	-	-
Other	2	1	3	2	2	3	4	3	3	2	2	2	1	1	1
Unk./No resp.	18	21	14	15	17	30	25	16	12	16	18	17	30	5	8
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	+	-	-	-	+	-	+	-	+	-
10-19	18	22	20	15	17	22	20	18	15	16	25	19	11	27	18
20-29	43	40	45	45	30	42	37	43	39	44	42	36	39	50	38
30-39	20	21	17	22	20	17	17	21	24	20	14	22	25	13	16
40-49	9	9	8	8	17	9	12	10	10	12	9	12	14	5	11
50 & Over	9	6	8	8	14	9	13	9	10	9	9	9	11	5	15
Unk./No resp.	1	1	+	1	+	1	+	-	2	1	1	+	1	+	2
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	+	-	-	-	+	-	+	-	+	-
10-17	10	14	10	7	8	13	12	9	9	8	18	9	6	16	9
18-20	13	14	14	11	13	13	13	13	10	13	13	16	8	17	13
21-25	24	22	22	24	15	22	20	27	21	24	25	20	21	29	18
26-30	18	14	24	21	15	18	14	14	18	19	14	14	19	18	19
31-44	22	25	17	23	32	20	21	24	25	22	15	24	29	13	20
45 & Over	13	9	13	12	17	13	20	14	15	14	14	16	17	7	19
Unk./No resp.	1	1	+	1	+	1	+	-	2	1	1	+	1	+	2
Race (%)															
White	73	76	83	85	74	64	74	83	48	63	85	69	66	73	75
Black	11	9	13	6	12	16	12	8	3	24	6	10	11	9	1
Other	3	+	+	2	3	6	+	4	3	+	-	1	4	5	1
Unk./No resp.	13	14	4	7	11	15	13	4	46	13	9	20	19	13	23
Sex (%)															
Male	41	39	48	43	35	36	36	33	41	37	45	30	35	51	35
Female	59	61	51	57	64	63	64	67	59	63	55	70	65	49	65
Unk./No resp.	+	-	+	-	1	+	-	-	-	-	+	-	+	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

476

Rank in TDS

6

Concomitance	N	%
Alone	88	18
In Comb.	388	82

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	219	46	19	4
Accid./Unexp.	105	22	53	11
Unk./No resp.	68	14	12	3

Age	N	%		N	%
6-9	-	-	40-49	76	16
10-19	37	8	50 & Over	109	23
20-29	166	35	Unk./No resp.	1	+
30-39	87	18			

Race	N	%
White	421	88
Black	37	8
Other	14	3
Unk./No resp.	4	1

Sex	N	%
Male	258	54
Female	218	46

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.03 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	14,780	220	2,151	118	132	1,022	390	234	115	448	240	331	393	1,551
Alone (%)	40	58	32	54	39	44	34	31	42	36	34	34	45	43
Rank in TDS/SMSA	3	5	4	3	3	3	3	3	3	2	3	3	4	3
Source (%)														
Legal RX	34	41	17	43	30	28	46	54	51	56	36	34	27	47
Forged RX	+	5	+	1	2	+	-	-	-	-	-	+	-	+
Stolen	1	2	1	1	1	+	2	3	2	2	-	1	2	1
Street buy	15	12	40	2	3	7	10	3	5	4	25	4	3	4
Over-the-counter	14	10	5	31	11	9	22	12	21	13	13	26	21	21
Gift	2	4	2	2	4	2	3	4	-	2	+	+	1	2
Other	+	-	+	-	-	+	1	-	-	-	-	-	-	+
Unk./No resp.	34	27	35	22	50	53	16	26	21	24	26	35	45	26
Motivation (%)														
Psychic effects	19	36	20	11	11	19	18	11	8	14	16	16	13	14
Dependence	11	11	35	2	2	8	9	6	1	9	6	4	6	3
Suic.att./gest.	51	43	30	66	55	41	58	56	70	57	74	70	67	66
Unknow./Unwill.	+	-	+	-	1	-	-	-	-	-	-	+	-	-
Other	2	1	1	3	1	1	3	1	-	5	3	2	1	2
Unk./No resp.	18	9	15	18	30	33	13	25	21	19	4	9	13	16
Age (%) DAWN Grouping														
6-9	+	-	+	-	-	-	1	-	-	-	-	-	-	-
10-19	18	19	19	19	21	22	15	15	16	9	7	14	19	19
20-29	43	43	51	48	43	44	36	39	38	40	47	40	35	36
30-39	20	21	19	17	22	18	21	21	29	29	32	21	23	21
40-49	9	10	4	9	10	8	15	12	10	7	6	16	9	12
50 & Over	9	6	6	7	4	9	12	13	6	13	8	8	13	11
Unk./No resp.	1	1	1	-	-	1	+	+	1	1	+	1	1	+
Age (%) CODAP Grouping														
6-9	+	-	+	-	-	-	1	-	-	-	-	-	-	-
10-17	10	10	10	7	8	12	7	9	10	5	2	6	10	12
18-20	13	15	13	17	19	14	13	9	10	6	6	12	11	12
21-25	24	24	28	29	23	24	19	27	22	24	24	20	20	20
26-30	18	17	22	17	20	18	16	13	19	18	28	18	16	14
31-44	22	22	18	19	24	18	24	22	28	31	29	28	24	25
45 & Over	13	10	7	11	6	13	20	20	10	16	11	15	18	17
Unk./No resp.	1	1	1	-	-	1	+	+	1	1	+	1	1	+
Race (%)														
White	73	73	75	82	76	81	84	74	61	68	70	74	65	79
Black	11	22	12	17	5	13	3	12	9	8	7	5	18	7
Other	3	+	4	-	2	3	7	1	23	4	5	5	2	2
Unk./No resp.	13	5	10	1	17	4	6	12	8	20	18	16	15	12
Sex (%)														
Male	41	41	53	29	32	45	33	43	32	35	51	35	39	32
Female	59	58	47	71	68	55	67	57	66	65	49	65	61	68
Unk./No resp.	+	+	+	-	-	+	-	-	2	+	-	-	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Non-barbiturate sedatives are drugs promoted for their sedative and hypnotic effects which lack a barbituric acid derivative in their chemical structure. They comprise a wide variety of chemical compounds that are mostly unrelated. As a class they are less potent central nervous system depressants than the barbiturates. This therapeutic class of drugs while possessing some of the disadvantages of the barbiturates, constitutes a satisfactory alternative to barbiturate use.

TABLE 3.031 - FLURAZEPAM

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	4,666	112	70	187	102	230	133	104	157	255	74	103	478	200	150
Alone (%)	38	33	41	30	36	39	41	57	35	36	28	34	40	46	33
Rank in TDS/SMSA	6	4	12	6	7.5	7	6	4	5	7	6	4	4	8	4
Source (%)															
Legal RX	63	59	71	58	47	57	67	61	76	75	54	66	45	80	80
Forged RX	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	4	3	1	3	+	2	1	1	2	-	2	1	6	1
Street buy	1	-	1	1	-	3	1	-	-	1	1	1	1	1	-
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	1	2	-	2	1	1	1	2	1	2	1	3	1	1	1
Other	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unk./No resp.	32	35	24	39	49	40	30	37	23	22	43	28	53	13	18
Motivation (%)															
Psychic effects	12	11	9	10	10	13	6	24	7	12	27	5	10	22	10
Dependence	5	4	9	7	4	3	3	1	1	5	3	1	3	9	3
Suic.att./gest.	66	62	71	71	72	59	67	67	77	65	55	75	59	62	78
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	-	-	+	-	-
Other	2	2	3	2	3	1	5	2	5	2	4	2	1	2	1
Unk./No resp.	16	22	10	13	14	26	21	6	10	18	14	17	27	7	9
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	+	-	-	-	-	-	1	-	-	-
10-19	11	11	13	10	16	16	11	11	10	11	11	13	6	13	10
20-29	29	30	31	28	25	34	24	30	31	29	34	24	29	27	27
30-39	25	33	19	31	24	22	24	30	27	23	16	25	27	22	23
40-49	16	14	20	14	22	13	19	14	17	19	20	22	19	19	17
50 & Over	18	12	17	16	13	14	22	15	16	18	18	15	17	21	23
Unk./No resp.	+	-	-	1	1	-	1	-	-	-	1	-	1	-	-
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	+	-	-	-	-	-	1	-	-	-
10-17	7	9	10	4	7	7	4	4	7	6	8	7	5	9	5
18-20	6	4	4	7	11	11	8	10	5	7	3	7	2	7	7
21-25	14	17	6	14	12	15	10	15	15	14	20	14	14	15	12
26-30	16	13	29	17	16	19	15	14	18	16	14	15	19	13	16
31-44	30	38	21	35	35	27	30	35	31	31	26	30	33	28	29
45 & Over	25	18	30	22	19	20	32	22	24	25	28	27	26	30	30
Unk./No resp.	+	-	-	1	1	-	1	-	-	-	1	-	1	-	-
Race (%)															
White	72	70	87	85	68	62	67	85	50	63	82	67	66	70	79
Black	11	9	11	4	16	21	14	8	3	24	8	9	9	10	1
Other	3	-	-	2	4	7	1	3	1	-	-	-	4	5	1
Unk./No resp.	14	21	1	10	13	10	18	5	46	14	9	24	20	16	20
Sex (%)															
Male	30	34	44	29	29	21	31	33	38	25	28	21	29	31	29
Female	70	66	56	71	71	78	69	67	62	75	72	79	70	69	71
Unk./No resp.	+	-	-	-	-	1	-	-	-	-	-	-	+	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

105

Rank in TDS

17.5

Concomitance	N	%
Alone	10	10
In Comb.	95	90

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	68	65	2	2
Accid./Unexp.	7	7	6	6
Unk./No resp.	17	16	5	5

Age	N	%		N	%
6-9	-	-	40-49	22	21
10-19	3	3	50 & Over	43	41
20-29	25	24	Unk./No resp.	-	-
30-39	12	11			

Race	N	%
White	93	89
Black	6	6
Other	5	5
Unk./No resp.	1	1

Sex	N	%
Male	47	45
Female	58	55

*Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.031 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	4,666	60	374	45	55	326	156	93	54	182	79	130	144	613
Alone (%)	38	58	36	42	55	40	28	30	39	33	32	25	38	40
Rank in TDS/SMSA	6	14	17.5	6	3	3	4	3	4.5	4.5	6	4	7	4
Source (%)														
Legal RX	63	57	55	73	44	52	74	66	69	75	73	60	52	75
Forged RX	+	3	-	-	-	1	-	-	-	-	-	1	-	+
Stolen	2	5	5	-	-	1	1	4	2	3	-	1	2	1
Street buy	1	2	4	-	2	1	6	1	2	1	6	1	-	-
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	1	2	1	2	-	1	1	4	-	3	-	-	1	1
Other	+	-	-	-	-	+	2	-	-	-	-	-	-	+
Unk./No resp.	32	32	37	24	55	44	15	25	28	18	20	38	45	22
Motivation (%)														
Psychic effects	12	25	8	11	9	16	14	10	2	12	6	11	12	13
Dependence	5	3	20	-	4	2	9	-	-	2	1	3	3	3
Suic.att./gest.	66	62	59	67	58	53	60	63	70	67	91	75	76	73
Unknow./Unwill.	+	-	-	-	2	-	-	-	-	-	-	1	-	-
Other	2	2	1	2	-	1	8	1	-	4	1	1	1	1
Unk./No resp.	16	8	13	20	27	29	12	26	28	17	3	12	10	11
Age (%) DAWN Grouping														
6-9	+	-	-	-	-	-	3	-	-	-	-	-	-	-
10-19	11	18	11	7	16	13	6	15	11	9	4	10	10	12
20-29	29	35	31	40	35	28	22	31	35	30	35	25	26	29
30-39	25	25	25	22	25	22	26	26	31	34	34	24	27	22
40-49	16	12	9	22	18	16	21	12	13	8	8	27	13	17
50 & Over	18	10	22	9	5	20	21	15	9	19	19	13	22	19
Unk./No resp.	+	-	1	-	-	1	1	1	-	1	-	1	1	+
Age (%) CODAP Grouping														
6-9	+	-	-	-	-	-	3	-	-	-	-	-	-	-
10-17	7	13	6	4	7	8	4	11	7	4	1	6	6	9
18-20	6	7	8	11	13	7	4	5	9	5	3	5	6	5
21-25	14	23	14	16	22	15	11	24	20	16	15	12	11	15
26-30	16	13	18	20	15	15	15	10	19	14	24	16	15	15
31-44	30	30	26	31	33	26	27	30	31	38	35	36	32	29
45 & Over	25	13	27	18	11	29	36	19	13	21	22	24	28	26
Unk./No resp.	+	-	1	-	-	1	1	1	-	1	-	1	1	+
Race (%)														
White	72	65	71	82	71	76	85	73	56	66	68	78	62	81
Black	11	32	15	18	5	12	2	15	9	8	10	5	19	6
Other	3	-	5	-	4	6	8	1	28	5	8	2	1	2
Unk./No resp.	14	3	9	-	20	4	5	11	7	20	14	15	18	11
Sex (%)														
Male	30	28	40	18	25	32	27	34	30	28	44	28	33	26
Female	70	72	60	82	75	68	73	66	69	71	56	72	67	74
Unk./No resp.	+	-	+	-	-	+	-	-	2	1	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Flurazepam is a non-barbiturate sedative used in the treatment of insomnia. Because flurazepam works by depressing the action of the central nervous system, its action may be potentiated by other central nervous system depressants such as alcohol. Normal dose levels of flurazepam have not been known to produce either physical or psychological dependence.

TABLE 3.032 - METHAQUALONE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	3,270	92	85	84	9**	73	57	27	53	61	72	42	179	905	23
Alone (%)	35	28	35	25	33	42	35	33	34	36	28	31	37	32	26
Rank in TDS/SMSA	11	7	10	18	34.5	22	13	17	17	25.5	8	15.5	14	2	24.5
Source (%)															
Legal RX	13	15	14	8		10	14	22	25	36	13	24	18	7	43
Forged RX	+	1	1	-		-	-	-	-	2	-	-	-	-	-
Stolen	1	1	1	1		1	-	-	-	2	1	-	2	+	-
Street buy	43	17	38	30		26	21	4	8	15	13	14	10	70	22
Over-the-counter	-	-	-	-		-	-	-	-	-	-	-	-	-	-
Gift	4	2	2	5		7	4	4	4	5	1	10	2	4	13
Other	+	-	-	-		-	2	-	-	-	-	-	-	-	-
Unk./No resp.	39	63	44	56		56	60	70	64	41	72	52	68	19	22
Motivation (%)															
Psychic effects	39	32	31	20		34	30	26	42	28	40	24	28	61	35
Dependence	18	11	15	18		10	7	7	8	11	8	2	3	17	4
Suic.att./gest.	28	40	36	45		29	35	33	42	51	32	50	42	17	52
Unknow./Unwill.	+	-	-	-		-	-	-	-	-	-	-	-	-	-
Other	1	1	1	2		5	5	-	6	2	3	2	1	1	4
Unk./No resp.	15	18	19	17		26	30	33	11	10	24	21	26	5	4
Age (%) DAWN Grouping															
6-9	+	-	-	-		-	-	-	-	-	-	-	-	+	-
10-19	29	30	27	13		37	35	30	8	34	42	24	18	34	9
20-29	56	49	59	62		55	58	56	62	48	54	52	60	56	57
30-39	11	16	8	20		7	5	11	25	11	3	21	16	8	17
40-49	1	3	4	1		-	-	-	2	3	-	-	2	1	9
50 & Over	1	1	1	-		1	2	4	-	2	1	2	2	1	4
Unk./No resp.	1	-	1	4		-	-	-	4	2	-	-	2	+	4
Age (%) CODAP Grouping															
6-9	+	-	-	-		-	-	-	-	-	-	-	-	+	-
10-17	16	16	11	8		21	26	7	2	13	29	12	10	19	-
18-20	21	26	20	10		22	14	30	9	28	25	24	15	22	9
21-25	34	29	38	33		36	39	41	30	30	33	26	36	34	30
26-30	18	11	22	27		15	14	7	32	13	8	19	20	17	35
31-44	10	16	6	18		5	5	11	23	11	3	17	14	6	17
45 & Over	1	1	2	-		1	2	4	-	3	1	2	3	1	4
Unk./No resp.	1	-	1	4		-	-	-	4	2	-	-	2	+	4
Race (%)															
White	80	86	89	85		77	91	89	40	64	83	79	65	75	70
Black	6	4	4	8		4	-	11	4	7	3	7	7	7	-
Other	3	1	1	1		5	-	-	2	-	-	2	4	5	-
Unk./No resp.	11	9	6	6		14	9	-	55	30	14	12	25	12	30
Sex (%)															
Male	57	57	59	60		59	54	56	57	66	54	57	49	58	61
Female	42	43	40	40		41	46	44	43	34	44	43	50	42	39
Unk./No resp.	+	-	1	-		-	-	-	-	-	1	-	1	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

87

Rank in TDS

19

Concomitance	N	%
Alone	18	21
In Comb.	69	79

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	18	21	13	15
Accid./Unexp.	13	15	32	37
Unk./No resp.	10	11	1	1

Age	N	%		N	%
6-9	-	-	40-49	6	7
10-19	20	23	50 & Over	7	8
20-29	46	53	Unk./No resp.	-	-
30-39	8	9			

Race	N	%
White	83	95
Black	2	2
Other	2	2
Unk./No resp.	-	-

Sex	N	%
Male	63	72
Female	24	28

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.032 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	3,270	77	644	20	18**	255	56	18**	13**	63	63	41	62	178
Alone (%)	35	57	32	75	33	45	32	22	38	37	32	27	34	37
Rank in TDS/SMSA	11	8	10	12	17.5	6	17	24.5	17	14	11.5	21.5	16	16
Source (%)														
Legal RX	13	35	3	45		14	27			33	11	15	5	24
Forged RX	+	6	-	-		-	-			-	-	-	-	1
Stolen	1	-	+	-		-	2			3	-	5	2	1
Street buy	43	29	66	5		19	30			19	65	22	15	21
Over-the-counter	-	-	-	-		-	-			-	-	-	-	-
Gift	4	5	4	5		4	13			3	2	-	-	7
Other	+	-	-	-		-	-			-	-	-	-	-
Unk./No resp.	39	25	27	45		64	30			41	22	59	79	48
Motivation (%)														
Psychic effects	39	48	32	20		27	43			14	46	37	27	22
Dependence	18	22	37	5		16	16			25	8	7	18	5
Suic.att./gest.	28	22	22	40		21	32			33	41	49	35	49
Unknow./Unwill.	+	-	+	-		-	-			-	-	-	-	-
Other	1	-	1	15		1	-			3	2	5	3	3
Unk./No resp.	15	9	8	20		39	13			24	8	5	18	21
Age (%) DAWN Grouping														
6-9	+	-	-	-		-	-			-	-	-	-	-
10-19	29	18	30	30		34	29			8	13	17	34	33
20-29	56	58	59	65		53	52			59	63	54	47	54
30-39	11	17	10	-		13	9			22	22	22	18	11
40-49	1	4	+	-		1	7			6	2	5	-	2
50 & Over	1	3	+	5		-	4			-	-	2	2	-
Unk./No resp.	1	-	+	-		-	-			5	-	-	-	-
Age (%) CODAP Grouping														
6-9	+	-	-	-		-	-			-	-	-	-	-
10-17	16	5	17	5		18	14			2	5	10	19	18
18-20	21	22	22	30		24	16			8	11	12	18	21
21-25	34	34	34	60		31	30			33	37	22	34	34
26-30	18	19	19	-		16	21			27	27	27	18	15
31-44	10	16	8	-		10	13			22	19	24	10	11
45 & Over	1	4	+	5		+	5			3	2	5	2	1
Unk./No resp.	1	-	+	-		-	-			5	-	-	-	-
Race (%)														
White	80	71	83	95		93	91			70	76	88	85	86
Black	6	23	6	5		4	-			6	3	7	6	6
Other	3	1	1	-		1	9			5	6	-	2	1
Unk./No resp.	11	4	9	-		2	-			19	14	5	6	7
Sex (%)														
Male	57	55	59	65		63	57			62	54	51	58	52
Female	42	45	41	35		36	43			38	46	49	42	47
Unk./No resp.	+	-	+	-		1	-			-	-	-	-	1

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Methaqualone, a synthetic non-barbiturate sedative has been found to have a high potential for both physiological and psychological dependence with prolonged use. Tolerance effects have also been noted. Because of its depressant action on the central nervous system, methaqualone may be potentiated by alcohol, the barbiturates and other sedatives.

TABLE 3.033 - GLUTETHIMIDE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	495	7**	15**	30	22	25	16**	4**	6**	15	2**	9**	74	18**	3**
Alone (%)	40	57	33	27	59	40	69	75	17	20	-	56	32	22	33
Rank in TDS/SMSA	35	37.5	31.5	32	28	31	32	39	36.5	36.5	40.5	31	24	36	40.5
Source (%)															
Legal RX	52			30	55	56							41		
Forged RX	+			3	-	-							-		
Stolen	1			-	-	-							-		
Street buy	4			20	5	4							-		
Over-the-counter	-			-	-	-							-		
Gift	1			-	-	-							-		
Other	-			-	-	-							-		
Unk./No resp.	42			53	41	40							59		
Motivation (%)															
Psychic effects	12			23	5	16							7		
Dependence	13			10	9	12							12		
Suic.att./gest.	52			43	82	52							45		
Unknow./Unwill.	-			-	-	-							-		
Other	3			7	-	8							1		
Unk./No resp.	23			20	9	20							36		
Age (%) DAWN Grouping															
6-9	-			-	-	-							-		
10-19	8			7	5	12							1		
20-29	34			67	9	32							47		
30-39	25			20	27	20							24		
40-49	16			3	45	24							20		
50 & Over	15			3	14	12							7		
Unk./No resp.	1			-	-	-							-		
Age (%) CODAP Grouping															
6-9	-			-	-	-							-		
10-17	5			3	-	8							-		
18-20	5			3	5	4							5		
21-25	18			37	-	12							27		
26-30	18			30	14	20							24		
31-44	31			20	68	32							30		
45 & Over	21			7	14	24							14		
Unk./No resp.	1			-	-	-							-		
Race (%)															
White	77			97	91	52							76		
Black	12			-	5	20							14		
Other	1			-	-	-							1		
Unk./No resp.	10			3	5	28							9		
Sex (%)															
Male	40			53	14	24							51		
Female	60			47	86	76							49		
Unk./No resp.	-			-	-	-							-		

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

55

Rank in TDS

22

Concomitance	N	%
Alone	16	29
In Comb.	39	71

Cause/Manner of Death

	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	25	45	-	-
Accid./Unexp.	16	29	-	-
Unk./No resp.	12	22	2	4

Age	N	%		N	%
6-9	-	-	40-49	13	24
10-19	4	7	50 & Over	14	25
20-29	13	24	Unk./No resp.	-	-
30-39	11	20			

Race	N	%
White	47	85
Black	6	11
Other	1	2
Unk./No resp.	1	2

Sex	N	%
Male	24	44
Female	31	56

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.033 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	495	5**	66	1**	-	61	4**	10**	2**	19**	5**	5**	14**	57
Alone (%)	40	20	55	100	-	33	50	50	50	21	60	40	50	42
Rank in TDS/SMSA	35	40	31.5	38	-	33	38	29	36	31	37	38.5	35	35
Source (%)														
Legal RX	52		68			10								74
Forged RX	+		-			2								-
Stolen	1		2			-								2
Street buy	4		8			5								-
Over-the-counter	-		-			-								-
Gift	1		2			3								2
Other	-		-			-								-
Unk./No resp.	208		21			84								25
Motivation (%)														
Psychic effects	12		5			25								9
Dependence	13		12			13								7
Suic.att./gest.	52		77			28								56
Unknow./Unwill.	-		-			-								-
Other	3		2			-								5
Unk./No resp.	23		8			39								25
Age (%) DAWN Grouping														
6-9	-		-			-								-
10-19	8		3			16								11
20-29	34		35			44								18
30-39	25		32			21								37
40-49	16		12			5								19
50 & Over	15		17			13								16
Unk./No resp.	1		2			-								-
Age (%) CODAP Grouping														
6-9	-		-			-								-
10-17	5		2			11								5
18-20	5		3			8								7
21-25	18		23			16								11
26-30	18		14			33								5
31-44	31		35			13								49
45 & Over	21		23			18								23
Unk./No resp.	1		2			-								-
Race (%)														
White	77		82			69								86
Black	12		15			20								2
Other	1		-			2								4
Unk./No resp.	10		3			10								9
Sex (%)														
Male	40		39			49								40
Female	60		61			51								60
Unk./No resp.	-		-			-								-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Glutethimide is a non-barbiturate sedative which works as a depressant on the central nervous system. Like the barbiturates, excessive use of glutethimide can result in both physical and psychological dependence. Alcohol, barbiturates and other central nervous system depressants can potentiate glutethimide effects, producing respiratory depression, coma, and death.

TABLE 3.034 - ETHCHLORVYNOL

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,965	48	31	31	15**	195	26	29	18**	164	64	17**	128	148	10**
Alone (%)	37	42	35	29	20	37	38	52	39	38	30	41	48	49	20
Rank in TDS/SMSA	21	15	25	30.5	30.5	9	30	15	30	11	9	26.5	20.5	14	31.5
Source (%)															
Legal RX	37	54	45	39		33	54	59		51	30		34	62	
Forged RX	1	-	-	-		-	-	-		-	-		-	-	
Stolen	1	2	6	-		2	4	-		2	-		-	1	
Street buy	11	2	6	-		6	8	7		4	8		2	12	
Over-the-counter	-	-	-	-		-	-	-		-	-		-	-	
Gift	2	4	-	3		2	-	3		1	2		4	5	
Other	-	-	-	-		-	-	-		-	-		-	-	
Unk./No resp.	48	38	42	58		57	35	31		42	61		60	20	
Motivation (%)															
Psychic effects	21	17	16	6		24	15	24		15	22		13	40	
Dependence	18	10	13	26		15	8	-		15	16		6	20	
Suic.att./gest.	34	52	58	48		28	58	38		50	39		38	33	
Unknow./Unwill.	-	-	-	-		-	-	-		-	-		-	-	
Other	2	2	-	3		3	4	14		3	3		1	1	
Unk./No resp.	26	23	16	16		35	23	28		20	22		42	5	
Age (%) DAWN Grouping															
6-9	+	-	-	-		-	-	-		1	-		-	-	
10-19	9	23	10	-		16	23	14		9	25		5	11	
20-29	50	50	48	68		50	35	45		55	41		35	46	
30-39	25	17	32	13		17	19	28		23	19		38	32	
40-49	8	8	3	6		9	12	7		10	6		13	7	
50 & Over	5	2	6	10		5	12	7		2	9		9	5	
Unk./No resp.	2	-	-	3		3	-	-		1	-		1	-	
Age (%) CODAP Grouping															
6-9	+	-	-	-		-	-	-		1	-		-	-	
10-17	4	17	3	-		8	12	10		3	20		3	7	
18-20	9	10	13	3		12	15	3		11	11		4	8	
21-25	27	27	19	19		27	8	31		31	23		19	18	
26-30	24	21	32	58		22	27	14		21	14		17	28	
31-44	25	21	26	3		20	19	28		26	17		44	31	
45 & Over	9	4	6	13		9	19	14		7	14		13	8	
Unk./No resp.	2	-	-	3		3	-	-		1	-		1	-	
Race (%)															
White	75	83	84	84		65	77	93		71	92		67	77	
Black	8	6	6	3		9	19	3		20	2		13	3	
Other	4	-	-	3		5	-	3		-	-		3	5	
Unk./No resp.	13	10	10	10		21	4	-		9	6		17	15	
Sex (%)															
Male	49	33	58	58		53	38	41		43	52		24	52	
Female	51	67	42	42		47	62	59		57	48		76	48	
Unk./No resp.	+	-	-	-		-	-	-		-	-		-	-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

157

Rank in TDS

12

Concomitance	N	%
Alone	27	17
In Comb.	130	83

Cause/Manner of Death

	Drug-Induced Deaths		Drug-Related Deaths	
	N	%	N	%
Suicide	60	38	3	2
Accid./Unexp.	52	33	12	8
Unk./No resp.	26	17	4	3

Age	N	%
6-9	-	-
10-19	9	6
20-29	58	37
30-39	46	29
40-49	18	11
50 & Over	26	17
Unk./No resp.	-	-

Race	N	%
White	135	86
Black	17	11
Other	5	3
Unk./No resp.	-	-

Sex	N	%
Male	85	54
Female	72	46

**Percentages for demographics not computed due to small numbers..

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.034 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,965	44	510	2**	28	145	38	44	9**	30	22	23	35	111
Alone (%)	37	48	32	50	29	35	34	20	22	37	36	30	40	44
Rank in TDS/SMSA	21	22	15	32.5	8.5	20	26.5	11	21.5	27	27	29	23.5	28
Source (%)														
Legal RX	37	43	11		32	32	76	73		57	50	43	40	59
Forged RX	1	11	+		7	1	-	-		-	-	-	-	-
Stolen	1	2	+		-	-	5	2		-	-	-	3	2
Street buy	11	7	26		-	6	8	-		7	14	4	3	2
Over-the-counter	-	-	-		-	-	-	-		-	-	-	-	-
Gift	2	2	1		4	2	-	2		-	-	-	3	3
Other	-	-	-		-	-	-	-		-	-	-	-	-
Unk./No resp.	18	34	61		57	58	13	23		37	36	52	51	35
Motivation (%)														
Psychic effects	21	41	24		14	17	16	7		13	-	39	14	20
Dependence	18	9	35		-	9	18	14		27	18	-	14	5
Suic.att./gest.	34	39	10		54	40	47	41		40	64	52	60	48
Unknow./Unwill.	-	-	-		-	-	-	-		-	-	-	-	-
Other	2	2	+		-	2	3	2		-	14	-	-	3
Unk./No resp.	26	9	31		32	34	18	36		33	9	9	11	27
Age (%) DAWN Grouping														
6-9	+	-	-		-	-	-	-		-	-	-	-	-
10-19	9	20	4		25	9	8	7		3	5	13	3	11
20-29	50	41	59		54	65	45	41		43	50	35	40	46
30-39	25	23	27		14	17	21	16		40	36	39	23	22
40-49	8	9	6		4	4	13	23		10	9	4	14	13
50 & Over	5	7	1		4	3	13	14		3	-	9	20	9
Unk./No resp.	2	-	4		-	3	-	-		-	-	-	-	-
Age (%) CODAP Grouping														
6-9	+	-	-		-	-	-	-		-	-	-	-	-
10-17	4	11	1		-	3	3	5		-	-	-	-	4
18-20	9	20	6		25	10	8	5		7	5	17	6	14
21-25	27	14	32		25	41	29	34		27	23	13	29	22
26-30	24	18	29		32	25	16	11		20	41	22	14	22
31-44	25	20	26		14	16	29	18		37	23	39	26	24
45 & Over	9	16	2		4	3	16	27		10	9	9	26	15
Unk./No resp.	2	-	4		-	3	-	-		-	-	-	-	-
Race (%)														
White	75	89	67		93	88	87	84		73	77	91	80	79
Black	8	11	10		-	7	-	2		10	-	-	9	5
Other	4	-	7		-	2	5	-		-	-	-	6	1
Unk./No resp.	13	-	15		7	3	8	14		17	23	9	6	15
Sex (%)														
Male	49	48	60		29	46	39	61		40	73	30	46	41
Female	51	52	40		71	53	61	39		60	27	70	54	59
Unk./No resp.	+	-	-		-	1	-	-		-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Ethchlorvynol, a non-barbiturate sedative, works as a depressant on the central nervous system, with effects similar to those of the short-acting secobarbital. As with the barbiturates, excessive use of ethchlorvynol can result in both physical and psychological dependence. Alcohol and other central nervous system depressants have the ability to potentiate ethchlorvynol effects, increasing the risk of coma or death.

TABLE 3.035 - OVER-THE-COUNTER SLEEP AIDS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	2,260	65	38	108	43	91	83	48	97	137	60	52	141	78	104
Alone (%)	57	66	47	60	58	48	47	56	64	60	55	65	70	62	52
Rank in TDS/SMSA	18	11	20	14	19	19	9	10	7	14	10.5	9	17.5	25	7
Source (%)															
Legal RX	3	2	3	2	5	5	2	2	2	2	-	-	1	-	1
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	1	-	-	-	2	-	1	-	-	1	-	-	1	-	-
Street buy	2	-	-	5	-	-	1	2	2	2	-	6	-	-	3
Over-the-counter	85	91	92	85	91	76	78	85	91	83	93	88	88	86	95
Gift	+	-	-	-	-	-	-	-	-	1	-	-	1	-	-
Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unk./No resp.	10	8	5	8	2	19	17	10	5	11	7	6	10	14	1
Motivation (%)															
Psychic effects	11	15	21	6	7	10	11	29	7	14	32	10	8	17	7
Dependence	1	3	3	2	-	-	-	-	-	2	-	2	-	1	1
Suic.att./gest.	72	55	68	76	70	58	59	52	82	69	62	77	70	81	86
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	1	-	-	-	-	-
Other	1	-	5	2	-	2	2	-	2	2	-	2	1	-	1
Unk./No resp.	15	26	3	14	23	31	29	19	8	12	10	10	21	1	6
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-19	28	31	32	33	35	35	24	31	33	19	25	29	28	28	33
20-29	46	48	32	49	44	41	48	54	41	55	40	44	48	54	47
30-39	16	8	32	10	9	13	13	10	20	18	18	21	11	8	7
40-49	6	8	-	5	-	5	11	4	4	4	10	2	9	5	3
50 & Over	4	6	5	2	12	5	4	-	2	4	3	2	5	5	8
Unk./No resp.	1	-	-	1	-	-	-	-	-	-	3	2	-	-	3
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-17	16	17	16	14	19	27	16	19	19	8	13	12	12	14	17
18-20	19	23	16	24	26	13	16	21	19	21	18	21	21	21	20
21-25	27	25	16	31	26	23	29	35	24	30	23	27	32	33	24
26-30	16	14	18	16	9	13	13	13	15	20	22	17	14	17	20
31-44	16	12	29	9	9	16	16	10	21	15	12	19	15	9	6
45 & Over	6	9	5	5	12	7	11	2	3	6	8	2	6	6	10
Unk./No resp.	1	-	-	1	-	-	-	-	-	-	3	2	-	-	3
Race (%)															
White	68	68	76	81	79	63	75	71	52	59	82	67	61	50	76
Black	13	18	21	12	5	16	17	10	3	29	12	10	8	29	-
Other	4	-	-	3	2	5	-	10	5	1	-	2	7	3	1
Unk./No resp.	15	14	3	5	14	15	8	8	40	11	7	21	24	18	23
Sex (%)															
Male	34	31	45	44	40	31	34	25	41	32	40	19	26	29	39
Female	66	69	55	56	60	69	66	75	59	68	60	81	74	71	60
Unk./No resp.	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

5**

Rank in TDS

36.5

Concomitance	N	%
Alone	3	60
In Comb.	2	40

Cause/Manner of Death

	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%		N	%
6-9			40-49		
10-19			50 & Over		
20-29			Unk./No resp.		
30-39					

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.035 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	2,260	23	132	27	19**	109	93	29	23	61	33	94	98	364
Alone (%)	57	78	61	65	32	61	46	59	52	52	55	8	62	55
Rank in TDS/SMSA	18	31	26	8	16	25	8	18	9.5	15	21.5	5	11	10
Source (%)														
Legal RX	3	-	2	-		2	4	-	4	3	-	1	1	6
Forged RX	-	-	-	-		-	-	-	-	-	-	-	-	-
Stolen	1	-	4	3		-	-	-	-	-	-	-	-	1
Street buy	2	-	4	3		6	4	-	-	-	-	-	1	2
Over-the-counter	85	91	70	97		78	88	90	96	90	94	88	83	83
Gift	+	4	1	-		-	-	-	-	-	-	1	-	+
Other	-	-	-	-		-	-	-	-	-	-	-	-	-
Unk./No resp.	10	4	19	-		14	3	10	-	7	6	10	15	8
Motivation (%)														
Psychic effects	11	26	2	8		17	11	7	13	21	-	4	8	10
Dependence	1	-	2	-		-	2	-	4	2	-	-	-	2
Suic.att./gest.	72	70	81	78		52	77	83	78	64	97	85	81	73
Unknow./Unwill.	+	-	-	-		-	-	-	-	-	-	-	-	-
Other	1	-	-	-		4	-	-	-	5	-	2	-	2
Unk./No resp.	15	4	14	14		28	10	10	4	11	3	9	11	14
Age (%) DAWN Grouping														
6-9	+	-	1	-		-	-	-	-	-	-	-	-	-
10-19	28	22	28	30		39	24	24	30	21	12	16	28	27
20-29	46	35	42	51		44	45	52	48	54	58	57	41	41
30-39	16	26	14	14		12	19	17	17	18	24	13	21	21
40-49	6	9	5	-		4	8	-	4	2	3	10	6	8
50 & Over	4	4	8	5		2	4	7	-	5	-	2	4	3
Unk./No resp.	1	4	2	-		-	-	-	-	-	3	2	-	+
Age (%) CODAP Grouping														
6-9	+	-	1	-		-	-	-	-	-	-	-	-	-
10-17	15	13	20	8		21	9	14	17	16	-	7	17	16
18-20	19	13	12	24		24	27	21	17	10	15	16	16	17
21-25	27	22	28	30		21	22	24	35	38	33	33	24	26
26-30	16	17	16	22		17	15	21	17	16	30	18	15	12
31-44	16	22	14	11		15	20	14	13	15	15	16	20	24
45 & Over	6	9	8	5		3	8	7	-	5	3	7	6	5
Unk./No resp.	1	4	2	-		-	-	-	-	-	3	2	-	+
Race (%)														
White	68	57	70	78		65	82	66	61	59	48	61	53	77
Black	13	30	13	22		29	5	10	9	7	12	7	24	8
Other	4	-	9	-		1	6	3	22	3	9	13	3	2
Unk./No resp.	15	13	8	-		5	6	21	9	31	30	19	19	13
Sex (%)														
Male	34	22	36	30		43	28	38	39	33	36	43	40	28
Female	66	74	64	70		57	72	62	61	67	64	57	60	72
Unk./No resp.	+	4	-	-		-	-	-	-	-	-	-	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denctes zero (0) mentions

SUPPLEMENTARY INFORMATION

Over-the-counter (O.T.C.) sleep aids are non-prescription products used as an aid in the relief of insomnia and restlessness. These products contain antihistamines which have prominent sedative effects. Analgesics, which are included in some formulations, contribute to the relief of insomnia when pain may be a contributing factor.

TABLE 3.04 - ALCOHOL-IN-COMBINATION

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	25,032	566	533	1,349	774	1,422	572	336	726	1,747	496	358	1,535	1,613	624
Alone (%)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rank in TDS/SMSA	1	1	1	1	1	1	1	2	1	1	1	1	2	1	1
Source (%)															
Legal RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	1	1	+	+	1	+	+	3	1	1	1	1	+	1	+
Street buy	3	3	2	2	1	3	8	4	2	2	1	1	3	1	4
Over-the-counter	83	80	85	84	89	80	68	87	85	85	80	81	79	86	89
Gift	2	2	1	1	1	1	1	1	2	2	1	2	1	5	+
Other	+	+	+	+	-	-	-	-	+	+	-	+	-	-	+
Unk./No resp.	12	15	12	13	9	15	23	6	11	10	17	15	17	8	6
Motivation (%)															
Psychic effects	26	26	42	19	30	36	23	38	27	18	35	21	21	71	28
Dependence	20	25	12	23	15	20	5	1	4	26	4	4	4	11	8
Suic.att./gest.	37	31	33	42	42	29	38	46	57	40	40	46	37	16	54
Unknow./Unwill.	+	+	+	+	1	+	1	-	1	1	+	-	+	-	-
Other	2	4	2	4	2	2	3	2	3	1	2	3	2	+	2
Unk./No resp.	17	18	14	14	15	28	32	13	11	15	22	27	36	2	11
Age (%) DAWN Grouping															
6-9	+	-	-	+	-	-	-	+	-	-	-	-	-	-	-
10-19	17	13	19	15	18	18	27	22	16	15	23	23	14	17	19
20-29	40	33	43	43	43	42	37	38	37	43	39	37	36	44	43
30-39	23	21	20	22	20	21	16	26	27	24	20	18	24	22	20
40-49	12	16	10	11	12	12	10	9	12	12	12	15	15	10	10
50 & Over	8	16	8	7	7	7	9	4	8	5	7	7	10	6	8
Unk./No resp.	1	2	1	1	1	1	2	1	1	1	+	1	1	+	1
Age (%) CODAP Grouping															
6-9	+	-	-	+	-	-	-	+	-	-	-	-	-	-	-
10-17	10	8	10	8	11	10	17	12	9	7	17	14	7	8	10
18-20	12	10	14	10	10	13	14	13	11	12	10	12	11	15	14
21-25	21	18	23	23	25	23	22	22	18	22	22	21	19	22	24
26-30	18	13	19	20	16	18	12	17	20	22	15	15	16	19	17
31-44	26	27	22	25	25	24	21	27	29	27	24	22	29	24	23
45 & Over	13	22	12	12	12	12	12	7	13	10	12	15	16	11	11
Unk./No resp.	1	2	1	1	1	1	2	1	1	1	+	1	1	+	1
Race (%)															
White	65	65	68	76	72	58	67	79	35	54	83	69	63	57	72
Black	19	27	29	17	19	27	18	13	3	35	8	11	16	28	1
Other	4	+	1	1	1	5	+	5	7	+	+	+	4	5	2
Unk./No resp.	11	8	2	5	8	9	15	3	55	11	8	20	17	11	26
Sex (%)															
Male	52	52	57	54	54	54	46	41	46	49	44	44	48	57	46
Female	48	48	42	46	46	46	54	59	54	51	56	55	52	43	54
Unk./No resp.	+	-	+	+	+	+	+	-	+	+	+	+	+	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

993

Rank in TDS

1

Concomitance	N	%
Alone	-	-
In Comb.	993	100

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	277	28	33	3
Accid./Unexp.	292	29	112	11
Unk./No resp.	234	24	45	5

Age	N	%		N	%
6-9	-	-	40-49	160	16
10-19	36	4	50 & Over	181	18
20-29	371	37	Unk./No resp.	1	+
30-39	244	25			

Race	N	%
White	709	71
Black	210	21
Other	56	6
Unk./No resp.	18	2

Sex	N	%
Male	644	65
Female	349	35

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.04 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	25,032	144	4,737	114	165	1,003	688	256	167	695	400	882	717	2,413
Alone (%)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rank in TDS/SMSA	1	5	1	2	2	2	1	2	1.5	1	2	1	1	1
Source (%)														
Legal RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	1	1	1	1	-	+	1	+	2	1	-	+	2	1
Street buy	3	5	3	4	5	4	4	4	5	3	2	3	2	4
Over-the-counter	83	81	88	85	70	70	87	77	73	86	90	88	77	75
Gift	2	2	2	-	1	2	4	2	-	1	1	+	3	1
Other	+	-	-	-	-	+	-	+	-	-	-	-	-	+
Unk./No resp.	12	11	6	10	24	23	4	16	20	10	7	8	15	19
Motivation (%)														
Psychic effects	26	19	17	24	21	29	30	22	10	23	24	24	18	21
Dependence	20	10	56	2	4	8	11	12	1	10	14	9	22	5
Suic.att./gest.	37	47	18	57	48	34	47	41	56	48	63	56	47	54
Unknow./Unwill.	+	1	+	-	1	1	+	+	1	1	1	+	+	+
Other	2	1	+	2	2	2	4	1	2	3	2	3	2	2
Unk./No resp.	17	22	9	18	24	30	10	26	31	17	6	11	13	20
Age (%) DAWN Grouping														
6-9	+	-	+	-	-	-	-	-	1	-	-	-	-	-
10-19	17	20	15	15	26	20	17	22	22	14	5	15	17	20
20-29	40	44	39	38	43	41	37	41	39	41	44	40	39	38
30-39	23	19	27	28	18	19	25	18	17	24	34	21	25	21
40-49	12	9	11	11	10	11	11	11	13	11	10	14	11	13
50 & Over	8	8	8	8	2	8	9	6	7	9	7	9	7	8
Unk./No resp.	1	-	1	-	1	1	+	1	2	1	1	1	1	+
Age (%) CODAP Grouping														
6-9	+	-	+	-	-	-	-	-	1	-	-	-	-	-
10-17	10	11	9	5	15	12	9	14	14	7	2	9	10	11
18-20	12	16	10	15	16	12	13	11	13	10	5	10	9	14
21-25	21	16	19	20	25	23	20	23	23	22	19	19	22	21
26-30	18	24	20	16	18	17	16	17	13	19	29	21	17	15
31-44	26	21	29	30	19	21	27	20	22	27	33	26	27	25
45 & Over	13	12	12	14	8	14	14	13	13	14	11	15	13	13
Unk./No resp.	1	-	1	-	1	1	+	1	2	1	1	1	1	+
Race (%)														
White	65	70	62	80	76	72	79	65	53	69	68	75	54	78
Black	19	19	26	19	5	20	5	14	8	10	12	9	35	7
Other	4	-	7	-	1	1	10	1	35	4	8	5	1	2
Unk./No resp.	11	10	5	1	18	6	7	20	4	17	13	11	11	14
Sex (%)														
Male	52	48	62	35	35	51	42	54	47	46	61	44	48	45
Female	48	52	37	65	65	49	58	46	51	54	39	56	52	54
Unk./No resp.	+	-	+	-	-	+	+	-	2	+	-	+	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

DAWN only collects data on alcohol that is taken concomitantly with another substance; not alcohol used alone. Alcohol is a depressant of the central nervous system and is slowly metabolized. Since alcohol has the ability to potentiate many drugs, it may be mentioned in many drug abuse episodes reported to DAWN where the ingested amounts of either the alcohol or the accompanying drug(s) would not result in a medical emergency if taken alone.

TABLE 3.05 THERAPEUTIC CLASS - NARCOTIC ANALGESICS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	13,525	171	354	748	121	744	200	75	192	1,450	65	60	595	666	81
Alone (%)	50	41	46	41	40	54	36	44	41	77	43	42	46	43	25
Rank in TDS/SMSA	4	5	2	2	8	3	5	6	4	2	8	9	7	3	10
Source (%)															
Legal RX	23	39	25	23	33	11	32	37	38	7	26	40	21	52	38
Forged RX	+	-	+	1	-	+	1	-	-	-	-	-	-	+	1
Stolen	1	5	1	1	1	+	4	4	4	+	5	5	+	1	7
Street buy	47	19	52	47	28	51	21	7	22	68	18	13	15	40	26
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	1	2	1	1	2	1	2	3	1	1	5	3	1	1	2
Other	+	1	-	+	-	+	-	-	-	+	2	3	-	-	-
Unk./No resp.	28	35	21	27	36	36	43	49	39	24	45	42	63	6	25
Motivation (%)															
Psychic effects	16	16	26	10	21	38	17	28	24	4	25	10	10	32	25
Dependence	60	43	54	59	49	63	30	23	27	86	38	30	30	53	31
Suic.att./gest.	14	28	16	16	25	6	36	28	39	6	20	40	25	12	35
Unknow./Unwill.	+	-	-	-	-	+	1	-	-	+	-	-	-	-	-
Other	2	5	1	5	2	1	4	12	4	+	9	3	1	1	2
Unk./No resp.	12	14	10	11	9	17	19	11	13	4	15	17	34	2	10
Age (%) DAWN Grouping															
6-9	+	-	-	+	-	-	-	-	-	-	-	-	-	-	-
10-19	7	13	6	7	12	6	13	19	10	3	12	18	8	5	9
20-29	55	51	57	59	50	57	56	56	52	60	62	47	47	53	51
30-39	27	20	27	24	16	29	17	15	23	27	14	25	26	32	26
40-49	7	12	6	4	17	6	7	4	6	7	8	2	13	5	6
50 & Over	3	4	2	4	4	2	7	7	8	2	5	8	5	5	7
Unk./No resp.	1	-	1	1	-	1	1	-	1	+	-	-	1	-	1
Age (%) CODAP Grouping															
6-9	+	-	-	+	-	-	-	-	-	-	-	-	-	-	-
10-17	3	8	4	3	5	2	8	9	6	1	8	7	4	2	6
18-20	6	8	6	7	11	6	10	20	9	4	11	18	7	6	5
21-25	27	37	26	31	21	32	34	29	28	27	42	15	23	25	27
26-30	30	16	33	30	29	28	19	20	23	36	22	33	26	30	25
31-44	26	22	26	22	17	28	19	11	23	26	11	17	31	31	25
45 & Over	6	9	4	5	18	4	10	11	10	5	8	10	10	7	11
Unk./No resp.	1	-	1	1	-	1	1	-	1	+	-	-	1	-	1
Race (%)															
White	49	65	46	59	65	26	53	85	42	20	75	70	60	60	63
Black	37	25	51	33	28	54	32	12	3	75	14	13	22	31	1
Other	5	1	-	3	-	10	2	1	16	+	-	-	5	2	-
Unk./No resp.	9	9	3	4	7	9	13	1	40	5	11	17	13	8	36
Sex (%)															
Male	61	51	63	63	56	59	49	39	57	58	65	43	54	59	60
Female	38	49	37	37	44	41	51	61	43	42	35	57	46	41	40
Unk./No resp.	+	-	-	+	-	-	1	-	-	+	-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

1,445

Rank in TDS

1

Concomitance	N	%
Alone	239	17
In Comb.	1,206	83

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	132	9	15	1
Accid./Unexp.	535	37	96	7
Unk./No resp.	561	39	106	7

Age	N	%		N	%
6-9	-	-	40-49	151	10
10-19	45	3	50 & Over	97	7
20-29	725	50	Unk./No resp.	1	+
30-39	426	29			

Race	N	%
White	872	60
Black	436	30
Other	120	8
Unk./No resp.	17	1

Sex	N	%
Male	1,010	70
Female	435	30

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.05 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	13,525	377	4,184	41	53	529	343	74	39	393	578	202	615	575
Alone (%)	50	42	50	37	36	38	36	43	28	48	65	28	61	41
Rank in TDS/SMSA	4	3	2	6	6.5	7	4	5	6	4	2	6	3	6
Source (%)														
Legal RX	23	25	21	61	25	26	38	35	44	22	9	33	10	42
Forged RX	+	2	+	-	-	+	1	1	-	-	-	-	-	1
Stolen	1	+	+	2	-	2	3	-	-	1	+	+	1	2
Street buy	47	58	56	5	6	21	46	30	23	46	73	20	58	15
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	1	2	1	7	6	3	3	4	-	2	1	2	2	1
Other	+	5	-	-	-	+	-	-	3	1	+	-	1	+
Unk./No resp.	28	9	22	24	64	48	15	30	31	29	17	44	28	38
Motivation (%)														
Psychic effects	16	46	9	15	15	30	15	15	10	21	11	21	13	18
Dependence	60	41	73	10	11	38	60	54	23	50	77	24	70	29
Suic.att./gest.	14	10	6	41	36	20	22	19	38	20	12	40	12	41
Unknow./Unwill.	+	-	+	-	-	-	-	-	3	-	-	-	+	+
Other	2	1	+	10	2	3	1	5	3	3	2	5	1	3
Unk./No resp.	12	3	12	27	36	21	6	9	23	12	4	12	5	13
Age (%) DAWN Grouping														
6-9	+	1	+	-	-	-	-	-	-	-	-	-	-	-
10-19	7	7	4	24	13	10	11	11	8	6	4	13	10	16
20-29	55	55	56	44	51	53	49	61	54	59	51	45	53	50
30-39	27	31	30	22	26	24	24	20	28	23	31	25	28	21
40-49	7	6	6	2	6	7	8	7	5	6	8	9	7	8
50 & Over	3	1	2	7	4	5	8	1	3	4	4	7	2	5
Unk./No resp.	1	-	2	-	-	1	-	-	3	1	1	1	1	1
Age (%) CODAP Grouping														
6-9	+	1	+	-	-	-	-	-	-	-	-	-	-	-
10-17	3	2	1	12	11	5	5	5	5	2	1	7	4	8
18-20	6	6	4	22	9	9	9	7	5	8	7	9	8	11
21-25	27	32	27	20	17	29	27	28	33	28	23	16	28	30
26-30	30	27	34	24	28	27	22	31	21	32	32	29	27	19
31-44	26	29	28	15	28	21	27	24	31	23	29	25	28	23
45 & Over	6	3	4	7	6	9	11	4	3	7	8	13	4	8
Unk./No resp.	1	-	2	-	-	1	-	-	3	1	1	1	1	1
Race (%)														
White	49	55	45	80	85	63	78	57	59	63	52	71	31	75
Black	37	44	36	20	2	31	5	34	10	18	26	12	64	13
Other	5	-	9	-	-	3	11	-	28	8	4	3	1	1
Unk./No resp.	9	1	10	-	13	3	6	9	3	10	18	14	4	12
Sex (%)														
Male	61	68	69	46	53	61	55	66	51	61	59	39	66	50
Female	38	31	31	54	47	39	45	34	49	39	41	61	34	50
Unk./No resp.	+	1	+	-	-	-	-	-	-	+	-	-	+	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Narcotic analgesics are drugs whose primary use is the relief of pain (analgesia). All narcotics are addictive, producing physical and sometimes psychological dependence. The narcotic analgesic class includes all narcotic substances reported to DAWN except codeine combinations which is a separate therapeutic class.

TABLE 3.051 - HEROIN/MORPHINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	6,822	44	190	368	36	577	47	14**	48	1,147	18**	8**	255	173	15**
Alone (%)	64	68	56	56	36	60	51	71	56	85	56	25	66	39	47
Rank in TDS/SMSA	3	17.5	3	3	22	3	20	27.5	18	3	25	33.5	7	10	29
Source (%)															
Legal RX	+	-	1	+	-	+	2		4	-			+	1	
Forged RX	+	-	1	+	-	+	2		-	-			-	1	
Stolen	+	-	-	-	-	-	2		-	-			-	-	
Street buy	77	61	85	88	75	63	64		75	77			32	95	
Over-the-counter	-	-	-	-	-	-	-		-	-			-	-	
Gift	1	2	1	1	-	1	4		-	+			2	-	
Other	+	2	-	-	-	-	-		-	+			-	-	
Unk./No resp.	22	34	13	11	25	36	28		23	22			65	3	
Motivation (%)															
Psychic effects	15	20	28	10	28	41	15		35	3			10	27	
Dependence	77	64	72	79	69	65	68		52	94			50	71	
Suic.att./gest.	4	5	3	4	6	4	11		8	2			9	2	
Unknow./Unwill.	+	-	-	-	-	-	-		-	+			-	-	
Other	1	5	-	3	-	1	-		6	+			-	-	
Unk./No resp.	8	11	7	5	6	16	13		10	2			32	1	
Age (%) DAWN Grouping															
6-9	+	-	-	+	-	-	-		-	-			-	-	
10-19	4	9	4	5	8	5	6		8	2			7	5	
20-29	59	75	65	64	69	59	62		73	60			54	64	
30-39	28	9	24	26	17	30	19		10	29			24	26	
40-49	6	5	5	2	6	5	9		6	7			11	3	
50 & Over	2	2	1	1	-	2	2		2	2			2	2	
Unk./No resp.	1	-	2	1	-	+	2		-	+			2	-	
Age (%) CODAP Grouping															
6-9	+	-	-	+	-	-	-		-	-			-	-	
10-17	1	5	2	1	-	1	2		4	+			3	2	
18-20	5	11	5	9	8	5	6		10	3			5	6	
21-25	29	52	31	33	33	32	38		44	27			26	31	
26-30	33	18	37	31	36	30	21		25	37			29	32	
31-44	26	9	22	22	19	27	23		13	27			28	25	
45 & Over	4	5	2	2	3	3	6		4	5			6	4	
Unk./No resp.	1	-	2	1	-	+	2		-	+			2	-	
Race (%)															
White	34	43	27	42	42	20	40		29	14			55	39	
Black	52	43	73	51	47	62	55		8	83			28	52	
Other	6	2	-	5	-	11	2		25	+			7	2	
Unk./No resp.	7	11	-	2	11	7	2		38	3			9	8	
Sex (%)															
Male	67	68	68	70	69	60	64		77	58			67	67	
Female	32	32	32	30	31	40	34		23	41			33	33	
Unk./No resp.	+	-	-	1	-	-	2		-	+			-	-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

619

Rank in TDS

2

Concomitance	N	%
Alone	136	22
In Comb.	483	78

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	30	5	5	1
Accid./Unexp.	280	45	42	7
Unk./No resp.	225	36	37	6

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	53	9	White	339	55	Male	475	77
10-19	20	3	50 & Over	23	4	Black	230	37	Female	144	23
20-29	336	54	Unk./No resp.	-	-	Other	40	6			
30-39	187	30				Unk./No resp.	10	2			

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.051 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	6,822	168	2,201	4**	4**	149	99	27	10**	227	426	52	379	136
Alone (%)	64	45	60	50	25	53	53	52	40	63	78	40	75	54
Rank in TDS/SMSA	3	3	3	27.5	35	19	6	19	19.5	3	1	15.5	3	22.5
Source (%)														
Legal RX	+	1	+			1	-	-		+	-	2	+	1
Forged RX	+	1	+			-	-	-		-	-	-	-	1
Stolen	+	-	+			-	-	-		-	-	-	-	1
Street buy	77	96	81			62	93	70		68	91	63	78	49
Over-the-counter	-	-	-			-	-	-		-	-	-	-	-
Gift	1	-	+			3	2	-		2	1	4	3	2
Other	+	-	-			-	-	-		+	-	-	-	-
Unk./No resp.	22	2	18			34	6	30		29	9	31	19	45
Motivation (%)														
Psychic effects	15	45	8			37	10	11		26	7	35	13	22
Dependence	77	52	80			54	90	85		65	90	40	81	63
Suic.att./gest.	4	1	2			6	4	4		7	5	12	2	13
Unknow./Unwill.	+	-	-			-	-	-		-	-	-	-	-
Other	1	-	+			3	1	-		1	1	2	1	1
Unk./No resp.	8	2	10			16	1	7		10	2	17	5	11
Age (%) DAWN Grouping														
6-9	+	-	-			-	-	-		-	-	-	-	-
10-19	4	4	3			1	9	4		4	3	4	6	8
20-29	59	58	57			58	62	67		68	55	62	58	56
30-39	28	35	30			28	23	26		23	31	27	28	28
40-49	6	4	6			10	6	4		3	7	4	7	6
50 & Over	2	-	1			2	-	-		1	3	2	1	1
Unk./No resp.	1	-	2			1	-	-		1	1	2	2	1
Age (%) CODAP Grouping														
6-9	+	-	-			-	-	-		-	-	-	-	-
10-17	1	1	1			-	1	-		1	+	2	2	2
18-20	5	2	4			5	10	7		6	5	2	5	10
21-25	29	33	27			30	36	37		33	27	25	30	28
26-30	33	34	34			31	26	26		36	32	42	30	27
31-44	26	28	27			25	25	26		22	29	25	29	28
45 & Over	4	2	4			9	1	4		1	6	2	2	4
Unk./No resp.	1	-	2			1	-	-		1	1	2	2	1
Race (%)														
White	34	36	37			41	79	41		57	50	58	16	60
Black	52	63	44			53	6	52		21	28	25	82	26
Other	6	-	9			4	11	-		13	4	6	+	1
Unk./No resp.	7	1	10			2	4	7		9	18	12	2	13
Sex (%)														
Male	67	79	73			70	69	81		69	58	67	71	68
Female	32	20	27			30	31	19		30	42	33	29	32
Unk./No resp.	+	1	+			-	-	-		+	-	-	+	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Morphine, a natural alkaloid found in opium, is a powerful narcotic analgesic. Although heroin may be the ingested drug, it is metabolized into morphine. To prevent confusion, therefore, particularly with respect to attribution of cause of death, "heroin/morphine" is treated as a single drug, and the number of its mentions is the sum of the number of heroin and morphine mentions actually reported.

TABLE 3.052 - METHADONE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	2,415	13**	55	86	9**	100	14**	3**	17**	61	6**	4**	36	156	3**
Alone (%)	40	38	35	36	56	29	43	100	53	48	50	50	50	44	33
Rank in TDS/SMSA	17	31	16	16	34.5	18	34	40.5	31	25.5	35	38	32	12	40.5
Source (%)															
Legal RX	50		64	78		61				54			56	95	
Forged RX	+		-	-		-				-			-	-	
Stolen	1		2	-		1				-			-	-	
Street buy	25		22	5		8				21			-	2	
Over-the-counter	-		-	-		-				-			-	-	
Gift	1		5	-		1				-			-	-	
Other	1		-	-		-				-			-	-	
Unk./No resp.	24		11	19		31				26			44	3	
Motivation (%)															
Psychic effects	17		27	10		37				5			8	26	
Dependence	66		58	76		75				80			36	67	
Suic.att./gest.	6		13	6		4				8			14	8	
Unknow./Unwill.	+		-	-		1				-			-	-	
Other	1		2	5		-				2			-	-	
Unk./No resp.	14		7	5		12				8			42	1	
Age (%) DAWN Grouping															
6-9	+		-	-		-				-			-	-	
10-19	3		-	2		3				3			6	1	
20-29	58		55	65		56				66			50	57	
30-39	30		40	26		28				25			25	38	
40-49	6		4	3		11				3			11	3	
50 & Over	2		2	3		1				3			6	1	
Unk./No resp.	2		-	-		1				-			3	-	
Age (%) CODAP Grouping															
6-9	+		-	-		-				-			-	-	
10-17	1		-	1		1				-			3	-	
18-20	4		4	1		4				7			6	1	
21-25	29		33	27		33				21			28	23	
26-30	33		20	43		22				48			22	41	
31-44	28		42	23		36				20			28	33	
45 & Over	4		2	5		3				5			11	2	
Unk./No resp.	2		-	-		1				-			3	-	
Race (%)															
White	56		53	70		43				41			75	62	
Black	26		47	27		29				51			11	32	
Other	8		-	1		8				-			3	3	
Unk./No resp.	10		-	2		20				8			11	4	
Sex (%)															
Male	66		75	73		58				67			58	58	
Female	34		25	27		42				31			42	42	
Unk./No resp.	+		-	-		-				2			-	-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

363

Rank in TDS

5

Concomitance	N	%
Alone	55	15
In Comb.	308	85

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	17	5	3	1
Accid./Unexp.	101	28	16	4
Unk./No resp.	178	49	48	13

Age	N	%		N	%
6-9	-	-	40-49	23	6
10-19	9	2	50 & Over	11	3
20-29	219	60	Unk./No resp.	-	-
30-39	101	28			

Race	N	%
White	233	64
Black	82	23
Other	44	12
Unk./No resp.	4	1

Sex	N	%
Male	265	73
Female	98	27

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.052 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	2,415	68	1,490	1**	5**	117	33	3**	3**	24	31	10**	25	42
Alone (%)	40	65	38	-	60	37	39	100	33	38	23	20	56	60
Rank in TDS/SMSA	17	9	4	38	33.5	23	29	37.5	33	30	24	34.5	30	37
Source (%)														
Legal RX	50	63	41			43	79			42	55		60	52
Forged RX	+	1	+			-	-			-	-		-	-
Stolen	1	-	+			2	-			-	-		4	-
Street buy	25	3	34			10	33			29	10		8	14
Ove.-the-counter	-	-	-			-	-			-	-		-	-
Gift	1	4	+			3	3			-	-		-	2
Other	1	25	-			1	-			4	3		16	2
Unk./No resp.	24	4	25			42	9			25	32		20	29
Motivation (%)														
Psychic effects	17	69	11			33	9			17	23		8	14
Dependence	66	32	68			51	82			67	61		88	55
Suic.att./gest.	6	-	5			10	9			4	26		-	12
Unknow./Unwill.	+	-	-			-	-			-	-		-	-
Other	1	-	+			3	-			4	3		4	10
Unk./No resp.	14	-	17			21	-			13	3		4	17
Age (%) DAWN Grouping														
6-9	+	-	+			-	-			-	-		-	-
10-19	3	-	2			11	-			4	10		4	10
20-29	58	49	57			62	64			71	35		56	74
30-39	30	35	30			24	24			21	39		32	17
40-49	6	15	7			2	6			-	6		-	-
50 & Over	2	1	1			2	6			-	10		8	-
Unk./No resp.	2	-	3			-	-			4	[illegible]		-	-
Age (%) CODAP Grouping														
6-9	+	-	+			-	-			-	-		-	-
10-17	1	-	1			4	-			4	-		4	7
18-20	4	4	4			9	-			13	13		-	2
21-25	29	25	28			35	36			33	26		24	60
26-30	33	24	34			36	30			29	19		32	17
31-44	28	43	28			13	21			17	29		32	14
45 & Over	4	4	3			3	12			-	13		8	-
Unk./No resp.	2	-	3			-	-			4	-		-	-
Race (%)														
White	56	71	53			66	67			92	58		56	71
Black	26	29	26			26	12			-	13		36	14
Other	8	-	10			4	18			4	-		4	-
Unk./No resp.	10	-	11			3	3			4	29		4	14
Sex (%)														
Male	66	69	67			69	64			58	55		68	64
Female	34	31	33			31	36			42	45		32	36
Unk./No resp.	+	-	+			-	-			-	-		-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Methadone, a synthetic opiate, was developed during World War II. Methadone's analgesic properties are slightly more potent than morphine and somewhat shorter acting. Because of cross tolerance between the opiates, methadone can prevent the withdrawal symptoms associated with heroin addiction, and is therefore used in the treatment of heroin and morphine dependence.

TABLE 3.053 - CODEINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,197	11**	34	85	38	29	51	17**	19**	57	7**	8**	216	21	10**
Alone (%)	24	27	29	14	13	28	27	29	21	21	29	25	24	33	10
Rank in TDS/SMSA	30	34	23.5	17	21	30	18	23.5	29	27	33	33.5	9	35	31.5
Source (%)															
Legal RX	42		50	46	37	24	37			47			35	90	
Forged RX	+		-	1	-	-	-			-			-	-	
Stolen	2		-	2	3	-	8			-			+	5	
Street buy	7		-	6	3	10	4			5			1	-	
Over-the-counter	-		-	-	-	-	-			-			-	-	
Gift	2		-	1	5	10	2			-			+	-	
Other	+		-	1	-	3	-			-			-	-	
Unk./No resp.	48		50	45	53	52	53			47			63	5	
Motivation (%)															
Psychic effects	18		24	13	16	21	12			21			13	24	
Dependence	18		15	20	5	21	4			39			13	19	
Suic.att./gest.	45		50	51	63	38	61			32			38	43	
Unknow./Unwill.	+		-	-	-	-	-			-			-	-	
Other	3		3	8	5	-	2			-			1	-	
Unk./No resp.	18		12	13	13	28	24			12			36	14	
Age (%) DAWN Grouping															
6-9	+		-	-	-	-	-			-			-	-	
10-19	16		15	20	21	24	22			7			13	-	
20-29	45		41	48	55	48	53			42			41	38	
30-39	22		32	22	11	14	8			23			25	33	
40-49	10		6	6	3	10	10			18			15	5	
50 & Over	7		6	4	11	-	8			9			6	24	
Unk./No resp.	1		-	-	-	3	-			2			-	-	
Age (%) CODAP Grouping															
6-9	+		-	-	-	-	-			-			-	-	
10-17	9		15	13	13	10	18			5			6	-	
18-20	12		9	8	16	34	12			4			10	-	
21-25	22		15	29	26	17	29			14			18	14	
26-30	22		24	21	21	10	16			30			23	29	
31-44	24		29	22	13	17	14			30			33	33	
45 & Over	10		9	6	11	7	12			16			11	24	
Unk./No resp.	1		-	-	-	3	-			2			-	-	
Race (%)															
White	64		71	72	68	48	55			51			59	62	
Black	21		26	15	29	34	20			32			22	24	
Other	2		-	1	-	7	2			2			2	-	
Unk./No resp.	13		3	12	3	10	24			16			17	14	
Sex (%)															
Male	40		35	36	32	55	31			35			41	33	
Female	60		65	64	68	45	69			65			59	67	
Unk./No resp.	-		-	-	-	-	-			-			-	-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

250

Rank in TDS

8

Concomitance	N	%
Alone	23	9
In Comb.	227	91

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	59	24	4	2
Accid./Unexp.	117	47	28	11
Unk./No resp.	41	16	1	+

Age	N	%		N	%
6-9	-	-	40-49	51	20
10-19	7	3	50 & Over	42	17
20-29	78	31	Unk./No resp.	1	+
30-39	71	28			

Race	N	%
White	186	74
Black	55	22
Other	9	4
Unk./No resp.	-	-

Sex	N	%
Male	120	48
Female	130	52

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.053 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,197	33	112	7**	3**	64	44	11**	1**	73	65	41	26	114
Alone (%)	24	39	31	29	67	17	20	36	100	16	20	15	19	29
Rank in TDS/SMSA	30	26	27	23.5	36.5	32	23.5	26.5	38	12	9.5	21.5	29	26
Source (%)														
Legal RX	42	55	34			17	50			60	34	44	42	53
Forged RX	+	6	-			-	-			-	-	-	-	-
Stolen	2	-	2			3	2			4	-	-	-	1
Street buy	7	15	14			3	23			5	25	-	12	4
Over-the-counter	-	-	-			-	-			-	-	-	-	-
Gift	2	6	1			3	5			3	-	2	-	-
Other	+	-	-			-	-			-	-	-	-	-
Unk./No resp.	48	18	49			73	25			27	42	54	46	43
Motivation (%)														
Psychic effects	18	61	12			23	25			10	25	22	8	18
Dependence	18	6	34			19	36			15	35	7	23	15
Suic.att./gest.	45	24	40			36	34			53	37	54	50	54
Unknow./Unwill.	+	-	-			-	-			-	-	-	-	1
Other	3	-	3			3	-			7	5	7	-	3
Unk./No resp.	18	9	12			23	9			15	6	10	19	12
Age (%) DAWN Grouping														
6-9	+	3	-			-	-			-	-	-	-	-
10-19	16	15	13			23	14			11	6	20	27	23
20-29	45	39	48			55	43			44	37	41	38	46
30-39	22	27	23			17	27			25	28	17	35	19
40-49	10	9	6			2	9			12	15	17	-	6
50 & Over	7	6	7			2	7			8	12	5	-	6
Unk./No resp.	1	-	2			2	-			-	2	-	-	-
Age (%) CODAP Grouping														
6-9	+	3	-			-	-			-	-	-	-	-
10-17	9	9	8			14	5			5	2	10	15	11
18-20	12	6	9			14	14			10	8	22	23	17
21-25	22	33	22			30	32			22	11	12	19	26
26-30	22	12	26			22	9			25	29	17	23	18
31-44	24	27	23			17	27			23	35	22	19	21
45 & Over	10	9	10			2	14			15	14	17	-	8
Unk./No resp.	1	-	2			2	-			-	2	-	-	-
Race (%)														
White	64	52	72			64	77			64	51	68	42	75
Black	21	48	18			28	2			19	29	7	27	11
Other	2	-	2			3	14			3	3	5	-	-
Unk./No resp.	13	-	8			5	7			14	17	20	31	14
Sex (%)														
Male	40	48	43			39	41			38	57	15	46	39
Female	60	52	57			61	59			62	43	85	54	61
Unk./No resp.	-	-	-			-	-			-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Codeine is an alkaloid of opium. It has approximately one-eighth the analgesic effect of morphine and therefore is used for minor pain or for its antitussive action. Physical dependence on codeine is uncommon; when it does occur, the withdrawal symptoms are of a much less serious nature than those connected with morphine, heroin, or the barbiturates. Tolerance effects develop with prolonged codeine use and cross tolerance with the other opiates has been noted.

TABLE 3.054 - MEPERIDINE HCl

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	729	37	17**	40	7**	10**	31	8**	20	34	6**	18**	16**	57	16**
Alone (%)	40	27	53	30	43	70	29	13	45	26	33	39	38	51	19
Rank in TDS/SMSA	33	22	29	26.5	37	35.5	28	34.5	28	33	35	25	36	29.5	27.5
Source (%)															
Legal RX	52	41		48			48		45	47				67	
Forged RX	1	-		-			-		-	-				-	
Stolen	2	5		-			-		-	6				-	
Street buy	12	3		3			6		-	9				23	
Over-the-counter	-	-		-			-		-	-				-	
Gift	2	3		3			-		-	-				2	
Other	+	-		-			-		-	3				-	
Unk./No resp.	32	49		48			45		55	35				9	
Motivation (%)															
Psychic effects	16	19		15			6		15	9				49	
Dependence	40	46		28			23		30	24				33	
Suic.att./gest.	30	30		35			42		45	47				14	
Unknow./Unwill.	+	-		-			-		-	-				-	
Other	4	8		5			10		-	-				-	
Unk./No resp.	12	5		18			23		15	24				4	
Age (%) DAWN Grouping															
6-9	-	-		-			-		-	-				-	
10-19	10	5		3			16		15	12				5	
20-29	40	46		53			52		35	47				42	
30-39	31	27		15			13		35	21				39	
40-49	8	14		8			10		5	6				2	
50 & Over	10	8		23			10		10	15				12	
Unk./No resp.	+	-		-			-		-	-				-	
Age (%) CODAP Grouping															
6-9	-	-		-			-		-	-				-	
10-17	6	5		3			10		5	3				2	
18-20	7	-		8			13		10	15				4	
21-25	20	32		25			23		20	24				23	
26-30	23	16		23			23		15	18				21	
31-44	29	32		20			19		35	24				39	
45 & Over	14	14		23			13		15	18				12	
Unk./No resp.	+	-		-			-		-	-				-	
Race (%)															
White	65	65		93			58		40	62				63	
Black	25	27		5			13		-	29				30	
Other	1	-		-			-		-	-				2	
Unk./No resp.	9	8		3			26		60	9				5	
Sex (%)															
Male	54	59		50			42		55	47				60	
Female	45	41		50			58		45	53				40	
Unk./No resp.	+	-		-			-		-	-				-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

27

Rank in TDS

28

Concomitance	N	%
Alone	4	15
In Comb.	23	85

Cause/Manner of Death

	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	4	15	-	-
Accid./Unexp.	11	41	3	11
Unk./No resp.	8	30	1	4

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	3	11	White	19	70	Male	21	78
10-19	1	4	50 & Over	5	19	Black	3	11	Female	6	22
20-29	9	33	Unk./No resp.	-	-	Other	4	15			
30-39	9	33				Unk./No resp.	1	4			

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.054 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	729	26	144	9**	15**	26	38	10**	6**	10**	12**	17**	29	70
Alone (%)	40	15	67	33	27	35	18	40	17	40	42	35	17	41
Rank in TDS/SMSA	33	30	24	21.5	22	39	26.5	29	25.5	35	30	32	28	33
Source (%)														
Legal RX	52	31	74			42	53						31	50
Forged RX	1	4	1			4	3						-	-
Stolen	2	-	1			-	3						-	6
Street buy	12	50	10			-	32						3	6
Over-the-counter	-	-	-			-	-						-	-
Gift	2	-	2			8	5						-	1
Other	+	-	-			-	-						-	-
Unk./No resp.	32	15	13			46	11						66	37
Motivation (%)														
Psychic effects	16	38	4			19	18						7	20
Dependence	40	35	81			23	42						34	16
Suic.att./gest.	30	27	10			31	26						48	47
Unknow./Unwill.	+	-	1			-	-						3	-
Other	4	-	2			8	5						3	3
Unk./No resp.	12	-	2			31	8						7	19
Age (%) DAWN Grouping														
6-9	-	-	-			-	-						-	-
10-19	10	15	8			12	11						24	10
20-29	40	50	26			35	29						41	47
30-39	31	27	53			19	37						17	20
40-49	8	8	6			12	13						7	10
50 & Over	10	-	7			19	11						10	10
Unk./No resp.	+	-	-			4	-						-	3
Age (%) CODAP Grouping														
6-9	-	-	-			-	-						-	-
10-17	6	-	5			8	11						14	6
18-20	7	19	5			4	8						17	4
21-25	20	27	15			15	8						14	34
26-30	23	23	28			19	16						24	16
31-44	29	23	39			19	42						21	20
45 & Over	14	8	8			31	16						10	17
Unk./No resp.	+	-	-			4	-						-	3
Race (%)														
White	65	77	33			65	84						69	81
Black	25	23	65			31	-						24	7
Other	1	-	1			-	13						-	1
Unk./No resp.	9	-	1			4	3						7	10
Sex (%)														
Male	54	46	72			81	53						48	43
Female	45	54	28			19	47						52	56
Unk./No resp.	+	-	-			-	-						-	1

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Meperidine is synthetic narcotic used as a potent analgesic. Its duration of action is shorter than that of morphine. Like other narcotic analgesics, meperidine has a very high potential for physiological and psychological dependence. Tolerance to meperidine's analgesic effects develops rather slowly, but a user may show rapid tolerance of its sedative action. Alcohol and other central nervous system depressants may potentiate the effects of meperidine.

TABLE 3.055 - HYDROMORPHONE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	485	14**	10**	28	23	2**	8**	6**	11**	12**	6**	5**	9**	84	5**
Alone (%)	41	43	40	32	74	50	25	67	18	50	50	60	44	54	40
Rank in TDS/SMSA	36	29.5	35	33	27	42	37.5	36.5	32	39	35	36.5	39.5	23	36
Source (%)															
Legal RX	23			18	65									21	
Forged RX	1			4	-									-	
Stolen	2			7	-									2	
Street buy	37			21	13									68	
Over-the-counter	-			-	-									-	
Gift	1			-	-									2	
Other	+			-	-									-	
Unk./No resp.	36			50	22									6	
Motivation (%)															
Psychic effects	24			7	9									38	
Dependence	59			50	78									61	
Suic.att./gest.	11			11	4									1	
Unknow./Unwill.	+			-	-									-	
Other	2			7	-									-	
Unk./No resp.	9			25	9									-	
Age (%) DAWN Grouping															
6-9	-			-	-									-	
10-19	8			11	4									7	
20-29	56			50	22									54	
30-39	26			36	13									30	
40-49	8			-	61									6	
50 & Over	1			-	-									4	
Unk./No resp.	+			4	-									-	
Age (%) CODAP Grouping															
6-9	-			-	-									-	
10-17	3			4	4									4	
18-20	10			14	-									8	
21-25	28			25	4									20	
26-30	31			25	26									36	
31-44	21			29	4									26	
45 & Over	6			-	61									6	
Unk./No resp.	+			4	-									-	
Race (%)															
White	80			93	96									71	
Black	10			7	-									20	
Other	1			-	-									-	
Unk./No resp.	9			-	4									8	
Sex (%)															
Male	69			68	83									71	
Female	31			32	17									29	
Unk./No resp.	-			-	-									-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

20

Rank in TDS

30.5

Concomitance	N	%
Alone	6	30
In Comb.	14	70

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	2	10	-	-
Accid./Unexp.	15	75	-	-
Unk./No resp.	3	15	-	-

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	1	5	White	12	60	Male	13	65
10-19	1	5	50 & Over	1	5	Black	8	40	Female	7	35
20-29	10	50	Unk./No resp.	-	-	Other	-	-			
30-39	7	35				Unk./No resp.	-	-			

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.055 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	485	37	23	1**	6**	35	33	11**	5**	3**	12**	9**	57	30
Alone (%)	41	19	26	-	50	40	36	45	20	67	25	11	40	50
Rank in TDS/SMSA	36	23	37	38	32	37	29	26.5	27	41.5	30	36.5	17	38
Source (%)														
Legal RX	23	14	22			17	24						9	47
Forged RX	1	-	4			-	-						-	3
Stolen	2	-	-			3	3						2	7
Street buy	37	73	22			11	61						40	17
Over-the-counter	-	-	-			-	-						-	-
Gift	1	-	-			6	-						-	-
Other	+	-	-			-	-						-	-
Unk./No resp.	36	14	52			63	18						49	30
Motivation (%)														
Psychic effects	24	38	13			40	15						11	10
Dependence	59	57	52			51	91						77	50
Suic.att./gest.	11	3	22			17	3						9	20
Unknow./Unwill.	+	-	-			-	-						-	-
Other	2	-	-			3	-						2	7
Unk./No resp.	9	3	17			17	3						5	17
Age (%) DAWN Grouping														
6-9	-	-	-			-	-						-	-
10-19	8	8	-			6	12						11	20
20-29	56	78	61			69	61						51	67
30-39	26	14	39			23	21						33	7
40-49	8	-	-			3	3						5	7
50 & Over	1	-	-			-	3						-	-
Unk./No resp.	+	-	-			-	-						-	-
Age (%) CODAP Grouping														
6-9	-	-	-			-	-						-	-
10-17	3	-	-			-	3						2	10
18-20	10	11	-			17	12						12	20
21-25	28	49	30			34	21						32	47
26-30	31	30	43			37	39						28	10
31-44	21	11	26			11	21						25	10
45 & Over	6	-	-			-	3						2	3
Unk./No resp.	+	-	-			-	-						-	-
Race (%)														
White	80	84	83			80	91						79	83
Black	10	16	4			9	-						18	7
Other	1	-	-			3	6						-	-
Unk./No resp.	9	-	13			9	3						4	10
Sex (%)														
Male	69	73	65			71	73						65	67
Female	31	27	35			29	27						35	33
Unk./No resp.	-	-	-			-	-						-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Hydromorphone (dihydromorphinone), a semi-synthetic derivative of morphine, is a more potent and shorter acting narcotic analgesic than morphine, but has similar addictive powers.

TABLE 3.056 - OXYCODONE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,226	44	36	120	4**	7**	44	18**	55	40	9**	12**	32	121	24
Alone (%)	29	30	25	22	75	43	32	44	25	38	44	50	9	29	17
Rank in TDS/SMSA	28	17.5	21.5	13	39	38	21	21.5	16	31.5	32	29	33	17	23
Source (%)															
Legal RX	56	68	64	34			45		60	55			56	76	63
Forged RX	+	-	-	2			-		-	-			-	-	-
Stolen	2	7	3	2			5		-	5			-	1	-
Street buy	5	-	8	5			7		2	8			-	7	8
Over-the-counter	-	-	-	-			-		-	-			-	-	-
Gift	2	-	-	4			2		2	8			-	3	4
Other	+	-	-	-			-		-	-			-	-	-
Unk./No resp.	34	25	25	53			41		38	25			44	13	25
Motivation (%)															
Psychic effects	16	11	28	8			18		13	8			3	36	13
Dependence	23	18	17	35			18		7	23			13	27	21
Suic.att./gest.	45	43	39	29			36		67	50			69	29	54
Unknow./Unwill.	-	-	-	-			-		-	-			-	-	-
Other	4	2	-	7			5		4	3			3	3	4
Unk./No resp.	14	30	17	22			25		13	18			13	4	8
Age (%) DAWN Grouping															
6-9	-	-	-	-			-		-	-			-	-	-
10-19	12	18	14	8			14		9	18			3	7	-
20-29	45	36	50	55			48		53	50			38	48	50
30-39	22	20	22	19			25		20	18			28	26	25
40-49	10	18	11	10			2		4	10			9	7	8
50 & Over	10	7	3	5			11		13	5			19	12	13
Unk./No resp.	1	-	-	3			-		2	-			3	-	4
Age (%) CODAP Grouping															
6-9	-	-	-	-			-		-	-			-	-	-
10-17	6	9	6	5			5		7	10			-	1	-
18-20	9	11	8	5			11		7	10			3	11	-
21-25	24	32	17	28			34		24	30			28	26	33
26-30	22	7	39	28			16		25	20			13	20	17
31-44	24	27	19	23			20		20	25			28	30	25
45 & Over	14	14	11	9			14		15	5			25	13	21
Unk./No resp.	1	-	-	3			-		2	-			3	-	4
Race (%)															
White	75	86	78	75			59		44	73			84	76	63
Black	12	2	14	17			34		-	15			-	9	4
Other	1	-	-	-			2		7	3			-	2	-
Unk./No resp.	12	11	8	8			5		49	10			16	12	33
Sex (%)															
Male	44	43	56	52			41		38	48			34	45	42
Female	56	57	44	48			59		62	53			66	55	58
Unk./No resp.	-	-	-	-			-		-	-			-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

5**

Rank in TDS

36.5

Concomitance	N	%
Alone	1	20
In Comb.	4	80

Cause/Manner of Death

	Drug-Induced Deaths		Drug-Related Deaths	
	N	%	N	%
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%		N	%
6-9			40-49		
10-19			50 & Over		
20-29			Unk./No resp.		
30-39					

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.056 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,225	33	141	10**	12**	114	64	9**	9**	31	10**	52	43	132
Alone (%)	29	33	40	40	17	29	28	22	-	29	10	25	21	30
Rank in TDS/SMSA	28	26	25	19	24.5	24	14	31	21.5	26	32	15.5	20	24
Source (%)														
Legal RX	56	42	64			46	63			61		42	40	61
Forged RX	+	-	1			1	2			-		-	-	-
Stolen	2	3	4			1	5			-		2	9	2
Street buy	5	30	8			1	17			3		-	-	1
Over-the-counter	-	-	-			-	-			-		-	-	-
Gift	2	-	3			1	3			6		4	-	1
Other	+	-	-			-	-			-		-	-	-
Unk./No resp.	34	24	21			51	19			29		52	51	36
Motivation (%)														
Psychic effects	16	18	10			19	16			16		10	16	16
Dependence	23	30	54			17	25			29		10	16	9
Suic.att./gest.	45	39	30			40	47			39		67	58	63
Unknow./Unwill.	-	-	-			-	-			-		-	-	-
Other	4	3	2			4	2			3		6	7	1
Unk./No resp.	14	9	4			24	11			16		8	5	13
Age (%) DAWN Grouping														
6-9	-	-	-			-	-			-		-	-	-
10-19	12	18	6			15	13			3		15	16	19
20-29	45	42	52			39	39			35		37	28	43
30-39	22	33	17			20	19			19		27	33	17
40-49	10	6	12			12	9			19		10	12	11
50 & Over	10	-	13			13	20			23		10	9	9
Unk./No resp.	1	-	-			-	-			-		2	2	-
Age (%) CODAP Grouping														
6-9	-	-	-			-	-			-		-	-	-
10-17	6	3	5			8	9			-		10	9	10
18-20	9	15	8			11	5			10		6	7	11
21-25	24	27	20			23	19			13		12	21	26
26-30	22	18	30			17	22			19		31	12	16
31-44	24	33	20			25	23			23		23	37	25
45 & Over	14	3	18			17	22			35		17	12	12
Unk./No resp.	1	-	-			-	-			-		2	2	-
Race (%)														
White	75	79	71			80	77			77		79	65	84
Black	12	21	23			16	8			6		4	21	5
Other	1	-	-			1	3			-		2	2	-
Unk./No resp.	12	-	6			4	13			16		15	12	11
Sex (%)														
Male	44	48	48			46	38			45		29	40	39
Female	56	52	52			54	63			55		71	60	61
Unk./No resp.	-	-	-			-	-			-		-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Oxycodone is a semisynthetic narcotic analgesic with multiple actions qualitatively similar to those of morphine, although quantitatively it is slightly less potent. It can also produce physical and psychological dependence effects similar to morphine.

TABLE 3.06 THERAPEUTIC CLASS - NON-NARCOTIC ANALGESICS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	17,921	440	346	714	532	1,338	534	383	793	1,220	414	372	925	493	521
Alone (%)	41	39	45	37	40	34	45	43	47	36	42	37	48	48	43
Rank in TDS/SMSA	2	2	3	3	2	2	2	2	2	3	2	2	5	6	2
Source (%)															
Legal RX	26	25	33	24	19	17	24	23	21	31	20	26	22	35	24
Forged RX	+	-	-	+	-	+	-	-	+	+	-	-	-	-	-
Stolen	2	1	4	1	1	+	4	3	1	3	2	2	1	2	1
Street buy	5	+	1	3	6	20	3	1	1	2	1	1	1	1	2
Over-the-counter	44	53	46	41	48	33	46	45	58	39	45	46	45	48	64
Gift	1	2	1	2	1	1	1	+	1	2	1	1	+	1	+
Other	+	-	+	+	-	+	-	-	-	+	-	+	+	-	-
Unk./No resp.	22	18	16	29	25	29	23	28	18	24	30	24	32	14	10
Motivation (%)															
Psychic effects	15	18	16	8	11	25	16	28	9	13	27	8	10	25	10
Dependence	7	4	2	8	11	21	3	1	2	8	4	3	2	7	2
Suic.att./gest.	60	56	66	61	64	38	56	56	75	61	51	66	62	61	78
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	+	-	-	+	-	-
Other	3	6	4	6	3	4	5	2	3	3	6	4	3	1	3
Unk./No resp.	16	18	12	18	14	25	21	13	12	17	15	21	23	6	8
Age (%) DAWN Grouping															
6-9	+	+	-	-	-	-	+	+	+	-	+	-	-	-	-
10-19	32	35	33	30	27	29	36	36	32	28	34	29	27	30	38
20-29	38	39	41	37	42	43	34	38	34	39	35	42	38	37	31
30-39	18	15	16	19	17	17	16	15	20	21	15	17	18	21	20
40-49	7	6	7	7	7	6	8	6	8	7	11	8	8	5	6
50 & Over	5	3	3	5	7	4	6	4	6	5	4	4	8	7	4
Unk./No resp.	1	1	-	1	1	1	+	1	1	+	+	1	+	-	1
Age (%) CODAP Grouping															
6-9	+	+	-	-	-	-	+	+	+	-	+	-	-	-	-
10-17	21	24	23	21	18	21	25	21	21	17	24	18	17	20	25
18-20	15	16	15	13	12	13	15	20	15	14	13	18	15	16	18
21-25	21	20	22	21	27	23	20	20	18	20	20	24	21	19	17
26-30	16	17	18	16	14	18	12	15	16	19	13	14	15	15	13
31-44	19	16	16	20	19	18	19	16	20	22	21	19	21	20	20
45 & Over	8	5	6	8	10	6	8	7	9	8	9	7	11	10	7
Unk./No resp.	1	1	-	1	1	1	+	1	1	+	+	1	+	-	1
Race (%)															
White	60	60	67	78	62	40	56	74	44	52	73	65	60	55	74
Black	24	26	29	13	26	47	33	15	3	37	20	13	15	27	2
Other	4	+	1	2	1	4	1	6	7	+	+	1	6	5	2
Unk./No resp.	13	14	3	7	11	8	11	4	45	11	7	22	19	13	22
Sex (%)															
Male	30	25	29	33	31	37	26	26	32	26	28	30	24	31	29
Female	70	75	71	67	69	63	74	74	68	74	71	69	76	68	71
Unk./No resp.	+	-	-	-	+	+	+	-	+	+	+	1	-	+	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

659

Rank in TDS

4

Concomitance	N	%
Alone	141	21
In Comb.	518	79

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	268	41	12	2
Accid./Unexp.	187	28	36	5
Unk./No resp.	143	22	13	2

Age	N	%		N	%
6-9	1	+	40-49	113	17
10-19	39	6	50 & Over	149	23
20-29	222	34	Unk./No resp.	1	+
30-39	134	20			

Race	N	%
White	496	75
Black	128	19
Other	22	3
Unk./No resp.	13	2

Sex	N	%
Male	299	45
Female	360	55

+Less than 0.5%

-Denotes zero (0) mentions

best copy available

TABLE 3.06 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	17,921	546	1,402	206	161	1,135	517	310	224	424	141	459	641	2,730
Alone (%)	41	25	48	44	32	40	38	28	46	42	44	36	40	42
Rank in TDS/SMSA	2	2	6	2	2	2	2	2	2	3	8	2	2	2
Source (%)														
Legal RX	26	20	27	34	27	25	38	23	30	32	22	23	16	30
Forged RX	+	2	+	-	1	-	+	+	-	-	-	+	+	+
Stolen	2	2	9	1	-	2	4	3	2	3	-	2	6	2
Street buy	5	43	2	1	1	4	3	10	2	1	2	+	+	1
Over-the-counter	44	19	39	49	35	33	44	31	47	52	62	56	51	47
Gift	1	3	+	1	3	1	2	3	-	1	-	+	1	1
Other	+	-	+	-	-	-	+	-	-	-	-	+	-	+
Unk./No resp.	22	10	22	14	34	35	9	30	18	11	14	19	25	19
Motivation (%)														
Psychic effects	15	41	8	11	9	19	15	25	4	12	4	10	11	13
Dependence	7	26	14	2	1	8	9	15	+	5	4	3	4	2
Suic.att./gest.	60	25	63	63	65	46	67	43	71	64	78	76	74	66
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	-	+	+	+
Other	3	2	2	4	2	5	3	3	2	4	5	4	2	3
Unk./No resp.	16	7	13	19	23	25	9	16	23	16	11	7	10	16
Age (%) DAWN Grouping														
6-9	+	+	+	+	1	+	-	+	+	-	-	-	+	+
10-19	32	18	36	33	30	30	34	27	37	29	11	29	39	36
20-29	38	52	36	36	42	38	35	45	40	40	52	38	36	35
30-39	18	21	15	16	20	18	16	18	13	19	23	18	17	16
40-49	7	6	6	9	4	8	8	7	6	6	4	9	5	8
50 & Over	5	3	6	4	3	5	6	3	3	6	9	6	4	4
Unk./No resp.	1	+	+	1	-	1	+	+	-	+	-	-	+	+
Age (%) CODAP Grouping														
6-9	+	+	+	+	1	+	-	+	+	-	-	-	+	+
10-17	21	11	26	21	22	21	24	15	24	19	2	17	27	23
18-20	15	11	15	18	12	14	14	18	19	16	16	16	15	17
21-25	21	28	19	18	22	20	17	27	22	19	25	20	21	19
26-30	16	23	15	16	20	16	17	16	14	19	23	17	13	14
31-44	19	20	15	18	19	20	18	18	16	19	23	20	17	19
45 & Over	8	6	9	7	5	8	9	5	5	7	11	10	6	7
Unk./No resp.	1	+	+	1	-	1	+	+	-	+	-	-	+	+
Race (%)														
White	60	34	62	67	77	52	73	43	50	65	47	68	44	73
Black	24	63	22	32	4	35	7	42	8	8	14	8	46	14
Other	4	1	9	+	4	6	15	+	38	5	13	5	1	2
Unk./No resp.	13	2	8	+	14	7	5	15	4	23	26	19	10	12
Sex (%)														
Male	30	50	29	24	20	35	32	46	23	24	46	29	24	29
Female	70	49	70	75	79	65	68	54	76	76	54	71	76	71
Unk./No resp.	+	1	+	+	1	+	-	-	+	+	-	+	+	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Non-narcotic analgesics are therapeutics primarily used for the relief of pain. Included in this class are various formulations of d-propoxyphene, aspirin and acetaminophen.

TABLE 3.061 - ASPIRIN

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	6,682	184	122	275	189	426	208	133	343	413	144	148	391	198	249
Alone (%)	51	48	46	50	41	54	51	50	56	43	53	51	58	59	50
Rank in TDS/SMSA	4	3	6	4	4	5	3	3	3	5	3	3	5	9	2
Source (%)															
Legal RX	5	2	6	8	1	9	3	5	3	6	3	7	3	2	2
Forged RX	+	-	-	+	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	1	2	+	1	+	1	2	1	3	1	1	1	3	1
Street buy	1	1	-	3	-	1	1	2	1	+	1	1	1	1	2
Over-the-counter	80	85	83	77	92	75	83	86	87	75	84	78	81	88	92
Gift	+	2	-	1	-	-	-	-	1	+	-	-	-	-	-
Other	+	-	-	-	-	-	-	-	-	-	-	1	-	-	-
Unk./No resp.	11	10	10	10	7	14	12	6	8	15	11	12	15	6	3
Motivation (%)															
Psychic effects	12	17	16	7	8	8	14	22	8	13	24	11	10	18	8
Dependence	1	2	1	2	2	1	+	1	1	3	1	1	1	1	1
Suic.att./gest.	68	55	72	68	71	55	55	61	79	68	58	66	65	76	82
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	3	7	5	5	2	6	6	1	2	2	6	5	2	1	3
Unk./No resp.	16	20	7	19	17	29	24	16	10	15	13	20	23	5	7
Age (%) DAWN Grouping															
6-9	+	1	-	-	-	-	1	1	+	-	1	-	-	-	-
10-19	41	43	41	42	37	44	41	38	40	36	43	36	33	46	45
20-29	33	36	39	31	35	32	33	38	29	34	28	37	39	29	28
30-39	15	10	12	13	14	13	15	16	16	18	15	17	15	19	17
40-49	6	3	5	6	8	5	4	5	8	5	10	5	7	3	6
50 & Over	5	4	3	7	5	6	6	2	6	7	3	4	6	4	4
Unk./No resp.	+	2	-	1	1	+	+	1	1	+	-	1	1	-	+
Age (%) CODAP Grouping															
6-9	+	1	-	-	-	-	1	1	+	-	1	-	-	-	-
10-17	29	29	31	31	27	33	32	24	27	25	33	26	23	33	31
18-20	17	18	12	15	13	16	14	20	18	15	13	18	15	17	19
21-25	18	18	21	17	22	19	19	22	16	18	13	23	23	18	16
26-30	12	15	20	12	11	9	11	12	11	18	13	9	13	11	8
31-44	16	12	11	15	17	14	16	17	16	17	20	18	18	16	19
45 & Over	7	5	4	8	10	8	7	3	10	8	7	5	8	6	6
Unk./No resp.	+	2	-	1	1	+	+	1	1	+	-	1	1	-	+
Race (%)															
White	61	54	66	79	72	60	58	68	45	54	69	59	59	43	76
Black	19	30	30	12	16	23	30	17	4	33	20	10	15	32	1
Other	5	-	1	3	2	6	+	11	8	+	1	1	9	6	2
Unk./No resp.	14	16	4	7	10	11	12	5	43	13	10	30	18	18	22
Sex (%)															
Male	28	23	25	29	26	22	26	23	33	23	26	33	24	30	30
Female	72	77	75	71	74	77	74	77	67	77	73	67	76	70	70
Unk./No resp.	+	-	-	-	-	+	-	-	-	-	1	-	-	1	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

120

Rank in TDS

14

Concomitance	N	%
Alone	38	32
In Comb.	82	68

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	54	45	6	5
Accid./Unexp.	21	18	9	8
Unk./No resp.	27	23	3	3

Age	N	%		N	%
6-9	1	1	40-49	20	17
10-19	6	5	50 & Over	42	35
20-29	24	20	Unk./No resp.	-	-
30-39	27	23			

Race	N	%
White	93	78
Black	22	18
Other	2	2
Unk./No resp.	3	3

Sex	N	%
Male	48	40
Female	72	60

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.061 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	6,682	91	530	65	46	322	174	77	99	182	65	204	286	1,118
Alone (%)	51	58	55	54	46	54	51	55	56	53	54	45	46	50
Rank in TDS/SMSA	4	7	13	3	4	4	3	6	3	4.5	9.5	3	4	3
Source (%)														
Legal RX	5	14	4	6	2	4	9	5	5	7	3	2	1	9
Forged RX	+	1	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	2	12	2	-	2	1	-	2	1	2	-	1	2
Street buy	1	3	+	2	-	1	2	-	-	1	-	1	7	+
Over-the-counter	80	67	72	88	74	79	83	81	80	86	95	87	78	75
Gift	+	7	+	-	2	-	1	3	-	1	-	-	+	1
Other	+	-	-	-	-	-	-	-	-	-	-	+	-	+
Unk./No resp.	11	5	12	3	22	15	5	12	13	5	-	9	13	13
Motivation (%)														
Psychic effects	12	41	5	12	11	17	11	6	3	10	5	10	11	13
Dependence	1	3	2	-	-	-	1	1	-	3	3	1	3	+
Suic.att./gest.	68	40	78	62	76	58	74	64	71	68	78	79	76	69
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	-	+	-	-
Other	3	2	2	6	-	5	4	8	3	6	8	4	2	2
Unk./No resp.	16	15	13	20	13	21	11	21	23	15	9	5	8	15
Age (%) DAWN Grouping														
6-9	+	1	1	2	-	-	-	-	1	-	-	-	+	-
10-19	41	32	48	38	52	41	43	40	40	41	11	33	43	43
20-29	33	42	32	34	30	32	29	29	40	36	52	37	33	30
30-39	15	16	9	20	17	14	17	18	11	14	26	17	14	16
40-49	6	5	4	6	-	7	6	4	5	3	3	7	4	7
50 & Over	5	2	6	-	-	5	5	9	2	5	8	6	4	3
Unk./No resp.	+	1	-	-	-	1	1	-	-	-	-	-	1	1
Age (%) CODAP Grouping														
6-9	+	1	1	2	-	-	-	-	1	-	-	-	+	-
10-17	29	24	36	34	39	31	31	25	29	28	2	23	32	30
18-20	17	16	18	8	20	16	15	22	22	20	17	14	16	18
21-25	18	23	18	14	13	18	14	13	23	15	31	21	19	15
26-30	12	13	10	23	15	10	14	10	7	16	17	16	12	12
31-44	16	14	10	20	13	16	18	21	13	15	25	16	13	17
45 & Over	7	7	7	-	-	9	7	9	4	5	9	10	7	6
Unk./No resp.	+	1	-	-	-	1	1	-	-	-	-	-	1	1
Race (%)														
White	61	36	63	60	85	60	70	60	43	63	40	68	41	70
Black	19	49	20	38	2	31	3	25	9	8	18	7	44	14
Other	5	7	10	-	9	2	22	-	44	6	15	5	1	2
Unk./No resp.	14	8	8	2	4	8	6	16	3	24	26	20	13	14
Sex (%)														
Male	28	26	27	18	26	29	30	32	27	26	42	26	24	32
Female	72	70	72	80	74	71	70	68	73	74	58	74	76	67
Unk./No resp.	+	3	+	2	-	-	-	-	-	-	-	-	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Aspirin is probably the best known and one of the most readily available over-the-counter medications. Its analgesic properties are well known. Aspirin does not appear to create psychological or physiological dependence, and tolerance effects are rare.

TABLE 3.062 - d-PROPOXYPHENE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	3,585	75	102	198	104	162	134	85	125	287	108	75	185	98	68
Alone (%)	33	28	42	24	33	33	37	31	38	32	31	13	37	45	28
Rank in TDS/SMSA	8	9.5	7	5	6	14	5	7	6	6	4	6	12	21	11
Source (%)															
Legal RX	59	67	67	43	48	57	54	49	59	66	31	55	52	85	76
Forged RX	+	-	-	1	-	-	-	-	-	-	-	-	-	-	-
Stolen	3	1	6	3	2	1	7	4	1	2	4	1	-	2	-
Street buy	2	-	-	4	-	1	1	-	2	1	1	1	1	-	1
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	2	3	2	3	3	2	-	1	-	3	3	3	1	-	1
Other	+	-	1	1	-	-	-	-	-	-	-	-	-	-	-
Unk./No resp.	34	29	25	47	47	40	39	46	39	28	61	40	47	13	21
Motivation (%)															
Psychic effects	15	23	23	10	11	13	15	29	10	13	28	5	15	36	16
Dependence	9	7	2	15	5	6	5	1	3	8	6	7	4	9	3
Suic.att./gest.	57	52	57	54	70	51	55	56	74	61	48	72	57	49	72
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	+	-	-	1	-	-
Other	3	3	3	7	4	1	5	4	2	4	5	3	4	1	3
Unk./No resp.	17	20	17	17	11	33	22	9	13	16	17	13	21	5	7
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-19	23	28	26	17	22	26	24	39	22	23	27	8	19	19	22
20-29	39	32	49	43	38	42	41	33	34	40	31	53	36	40	34
30-39	20	23	14	27	20	17	13	14	25	21	19	19	22	20	28
40-49	10	11	9	6	10	8	13	8	11	10	14	12	11	6	6
50 & Over	7	4	2	7	9	6	8	6	7	6	9	8	12	14	7
Unk./No resp.	+	3	-	-	1	1	1	-	1	-	1	-	-	-	3
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-17	14	23	13	9	13	16	15	24	14	12	19	5	8	11	12
18-20	13	11	19	12	12	15	13	21	9	15	7	7	15	16	12
21-25	22	20	28	23	19	23	25	14	16	21	21	29	21	22	16
26-30	17	9	19	22	18	15	14	14	21	17	9	23	15	11	24
31-44	23	27	14	23	28	20	20	19	29	25	26	21	27	22	22
45 & Over	11	8	8	11	9	10	11	8	10	10	16	15	14	16	12
Unk./No resp.	+	3	-	-	1	1	1	-	1	-	1	-	-	-	3
Race (%)															
White	65	77	64	78	63	56	57	80	38	57	81	63	68	62	66
Black	19	12	31	13	22	27	34	12	2	33	12	11	13	23	4
Other	4	-	1	2	2	6	1	2	6	+	-	-	3	3	4
Unk./No resp.	12	11	4	8	13	11	8	6	54	10	7	27	16	11	25
Sex (%)															
Male	31	35	36	40	25	27	27	28	30	25	31	29	31	33	37
Female	68	65	64	60	75	73	72	72	70	75	69	71	69	66	63
Unk./No resp.	+	-	-	-	-	-	1	-	1	-	1	-	-	1	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

379

Rank in TDS

4

Concomitance	N	%
Alone	86	23
In Comb.	293	77

Cause/Manner of Death

	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	156	41	4	1
Accid./Unexp.	109	29	16	4
Unk./No resp.	88	23	6	2

Age	N	%		N	%
6-9	-	-	40-49	65	17
10-19	29	8	50 & Over	69	18
20-29	140	37	Unk./No resp.	1	+
30-39	75	20			

Race	N	%
White	283	75
Black	70	18
Other	17	4
Unk./No resp.	9	2

Sex	N	%
Male	171	45
Female	208	55

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.062 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	3,585	66	357	47	26	270	126	65	42	84	23	72	101	500
Alone (%)	33	36	40	36	19	40	25	26	31	26	39	25	36	33
Rank in TDS/SMSA	8	11	21	5	10.5	5	5	8	6	9	26	11	10	6
Source (%)														
Legal RX	59	56	53	72	58	52	72	68	64	69	61	53	48	70
Forged RX	+	2	+	-	4	-	-	-	-	-	-	1	1	+
Stolen	3	5	7	2	-	3	6	8	5	7	-	1	5	2
Street buy	2	11	4	-	-	1	6	2	2	2	9	1	-	1
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	2	6	1	2	4	1	3	3	-	4	-	1	3	1
Other	+	-	-	-	-	-	-	-	-	-	-	-	-	+
Unk./No resp.	34	21	36	23	35	44	14	20	29	18	30	42	45	26
Motivation (%)														
Psychic effects	15	44	12	9	8	16	17	18	2	15	-	14	10	14
Dependence	9	9	27	4	-	7	14	11	-	10	4	6	7	6
Suic.att./gest.	57	33	47	68	54	51	60	52	62	58	70	67	70	61
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	-	-	1	+
Other	3	3	1	6	4	4	2	2	-	1	4	-	5	3
Unk./No resp.	17	11	13	13	35	27	9	20	36	17	22	14	9	18
Age (%) DAWN Grouping														
6-9	+	-	-	-	-	-	-	2	-	-	-	-	-	-
10-19	23	17	25	30	12	27	26	26	26	14	13	22	34	24
20-29	39	36	42	34	54	39	35	38	36	42	61	32	41	39
30-39	20	27	20	15	19	18	17	17	19	27	13	28	16	18
40-49	10	11	7	11	4	9	9	14	12	7	9	10	7	13
50 & Over	7	9	6	9	12	7	13	3	7	10	4	8	3	6
Unk./No resp.	+	-	+	2	-	+	-	-	-	-	-	-	-	+
Age (%) CODAP Grouping														
6-9	+	-	-	-	-	-	-	2	-	-	-	-	-	-
10-17	14	15	16	19	12	18	17	15	12	11	4	8	22	14
18-20	13	6	11	17	4	13	13	15	14	8	13	18	15	14
21-25	22	14	24	17	38	21	13	25	24	19	35	17	21	22
26-30	17	21	22	11	12	16	20	12	17	23	22	17	20	15
31-44	23	30	18	19	23	21	20	20	21	29	22	31	18	23
45 & Over	11	14	8	15	12	11	17	11	12	11	4	10	5	11
Unk./No resp.	+	-	+	2	-	+	-	-	-	-	-	-	-	+
Race (%)														
White	65	61	59	74	58	63	73	63	50	71	57	68	59	77
Black	19	38	23	26	-	26	10	26	10	4	13	7	30	11
Other	4	-	10	-	8	6	12	2	33	2	9	7	1	2
Unk./No resp.	12	2	7	-	35	5	5	9	7	23	22	18	10	10
Sex (%)														
Male	31	41	34	26	12	32	37	31	19	31	65	44	31	28
Female	68	59	66	74	85	68	63	69	79	69	35	54	69	72
Unk./No resp.	+	-	+	-	4	+	-	-	2	-	-	1	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

d-Propoxyphene, an analgesic chemically related to methadone, produces analgesia by acting on the central nervous system. Like codeine, a combination of propoxyphene with aspirin affords much better analgesia than that resulting from either agent given alone. Psychic dependence can be produced by long term d-propoxyphene use, while tolerance and physical dependence occur less frequently.

TABLE 3.063 - PENTAZOCINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,640	10**	10**	20	78	416	36	17**	22	111	16**	19**	58	36	16**
Alone (%)	18	20	30	25	44	7	50	59	27	35	69	11	24	36	31
Rank in TDS/SMSA	26	36	35	36	13	6	24	23.5	27	19	28.5	24	28.5	32	27.5
Source (%)															
Legal RX	23			35	19	3	31		50	37			55	75	
Forged RX	1			-	-	+	-		5	-			-	-	
Stolen	1			-	1	-	6		-	3			-	-	
Street buy	36			-	36	59	25		-	12			-	3	
Over-the-counter	-			-	-	-	-		-	-			-	-	
Gift	2			-	-	+	8		5	2			2	8	
Other	+			-	-	+	-		-	-			-	-	
Unk./No resp.	37			65	44	38	33		41	48			43	14	
Motivation (%)															
Psychic effects	35			5	19	58	50		27	6			3	44	
Dependence	41			15	51	62	28		9	40			7	31	
Suic.att./gest.	20			60	24	3	22		41	36			50	17	
Unknow./Unwill.	+			-	-	-	-		-	-			-	-	
Other	2			5	5	1	3		5	4			7	-	
Unk./No resp.	14			15	6	16	6		18	16			33	8	
Age (%) DAWN Grouping															
6-9	-			-	-	-	-		-	-			-	-	
10-19	8			10	12	5	19		9	8			3	8	
20-29	55			60	58	60	31		27	54			48	39	
30-39	25			15	22	26	28		50	25			29	33	
40-49	7			15	3	6	17		-	6			7	11	
50 & Over	4			-	5	1	6		14	5			12	8	
Unk./No resp.	1			-	1	1	-		-	2			-	-	
Age (%) CODAP Grouping															
6-9	-			-	-	-	-		-	-			-	-	
10-17	3			10	1	1	6		5	5			-	3	
18-20	9			-	14	8	14		5	6			10	6	
21-25	29			50	37	26	19		18	23			14	14	
26-30	27			10	19	35	19		23	32			33	31	
31-44	25			25	22	25	31		36	25			28	33	
45 & Over	7			5	5	3	11		14	6			16	14	
Unk./No resp.	1			-	1	1	-		-	2			-	-	
Race (%)															
White	29			80	27	6	39		41	29			50	86	
Black	61			15	62	89	61		5	67			16	6	
Other	3			-	-	2	-		-	-			3	3	
Unk./No resp.	7			5	12	3	-		55	5			31	6	
Sex (%)															
Male	56			40	53	66	44		36	43			21	56	
Female	44			60	47	34	56		64	56			79	44	
Unk./No resp.	+			-	-	-	-		-	1			-	-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

29

Rank in TDS

27

Concomitance	N	%
Alone	9	31
In Comb.	20	69

Cause/Manner of Death

	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	8	28	1	3
Accid./Unexp.	11	38	4	14
Unk./No resp.	5	17	-	-

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	6	21	White	14	48	Male	15	52
10-19	-	-	50 & Over	2	7	Black	15	52	Female	14	48
20-29	10	34	Unk./No resp.	-	-	Other	-	-			
30-39	11	38				Unk./No resp.	-	-			

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.063 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,640	262	66	13**	9**	181	20	92	6**	17**	9**	10**	13**	77
Alone (%)	18	1	45	8	22	15	20	7	33	24	22	30	-	32
Rank in TDS/SMSA	26	2	31.5	17	28.5	14	33	4	25.5	33	33.5	34.5	36	32
Source (%)														
Legal RX	23	4	56			15	65	4						60
Forged RX	1	4	-			-	5	1						-
Stolen	1	+	2			1	5	1						1
Street buy	36	85	9			18	20	30						-
Over-the-counter	-	-	-			-	-	-						-
Gift	2	2	2			4	-	2						-
Other	+	-	-			-	-	-						-
Unk./No resp.	37	5	32			61	5	61						39
Motivation (%)														
Psychic effects	35	47	6			35	15	46						14
Dependence	41	48	47			35	40	40						9
Suic.att./gest.	20	3	35			13	35	2						51
Unknow./Unwill.	+	-	-			-	-	-						1
Other	2	-	2			2	5	-						9
Unk./No resp.	14	2	12			23	10	15						21
Age (%) DAWN Grouping														
6-9	-	-	-			-	-	-						-
10-19	8	8	9			6	-	8						13
20-29	55	67	42			51	60	72						36
30-39	25	21	32			29	5	16						27
40-49	7	3	6			10	20	3						16
50 & Over	4	1	11			4	15	-						8
Unk./No resp.	1	-	-			-	-	1						-
Age (%) CODAP Grouping														
6-9	-	-	-			-	-	-						-
10-17	3	2	3			2	-	4						8
18-20	9	10	9			8	10	11						10
21-25	29	38	21			28	40	46						22
26-30	27	29	24			27	10	24						10
31-44	25	18	30			29	20	14						35
45 & Over	7	3	12			7	20	-						14
Unk./No resp.	1	-	-			-	-	1						-
Race (%)														
White	29	13	65			15	85	7						78
Black	61	87	21			68	10	75						4
Other	3	-	6			14	-	-						3
Unk./No resp.	7	-	8			3	5	18						16
Sex (%)														
Male	56	72	47			69	30	73						35
Female	44	28	53			31	70	27						65
Unk./No resp.	+	-	-			-	-	-						-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Pentazocine, a non-narcotic analgesic, is more than twice as potent as meperidine, but less effective than morphine in both potency and duration of action. Tolerance may develop, and instances of psychological and physical dependence on pentazocine have been noted. The respiratory depressant effects of pentazocine may be potentiated by other central nervous system depressants such as alcohol and barbiturates.

TABLE 3.064 - ACETAMINOPHEN

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	3,296	96	64	99	89	197	88	90	190	239	73	74	162	70	103
Alone (%)	41	35	48	32	42	43	45	44	48	31	38	36	48	39	49
Rank in TDS/SMSA	10	6	14	15	10	8	8	6	4	8	7	7	15	27	8
Source (%)															
Legal RX	10	14	5	9	3	12	6	4	5	14	7	9	4	4	6
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	-	2	1	-	-	2	3	1	3	3	1	1	-	1
Street buy	1	-	3	2	2	4	1	-	2	-	1	-	-	-	2
Over-the-counter	67	71	77	69	84	56	76	56	79	60	73	68	56	81	82
Gift	+	-	-	1	-	1	-	-	1	2	-	1	-	-	-
Other	+	-	-	-	-	-	-	-	-	+	-	-	-	-	-
Unk./No resp.	19	16	14	18	10	28	15	37	13	21	16	20	40	14	10
Motivation (%)															
Psychic effects	12	15	6	8	8	13	13	39	5	16	27	3	9	11	9
Dependence	2	1	5	7	3	6	-	-	-	6	-	-	1	-	2
Suic.att./gest.	67	63	73	70	66	58	64	50	80	64	53	65	65	80	79
Unknow./Unwill.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	3	4	2	7	4	4	3	2	3	3	5	4	2	1	3
Unk./No resp.	16	18	14	10	18	23	20	9	12	13	16	28	22	7	8
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-19	36	34	39	29	27	46	49	42	33	31	33	41	31	36	43
20-29	37	46	34	42	42	32	27	37	38	36	44	35	36	37	27
30-39	16	14	17	16	12	11	16	12	17	22	18	16	16	17	17
40-49	6	5	6	5	7	7	6	6	6	6	5	7	7	-	6
50 & Over	4	1	3	4	11	3	2	2	5	5	-	1	9	10	5
Unk./No resp.	1	-	-	3	1	1	-	1	1	1	-	-	-	-	3
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-17	24	26	31	23	19	37	34	23	21	18	22	23	18	20	23
18-20	18	11	17	13	11	16	22	27	17	16	18	28	18	24	23
21-25	20	23	16	24	30	21	16	20	19	21	23	15	19	21	15
26-30	14	21	13	14	11	6	8	11	17	13	15	12	16	9	12
31-44	17	16	20	17	11	13	18	11	17	24	21	18	18	16	17
45 & Over	7	3	3	5	16	7	2	7	7	7	1	4	12	10	8
Unk./No resp.	1	-	-	3	1	1	-	1	1	1	-	-	-	-	3
Race (%)															
White	59	49	59	71	64	49	47	69	44	51	67	72	59	59	76
Black	24	36	34	17	25	37	34	22	4	34	26	14	19	23	-
Other	4	-	2	2	1	3	-	6	9	+	1	-	3	4	1
Unk./No resp.	13	15	5	10	10	11	19	3	43	14	5	15	20	14	23
Sex (%)															
Male	27	24	30	34	28	24	22	26	33	24	29	27	25	24	26
Female	73	76	70	66	72	76	78	74	67	76	71	72	75	76	74
Unk./No resp.	+	-	-	-	-	-	-	-	-	-	-	1	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

105

Rank in TDS

17.5

Concomitance	N	%
Alone	8	8
In Comb.	97	92

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	35	33	-	-
Accid./Unexp.	41	39	5	5
Unk./No resp.	20	19	4	4

Age	N	%
6-9	-	-
10-19	4	4
20-29	40	38
30-39	15	14
40-49	19	18
50 & Over	27	26
Unk./No resp.	-	-

Race	N	%
White	85	81
Black	17	16
Other	2	2
Unk./No resp.	1	1

Sex	N	%
Male	52	50
Female	53	50

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.064 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	3,296	63	252	51	26	174	97	42	27	70	30	93	155	582
Alone (%)	41	48	53	41	31	36	43	31	56	39	30	31	37	40
Rank in TDS/SMSA	10	12.5	23	4	10.5	15	7	12	7	13	25	6.5	5	5
Source (%)														
Legal RX	10	17	8	12	8	11	15	12	15	7	3	5	4	14
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	2	11	-	-	1	7	2	-	4	-	1	6	1
Street buy	1	5	2	2	4	1	2	-	4	-	-	1	1	2
Over-the-counter	67	65	58	80	65	61	71	71	70	84	77	73	63	66
Gift	+	2	+	-	-	-	1	2	-	-	-	-	1	+
Other	+	-	+	-	-	-	-	-	-	-	-	-	-	-
Unk./No resp.	19	10	21	6	23	25	3	12	11	4	20	19	26	15
Motivation (%)														
Psychic effects	12	22	8	14	8	18	18	14	4	14	3	13	8	12
Dependence	2	2	2	-	-	2	2	5	-	3	3	1	1	+
Suic.att./gest.	67	57	72	61	62	47	74	69	81	67	77	76	78	67
Unknow./Unwill.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	3	5	1	2	4	5	3	2	4	1	3	6	1	3
Unk./No resp.	16	14	17	24	27	29	7	12	11	16	13	5	12	18
Age (%) DAWN Grouping														
6-9	+	-	1	-	4	-	-	-	-	-	-	-	-	-
10-19	36	25	42	35	31	39	41	29	52	26	7	25	40	38
20-29	37	37	34	41	42	36	34	40	33	44	53	41	35	37
30-39	16	16	10	12	15	16	15	19	15	20	20	15	21	14
40-49	6	14	6	6	8	6	9	12	-	6	7	11	3	7
50 & Over	4	8	7	4	-	2	-	-	-	4	13	9	1	3
Unk./No resp.	1	-	+	2	-	1	-	-	-	-	-	-	1	+
Age (%) CODAP Grouping														
6-9	+	-	1	-	4	-	-	-	-	-	-	-	-	-
10-17	24	16	32	12	15	28	30	12	37	13	-	15	28	24
18-20	18	13	17	31	15	16	15	21	15	23	10	14	17	18
21-25	20	14	16	22	19	20	23	[illegible]	11	24	17	20	20	21
26-30	14	21	12	14	31	16	10	12	22	16	33	18	12	13
31-44	17	24	12	16	12	17	19	24	15	17	23	18	19	18
45 & Over	7	13	9	4	4	3	3	2	-	7	17	14	3	5
Unk./No resp.	1	-	+	2	-	1	-	-	-	-	-	-	1	+
Race (%)														
White	59	57	57	75	73	45	70	57	56	63	53	63	34	72
Black	24	38	25	24	12	41	8	38	7	9	7	11	61	16
Other	4	-	8	2	4	5	19	-	30	10	13	6	1	1
Unk./No resp.	13	5	10	-	12	9	3	5	7	19	27	19	5	11
Sex (%)														
Male	27	32	26	27	27	30	33	43	11	16	53	29	21	25
Female	73	67	74	73	73	70	67	57	89	84	47	71	78	75
Unk./No resp.	+	2	+	-	-	-	-	-	-	-	-	-	1	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Acetaminophen produces analgesia by elevation of the pain threshold and antipyresis (fever reduction) through action on the hypothalamic heat-regulating center. Acetaminophen has rarely been found to produce any side effects.

TABLE 3.07 - THERAPEUTIC CLASS - AMPHETAMINES

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	3,726	83	47	106	57	146	76	67	100	124	58	68	99	149	130
Alone (%)	40	42	36	28	32	50	38	51	49	43	53	43	49	40	44
Rank in TDS/SMSA	9	9	10	10	10	11	9	8	10	10	10	8	11	10	6
Source (%)															
Legal RX	7	6	9	4	7	4	8	13	7	9	10	13	12	28	1
Forged RX	+	-	-	1	-	-	1	-	-	-	-	-	-	-	-
Stolen	1	4	-	-	-	-	-	-	-	2	2	-	-	1	3
Street buy	50	34	36	43	35	34	26	19	38	47	21	22	13	62	55
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	5	7	4	5	-	7	3	3	5	5	17	3	5	3	1
Other	+	-	-	-	-	-	1	-	-	2	-	-	-	-	-
Unk./No resp.	37	51	51	49	58	56	62	66	51	35	50	62	70	7	40
Motivation (%)															
Psychic effects	39	59	55	34	46	46	30	43	63	23	55	32	25	62	48
Dependence	32	10	11	32	32	16	17	15	6	43	7	12	15	29	24
Suic.att./gest.	17	17	15	20	21	17	21	27	27	18	14	25	21	7	22
Unknow./Unwill.	+	1	-	-	-	1	1	-	1	1	3	-	-	-	-
Other	1	1	2	4	4	2	4	1	1	-	7	1	1	-	1
Unk./No resp.	13	14	19	13	2	27	33	13	9	18	16	29	38	2	5
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-19	27	35	36	30	37	40	30	37	34	28	34	43	15	29	23
20-29	53	51	43	50	40	42	51	40	43	44	60	41	49	48	56
30-39	15	6	17	17	19	14	13	15	15	22	3	7	27	15	15
40-49	3	5	2	3	2	3	3	6	5	3	2	4	6	7	4
50 & Over	1	2	-	-	2	1	3	1	1	2	-	3	1	-	-
Unk./No resp.	1	1	2	-	-	-	-	-	2	1	-	1	1	-	2
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-17	14	16	28	13	18	23	13	25	20	14	19	26	8	11	13
18-20	19	25	15	21	23	22	22	16	20	19	21	22	12	23	19
21-25	31	29	21	34	28	29	34	33	23	26	31	21	29	24	31
26-30	20	17	17	14	14	10	13	7	16	19	24	16	18	22	18
31-44	14	6	15	17	16	14	12	10	17	19	5	7	25	18	15
45 & Over	2	6	2	1	2	2	5	7	2	2	-	6	6	1	2
Unk./No resp.	1	1	2	-	-	-	-	-	2	1	-	1	1	-	2
Race (%)															
White	71	83	74	86	65	66	62	81	43	69	78	65	60	79	78
Black	17	6	21	10	23	18	26	13	2	23	12	13	15	12	2
Other	2	-	-	-	-	3	-	3	5	-	-	1	5	1	1
Unk./No resp.	10	11	4	4	12	12	12	3	50	9	10	21	20	8	20
Sex (%)															
Male	58	63	53	55	67	56	51	52	47	60	59	47	51	54	60
Female	41	37	47	45	33	44	49	48	53	40	41	53	48	46	39
Unk./No resp.	+	-	-	-	-	-	-	-	-	-	-	-	1	-	1

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

60

Rank in TDS

9

Concomitance	N	%
Alone	15	25
In Comb.	45	75

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	5	8	5	8
Accid./Unexp.	30	50	12	20
Unk./No resp.	5	8	3	5

Age	N	%		N	%
6-9	-	-	40-49	3	5
10-19	3	5	50 & Over	-	-
20-29	46	77	Unk./No resp.	-	-
30-39	8	13			

Race	N	%
White	46	77
Black	13	22
Other	1	2
Unk./No resp.	-	-

Sex	N	%
Male	45	75
Female	15	25

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.07 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	3,726	64	816	11**	31	592	104	45	17**	97	142	94	77	326
Alone (%)	40	42	18	36	32	58	35	38	47	57	59	38	39	40
Rank in TDS/SMSA	9	9	8	10	8.5	4	9	8	9	9	7	9	10.5	10
Source (%)														
Legal RX	7	19	3		3	5	13	9		2	1	9	10	13
Forged RX	+	3	-		-	-	-	2		-	-	-	-	-
Stolen	1	-	+		-	+	3	-		1	-	-	1	1
Street buy	50	55	84		45	46	48	27		46	67	44	29	33
Over-the-counter	-	-	-		-	-	-	-		-	-	-	-	-
Gift	5	6	2		3	8	12	9		4	3	5	4	4
Other	+	-	-		-	+	-	-		-	-	-	1	-
Unk./No resp.	37	17	10		48	42	25	53		46	30	43	55	49
Motivation (%)														
Psychic effects	39	55	20		26	44	50	49		41	51	56	32	42
Dependence	32	31	65		3	32	22	13		21	39	9	35	10
Suic.att./gest.	17	8	13		26	14	29	9		20	11	23	21	24
Unknow./Unwill.	+	-	+		-	+	-	2		1	1	-	3	-
Other	1	2	+		3	1	1	-		1	1	1	-	2
Unk./No resp.	13	6	2		42	16	3	29		19	5	12	9	23
Age (%) DAWN Grouping														
6-9	+	-	+		-	-	-	-		-	-	-	-	-
10-19	27	16	24		29	21	24	36		21	8	31	31	35
20-29	53	52	58		45	60	60	49		62	49	51	51	49
30-39	15	28	15		19	15	11	16		12	35	13	16	12
40-49	3	3	2		-	2	3	-		4	6	4	3	2
50 & Over	1	2	1		-	1	2	-		-	2	1	-	1
Unk./No resp.	1	-	+		6	+	1	-		1	-	-	-	+
Age (%) CODAP Grouping														
6-9	+	-	+		-	-	-	-		-	-	-	-	-
10-17	14	3	13		10	10	13	16		9	2	16	19	17
18-20	19	20	18		26	17	19	27		18	8	17	16	25
21-25	31	30	31		29	35	31	31		37	27	38	31	29
26-30	20	20	23		13	23	24	13		21	30	14	19	15
31-44	14	22	13		16	12	8	13		13	27	12	13	11
45 & Over	2	5	2		-	2	4	-		1	6	3	1	2
Unk./No resp.	1	-	+		6	+	1	-		1	-	-	-	+
Race (%)														
White	71	66	80		61	51	88	62		71	67	81	66	81
Black	17	30	16		3	42	4	13		5	13	4	22	6
Other	2	2	2		3	4	6	-		3	2	2	-	1
Unk./No resp.	10	3	2		32	3	3	24		21	18	13	12	12
Sex (%)														
Male	58	64	63		45	65	47	56		55	76	44	57	53
Female	41	36	37		55	34	53	44		45	24	56	43	47
Unk./No resp.	+	-	+		-	+	-	-		-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Products in this therapeutic class contain amphetamine or one of its derivatives and are used as antiobesity preparations or central nervous system stimulants. Amphetamines have a high potential for abuse. Tolerance, extreme psychological dependence and severe social disability can occur. Side effects may include dryness of the mouth, anorexia, euphoria, insomnia, and headaches. Physical dependence, however, does not occur.

TABLE 3.071 - AMPHETAMINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,996	29	22	45	18**	61	27	30	44	53	26	36	64	73	45
Alone (%)	38	59	32	33	44	49	37	47	66	32	62	53	55	42	49
Rank in TDS/SMSA	20	25	26	24	29	25	29	14	21	28	20.5	19	27	26	13
Source (%)															
Legal RX	9	7	5	9		8	-	27	2	9	19	14	11	42	2
Forged RX	+	-	-	2		-	4	-	-	-	-	-	-	-	-
Stolen	+	-	-	-		-	-	-	-	-	4	-	-	-	2
Street buy	55	34	50	42		21	26	10	39	42	15	25	16	48	64
Over-the-counter	-	-	-	-		-	-	-	-	-	-	-	-	-	-
Gift	4	3	5	2		3	4	-	2	2	31	6	5	3	-
Other	+	-	-	-		-	4	-	-	2	-	-	-	-	-
Unk./No resp.	32	59	41	49		69	67	63	57	45	31	56	69	7	31
Motivation (%)															
Psychic effects	33	72	55	31		43	26	30	68	21	50	33	27	56	49
Dependence	39	3	18	36		13	26	17	7	42	8	19	16	33	16
Suic.att./gest.	18	17	14	18		23	26	33	25	21	8	28	19	10	29
Unknow./Unwill.	+	-	-	-		-	4	-	-	-	8	-	-	-	-
Other	1	-	-	7		3	7	-	-	-	8	-	2	-	-
Unk./No resp.	11	10	18	9		28	30	20	11	19	19	19	39	1	7
Age (%) DAWN Grouping															
6-9	+	-	-	-		-	-	-	-	-	-	-	-	-	-
10-19	24	31	27	16		34	11	20	27	15	27	42	19	30	22
20-29	54	55	50	51		46	70	43	43	49	65	42	50	45	56
30-39	17	10	18	29		11	19	23	16	28	8	8	28	15	20
40-49	3	-	-	4		7	-	10	7	4	-	3	3	10	2
50 & Over	1	3	-	-		2	-	3	2	4	-	3	-	-	-
Unk./No resp.	1	-	5	-		-	-	-	5	-	-	3	-	-	-
Age (%) CODAP Grouping															
6-9	+	-	-	-		-	-	-	-	-	-	-	-	-	-
10-17	12	17	23	7		18	7	10	16	9	15	19	9	11	13
18-20	17	24	14	11		21	15	17	16	8	15	31	14	26	13
21-25	31	34	23	33		34	37	33	18	30	35	22	30	22	33
26-30	20	14	18	20		8	22	7	23	25	27	11	17	19	20
31-44	15	7	18	27		15	19	20	18	23	8	8	27	21	18
45 & Over	3	3	-	2		3	-	13	5	6	-	6	3	1	2
Unk./No resp.	1	-	5	-		-	-	-	5	-	-	3	-	-	-
Race (%)															
White	72	83	64	84		52	52	83	57	66	73	67	59	75	76
Black	18	7	32	13		23	33	10	2	25	19	14	19	15	4
Other	2	-	-	-		3	-	3	11	-	-	-	5	-	-
Unk./No resp.	7	10	5	2		21	15	3	30	9	8	19	17	10	20
Sex (%)															
Male	58	62	59	51		56	56	47	59	55	69	44	53	45	60
Female	42	38	41	49		44	44	53	41	45	31	56	45	55	40
Unk./No resp.	+	-	-	-		-	-	-	-	-	-	-	2	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

32

Rank in TDS

26

Concomitance	N	%
Alone	5	16
In Comb.	27	84

Cause/Manner of Death

	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	2	6	2	6
Accid./Unexp.	15	47	8	25
Unk./No resp.	3	9	2	6

Age	N	%		N	%
6-9	-	-	40-49	2	6
10-19	1	3	50 & Over	-	-
20-29	24	75	Unk./No resp.	-	-
30-39	5	16			

Race	N	%
White	25	78
Black	6	19
Other	1	3
Unk./No resp.	-	-

Sex	N	%
Male	21	66
Female	11	34

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.071 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,996	46	723	5**	11**	248	57	18**	3**	52	63	31	35	131
Alone (%)	38	46	18	60	18	62	33	44	100	62	60	39	46	47
Rank in TDS/SMSA	20	19	9	26	26	8	16	24.5	33	18	11.5	27	23.5	25
Source (%)														
Legal RX	9	20	3			8	11			4	2	19	17	18
Forged RX	+	4	-			-	-			-	-	-	-	-
Stolen	+	-	+			+	4			-	-	-	-	-
Street buy	55	59	85			44	49			42	65	23	26	30
Over-the-counter	-	-	-			-	-			-	-	-	-	-
Gift	4	2	2			9	12			2	2	6	6	5
Other	+	-	-			-	-			-	-	-	-	-
Unk./No resp.	32	15	9			41	25			52	32	52	51	47
Motivation (%)														
Psychic effects	33	54	19			40	49			35	48	42	26	34
Dependence	39	39	66			31	25			27	49	10	34	11
Suic.att./gest.	18	4	13			19	26			15	8	35	26	32
Unknow./Unwill.	+	-	+			+	-			2	2	-	3	-
Other	1	2	+			1	2			-	-	3	-	2
Unk./No resp.	11	2	2			16	2			23	3	13	11	21
Age (%) DAWN Grouping														
6-9	+	-	+			-	-			-	-	-	-	-
10-19	24	9	25			20	19			13	13	32	23	33
20-29	54	54	57			59	61			65	38	48	60	52
30-39	17	30	15			17	11			12	38	16	14	9
40-49	3	4	2			2	5			8	8	3	3	3
50 & Over	1	2	1			2	2			-	3	-	-	2
Unk./No resp.	1	-	+			1	2			2	-	-	-	1
Age (%) CODAP Grouping														
6-9	+	-	+			-	-			-	-	-	-	-
10-17	12	2	14			9	7			10	3	16	11	20
18-20	17	15	18			15	25			8	13	16	20	19
21-25	31	33	31			38	23			35	14	39	37	35
26-30	20	22	22			21	30			27	32	16	17	12
31-44	15	22	13			13	9			17	30	10	11	10
45 & Over	3	7	2			3	5			2	8	3	3	3
Unk./No resp.	1	-	+			1	2			2	-	-	-	1
Race (%)														
White	72	61	82			52	88			69	63	87	69	82
Black	18	33	15			43	7			8	17	3	23	7
Other	2	2	2			2	5			2	3	3	-	2
Unk./No resp.	7	4	2			2	-			21	16	6	9	9
Sex (%)														
Male	58	57	62			60	56			56	70	39	54	53
Female	42	43	38			39	44			44	30	61	46	47
Unk./No resp.	+	-	-			1	-			-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Amphetamines act as stimulants to the central nervous system. They are usually prescribed as appetite suppressants, as an aid in the control of narcolepsy and, paradoxically, for hyperkinesis in children. Tolerance to the effects of amphetamine (especially the appetite-suppressant action) frequently occurs, requiring the user to continually increase his dosage of the drug to maintain the desired effects.

TABLE 3.072 - d-AMPHETAMINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	203	7**	6**	6**	7**	8**	6**	15**	6**	9**	1**	3**	9**	6**	10**
Alone (%)	43	14	50	50	29	63	50	53	33	22	100	67	44	50	60
Rank in TDS/SMSA	40	37.5	38.5	40	37	37	39	26	36.5	41	42	40	39.5	40	31.5
Source (%)															
Legal RX	24														
Forged RX	-														
Stolen	3														
Street buy	21														
Over-the-counter	-														
Gift	5														
Other	-														
Unk./No resp.	47														
Motivation (%)															
Psychic effects	32														
Dependence	16														
Suic.att./gest.	35														
Unknow./Unwill.	-														
Other	+														
Unk./No resp.	18														
Age (%) DAWN Grouping															
6-9	-														
10-19	33														
20-29	42														
30-39	18														
40-49	4														
50 & Over	1														
Unk./No resp.	+														
Age (%) CODAP Grouping															
6-9	-														
10-17	18														
18-20	20														
21-25	24														
26-30	17														
31-44	17														
45 & Over	3														
Unk./No resp.	+														
Race (%)															
White	73														
Black	14														
Other	2														
Unk./No resp.	11														
Sex (%)															
Male	45														
Female	55														
Unk./No resp.	-														

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

-

Rank in TDS

-

Concomitance	N	%
Alone	-	-
In Comb.	-	-

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%		N	%
6-9			40-49		
10-19			50 & Over		
20-29			Unk./No resp.		
30-39					

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.072 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	203	10**	8**	2**	7**	23	10**	2**	3**	7**	1**	3**	5**	23
Alone (%)	43	40	25	-	29	74	20	-	67	43	-	-	40	39
Rank in TDS/SMSA	40	35.5	39	32.5	31	40	36	39.5	33	38	41	40	39	39
Source (%)														
Legal RX	24					17								43
Forged RX	-					-								-
Stolen	3					-								-
Street buy	21					30								4
Over-the-counter	-					-								-
Gift	5					13								4
Other	-					-								-
Unk./No resp.	47					39								48
Motivation (%)														
Psychic effects	32					30								17
Dependence	16					35								9
Suic.att./gest.	35					17								43
Unknow./Unwill.	-					-								-
Other	+					-								-
Unk./No resp.	18					17								30
Age (%) DAWN Grouping														
6-9	-					-								-
10-19	33					13								39
20-29	42					57								35
30-39	18					22								17
40-49	4					4								9
50 & Over	1					4								-
Unk./No resp.	+					-								-
Age (%) CODAP Grouping														
6-9	-					-								-
10-17	18					9								22
18-20	20					9								17
21-25	24					26								30
26-30	17					30								4
31-44	17					17								26
45 & Over	3					9								-
Unk./No resp.	+					-								-
Race (%)														
White	73					70								70
Black	14					30								4
Other	2					-								-
Unk./No resp.	11					-								26
Sex (%)														
Male	45					57								30
Female	55					43								70
Unk./No resp.	-					-								-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Dextroamphetamine (d-amphetamine) is a central nervous system stimulant essentially identical to, but more potent than, amphetamine (racemic or dl-amphetamine) in its pharmacological, psychological, and behavioral actions on the brain and body. It is one of the more frequently used anorectics.

TABLE 3.073 - METHAMPHETAMINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	197	3**	2**	10**	1**	3**	4**	8**	4**	13**	5**	3**	4**	12**	8**
Alone (%)	53	67	-	10	100	33	50	63	75	46	80	33	-	67	50
Rank in TDS/SMSA	41	41	41	38	41	40	40	34.5	40.5	38	37	40	41	37	34
Source (%)															
Legal RX	7														
Forged RX	-														
Stolen	2														
Street buy	41														
Over-the-counter	-														
Gift	5														
Other	-														
Unk./No resp.	46														
Motivation (%)															
Psychic effects	48														
Dependence	25														
Suic.att./gest.	12														
Unknow./Unwill.	-														
Other	3														
Unk./No resp.	16														
Age (%) DAWN Grouping															
6-9	-														
10-19	22														
20-29	57														
30-39	17														
40-49	3														
50 & Over	1														
Unk./No resp.	1														
Age (%) CODAP Grouping															
6-9	-														
10-17	9														
18-20	19														
21-25	31														
26-30	25														
31-44	14														
45 & Over	2														
Unk./No resp.	1														
Race (%)															
White	78														
Black	11														
Other	1														
Unk./No resp.	10														
Sex (%)															
Male	68														
Female	32														
Unk./No resp.	-														

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

24

Rank in TDS

29

Concomitance	N	%
Alone	6	25
In Comb.	18	75

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	3	13	3	13
Accid./Unexp.	12	50	4	17
Unk./No resp.	1	4	1	4

Age	N	%		N	%
6-9	-	-	40-49	1	4
10-19	2	8	50 & Over	-	-
20-29	18	75	Unk./No resp.	-	-
30-39	3	13			

Race	N	%
White	17	71
Black	7	29
Other	-	-
Unk./No resp.	-	-

Sex	N	%
Male	20	83
Female	4	17

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.073 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	197	3**	5**	1**	1**	60	1**	1**	-	8**	12**	5**	2**	18**
Alone (%)	53	33	40	100	-	63	100	-	-	75	42	100	50	33
Rank in TDS/SMSA	41	41	41.5	38	40.5	34	41	41	-	36.5	30	38.5	41	41
Source (%)														
Legal RX	7					3								
Forged RX	-					-								
Stolen	2					2								
Street buy	41					30								
Over-the-counter	-					-								
Gift	5					7								
Other	-					-								
Unk./No resp.	46					58								
Motivation (%)														
Psychic effects	48					53								
Dependence	25					33								
Suic.att./gest.	12					3								
Unknow./Unwill.	-					-								
Other	3					2								
Unk./No resp.	16					15								
Age (%) DAWN Grouping														
6-9	-					-								
10-19	22					22								
20-29	57					62								
30-39	17					15								
40-49	3					2								
50 & Over	1					-								
Unk./No resp.	1					-								
Age (%) CODAP Grouping														
6-9	-					-								
10-17	9					8								
18-20	19					20								
21-25	31					35								
26-30	25					25								
31-44	14					12								
45 & Over	2					-								
Unk./No resp.	1					-								
Race (%)														
White	78					73								
Black	11					20								
Other	1					2								
Unk./No resp.	10					5								
Sex (%)														
Male	68					73								
Female	32					27								
Unk./No resp.	-					-								

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Methamphetamine, a central nervous system stimulant chemically related to amphetamine and ephedrine, resembles cocaine in both effects and potential for dependence. Tolerance to methamphetamine also occurs frequently. First used in combat fatigue cases during World War II, methamphetamine has been prescribed as an appetite depressant, in cases of depression, and as an analeptic in barbiturate overdose episodes.

TABLE 3.074 - SPEED

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,221	38	16**	43	29	68	33	13**	40	47	24	25	18**	52	67
Alone (%)	40	34	38	26	21	49	33	54	33	55	38	28	50	33	37
Rank in TDS/SMSA	29	21	30	25	25.5	24	27	29	22.5	30	23	21.5	34.5	31	12
Source (%)															
Legal RX	1	-		-	-	-	3		3	2	-	4		2	-
Forged RX	-	-		-	-	-	-		-	-	-	-		-	-
Stolen	+	8		-	-	-	-		-	2	-	-		-	-
Street buy	52	37		51	48	43	33		45	60	33	24		90	54
Over-the-counter	-	-		-	-	-	-		-	-	-	-		-	-
Gift	5	13		5	-	10	3		3	6	8	-		4	1
Other	+	-		-	-	-	-		-	-	-	-		-	-
Unk./No resp.	42	42		44	52	47	61		53	28	58	72		4	45
Motivation (%)															
Psychic effects	49	58		42	48	47	39		70	26	67	28		77	54
Dependence	25	11		30	34	21	15		8	57	8	4		21	30
Suic.att./gest.	13	11		14	21	10	9		18	6	21	16		2	15
Unknow./Unwill.	1	3		-	-	1	-		3	2	-	-		-	-
Other	1	3		2	-	-	-		3	-	4	4		-	-
Unk./No resp.	15	18		16	-	28	36		5	13	4	48		-	1
Age (%) DAWN Grouping															
6-9	-	-		-	-	-	-		-	-	-	-		-	-
10-19	32	42		51	45	38	48		40	30	42	44		31	27
20-29	52	50		40	45	41	39		45	43	54	44		60	57
30-39	12	-		7	10	19	6		13	23	-	4		8	12
40-49	2	8		2	-	1	6		3	2	4	4		2	1
50 & Over	+	-		-	-	-	-		-	-	-	4		-	-
Unk./No resp.	+	-		-	-	-	-		-	2	-	-		-	3
Age (%) CODAP Grouping															
6-9	-	-		-	-	-	-		-	-	-	-		-	-
10-17	16	13		23	21	25	24		25	15	21	40		13	15
18-20	22	34		30	28	19	27		20	21	25	4		23	22
21-25	31	26		30	34	26	33		35	23	33	24		27	31
26-30	18	18		7	10	12	3		8	17	17	20		29	16
31-44	11	-		9	7	16	6		13	21	4	4		8	12
45 & Over	1	8		-	-	1	6		-	-	-	8		-	-
Unk./No resp.	+	-		-	-	-	-		-	2	-	-		-	3
Race (%)															
White	67	84		86	69	74	70		33	70	79	64		81	81
Black	18	5		7	21	16	18		3	21	8	8		10	-
Other	3	-		-	-	3	-		-	-	-	4		2	-
Unk./No resp.	12	11		7	10	7	12		65	9	13	24		8	19
Sex (%)															
Male	60	63		60	69	59	48		43	70	54	52		69	61
Female	40	37		40	31	41	52		58	30	46	48		31	37
Unk./No resp.	+	-		-	-	-	-		-	-	-	-		-	1

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

-

Rank in TDS

-

Concomitance	N	%
Alone	-	-
In Comb.	-	-

Cause/Manner of Death

	Drug-Induced Deaths		Drug-Related Deaths	
	N	%	N	%
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%		N	%
6-9			40-49		
10-19			50 & Over		
20-29			Unk./No resp.		
30-39					

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.074 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,221	2**	74	2**	12**	251	33	21	10**	29	46	54	32	142
Alone (%)	40	-	19	-	50	53	39	38	30	45	65	33	28	36
Rank in TDS/SMSA	29	42	30	32.5	24.5	7	29	21	19.5	28	16.5	13	26	20
Source (%)														
Legal RX	1		1			+	-	-		-	-	2	-	2
Forged RX	-		-			-	-	-		-	-	-	-	-
Stolen	+		-			-	-	-		-	-	-	3	1
Street buy	52		85			54	61	38		66	76	56	38	42
Over-the-counter	-		-			-	-	-		-	-	-	-	-
Gift	5		4			5	12	10		-	2	6	3	4
Other	+		-			+	-	-		-	-	-	3	-
Unk./No resp.	42		9			40	27	52		34	22	37	53	52
Motivation (%)														
Psychic effects	49		30			46	58	57		48	57	59	38	52
Dependence	25		61			33	27	10		17	39	9	38	9
Suic.att./gest.	13		8			10	18	14		28	9	20	16	15
Unknow./Unwill.	1		-			+	-	5		-	-	-	3	-
Other	1		-			1	-	-		3	-	-	-	1
Unk./No resp.	15		3			18	6	19		7	2	11	6	25
Age (%) DAWN Grouping														
6-9	-		-			-	-	-		-	-	-	-	-
10-19	32		19			22	24	52		31	2	33	41	40
20-29	52		69			63	64	33		52	63	50	41	46
30-39	12		11			13	12	14		17	26	9	16	13
40-49	2		1			2	-	-		-	7	6	3	1
50 & Over	+		-			1	-	-		-	2	2	-	-
Unk./No resp.	+		-			-	-	-		-	-	-	-	-
Age (%) CODAP Grouping														
6-9	-		-			-	-	-		-	-	-	-	-
10-17	16		11			10	18	24		7	-	19	31	17
18-20	22		15			20	12	33		38	2	19	9	33
21-25	31		32			35	45	14		31	43	35	25	25
26-30	18		32			24	15	19		14	28	11	22	15
31-44	11		9			10	9	10		10	22	13	13	10
45 & Over	1		-			2	-	-		-	4	4	-	-
Unk./No resp.	+		-			-	-	-		-	-	-	-	-
Race (%)														
White	67		68			42	85	67		69	67	80	66	81
Black	18		26			49	-	14		3	11	4	19	5
Other	3		1			6	6	-		3	2	2	-	1
Unk./No resp.	12		5			3	9	19		24	20	15	16	13
Sex (%)														
Male	60		68			70	39	57		55	74	44	59	57
Female	40		32			30	61	43		45	26	56	41	43
Unk./No resp.	+		-			-	-	-		-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

"Speed" is a common street name for stimulants such as amphetamine, methamphetamine, and d-amphetamine. These are synthetic amines that exert a stimulating action on the central nervous system. Characteristics of the general amphetamine group frequently include tolerance effects, a potential for psychological dependence, and the absence of physical dependence.

TABLE 3.08 - COCAINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	2,846	62	70	135	30	142	54	12**	64	131	17**	21	71	494	37
Alone (%)	41	60	34	33	27	34	41	33	58	36	35	67	56	50	35
Rank in TDS/SMSA	13	13	12	10	24	15	16	30	13	16	26.5	23	26	5	19
Source (%)															
Legal RX	-	-	-	-	-	-	-		-	-		-	-	-	-
Forged RX	-	-	-	-	-	-	-		-	-		-	-	-	-
Stolen	+	2	-	-	-	-	2		-	-		-	-	-	3
Street buy	73	74	79	67	73	60	46		59	73		52	44	90	51
Over-the-counter	-	-	-	-	-	-	-		-	-		-	-	-	-
Gift	2	-	1	1	-	2	7		3	2		10	1	3	3
Other	+	-	-	1	-	-	-		2	-		-	-	-	-
Unk./No resp.	25	24	20	31	27	38	44		38	24		38	55	7	43
Motivation (%)															
Psychic effects	40	58	43	32	60	54	39		70	26		43	31	67	54
Dependence	46	26	44	44	33	39	33		11	56		29	28	29	27
Suic.att./gest.	6	8	7	10	7	2	11		11	7		10	6	3	11
Unknow./Unwill.	+	-	1	-	-	-	-		-	-		-	-	-	-
Other	1	-	-	1	-	1	4		2	2		-	3	+	-
Unk./No resp.	10	13	16	14	-	24	20		11	10		19	32	2	8
Age (%) DAWN Grouping															
6-9	-	-	-	-	-	-	-		-	-		-	-	-	-
10-19	13	10	13	15	3	18	15		16	8		33	11	15	19
20-29	59	63	67	71	83	58	67		75	66		52	61	60	65
30-39	22	18	16	13	13	20	11		8	18		10	24	21	8
40-49	5	5	4	1	-	4	6		2	6		5	3	4	5
50 & Over	1	2	-	-	-	1	2		-	1		-	-	+	-
Unk./No resp.	1	3	-	-	-	1	-		-	1		-	1	+	3
Age (%) CODAP Grouping															
6-9	-	-	-	-	-	-	-		-	-		-	-	-	-
10-17	5	3	4	4	3	6	6		6	3		14	4	5	11
18-20	13	16	14	18	10	18	17		9	11		19	11	13	16
21-25	32	26	39	42	50	28	37		44	36		43	42	36	46
26-30	26	32	26	25	27	25	24		31	28		14	17	23	14
31-44	21	18	16	10	10	20	13		9	18		10	24	19	11
45 & Over	3	2	1	1	-	1	4		-	3		-	-	2	-
Unk./No resp.	1	3	-	-	-	1	-		-	1		-	1	+	3
Race (%)															
White	43	27	53	55	57	33	46		45	36		71	56	41	78
Black	40	61	43	33	30	51	48		-	47		-	24	45	-
Other	6	-	1	1	3	5	2		5	-		-	3	5	3
Unk./No resp.	11	11	3	10	10	11	4		50	18		29	17	10	19
Sex (%)															
Male	67	56	71	76	73	67	56		53	71		67	69	57	59
Female	33	44	29	24	27	33	44		47	27		33	31	43	41
Unk./No resp.	+	-	-	-	-	-	-		-	2		-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

141

Rank in TDS

13

Concomitance	N	%
Alone	41	29
In Comb.	100	71

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	14	10	6	4
Accid./Unexp.	66	47	24	17
Unk./No resp.	26	18	5	4

Age	N	%		N	%
6-9	-	-	40-49	8	6
10-19	10	7	50 & Over	2	1
20-29	82	58	Unk./No resp.	1	1
30-39	38	27			

Race	N	%
White	113	80
Black	24	17
Other	3	2
Unk./No resp.	1	1

Sex	N	%
Male	96	68
Female	45	32

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.08 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	2,846	47	911	10**	8**	81	51	20	3**	57	73	46	86	113
Alone (%)	41	34	35	50	50	38	43	40	67	46	56	28	47	35
Rank in TDS/SMSA	13	18	7	19	30	30	19	22.5	33	17	7	18	12	27
Source (%)														
Legal RX	-	-	-			-	-	-		-	-	-	-	-
Forged RX	-	-	-			-	-	-		-	-	-	-	-
Stolen	+	-	+			-	-	-		-	-	-	1	-
Street buy	73	87	79			52	76	70		68	77	57	53	50
Over-the-counter	-	-	-			-	-	-		-	-	-	-	-
Gift	2	-	1			4	12	-		2	1	2	2	2
Other	+	-	-			1	-	-		-	1	-	-	-
Unk./No resp.	25	13	20			43	12	30		30	21	41	43	49
Motivation (%)														
Psychic effects	40	47	17			51	63	20		35	66	65	35	42
Dependence	46	49	73			25	37	50		32	26	17	44	27
Suic.att./gest.	6	2	3			2	8	10		14	8	17	9	21
Unknow./Unwill.	+	-	-			1	-	-		2	-	-	-	-
Other	1	-	+			1	-	-		-	1	2	-	2
Unk./No resp.	10	2	8			25	2	20		21	4	7	12	13
Age (%) DAWN Grouping														
6-9	-	-	-			-	-	-		-	-	-	-	-
10-19	13	11	7			23	31	30		12	10	7	17	22
20-29	59	64	54			42	51	35		63	51	65	60	51
30-39	22	21	28			31	16	25		23	27	24	19	22
40-49	5	4	8			4	-	5		-	8	4	2	3
50 & Over	1	-	2			-	2	5		-	3	-	-	-
Unk./No resp.	1	-	+			-	-	-		2	1	-	1	2
Age (%) CODAP Grouping														
6-9	-	-	-			-	-	-		-	-	-	-	-
10-17	5	4	3			10	8	10		-	3	4	9	10
18-20	13	15	8			16	31	25		19	14	7	13	19
21-25	32	28	25			27	24	20		40	23	39	38	27
26-30	26	38	30			17	20	10		16	32	30	20	22
31-44	21	15	29			28	16	30		23	22	17	17	21
45 & Over	3	-	5			1	2	5		-	5	2	1	-
Unk./No resp.	1	-	+			-	-	-		2	1	-	1	2
Race (%)														
White	43	53	29			42	82	65		68	51	65	60	72
Black	40	47	53			48	10	25		18	16	17	28	15
Other	6	-	10			1	8	-		5	10	4	1	-
Unk./No resp.	11	-	8			9	-	10		9	23	13	10	13
Sex (%)														
Male	67	72	71			72	57	70		68	75	70	67	64
Female	33	28	29			28	43	30		32	25	30	33	35
Unk./No resp.	+	-	+			-	-	-		-	-	-	-	1

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Cocaine is a very strong stimulant to the central nervous system. The euphoria generated is short-lived and habitual users have been known to inject cocaine as often as every ten minutes. While tolerance and physical dependence are not known to develop, a psychological dependence does occur. Cocaine has become known as a social or "party" drug and appears to be the drug of affluence.

TABLE 3.09 THERAPEUTIC CLASS - PSYCHOSTIMULANTS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	7,647	174	163	269	157	239	168	196	176	394	157	200	641	287	262
Alone (%)	42	39	41	38	38	44	38	50	41	36	36	40	52	38	36
Rank in TDS/SMSA	7	4	7	6	7	7	7	4	5	7	4	4	6	7	4
Source (%)															
Legal RX	60	66	69	53	62	65	57	51	56	72	55	63	38	84	76
Forged RX	+	-	-	+	-	-	-	-	1	+	-	-	-	+	+
Stolen	2	3	4	3	3	1	1	3	2	3	3	2	1	2	2
Street buy	3	1	6	1	1	1	2	1	-	1	-	1	+	1	-
Over-the-counter	2	5	2	3	1	3	1	1	4	3	1	1	1	2	8
Gift	1	1	1	1	3	1	2	3	2	2	1	1	+	-	+
Other	+	-	-	1	-	-	1	-	-	-	-	1	-	-	-
Unk./No resp.	31	26	17	37	31	30	37	44	36	21	41	33	60	12	13
Motivation (%)															
Psychic effects	13	13	21	10	10	9	10	28	6	13	18	9	10	31	11
Dependence	8	2	10	4	3	2	3	2	2	6	2	2	7	8	1
Suic.att./gest.	59	64	60	67	62	55	57	59	80	66	59	59	46	55	76
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	2	2	2	4	3	2	4	2	2	1	2	4	2	1	1
Unk./No resp.	19	19	9	17	23	33	27	11	11	17	21	27	36	5	12
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	1	-	1	-	1	-	1	-
10-19	13	14	10	12	15	14	15	16	13	11	17	17	11	10	18
20-29	36	32	39	38	36	34	37	37	38	38	38	35	37	33	38
30-39	27	32	33	25	23	29	25	25	24	27	25	27	25	28	24
40-49	14	14	9	12	11	15	13	11	13	13	13	10	16	20	11
50 & Over	10	6	8	11	13	8	8	10	10	9	6	10	9	9	9
Unk./No resp.	1	2	-	1	1	-	2	-	2	1	-	1	1	-	+
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	1	-	1	-	1	-	1	-
10-17	8	10	7	6	6	10	11	9	10	7	10	9	6	4	11
18-20	8	7	7	8	10	7	10	10	6	6	8	13	7	9	11
21-25	18	13	18	22	24	17	18	22	13	17	21	15	17	15	21
26-30	19	20	23	17	16	16	17	15	23	24	20	19	21	18	16
31-44	31	36	35	29	25	32	29	26	33	30	27	31	32	35	26
45 & Over	16	12	10	17	18	17	13	17	13	15	13	13	16	18	15
Unk./No resp.	1	2	-	1	1	-	2	-	2	1	-	1	1	-	+
Race (%)															
White	71	73	72	87	82	70	67	90	46	71	86	70	54	62	80
Black	15	14	25	4	5	11	18	8	1	19	8	11	26	15	1
Other	3	1	1	3	2	5	2	2	5	+	1	1	3	7	1
Unk./No resp.	11	13	1	6	11	13	13	1	48	10	6	19	16	15	18
Sex (%)															
Male	30	26	34	30	34	23	27	20	28	29	25	20	29	31	24
Female	70	74	66	70	66	76	73	80	72	71	75	80	71	69	76
Unk./No resp.	+	-	-	-	-	+	1	-	-	1	-	1	1	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

623

Rank in TDS

5

Concomitance	N	%
Alone	163	26
In Comb.	460	74

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	320	51	9	1
Accid./Unexp.	94	15	20	3
Unk./No resp.	149	24	31	5

Age	N	%		N	%
6-9	-	-	40-49	100	16
10-19	18	3	50 & Over	132	21
20-29	201	32	Unk./No resp.	-	-
30-39	172	28			

Race	N	%
White	486	78
Black	97	16
Other	27	4
Unk./No resp.	13	2

Sex	N	%
Male	232	37
Female	391	63

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.09 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	7,647	150	781	84	94	535	227	187	108	269	175	218	172	1,164
Alone (%)	42	54	39	50	43	44	36	33	44	29	45	39	44	45
Rank in TDS/SMSA	7	7	9	4	4	6	5	4	4	5	5	5	6	4
Source (%)														
Legal RX	60	59	54	75	51	50	78	64	66	70	29	52	47	71
Forged RX	+	2	+	-	-	-	-	-	-	-	-	-	-	+
Stolen	2	4	3	2	2	1	3	3	4	3	-	2	3	2
Street buy	3	7	8	-	-	2	1	-	3	1	53	5	1	+
Over-the-counter	2	2	2	2	4	1	4	1	4	2	1	4	5	2
Gift	1	5	1	1	4	1	1	2	1	1	2	1	-	1
Other	+	-	-	-	-	+	-	1	-	-	-	+	-	+
Unk./No resp.	31	22	33	19	39	44	13	30	23	23	15	35	44	23
Motivation (%)														
Psychic effects	13	25	10	19	6	19	15	10	6	7	13	12	8	10
Dependence	8	5	31	1	2	10	5	2	-	7	54	4	3	2
Suic.att./gest.	59	57	45	61	60	44	65	63	73	69	34	67	79	69
Unknow./Unwill.	+	-	-	-	-	+	-	-	-	+	1	-	-	-
Other	2	1	+	4	1	3	4	1	-	2	-	3	1	2
Unk./No resp.	19	12	15	17	31	28	15	25	20	16	3	14	10	19
Age (%) DAWN Grouping														
6-9	+	-	-	-	1	+	-	-	-	-	-	-	-	1
10-19	13	13	9	13	15	11	14	18	21	11	2	11	14	15
20-29	36	43	41	37	44	30	36	37	37	34	47	37	37	33
30-39	27	29	25	24	20	29	23	24	24	29	31	25	24	28
40-49	14	9	12	20	11	17	15	12	6	14	13	14	14	14
50 & Over	10	6	11	5	10	13	12	8	8	12	6	12	10	10
Unk./No resp.	1	1	1	1	-	1	+	1	3	1	1	-	!	1
Age (%) CODAP Grouping														
6-9	+	-	-	-	1	+	-	-	-	-	-	-	-	1
10-17	8	9	5	10	10	8	7	11	16	7	1	7	9	9
18-20	8	5	7	7	11	6	11	11	9	7	5	7	9	9
21-25	18	25	21	18	24	15	16	23	25	16	15	18	18	17
26-30	19	21	21	17	17	16	18	13	12	16	35	21	16	17
31-44	31	29	28	38	24	36	29	25	22	35	33	28	30	32
45 & Over	16	11	16	10	13	18	19	16	13	17	11	19	17	16
Unk./No resp.	1	1	1	1	-	1	+	1	3	1	1	-	1	1
Race (%)														
White	71	54	66	83	82	63	85	75	66	70	41	72	63	82
Black	15	41	18	15	5	30	2	10	8	10	49	13	22	6
Other	3	1	7	-	1	1	7	-	23	2	2	5	2	1
Unk./No resp.	11	4	10	1	12	5	5	15	3	17	9	10	13	11
Sex (%)														
Male	30	21	39	25	20	38	26	36	19	28	59	24	27	27
Female	70	78	60	75	80	62	74	64	81	71	41	76	73	73
Unk./No resp.	+	1	+	-	-	-	-	-	-	1	-	-	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

The therapeutic class of psychostimulants includes products used as mood elevators and analeptics separate and apart from amphetamine products. Clinically, psychostimulants are used for the treatment of depression.

TABLE 3.091 - METHYLPHENIDATE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	456	4**	4**	5**	1**	10**	8**	3**	5**	15**	4**	8**	83	8**	5**
Alone (%)	47	25	25	60	-	50	38	33	20	33	50	38	63	38	20
Rank in TDS/SMSA	38	39	40	41	41	35.5	37.5	40.5	39	36.5	38.5	33.5	23	39	36
Source (%)															
Legal RX	19												11		
Forged RX	-												-		
Stolen	2												-		
Street buy	28												-		
Over-the-counter	-												-		
Gift	3												-		
Other	+												-		
Unk./No resp.	49												89		
Motivation (%)															
Psychic effects	24												6		
Dependence	45												46		
Suic.att./gest.	16												12		
Unknow./Unwill.	1												-		
Other	1												-		
Unk./No resp.	18												36		
Age (%) DAWN Grouping															
6-9	+												-		
10-19	10												8		
20-29	36												35		
30-39	34												35		
40-49	13												12		
50 & Over	6												7		
Unk./No resp.	+												2		
Age (%) CODAP Grouping															
6-9	+												-		
10-17	8												8		
18-20	4												2		
21-25	15												7		
26-30	26												28		
31-44	36												40		
45 & Over	10												12		
Unk./No resp.	+												2		
Race (%)															
White	32												13		
Black	59												75		
Other	2												1		
Unk./No resp.	8												11		
Sex (%)															
Male	56												51		
Female	44												49		
Unk./No resp.	+												-		

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

7**

Rank in TDS

34

Concomitance	N	%
Alone	4	57
In Comb.	3	43

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%		N	%
6-9			40-49		
10-19			50 & Over		
20-29			Unk./No resp.		
30-39					

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.091 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	456	9**	5**	2**	1**	97	3**	4**	-	8**	107	29	6**	22
Alone (%)	47	-	40	100	100	36	67	-	-	25	56	41	83	55
Rank in TDS/SMSA	38	37	41.5	32.5	40.5	27	39	36	-	36.5	4	28	38	40
Source (%)														
Legal RX	19					4					1	10		55
Forged RX	-					-					-	-		-
Stolen	2					-					-	-		9
Street buy	28					12					87	38		-
Over-the-counter	-					-					-	-		-
Gift	3					7					-	-		9
Other	+					1					-	-		-
Unk./No resp.	49					75					12	52		27
Motivation (%)														
Psychic effects	24					44					14	52		9
Dependence	45					39					87	24		9
Suic.att./gest.	16					6					3	21		64
Unknow./Unwill.	1					1					1	-		-
Other	1					1					-	-		-
Unk./No resp.	18					24					1	3		18
Age (%) DAWN Grouping														
6-9	+					-					-	-		-
10-19	10					2					1	7		32
20-29	36					25					48	41		14
30-39	34					46					35	41		36
40-49	13					22					13	-		5
50 & Over	6					5					4	10		14
Unk./No resp.	+					-					-	-		-
Age (%) CODAP Grouping														
6-9	+					-					-	-		-
10-17	8					1					1	7		27
18-20	4					1					2	3		5
21-25	15					13					19	17		14
26-30	26					22					36	38		5
31-44	36					52					35	24		36
45 & Over	10					11					8	10		14
Unk./No resp.	+					-					-	-		-
Race (%)														
White	32					7					24	52		73
Black	59					90					64	38		14
Other	2					-					2	7		-
Unk./No resp.	8					3					9	3		14
Sex (%)														
Male	56					70					63	41		41
Female	44					30					37	59		59
Unk./No resp.	+					-					-	-		-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Methylphenidate is a mild cortical stimulant that differs chemically from central nervous system stimulants such as the amphetamines, but resembles them in numerous pharmacological respects. It is often prescribed as an antidepressant or as a "diet drug". This drug tends to have a euphoric effect on the user. Chronic abuse can lead to marked tolerance and psychic dependence with varying degrees of abnormal behavior. Frank psychotic episodes and severe depression can occur.

TABLE 3.092 - AMITRIPTYLINE

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	3,297	78	91	144	84	82	63	95	58	158	58	89	226	114	120
Alone (%)	39	37	30	35	38	41	35	45	38	35	34	43	46	32	37
Rank in TDS/SMSA	9	8	8	8	11	20	12	5	14	12.5	12	5	8	18	6
Source (%)															
Legal RX	63	71	65	51	62	66	65	45	71	72	50	63	45	88	83
Forged RX	+	-	-	1	-	-	-	-	-	1	-	-	-	1	-
Stolen	3	5	5	4	1	2	2	4	-	4	-	1	2	2	3
Street buy	3	1	11	2	-	-	-	2	-	-	-	1	-	1	-
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	1	1	1	2	4	1	-	2	-	3	2	1	+	-	1
Other	+	-	-	-	-	-	2	-	-	-	-	-	-	-	-
Unk./No resp.	31	23	18	40	33	30	32	48	29	21	48	34	53	11	13
Motivation (%)															
Psychic effects	12	13	23	8	11	11	8	32	5	9	16	11	11	36	10
Dependence	8	3	16	4	1	2	3	2	2	4	2	3	2	5	1
Suic.att./gest.	59	67	55	69	62	51	54	47	72	70	59	57	53	52	75
Unknow./Unwill.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	2	3	1	3	2	4	5	2	3	1	3	3	3	1	1
Unk./No resp.	20	17	10	16	24	33	30	17	19	16	24	25	31	6	13
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	1	-	1	-	-	-	-	-
10-19	11	17	5	8	18	9	14	16	10	11	14	18	11	5	15
20-29	36	24	38	40	32	39	30	39	38	33	34	31	36	37	34
30-39	27	31	37	25	23	29	30	20	29	30	29	28	27	31	24
40-49	14	15	10	13	17	12	13	13	10	13	19	12	19	23	15
50 & Over	10	9	9	12	11	11	6	12	10	12	3	9	8	4	11
Unk./No resp.	1	4	-	2	-	-	6	-	2	1	-	1	+	-	1
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	1	-	1	-	-	-	-	-
10-17	7	15	4	6	5	6	8	8	7	7	7	10	5	3	8
18-20	7	1	2	4	14	5	10	12	5	6	7	11	6	7	10
21-25	18	12	16	22	23	17	19	22	10	17	19	13	16	19	19
26-30	19	19	26	19	12	20	11	13	26	20	17	19	22	18	15
31-44	31	35	37	28	27	32	32	21	40	34	33	30	34	37	28
45 & Over	17	14	13	18	19	21	14	23	10	15	17	15	16	17	19
Unk./No resp.	1	4	-	2	-	-	6	-	2	1	-	1	+	-	1
Race (%)															
White	71	76	64	85	83	72	67	91	50	66	84	70	61	65	78
Black	14	14	34	6	6	11	22	6	-	23	9	12	19	15	2
Other	4	-	1	3	-	4	3	3	3	1	-	-	4	8	2
Unk./No resp.	11	10	1	6	11	13	8	-	47	10	7	18	17	12	18
Sex (%)															
Male	30	23	31	32	37	23	30	22	24	30	31	18	31	33	24
Female	70	77	69	68	63	76	68	78	76	70	69	81	69	67	76
Unk./No resp.	+	-	-	-	-	1	2	-	-	-	-	1	+	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

407

Rank in TDS

3

Concomitance	N	%
Alone	108	27
In Comb.	299	73

Cause/Manner of Death

	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	176	43	8	2
Accid./Unexp.	61	15	12	3
Unk./No resp.	123	30	27	7

Age	N	%		N	%
6-9	-	-	40-49	67	16
10-19	10	2	50 & Over	85	21
20-29	133	33	Unk./No resp.	-	-
30-39	112	28			

Race	N	%
White	297	73
Black	73	18
Other	25	6
Unk./No resp.	12	3

Sex	N	%
Male	169	42
Female	238	58

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.092 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	3,297	57	513	38	28	188	87	83	54	122	32	77	79	479
Alone (%)	39	61	34	61	32	43	41	40	43	28	28	38	38	47
Rank in TDS/SMSA	9	16	14	7	8.5	12	10	5	4.5	7	23	9	13	7
Source (%)														
Legal RX	63	58	49	76	39	61	84	60	69	72	69	65	54	75
Forged RX	+	4	+	-	-	-	-	-	-	-	-	-	-	+
Stolen	3	4	2	3	4	2	2	5	2	3	-	4	1	2
Street buy	3	2	11	-	-	1	-	-	6	1	-	-	1	+
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	1	5	1	3	-	1	2	2	2	-	6	1	-	1
Other	+	-	-	-	-	-	-	1	-	-	-	-	-	+
Unk./No resp.	31	28	37	18	61	37	11	31	22	24	25	30	43	22
Motivation (%)														
Psychic effects	12	21	11	13	-	14	11	8	7	3	16	9	5	9
Dependence	8	-	34	-	4	4	3	2	-	6	3	-	3	2
Suic.att./gest.	59	65	38	74	57	51	69	60	72	72	78	70	86	66
Unknow./Unwill.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	2	-	+	5	4	3	3	1	-	2	-	5	-	2
Unk./No resp.	20	14	19	11	36	29	17	28	20	17	6	16	6	22
Age (%) DAWN Grouping														
6-9	+	-	-	-	-	1	-	-	-	-	-	-	-	+
10-19	11	19	8	16	14	12	11	12	20	7	3	6	9	13
20-29	36	46	45	32	36	28	33	39	31	30	50	39	39	32
30-39	27	21	25	24	25	23	28	25	26	32	22	17	24	29
40-49	14	12	11	24	7	18	15	14	9	17	13	19	18	13
50 & Over	10	2	10	5	18	18	13	8	7	14	6	18	9	11
Unk./No resp.	1	-	2	-	-	1	-	1	6	-	6	-	1	1
Age (%) CODAP Grouping														
6-9	+	-	-	-	-	1	-	-	-	-	-	-	-	+
10-17	7	14	4	11	11	8	7	8	19	6	-	4	8	7
18-20	7	9	6	8	4	6	6	6	6	5	9	4	5	9
21-25	18	21	22	21	21	14	15	27	17	14	9	21	22	16
26-30	19	25	25	8	14	14	21	13	15	15	34	19	15	17
31-44	31	23	27	45	32	33	31	28	26	39	31	22	33	32
45 & Over	17	9	14	8	18	24	21	17	13	21	9	30	16	17
Unk./No resp.	1	-	2	-	-	1	-	1	6	-	6	-	1	1
Race (%)														
White	71	51	58	82	82	73	85	73	67	71	78	77	67	80
Black	14	44	22	18	7	18	1	12	6	7	16	9	19	7
Other	4	2	9	-	-	2	8	-	26	1	-	9	1	1
Unk./No resp.	11	4	11	-	11	7	6	14	2	20	6	5	13	12
Sex (%)														
Male	30	25	44	21	18	31	23	35	24	28	56	18	23	26
Female	70	75	56	79	82	69	77	65	76	72	44	82	77	74
Unk./No resp.	+	-	+	-	-	-	-	-	-	-	-	-	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Amitriptyline, a psychostimulant often prescribed as an antidepressant, differs from most other antidepressants, such as the amphetamines, in that it does not stimulate the central nervous system. This drug may enhance the response to alcohol and the effects of barbiturates and other central nervous system depressants.

TABLE 3.093 - AMITRIPTYLINE COMBINATIONS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,842	45	40	40	42	69	34	65	45	116	49	42	203	105	40
Alone (%)	46	49	58	43	45	42	53	66	47	35	43	45	51	41	38
Rank in TDS/SMSA	22	16	19	26.5	20	23	26	8	20	18	13.5	15.5	10	19	17
Source (%)															
Legal RX	67	64	85	50	67	68	41	55	69	80	59	67	39	87	78
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	2	-	-	-	2	-	-	-	7	1	4	5	1	1	-
Street buy	+	-	-	-	2	-	-	-	-	-	-	2	+	1	-
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	1	-	-	-	-	-	3	2	2	-	-	-	1	-	-
Other	+	-	-	-	-	-	-	-	-	-	-	2	-	-	-
Unk./No resp.	30	36	15	50	29	32	56	43	22	19	37	24	60	11	23
Motivation (%)															
Psychic effects	13	13	20	13	7	7	9	28	7	16	18	5	10	26	10
Dependence	4	-	3	5	5	1	-	-	2	3	2	-	1	7	-
Suic.att./gest.	62	60	68	65	64	61	62	68	82	68	55	67	49	61	73
Unknow./Unwill.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	1	-	3	-	-	1	-	2	2	-	2	5	1	1	3
Unk./No resp.	21	27	8	20	24	29	29	5	7	18	24	24	39	6	20
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	2	-
10-19	12	7	15	18	7	16	9	14	7	5	20	17	11	10	15
20-29	37	36	40	28	52	23	44	40	33	37	35	38	42	30	20
30-39	27	38	25	25	26	33	26	28	31	30	27	26	25	23	40
40-49	14	20	10	13	5	25	12	11	16	16	10	10	13	21	10
50 & Over	10	-	10	15	10	3	9	8	11	9	8	10	9	15	15
Unk./No resp.	+	-	-	3	-	-	-	-	2	2	-	-	+	-	-
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	-	-	-	-	2	-
10-17	7	4	8	8	5	10	6	8	4	4	6	10	5	5	10
18-20	8	7	15	10	2	10	3	8	7	4	16	17	7	6	5
21-25	19	13	13	18	31	9	32	28	16	17	14	19	23	10	3
26-30	18	22	23	15	26	14	15	17	16	22	20	14	21	23	25
31-44	31	40	33	25	26	41	32	28	40	34	33	31	28	32	38
45 & Over	16	13	10	23	10	16	12	12	16	16	10	10	15	22	20
Unk./No resp.	+	-	-	3	-	-	-	-	2	2	-	-	+	-	-
Race (%)															
White	75	67	93	93	81	71	74	88	51	79	90	71	57	53	85
Black	12	18	8	-	5	1	18	11	2	16	4	5	24	18	-
Other	3	2	-	5	7	13	3	-	2	-	2	-	4	9	-
Unk./No resp.	10	13	-	3	7	14	6	2	44	4	4	24	15	20	15
Sex (%)															
Male	24	24	38	25	33	17	18	12	24	31	18	29	17	30	20
Female	75	76	63	75	67	83	82	88	76	68	82	71	82	70	80
Unk./No resp.	+	-	-	-	-	-	-	-	-	1	-	-	1	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

3**

Rank in TDS

38.5

Concomitance	N	%
Alone	1	33
In Comb.	2	67

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%
6-9		
10-19		
20-29		
30-39		
40-49		
50 & Over		
Unk./No resp.		

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.093 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,842	56	89	18**	41	133	59	37	23	45	9**	35	38	324
Alone (%)	46	55	58	44	41	57	31	16	43	24	11	49	42	47
Rank in TDS/SMSA	22	17	29	13.5	5	22	15	13	9.5	21	33.5	24	22	11
Source (%)														
Legal RX	67	68	71		59	66	78	59	57	80		60	58	75
Forged RX	-	-	-		-	-	-	-	-	-		-	-	-
Stolen	2	5	1		2	-	3	3	13	2		3	5	1
Street buy	+	2	-		-	-	3	-	-	-		-	-	+
Over-the-counter	-	-	-		-	-	-	-	-	-		-	-	-
Gift	1	5	3		5	-	2	3	-	2		-	-	1
Other	+	-	-		-	-	-	-	-	-		3	-	-
Unk./No resp.	30	20	25		34	34	14	35	30	16		34	37	22
Motivation (%)														
Psychic effects	13	20	4		10	12	24	11	4	7		-	5	11
Dependence	4	2	33		-	5	8	3	-	9		3	3	2
Suic.att./gest.	62	66	54		59	49	59	68	70	64		74	84	69
Unknow./Unwill.	-	-	-		-	-	-	-	-	-		-	-	-
Other	1	2	-		-	2	-	-	-	4		3	-	2
Unk./No resp.	21	11	9		32	33	15	22	26	16		20	8	17
Age (%) DAWN Grouping														
6-9	+	-	-		2	1	-	-	-	-		-	-	-
10-19	12	9	6		22	14	12	22	22	7		6	13	15
20-29	37	39	44		37	36	41	43	43	38		29	34	35
30-39	27	34	20		20	25	15	24	26	20		40	29	27
40-49	14	9	11		12	12	22	5	4	13		11	11	16
50 & Over	10	7	19		7	12	10	5	4	20		14	13	7
Unk./No resp.	+	2	-		-	-	-	-	-	2		-	-	-
Age (%) CODAP Grouping														
6-9	+	-	-		2	1	-	-	-	-		-	-	-
10-17	7	7	3		15	11	5	5	9	2		3	8	9
18-20	8	2	8		15	6	14	24	13	9		11	5	9
21-25	19	27	22		20	19	25	24	39	22		9	21	19
26-30	18	16	20		15	17	8	14	4	11		17	16	18
31-44	31	34	19		22	29	31	24	26	29		40	34	32
45 & Over	16	13	27		12	17	17	8	9	24		20	16	13
Unk./No resp.	+	2	-		-	-	-	-	-	2		-	-	-
Race (%)														
White	75	52	81		83	77	85	86	57	64		77	63	86
Black	12	41	11		2	19	5	3	22	16		3	32	4
Other	3	2	2		-	1	7	-	22	4		-	-	1
Unk./No resp.	10	5	6		15	4	3	11	-	16		20	5	9
Sex (%)														
Male	24	18	35		24	31	17	30	17	22		11	24	25
Female	75	82	65		76	69	83	70	83	73		89	76	75
Unk./No resp.	+	-	-		-	-	-	-	-	4		-	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Entries in this category usually combine an antidepressant (amitriptyline) with either an antianxiety agent, such as chlordiazepoxide, or an antipsychotic agent, such as perphenazine. Both combinations are useful in the treatment of patients with moderate to severe anxiety and depression. Side effects are drowsiness or dizziness.

TABLE 3.10 - THERAPEUTIC CLASS - CANNABIS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	5,369	95	170	165	245	225	172	26	63	713	88	56	168	565	98
Alone (%)	28	26	19	27	42	41	47	15	27	36	32	30	26	24	17
Rank in TDS/SMSA	8	7	6	8	5	8	6	11	11	5	7	10	9	4	9
Source (%)															
Legal RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	+	3	-	-	-	-	-	-	-	-	-	-	1	-	-
Street buy	68	41	58	74	51	51	37	31	54	87	48	34	55	82	69
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	6	3	27	1	4	4	5	15	10	1	9	2	3	13	1
Other	+	2	1	-	-	-	-	-	2	+	2	-	-	-	1
Unk./No resp.	25	51	15	25	44	45	60	54	37	11	41	64	41	5	29
Motivation (%)															
Psychic effects	56	68	74	62	83	60	57	77	78	29	73	55	51	81	64
Dependence	29	9	16	19	11	12	8	-	5	61	9	14	4	16	19
Suic.att./gest.	5	3	4	12	5	6	5	15	5	4	3	9	5	1	11
Unknow./Unwill.	+	-	-	1	1	-	1	-	-	+	2	-	-	-	-
Other	1	2	4	2	-	3	1	4	5	1	2	-	1	+	2
Unk./No resp.	11	20	9	8	5	26	32	4	11	7	14	23	39	2	8
Age (%) DAWN Grouping															
6-9	+	-	-	-	+	-	-	-	-	-	-	-	1	-	-
10-19	39	43	29	34	41	40	54	50	41	31	58	54	38	39	47
20-29	43	44	42	55	47	44	39	50	41	52	36	29	46	48	41
30-39	14	6	22	8	10	13	6	-	11	14	5	13	14	10	9
40-49	4	4	5	2	1	2	-	-	5	2	-	5	2	3	1
50 & Over	1	1	1	1	-	+	-	-	-	+	1	-	1	1	-
Unk./No resp.	+	1	1	1	+	1	1	-	2	1	-	-	-	-	2
Age (%) CODAP Grouping															
6-9	+	-	-	-	+	-	-	-	-	-	-	-	1	-	-
10-17	24	21	22	18	24	25	36	46	33	14	40	34	22	23	29
18-20	21	32	14	23	24	20	23	12	17	25	25	25	23	23	29
21-25	26	26	21	32	29	27	28	42	19	32	25	20	32	29	19
26-30	13	11	17	18	12	13	8	-	14	16	7	7	11	15	12
31-44	14	8	22	8	9	13	5	-	14	12	2	11	11	9	9
45 & Over	2	1	4	1	+	1	-	-	-	1	1	4	1	2	-
Unk./No resp.	+	1	1	1	+	1	1	-	2	1	-	-	-	-	2
Race (%)															
White	54	59	51	69	66	47	63	65	24	34	82	64	55	51	82
Black	32	32	49	27	24	36	24	27	-	59	13	20	20	27	2
Other	5	-	-	2	2	7	1	4	2	+	-	-	6	7	-
Unk./No resp.	9	9	1	1	8	10	13	4	75	7	6	16	20	14	16
Sex (%)															
Male	68	72	78	62	74	67	65	73	60	74	60	64	65	67	73
Female	32	28	22	37	26	33	35	27	40	26	38	34	35	33	27
Unk./No resp.	+	-	-	1	-	-	-	-	-	-	2	2	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions: 23

Rank in TDS: 11

Concomitance	N	%
Alone	5	22
In Comb.	18	78

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	2	9	3	13
Accid./Unexp.	2	9	16	70
Unk./No resp.	-	-	-	-

Age	N	%		N	%
6-9	-	-	40-49	1	4
10-19	6	26	50 & Over	1	4
20-29	12	52	Unk./No resp.	-	-
30-39	3	13			

Race	N	%
White	19	83
Black	4	17
Other	-	-
Unk./No resp.	-	-

Sex	N	%
Male	20	87
Female	3	13

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.10 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	5,369	68	1,421	4**	22	294	51	30	4**	88	71	76	143	248
Alone (%)	28	32	17	25	64	41	31	27	25	20	41	18	36	31
Rank in TDS/SMSA	8	8	5	11	11	8	12	11	12	10	9	10	9	11
Source (%)														
Legal RX	-	-	-		-	-	-	-		-	-	-	-	-
Forged RX	-	-	-		-	-	-	-		-	-	-	-	-
Stolen	+	-	+		-	+	-	-		1	-	-	-	1
Street buy	68	82	83		64	48	67	43		75	58	42	39	43
Over-the-counter	-	-	-		-	-	-	-		-	-	-	-	-
Gift	6	1	7		5	6	10	7		1	6	1	13	3
Other	+	-	+		-	-	-	-		-	-	-	-	+
Unk./No resp.	25	16	10		32	46	24	50		23	37	57	48	52
Motivation (%)														
Psychic effects	56	63	42		59	53	82	67		75	87	75	57	63
Dependence	29	26	48		14	13	14	10		5	6	3	27	10
Suic.att./gest.	5	7	3		14	9	-	3		6	6	12	5	8
Unknow./Unwill.	+	-	+		-	+	-	-		1	-	-	1	+
Other	1	-	+		-	+	2	-		2	3	3	3	2
Unk./No resp.	11	7	7		14	27	4	20		11	3	9	11	19
Age (%) DAWN Grouping														
6-9	+	-	-		-	-	-	-		-	-	-	-	-
10-19	39	29	34		64	49	43	47		39	17	45	45	46
20-29	43	54	36		32	41	39	43		47	45	33	45	44
30-39	14	13	21		5	6	14	10		14	32	13	8	7
40-49	4	3	7		-	3	4	-		1	6	5	1	2
50 & Over	1	-	1		-	-	-	-		-	-	4	-	+
Unk./No resp.	+	-	+		-	-	-	-		-	-	-	-	1
Age (%) CODAP Grouping														
6-9	+	-	-		-	-	-	-		-	-	-	-	-
10-17	24	12	23		41	31	22	30		25	8	36	32	28
18-20	21	26	16		27	26	27	23		24	13	17	19	25
21-25	26	32	20		23	26	22	23		25	28	16	24	28
26-30	13	15	14		9	9	14	17		15	21	13	19	10
31-44	14	13	23		-	7	16	7		11	30	11	6	7
45 & Over	2	1	4		-	1	-	-		-	-	8	-	1
Unk./No resp.	+	-	+		-	-	-	-		-	-	-	-	1
Race (%)														
White	54	44	51		77	73	59	40		42	61	71	40	76
Black	32	51	34		9	22	24	27		33	15	12	41	10
Other	5	-	10		-	1	10	-		5	4	5	1	2
Unk./No resp.	9	4	5		14	4	8	33		20	20	12	17	13
Sex (%)														
Male	68	79	68		41	61	55	57		64	80	58	62	65
Female	32	21	32		59	38	45	43		36	20	42	38	35
Unk./No resp.	+	-	+		-	+	-	-		-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Cannabis is a general term for the flowering or fruiting tops of the hemp plant, the leaves, and sometimes the stems and seeds, which are taken for hallucinogenic effects. Hashish, a name applied to the resin exuded by the plant, is the most potent product in this classification. The psychoactive substances in the cannabis plant are the tetrahydrocannabinols (THC).

TABLE 3.101 - MARIJUANA

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	4,555	55	160	131	143	190	96	21	57	581	60	39	153	497	93
Alone (%)	25	27	19	25	32	38	40	14	26	33	27	23	25	23	17
Rank in TDS/SMSA	7	14	4	11	5	11	7	20	15	4	10.5	17	16	4	9
Source (%)															
Legal RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	+	2	-	-	-	-	-	-	-	-	-	-	1	-	-
Street buy	71	42	58	76	45	53	35	29	56	92	43	28	56	82	69
Over-the-counter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	7	4	28	2	4	3	3	19	11	2	8	-	3	15	1
Other	+	-	1	-	-	-	-	-	2	+	3	-	-	-	1
Unk./No resp.	22	53	14	23	51	44	63	52	33	6	45	72	39	3	29
Motivation (%)															
Psychic effects	55	67	75	64	82	59	68	76	79	22	72	62	52	82	65
Dependence	31	11	17	18	9	13	4	-	5	70	8	13	4	16	20
Suic.att./gest.	5	2	4	10	8	7	3	19	4	4	2	8	5	1	12
Unknow./Unwill.	+	-	-	-	1	-	-	-	-	1	3	-	-	-	-
Other	1	-	4	3	-	3	-	-	5	1	3	-	1	+	2
Unk./No resp.	10	24	8	8	4	26	27	5	11	4	15	21	39	1	6
Age (%) DAWN Grouping															
6-9	+	-	-	-	1	-	-	-	-	-	-	-	1	-	-
10-19	37	40	29	32	45	42	57	52	39	30	62	56	37	38	46
20-29	42	42	41	54	41	41	33	48	42	52	32	26	46	49	41
30-39	15	9	23	10	11	14	8	-	12	15	5	10	15	9	10
40-49	4	5	6	2	1	2	-	-	5	2	-	8	1	3	1
50 & Over	1	2	1	1	-	1	-	-	-	+	2	-	1	1	-
Unk./No resp.	+	2	1	1	1	-	1	-	2	+	-	-	-	-	2
Age (%) CODAP Grouping															
6-9	+	-	-	-	1	-	-	-	-	-	-	-	1	-	-
10-17	24	24	21	17	27	26	39	48	30	13	45	36	21	24	28
18-20	20	27	14	21	23	22	24	10	18	24	23	21	23	22	29
21-25	24	24	21	30	26	24	20	43	19	32	18	21	31	29	18
26-30	14	11	17	21	11	13	10	-	16	17	10	8	11	15	13
31-44	15	11	23	10	10	15	6	-	16	12	2	10	12	9	10
45 & Over	2	2	4	1	1	1	-	-	-	1	2	5	1	2	-
Unk./No resp.	+	2	1	1	1	-	1	-	2	+	-	-	-	-	2
Race (%)															
White	50	49	48	69	73	43	64	57	23	25	77	67	56	49	81
Black	35	38	52	28	20	41	26	33	-	69	15	15	21	29	2
Other	5	-	-	3	1	8	-	5	-	1	-	-	6	8	-
Unk./No resp.	9	13	1	-	5	9	10	5	77	5	8	18	18	14	17
Sex (%)															
Male	68	78	78	65	74	65	63	67	65	74	57	62	63	67	73
Female	32	22	22	34	26	35	38	33	35	26	42	36	37	33	27
Unk./No resp.	+	-	-	1	-	-	-	-	-	-	2	3	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

20

Rank in TDS

30.5

Concomitance	N	%
Alone	4	20
In Comb.	16	80

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	1	5	2	10
Accid./Unexp.	2	10	15	75
Unk./No resp.	-	-	-	-

Age	N	%		N	%
6-9	-	-	40-49	1	5
10-19	5	25	50 & Over	-	-
20-29	11	55	Unk./No resp.	-	-
30-39	3	15			

Race	N	%
White	17	85
Black	3	15
Other	-	-
Unk./No resp.	-	-

Sex	N	%
Male	17	85
Female	3	15

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.101 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	4,555	58	1,388	4**	13**	207	46	30	3**	85	69	67	139	170
Alone (%)	25	34	17	25	62	32	33	27	33	20	41	15	37	22
Rank in TDS/SMSA	7	15	5	27.5	23	11	21	16.5	33	8	8	12	8	18
Source (%)														
Legal RX	-	-	-			-	-	-		-	-	-	-	-
Forged RX	-	-	-			-	-	-		-	-	-	-	-
Stolen	+	-	+			-	-	-		1	-	-	-	1
Street buy	71	88	84			52	65	43		75	57	45	38	44
Over-the-counter	-	-	-			-	-	-		-	-	-	-	-
Gift	7	2	7			7	9	7		1	6	1	14	3
Other	+	-	+			-	-	-		-	-	-	-	-
Unk./No resp.	22	10	9			41	26	50		22	38	54	48	52
Motivation (%)														
Psychic effects	55	62	42			55	80	67		75	87	78	56	64
Dependence	31	29	49			16	15	10		5	6	3	27	11
Suic.att./gest.	5	7	3			8	-	3		6	6	9	5	8
Unknow./Unwill.	+	-	+			+	-	-		1	-	-	1	-
Other	1	-	+			+	2	-		2	3	3	3	2
Unk./No resp.	10	7	6			22	4	20		11	3	9	12	17
Age (%) DAWN Grouping														
6-9	+	-	-			-	-	-		-	-	-	-	-
10-19	37	33	34			44	46	47		36	17	45	45	46
20-29	42	52	36			42	35	43		48	46	31	46	42
30-39	15	12	22			9	15	10		14	30	13	9	7
40-49	4	3	7			5	4	-		1	6	6	1	2
50 & Over	1	-	1			-	-	-		-	-	4	-	1
Unk./No resp.	+	-	+			-	-	-		-	-	-	-	1
Age (%) CODAP Grouping														
6-9	+	-	-			-	-	-		-	-	-	-	-
10-17	24	12	23			31	24	30		24	9	34	32	28
18-20	20	29	16			20	28	23		24	13	18	19	24
21-25	24	28	20			25	20	23		26	29	15	24	26
26-30	14	17	14			12	11	17		15	22	13	19	11
31-44	15	12	24			11	17	7		12	28	10	6	8
45 & Over	2	2	4			2	-	-		-	-	9	-	1
Unk./No resp.	+	-	+			-	-	-		-	-	-	-	1
Race (%)														
White	50	38	50			64	63	40		41	59	69	39	73
Black	35	57	35			31	20	27		34	16	13	42	12
Other	5	-	10			1	9	-		5	4	4	1	2
Unk./No resp.	9	5	4			3	9	33		20	20	13	18	13
Sex (%)														
Male	68	81	69			61	59	57		62	81	60	60	68
Female	32	19	31			39	41	43		38	19	40	40	32
Unk./No resp.	+	-	+			+	-	-		-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Marijuana (marihuana) is the common name for a group of plants of the genus Cannabis. It is used primarily for psychic effects as a mild hallucinogenic or euphoriant. Marijuana use does not result in physical dependence. Psychological dependence is thought to develop only after extremely heavy use.

TABLE 3.102 - HASHISH

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	814	40	10**	34	102	35	76	5**	6**	132	28	17**	15**	68	5**
Alone (%)	47	25	30	32	55	57	57	20	33	52	43	47	40	31	20
Rank in TDS/SMSA	32	20	35	29	7.5	29	10	38	36.5	15	19	26.5	37	28	36
Source (%)															
Legal RX	-	-		-	-	-	-			-	-			-	
Forged RX	-	-		-	-	-	-			-	-			-	
Stolen	+	5		-	-	-	-			-	-			-	
Street buy	55	40		68	60	43	38			66	57			84	
Over-the-counter	-	-		-	-	-	-			-	-			-	
Gift	4	3		-	5	6	7			1	11			1	
Other	+	5		-	-	-	-			-	-			-	
Unk./No resp.	41	48		32	35	51	57			33	32			15	
Motivation (%)															
Psychic effects	62	70		53	84	63	43			58	75			79	
Dependence	14	8		21	15	9	12			23	11			16	
Suic.att./gest.	6	5		18	1	-	8			5	7			-	
Unknow./Unwill.	+	-		3	1	-	1			-	-			-	
Other	1	5		-	-	6	1			1	-			-	
Unk./No resp.	20	15		9	7	26	38			18	11			4	
Age (%) DAWN Grouping															
6-9	-	-		-	-	-	-			-	-			-	
10-19	44	48		41	36	29	50			39	50			46	
20-29	48	48		56	55	57	46			51	46			43	
30-39	7	3		-	8	9	3			8	4			10	
40-49	1	3		-	1	-	-			1	-			1	
50 & Over	-	-		-	-	-	-			-	-			-	
Unk./No resp.	1	-		3	-	6	1			2	-			-	
Age (%) CODAP Grouping															
6-9	-	-		-	-	-	-			-	-			-	
10-17	25	18		21	20	20	33			19	29			22	
18-20	28	38		32	25	11	21			32	29			32	
21-25	32	30		38	34	46	38			30	39			25	
26-30	9	10		6	14	14	4			11	-			15	
31-44	5	5		-	8	3	3			8	4			6	
45 & Over	+	-		-	-	-	-			-	-			-	
Unk./No resp.	1	-		3	-	6	1			2	-			-	
Race (%)															
White	73	73		71	56	71	62			75	93			69	
Black	14	23		24	30	11	21			12	7			12	
Other	2	-		-	2	3	1			-	-			4	
Unk./No resp.	11	5		6	12	14	16			13	-			15	
Sex (%)															
Male	66	63		53	74	74	67			73	68			68	
Female	33	38		47	26	26	33			27	29			32	
Unk./No resp.	+	-		-	-	-	-			-	4			-	

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

3**

Rank in TDS

38.5

Concomitance	N	%
Alone	1	33
In Comb.	2	67

Cause/Manner of Death	Drug-Induced Deaths		Drug-Related Deaths	
	N	%	N	%
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%		N	%
6-9			40-49		
10-19			50 & Over		
20-29			Unk./No resp.		
30-39					

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.102 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	814	10**	33	-	9**	87	5**	-	1**	3**	2**	9**	4**	78
Alone (%)	47	20	39	-	67	63	20	-	-	33	50	44	-	51
Rank in TDS/SMSA	32	35.5	36	-	28.5	28	37	-	38	41.5	39.5	36.5	40	31
Source (%)														
Legal RX	-		-			-								-
Forged RX	-		-			-								-
Stolen	+		-			1								-
Street buy	55		70			37								41
Over-the-counter	-		-			-								-
Gift	4		15			2								4
Other	+		-			-								1
Unk./No resp.	41		15			60								54
Motivation (%)														
Psychic effects	62		52			47								60
Dependence	14		24			5								9
Suic.att./gest.	6		6			10								9
Unknow./Unwill.	+		-			-								1
Other	1		-			-								3
Unk./No resp.	20		18			38								22
Age (%) DAWN Grouping														
6-9	-		-			-								-
10-19	44		45			59								46
20-29	48		36			41								46
30-39	7		18			-								6
40-49	1		-			-								-
50 & Over	-		-			-								-
Unk./No resp.	1		-			-								1
Age (%) CODAP Grouping														
6-9	-		-			-								-
10-17	25		24			30								27
18-20	28		24			40								26
21-25	32		27			28								32
26-30	9		15			2								9
31-44	5		9			-								5
45 & Over	+		-			-								-
Unk./No resp.	1		-			-								1
Race (%)														
White	73		73			94								82
Black	14		12			-								5
Other	2		-			1								-
Unk./No resp.	11		15			5								13
Sex (%)														
Male	66		55			62								59
Female	33		45			38								41
Unk./No resp.	+		-			-								-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Hashish is the name of the resin extracted from the marijuana plant. It is considered to be six to eight times as potent as marijuana. The tolerance potential of hashish is very slight, and physical dependence is said not to occur. However, psychological dependence may develop with prolonged, excessive use.

TABLE 3.11 - THERAPEUTIC CLASS - HALLUCINOGENS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	8,379	44	215	159	281	686	248	41	119	393	130	101	2,215	278	203
Alone (%)	64	50	58	35	60	63	71	63	61	51	68	59	84	54	42
Rank in TDS/SMSA	6	11	5	9	3	5	4	10	8	8	5	5	2	8	5
Source (%)															
Legal RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Forged RX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	+	-	+	-	1	-	-	-	1	-	1	-	+	-	+
Street buy	49	55	68	57	58	45	42	17	47	66	34	38	29	86	61
Over-the-counter	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	4	2	3	4	3	3	3	5	3	4	8	4	2	4	3
Other	1	-	+	3	1	1	-	-	1	1	1	4	+	1	+
Unk./No resp.	46	43	27	37	37	51	54	78	48	30	57	54	69	9	35
Motivation (%)															
Psychic effects	56	59	74	53	78	52	59	59	82	52	68	64	48	85	78
Dependence	12	2	14	13	11	10	6	20	4	26	5	6	2	10	12
Suic.att./gest.	5	14	5	14	5	6	7	5	6	8	3	7	3	3	6
Unknow./Unwill.	1	-	1	3	-	2	1	-	1	1	-	2	+	+	-
Other	1	-	1	3	2	1	2	7	3	2	1	2	+	-	1
Unk./No resp.	26	25	11	16	8	35	29	10	10	13	26	20	47	2	5
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	+	-	-	+	+	-
10-19	38	30	48	43	36	41	59	56	57	46	54	51	26	42	35
20-29	50	64	43	50	58	52	38	39	31	46	38	44	56	50	57
30-39	9	5	7	6	5	5	1	2	10	6	8	2	13	6	5
40-49	1	-	1	1	1	1	1	-	2	+	-	2	2	1	+
50 & Over	+	-	+	-	+	+	-	2	-	-	-	-	1	+	+
Unk./No resp.	1	2	+	1	+	1	1	-	-	1	-	1	2	-	1
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	+	-	-	+	+	-
10-17	20	16	23	29	20	23	34	22	32	27	32	28	11	18	20
18-20	26	27	31	21	24	27	32	46	32	26	27	31	24	34	29
21-25	30	39	26	34	34	33	23	24	19	30	30	31	33	28	31
26-30	14	14	13	9	17	11	8	2	7	11	7	7	17	15	14
31-44	8	2	6	6	4	5	2	2	9	6	5	3	11	5	5
45 & Over	1	-	+	-	1	1	-	2	1	-	-	-	1	+	+
Unk./No resp.	1	2	+	1	+	1	1	-	-	1	-	1	2	-	1
Race (%)															
White	54	80	82	82	68	65	79	76	43	75	85	74	31	74	69
Black	31	16	16	13	19	17	9	20	1	13	6	10	56	12	+
Other	4	2	+	1	1	7	2	2	5	1	-	2	3	5	2
Unk./No resp.	11	2	2	5	12	10	10	2	51	11	9	14	10	10	29
Sex (%)															
Male	71	73	67	69	75	69	71	73	66	72	77	67	72	76	74
Female	28	27	33	31	25	31	29	27	34	28	23	33	28	24	26
Unk./No resp.	+	-	-	-	-	-	-	-	-	+	-	-	+	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

119

Rank in TDS

7

Concomitance	N	%
Alone	57	48
In Comb.	62	52

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	4	3	11	9
Accid./Unexp.	46	39	37	31
Unk./No resp.	12	10	9	8

Age	N	%		N	%
6-9	-	-	40-49	6	5
10-19	14	12	50 & Over	3	3
20-29	79	66	Unk./No resp.	-	-
30-39	17	14			

Race	N	%
White	67	56
Black	47	39
Other	5	4
Unk./No resp.	-	-

Sex	N	%
Male	99	83
Female	20	17

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.11 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	8,379	165	1,399	12**	53	291	141	51	16**	219	156	140	233	390
Alone (%)	64	73	54	67	66	59	55	49	69	53	55	50	59	58
Rank in TDS/SMSA	6	6	7	9	6.5	9	7	7	10	7	6	7	5	7
Source (%)														
Legal RX	-	-	-		-	-	-	-		-	-	-	-	-
Forged RX	-	-	-		-	-	-	-		-	-	-	-	-
Stolen	+	-	+		-	-	-	-		-	-	-	1	+
Street buy	49	87	66		34	31	60	39		77	70	56	45	36
Over-the-counter	+	-	+		2	+	-	-		-	-	-	-	+
Gift	4	1	5		4	4	22	8		4	4	4	4	4
Other	1	1	1		-	+	1	-		1	2	2	-	1
Unk./No resp.	46	11	28		62	64	18	55		19	24	38	49	59
Motivation (%)														
Psychic effects	56	83	39		60	40	80	63		77	78	84	60	63
Dependence	12	12	33		8	10	9	4		9	4	2	28	6
Suic.att./gest.	5	2	3		17	8	3	4		4	10	6	6	9
Unknow./Unwill.	1	-	+		-	1	1	-		2	3	2	-	2
Other	1	-	1		-	1	2	-		2	3	1	2	3
Unk./No resp.	26	4	25		15	41	7	29		7	7	6	7	19
Age (%) DAWN Grouping														
6-9	+	-	-		-	-	-	-		-	-	-	-	1
10-19	38	26	40		42	48	45	53		38	15	43	42	49
20-29	50	61	49		51	41	40	41		50	54	41	48	44
30-39	9	9	9		2	7	11	6		8	24	14	6	5
40-49	1	2	2		-	2	2	-		2	5	1	1	1
50 & Over	+	-	1		-	+	1	-		-	2	-	-	1
Unk./No resp.	1	1	1		6	1	1	-		1	-	1	2	-
Age (%) CODAP Grouping														
6-9	+	-	-		-	-	-	-		-	-	-	-	1
10-17	20	14	21		21	30	20	20		17	7	27	22	30
18-20	26	21	26		26	29	28	49		26	15	25	27	27
21-25	30	39	30		38	25	27	16		32	26	22	28	27
26-30	14	15	13		9	8	11	10		15	32	14	14	11
31-44	8	10	8		-	6	11	6		8	17	9	6	3
45 & Over	1	1	1		-	1	1	-		1	4	1	-	1
Unk./No resp.	1	1	1		6	1	1	-		1	-	1	2	-
Race (%)														
White	54	44	43		64	81	58	57		32	60	79	59	81
Black	31	53	44		8	16	24	14		54	13	5	25	3
Other	4	-	7		4	1	13	-		3	6	5	1	2
Unk./No resp.	11	2	6		25	2	4	29		11	22	11	15	14
Sex (%)														
Male	71	66	72		60	69	70	69		69	85	74	75	71
Female	28	33	28		40	31	30	31		31	15	26	25	29
Unk./No resp.	+	1	+		-	-	-	-		-	-	-	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Included in this category of drugs are substances which produce dislocations and distortions of consciousness similar in some aspects to those suffered by psychotic patients. However, as opposed to the psychotic patient, the user of a hallucinogenic drug is almost invariably aware that what he is experiencing is a distortion of the physical environment. In a small number of cases, hallucinations persist or recur for weeks or months after the drug has been taken.

TABLE 3.111 - LSD

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	1,828	14**	87	49	59	132	50	22	84	52	29	46	72	57	69
Alone (%)	46	50	44	39	47	60	72	73	58	38	55	57	57	47	33
Rank in TDS/SMSA	24	29.5	9	23	16	16	19	19	10	29	18	11.5	25	29.5	10
Source (%)															
Legal RX	-		-	-	-	-	-	-	-	-	-	-	-	-	-
Forged RX	-		-	-	-	-	-	-	-	-	-	-	-	-	-
Stolen	+		-	-	-	-	-	-	1	-	-	-	-	-	-
Street buy	58		61	53	47	39	32	18	54	56	45	37	42	95	62
Over-the-counter	-		-	-	-	-	-	-	-	-	-	-	-	-	-
Gift	5		6	4	3	4	4	5	2	6	7	7	3	4	3
Other	1		-	2	2	1	-	-	1	2	-	4	-	-	1
Unk./No resp.	36		33	41	47	57	64	77	42	37	52	52	56	2	33
Motivation (%)															
Psychic effects	59		70	55	66	59	46	59	86	46	69	63	58	77	68
Dependence	20		14	8	15	8	6	27	5	42	7	7	6	19	16
Suic.att./gest.	7		5	16	7	5	12	-	6	4	3	4	6	4	10
Unknow./Unwill.	1		1	2	-	2	-	-	1	2	-	-	1	-	-
Other	1		2	4	-	-	2	5	2	-	-	2	-	-	3
Unk./No resp.	14		14	16	14	29	40	9	6	8	28	26	29	-	7
Age (%) DAWN Grouping															
6-9	+		-	-	-	-	-	-	-	-	-	-	-	-	-
10-19	45		52	37	36	61	58	68	62	37	62	59	60	18	42
20-29	44		38	51	58	35	40	27	27	46	31	37	31	63	49
30-39	8		7	8	3	4	-	5	11	17	7	2	8	16	4
40-49	1		1	2	2	-	2	-	-	-	-	-	1	4	1
50 & Over	+		1	-	-	1	-	-	-	-	-	-	-	-	1
Unk./No resp.	1		1	2	2	-	-	-	-	-	-	2	-	-	1
Age (%) CODAP Grouping															
6-9	+		-	-	-	-	-	-	-	-	-	-	-	-	-
10-17	25		23	22	20	38	32	27	36	21	52	35	35	11	23
18-20	28		34	20	20	30	30	50	35	23	14	26	36	12	32
21-25	26		22	33	41	20	26	18	15	31	24	28	14	40	25
26-30	12		13	14	14	8	10	-	5	8	7	9	7	25	12
31-44	7		6	8	2	4	2	5	10	17	3	-	8	11	6
45 & Over	1		1	-	2	1	-	-	-	-	-	-	-	-	1
Unk./No resp.	1		1	2	2	-	-	-	-	-	-	2	-	-	1
Race (%)															
White	72		78	82	75	72	86	77	42	73	86	83	71	74	70
Black	10		20	8	15	13	2	14	1	13	3	-	6	9	-
Other	5		1	-	-	5	4	5	5	-	-	2	7	7	1
Unk./No resp.	13		1	10	10	10	8	5	52	13	10	15	17	11	29
Sex (%)															
Male	72		68	73	76	69	70	77	65	75	83	57	64	81	78
Female	28		32	27	24	31	30	23	35	25	17	43	36	19	22
Unk./No resp.	+		-	-	-	-	-	-	-	-	-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

1**

Rank in TDS

40

Concomitance	N	%
Alone	-	-
In Comb.	1	100

Cause/Manner of Death

	Drug-Induced Deaths		Drug-Related Deaths	
	N	%	N	%
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%
6-9		
10-19		
20-29		
30-39		
40-49		
50 & Over		
Unk./No resp.		

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.111 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	1,828	11**	428	9**	18**	71	51	25	12**	36	57	53	76	159
Alone (%)	46	45	31	67	61	51	55	36	58	42	47	40	63	51
Rank in TDS/SMSA	24	33.5	16	21.5	17.5	31	19	20	18	25	14	14	14	19
Source (%)														
Legal RX	-		-			-	-	-		-	-	-	-	-
Forged RX	-		-			-	-	-		-	-	-	-	-
Stolen	+		-			-	-	-		-	-	-	1	-
Street buy	58		84			31	61	48		64	61	70	45	42
Over-the-counter	-		-			-	-	-		-	-	-	-	-
Gift	5		7			3	27	4		6	9	2	5	3
Other	1		-			-	2	-		-	2	2	-	1
Unk./No resp.	36		10			66	10	52		33	28	26	49	55
Motivation (%)														
Psychic effects	59		43			44	78	60		47	68	77	71	60
Dependence	20		46			13	16	8		17	9	2	20	6
Suic.att./gest.	7		6			6	-	-		14	14	9	3	12
Unknow./Unwill.	1		1			1	-	-		6	5	6	-	3
Other	1		+			-	4	-		3	7	2	1	3
Unk./No resp.	14		5			39	6	32		14	4	4	8	18
Age (%) DAWN Grouping														
6-9	+		-			-	-	-		-	-	-	-	1
10-19	45		36			52	63	52		44	9	34	49	55
20-29	44		52			32	27	44		42	61	45	39	37
30-39	8		9			11	10	4		14	18	17	7	5
40-49	1		2			1	-	-		-	7	-	3	1
50 & Over	+		+			-	-	-		-	5	-	-	1
Unk./No resp.	1		1			3	-	-		-	-	4	3	-
Age (%) CODAP Grouping														
6-9	+		-			-	-	-		-	-	-	-	1
10-17	25		18			30	29	16		8	4	21	20	30
18-20	28		26			31	37	52		42	12	25	41	29
21-25	26		29			17	16	16		31	30	26	21	26
26-30	12		16			10	10	12		6	32	15	9	9
31-44	7		9			10	8	4		14	14	9	7	5
45 & Over	1		1			-	-	-		-	9	-	-	1
Unk./No resp.	1		1			3	-	-		-	-	4	3	-
Race (%)														
White	72		69			87	78	68		56	63	83	62	79
Black	10		17			11	6	4		14	7	4	21	2
Other	5		7			1	10	-		6	9	2	1	3
Unk./No resp.	13		7			-	6	28		25	21	11	16	17
Sex (%)														
Male	72		75			69	78	72		75	74	72	86	64
Female	28		25			31	22	28		25	26	28	14	36
Unk./No resp.	+		+			-	-	-		-	-	-	-	1

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

LSD (d-lysergic acid diethylamide) is a semi-synthetic derivative of lysergic acid known to have hallucinogenic effects. The drug is considered highly unpredictable and its pharmacology is not fully understood. While tolerance occurs very rapidly and psychological dependence may develop, LSD does not cause physical dependence even after long term use.

TABLE 3.112 - PCP/PCP COMBINATIONS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	6,002	24	125	55	215	539	189	14**	23	200	90	45	2,131	201	130
Alone (%)	70	42	67	25	65	64	70	50	74	55	69	64	85	55	47
Rank in TDS/SMSA	5	26	5	21	3	4	4	27.5	26	10	5	13	1	7	5
Source (%)															
Legal RX	-	-	-	-	-	-	-		-	-	-	-	-	-	-
Forged RX	-	-	-	-	-	-	-		-	-	-	-	-	-	-
Stolen	+	-	-	-	1	-	-		-	-	1	-	+	-	1
Street buy	47	63	74	67	60	46	46		30	71	34	40	28	90	61
Over-the-counter	-	-	-	-	-	-	-		-	-	-	-	-	-	-
Gift	3	4	2	5	3	3	3		4	2	10	-	2	2	3
Other	+	-	1	2	1	1	-		-	2	-	-	+	-	-
Unk./No resp.	49	33	23	27	35	50	51		65	26	54	60	70	8	35
Motivation (%)															
Psychic effects	55	63	77	51	81	50	63		65	54	67	64	48	87	82
Dependence	10	-	14	18	9	10	5		4	27	6	7	2	7	10
Suic.att./gest.	4	13	6	15	5	7	5		9	7	2	7	3	3	4
Unknow./Unwill.	1	-	1	4	-	1	1		-	2	-	2	+	+	-
Other	1	-	-	4	2	1	2		4	1	1	2	+	-	1
Unk./No resp.	31	25	8	13	7	37	25		22	12	28	18	48	2	5
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-		-	-	-	-	+	+	-
10-19	34	29	46	44	35	35	59		48	37	53	47	25	46	31
20-29	53	63	47	51	58	57	38		35	58	40	49	57	49	62
30-39	9	8	6	5	6	5	2		9	5	7	-	13	3	6
40-49	2	-	1	-	+	1	1		9	1	-	4	2	1	-
50 & Over	+	-	-	-	+	+	-		-	-	-	-	1	+	-
Unk./No resp.	1	-	-	-	-	1	1		-	-	-	-	3	-	1
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-		-	-	-	-	+	+	-
10-17	17	21	22	29	20	18	34		26	18	26	18	10	19	18
18-20	26	21	30	20	26	26	33		22	26	32	42	23	39	25
21-25	33	38	28	36	32	37	23		26	38	31	31	34	26	35
26-30	15	17	14	9	18	12	8		9	15	8	4	18	12	15
31-44	8	4	6	5	4	5	2		13	4	3	4	11	2	5
45 & Over	1	-	-	-	1	1	-		4	-	-	-	1	+	-
Unk./No resp.	1	-	-	-	-	1	1		-	-	-	-	3	-	1
Race (%)															
White	47	79	84	80	66	64	77		43	72	82	67	29	73	68
Black	40	21	14	18	20	18	11		-	18	8	22	58	12	1
Other	4	-	-	-	2	8	1		9	-	-	2	3	4	2
Unk./No resp.	10	-	2	2	13	10	11		48	11	10	9	10	10	29
Sex (%)															
Male	71	83	66	69	75	70	70		70	76	73	80	72	75	71
Female	28	17	34	31	25	30	30		30	24	27	20	28	25	29
Unk./No resp.	+	-	-	-	-	-	-		-	1	-	-	+	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

117

Rank in TDS

15

Concomitance	N	%
Alone	56	48
In Comb.	61	52

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	4	3	11	9
Accid./Unexp.	44	38	37	32
Unk./No resp.	12	10	9	8

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	6	5	White	65	56	Male	97	83
10-19	14	12	50 & Over	3	3	Black	47	40	Female	20	17
20-29	77	66	Unk./No resp.	-	-	Other	5	4			
30-39	17	15				Unk./No resp.	-	-			

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.112 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	6,002	148	886	2**	33	213	84	20	4**	172	83	50	149	177
Alone (%)	70	77	66	50	70	62	55	70	100	54	60	54	57	61
Rank in TDS/SMSA	5	4	8	32.5	6	10	11	22.5	29	6	5	17	6	17
Source (%)														
Legal RX	-	-	-		-	-	-	-		-	-	-	-	-
Forged RX	-	-	-		-	-	-	-		-	-	-	-	-
Stolen	+	-	1		-	-	-	-		-	-	-	1	1
Street buy	47	89	58		45	32	61	35		83	80	62	46	33
Over-the-counter	-	-	-		-	-	-	-		-	-	-	-	-
Gift	3	1	5		6	5	18	15		3	2	2	4	4
Other	+	-	+		-	+	-	-		1	1	-	-	-
Unk./No resp.	49	10	37		52	62	23	50		14	17	36	50	62
Motivation (%)														
Psychic effects	55	85	34		61	38	83	65		85	84	86	54	62
Dependence	10	11	28		9	10	5	-		8	1	4	33	5
Suic.att./gest.	4	1	2		18	9	4	-		2	7	4	7	9
Unknow./Unwill.	1	-	+		-	+	2	-		1	1	-	-	2
Other	1	-	1		-	1	1	-		2	-	-	2	3
Unk./No resp.	31	3	36		12	41	7	35		4	7	8	7	20
Age (%) DAWN Grouping														
6-9	+	-	-		-	-	-	-		-	-	-	-	1
10-19	34	26	39		42	46	37	50		38	17	44	40	40
20-29	53	61	49		48	45	45	45		52	54	38	50	55
30-39	9	9	9		-	6	11	5		7	25	16	7	4
40-49	2	3	2		-	2	4	-		1	4	2	1	-
50 & Over	+	-	1		-	-	1	-		-	-	-	-	1
Unk./No resp.	1	1	1		9	1	2	-		1	-	-	2	-
Age (%) CODAP Grouping														
6-9	+	-	-		-	-	-	-		-	-	-	-	1
10-17	17	13	20		12	29	15	25		19	7	26	24	25
18-20	26	22	27		33	29	23	40		24	18	30	22	29
21-25	33	39	31		42	28	31	20		34	23	20	31	32
26-30	15	14	12		3	7	13	10		17	35	12	15	11
31-44	8	11	8		-	5	13	5		6	17	10	6	2
45 & Over	1	1	1		-	1	2	-		-	-	2	-	1
Unk./No resp.	1	1	1		9	1	2	-		1	-	-	2	-
Race (%)														
White	47	40	26		67	78	43	45		26	58	74	57	81
Black	40	59	61		12	17	37	30		64	19	6	28	5
Other	4	-	8		-	1	17	-		2	4	8	1	2
Unk./No resp.	10	1	5		21	3	4	25		8	19	12	14	13
Sex (%)														
Male	71	66	70		61	70	65	65		68	90	68	68	79
Female	28	34	29		39	30	35	35		32	10	32	32	21
Unk./No resp.	+	1	+		-	-	-	-		-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Phencyclidine, or PCP, is a licit veterinary anesthetic, but has been used illicitly as an hallucinogen. Tolerance effects can be produced by prolonged use of PCP, requiring the user to take increasingly larger doses of the drug in order to attain the desired effects. Because PCP produces its anesthetic and hallucinatory effects without depressing respiration or heart function, its action is not likely to be potentiated by alcohol and other central nervous system depressants.

TABLE 3.12 THERAPEUTIC CLASS - ANTICONVULSANTS/ANTINAUSEANTS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	3,066	88	55	207	44	221	48	51	104	121	20	44	159	225	57
Alone (%)	26	18	27	20	16	19	40	51	54	31	45	34	30	18	37
Rank in TDS/SMSA	10	8	9	7	11	9	10	9	9	11	12	11	10	9	11
Source (%)															
Legal RX	75	68	75	60	73	80	67	59	73	74	85	70	45	93	91
Forged RX	+	-	-	-	-	+	-	-	-	-	-	-	-	-	-
Stolen	2	2	2	2	2	+	6	2	-	3	-	5	1	+	-
Street buy	+	2	-	1	2	-	-	-	-	-	-	-	-	+	-
Over-the-counter	1	2	-	+	5	-	2	-	1	1	-	2	-	3	5
Gift	1	-	4	1	-	-	-	2	3	2	-	-	-	-	-
Other	+	-	-	-	-	-	-	-	-	1	-	-	-	-	-
Unk./No resp.	20	25	20	35	18	19	25	37	23	19	15	23	53	3	4
Motivation (%)															
Psychic effects	18	8	29	8	11	48	19	22	13	10	10	5	7	78	5
Dependence	25	40	7	38	2	50	8	-	5	11	5	2	8	3	4
Suic.att./gest.	43	27	51	36	70	25	44	51	75	65	40	68	49	18	84
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	3	7	7	8	-	3	8	8	2	2	10	-	2	-	-
Unk./No resp.	14	19	9	14	16	15	21	20	6	12	35	27	35	1	7
Age (%) DAWN Grouping															
6-9	+	-	2	-	-	-	-	-	-	-	-	-	-	-	-
10-19	16	14	20	8	14	10	17	35	24	22	30	20	13	9	11
20-29	33	32	27	35	36	40	31	41	37	36	25	39	39	17	46
30-39	26	22	36	24	39	25	19	12	18	25	30	32	23	32	25
40-49	13	18	9	21	11	14	21	12	10	12	-	9	13	23	9
50 & Over	10	13	5	12	-	10	13	-	12	4	10	-	12	17	11
Unk./No resp.	1	2	-	+	-	1	-	-	-	1	5	-	1	1	-
Age (%) CODAP Grouping															
6-9	+	-	2	-	-	-	-	-	-	-	-	-	-	-	-
10-17	10	5	15	6	5	5	13	29	13	15	25	14	5	5	4
18-20	9	9	9	2	14	9	10	14	13	12	5	11	11	5	12
21-25	17	25	15	19	20	21	17	25	21	17	15	20	19	8	26
26-30	16	9	15	19	25	17	8	10	16	19	10	18	18	13	18
31-44	30	32	38	32	30	30	25	18	21	26	30	34	28	39	30
45 & Over	16	18	7	21	7	17	27	4	15	11	10	2	18	29	11
Unk./No resp.	1	2	-	+	-	1	-	-	-	1	5	-	1	1	-
Race (%)															
White	59	41	56	70	75	30	58	78	50	56	75	73	57	36	68
Black	29	52	36	24	11	58	29	14	5	31	10	7	21	56	4
Other	3	1	4	1	2	4	-	-	9	-	-	2	6	2	-
Unk./No resp.	10	6	4	5	11	8	13	8	37	12	15	18	16	6	28
Sex (%)															
Male	51	57	58	65	48	66	31	35	43	40	60	36	33	59	39
Female	49	43	42	35	52	33	69	65	57	60	40	64	66	41	61
Unk./No resp.	+	-	-	-	-	+	-	-	-	-	-	-	1	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

61

Rank in TDS

8

Concomitance	N	%
Alone	2	3
In Comb.	59	97

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	27	44	4	7
Accid./Unexp.	6	10	8	13
Unk./No resp.	15	25	1	2

Age	N	%		N	%
6-9	-	-	40-49	11	18
10-19	1	2	50 & Over	11	18
20-29	24	39	Unk./No resp.	-	-
30-39	14	23			

Race	N	%
White	44	72
Black	14	23
Other	3	5
Unk./No resp.	-	-

Sex	N	%
Male	31	51
Female	30	49

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.12 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	3,066	40	638	22	30	129	87	35	25	72	37	60	77	370
Alone (%)	26	40	18	41	30	36	21	29	36	18	35	40	19	28
Rank in TDS/SMSA	10	11	10	8	10	10	10	10	8	11	11	11	10.5	8
Source (%)														
Legal RX	75	60	89	68	43	64	79	74	64	85	78	52	60	75
Forged RX	+	18	-	-	-	1	-	-	-	3	-	-	-	-
Stolen	2	-	2	9	10	2	3	3	4	3	-	3	4	2
Street buy	+	-	+	-	-	1	-	3	-	-	-	-	-	+
Over-the-counter	1	-	+	5	-	1	5	-	4	-	-	12	3	2
Gift	1	13	+	-	13	1	1	-	4	1	-	3	-	1
Other	+	3	-	-	-	-	-	-	-	-	-	-	-	-
Unk./No resp.	20	8	8	18	33	33	11	20	24	8	22	30	34	19
Motivation (%)														
Psychic effects	18	63	3	5	7	21	14	20	8	7	5	22	8	13
Dependence	25	-	73	-	-	3	3	11	-	4	3	3	12	3
Suic.att./gest.	43	28	18	73	73	46	71	34	64	64	84	62	62	57
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-	-	-	-	+
Other	3	5	+	-	-	7	3	3	-	6	3	3	4	6
Unk./No resp.	14	5	5	23	20	25	9	31	28	22	8	10	14	22
Age (%) DAWN Grouping														
6-9	+	-	1	-	-	1	-	-	-	-	-	-	-	1
10-19	16	10	11	36	27	21	29	31	52	18	3	35	18	23
20-29	33	43	29	32	23	35	25	37	24	43	38	33	35	40
30-39	26	30	31	23	23	22	34	14	20	29	43	10	25	20
40-49	13	15	15	5	23	12	9	9	4	6	5	10	9	10
50 & Over	10	3	14	5	3	8	-	9	-	4	8	10	12	6
Unk./No resp.	1	-	+	-	-	2	2	-	-	-	3	2	1	1
Age (%) CODAP Grouping														
6-9	+	-	1	-	-	1	-	-	-	-	-	-	-	1
10-17	10	8	7	32	17	12	20	17	36	13	-	33	13	14
18-20	9	3	7	9	17	10	15	17	20	8	14	5	10	13
21-25	17	18	14	18	7	19	16	14	8	22	14	20	18	21
26-30	16	30	16	14	13	18	14	23	12	21	14	12	13	16
31-44	30	30	35	23	37	24	30	17	24	29	43	13	29	25
45 & Over	16	13	20	5	10	15	3	11	-	7	14	15	16	10
Unk./No resp.	1	-	+	-	-	2	2	-	-	-	3	2	1	1
Race (%)														
White	59	45	59	55	87	61	74	69	72	63	62	72	56	73
Black	29	50	35	41	3	32	8	29	-	7	16	10	31	13
Other	3	-	2	-	-	4	14	-	28	6	11	7	-	2
Unk./No resp.	10	5	3	5	10	3	5	3	-	25	11	12	13	13
Sex (%)														
Male	51	48	62	18	23	41	38	46	40	38	70	42	51	41
Female	49	53	38	82	77	59	62	54	60	63	30	58	49	59
Unk./No resp.	+	-	-	-	-	-	-	-	-	-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

This category includes two therapeutic classes - anticonvulsants which are products used primarily to control convulsions, especially of epilepsy, and antinauseants, those drugs used primarily for treating nausea, vomiting and vertigo, including motion sickness.

TABLE 3.121 - HYDANTOIN

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	2,466	75	46	183	29	194	39	35	77	96	19**	30	128	207	40
Alone (%)	24	16	28	19	14	18	41	43	55	32	47	30	30	17	30
Rank in TDS/SMSA	16	9.5	17.5	7	25.5	10	22.5	12	11	23	24	20	20.5	6	17
Source (%)															
Legal RX	80	75	76	62	83	83	69	63	84	76		83	45	98	98
Forged RX	+	-	-	-	-	1	-	-	-	-		-	-	-	-
Stolen	2	3	2	2	3	-	8	3	-	4		-	2	+	-
Street buy	+	1	-	1	-	-	-	-	-	-		-	-	-	-
Over-the-counter	-	-	-	-	-	-	-	-	-	-		-	-	-	-
Gift	1	-	4	1	-	-	-	3	1	1		-	-	-	-
Other	-	-	-	-	-	-	-	-	-	-		-	-	-	-
Unk./No resp.	18	21	17	35	14	16	23	31	14	19		17	53	2	3
Motivation (%)															
Psychic effects	18	7	26	8	7	50	21	20	8	11		3	6	81	8
Dependence	30	47	9	42	3	54	10	-	6	14		3	7	3	5
Suic.att./gest.	39	24	52	33	76	22	41	43	77	61		77	47	14	78
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	-		-	-	-	-
Other	3	7	7	9	-	3	8	11	3	3		-	2	-	-
Unk./No resp.	14	17	11	13	14	14	21	26	8	11		20	38	1	10
Age (%) DAWN Grouping															
6-9	+	-	2	-	-	-	-	-	-	-		-	-	-	-
10-19	12	11	20	5	7	9	13	20	13	22		10	12	8	5
20-29	33	29	24	34	38	39	33	51	38	38		47	38	14	43
30-39	28	24	39	25	41	26	15	17	23	24		37	23	34	28
40-49	15	19	11	22	14	15	23	11	10	10		7	15	25	13
50 & Over	11	15	4	13	-	10	15	-	16	5		-	12	18	13
Unk./No resp.	1	3	-	1	-	1	-	-	-	1		-	1	+	-
Age (%) CODAP Grouping															
6-9	+	-	2	-	-	-	-	-	-	-		-	-	-	-
10-17	7	3	13	4	-	5	10	14	4	15		7	3	5	3
18-20	8	8	11	2	10	8	10	14	12	13		10	13	3	5
21-25	17	21	13	19	21	21	15	34	18	18		23	17	7	28
26-30	17	11	13	19	24	18	10	11	21	18		23	19	13	15
31-44	33	35	41	33	38	31	23	23	25	27		37	29	41	38
45 & Over	18	20	7	22	7	17	31	3	21	9		-	19	31	13
Unk./No resp.	1	3	-	1	-	1	-	-	-	1		-	1	+	-
Race (%)															
White	56	35	57	66	79	27	54	74	57	56		73	63	32	63
Black	32	57	37	27	14	62	33	17	6	33		3	20	59	5
Other	3	1	4	1	3	3	-	-	8	-		3	6	2	-
Unk./No resp.	9	7	2	6	3	7	13	9	29	10		20	11	6	33
Sex (%)															
Male	55	64	61	67	48	69	33	34	48	43		33	34	60	55
Female	45	36	39	33	52	30	67	66	52	57		67	65	40	45
Unk./No resp.	+	-	-	-	-	1	-	-	-	-		-	1	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

47

Rank in TDS

24

Concomitance	N	%
Alone	2	4
In Comb.	45	96

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	16	34	2	4
Accid./Unexp.	5	11	8	17
Unk./No resp.	15	32	1	2

Age	N	%		N	%
6-9	-	-	40-49	8	17
10-19	1	2	50 & Over	8	17
20-29	18	38	Unk./No resp.	-	-
30-39	12	26			

Race	N	%
White	33	70
Black	12	26
Other	2	4
Unk./No resp.	-	-

Sex	N	%
Male	26	55
Female	21	45

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.121 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	2,466	31	574	17**	21	99	51	32	18**	51	33	32	54	255
Alone (%)	24	42	17	35	29	36	10	25	44	22	36	31	15	27
Rank in TDS/SMSA	16	28	12	15	13.5	26	19	14	14	19	21.5	26	18	13
Source (%)														
Legal RX	80	65	92		48	63	86	72		86	85	72	65	80
Forged RX	+	19	-		-	1	-	-		2	-	-	-	-
Stolen	2	-	1		5	1	4	3		-	-	3	2	1
Street buy	+	-	+		-	-	-	3		-	-	-	-	-
Over-the-counter	-	-	-		-	-	-	-		-	-	-	-	-
Gift	1	10	+		14	-	2	-		-	-	-	-	+
Other	-	-	-		-	-	-	-		-	-	-	-	-
Unk./No resp.	18	6	6		33	35	8	22		12	15	25	33	18
Motivation (%)														
Psychic effects	18	71	2		5	17	16	16		10	6	9	6	12
Dependence	30	-	78		-	4	4	13		4	3	3	15	4
Suic.att./gest.	39	23	16		76	45	75	38		57	85	75	61	57
Unknow./Unwill.	+	-	-		-	-	-	-		-	-	-	-	+
Other	3	-	+		-	8	4	3		6	3	6	4	5
Unk./No resp.	14	6	4		19	26	4	31		27	6	6	15	24
Age (%) DAWN Grouping														
6-9	+	-	1		-	1	-	-		-	-	-	-	1
10-19	12	10	8		14	17	18	28		14	3	16	15	15
20-29	33	42	29		33	37	24	38		47	33	31	35	41
30-39	28	32	32		29	22	47	16		29	48	16	28	23
40-49	15	13	16		24	13	12	9		6	3	19	9	12
50 & Over	11	3	15		-	8	-	9		4	9	16	11	7
Unk./No resp.	1	-	+		-	1	-	-		-	3	3	2	1
Age (%) CODAP Grouping														
6-9	+	-	1		-	1	-	-		-	-	-	-	1
10-17	7	6	5		10	9	12	13		8	-	13	11	9
18-20	8	3	6		14	9	10	19		10	15	6	7	10
21-25	17	19	13		10	22	14	16		22	9	22	17	20
26-30	17	26	17		19	18	20	22		25	12	9	15	18
31-44	33	35	36		43	23	39	19		29	48	22	33	28
45 & Over	18	10	21		5	16	6	13		6	12	25	15	12
Unk./No resp.	1	-	+		-	1	-	-		-	3	3	2	1
Race (%)														
White	56	39	58		86	60	69	66		65	64	66	48	74
Black	32	55	37		5	32	10	31		8	12	9	37	12
Other	3	-	2		-	5	16	-		4	12	13	-	2
Unk./No resp.	9	6	3		10	3	6	3		24	12	13	15	13
Sex (%)														
Male	55	52	65		24	39	39	47		39	76	44	59	47
Female	45	48	35		76	61	61	53		61	24	56	41	53
Unk./No resp.	+	-	-		-	-	-	-		-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Diphenylhydantoin sodium is a member of the hydantoin family. The hydantoins are useful in the treatment of epilepsy. Chemically, diphenylhydantoin sodium is related to the barbiturates. Barbiturates may enhance the rate of metabolism of the hydantoins, however this effect is variable and unpredictable. Diphenylhydantoin sodium primarily affects the central nervous system and may cause dizziness, insomnia, depression, irritability and headaches.

TABLE 3.13 - THERAPEUTIC CLASS - CODEINE COMBINATIONS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	2,842	75	27	34	81	191	39	68	127	226	63	90	313	87	122
Alone (%)	31	31	33	47	37	34	38	38	19	30	25	29	31	29	25
Rank in TDS/SMSA	11	10	11	11	9	10	11	7	7	9	9	7	8	11	8
Source (%)															
Legal RX	63	63	59	56	43	57	67	59	66	64	43	54	56	85	71
Forged RX	+	-	4	-	-	-	-	-	-	+	-	-	-	-	1
Stolen	3	5	4	-	1	1	3	4	-	3	-	-	2	3	4
Street buy	+	-	-	-	5	-	-	-	-	1	-	-	-	-	-
Over-the-counter	1	-	-	-	1	1	-	1	1	1	3	1	-	-	1
Gift	2	-	-	6	1	2	-	-	3	4	-	2	1	-	2
Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unk./No resp.	31	33	33	38	49	39	31	35	30	28	54	42	41	11	22
Motivation (%)															
Psychic effects	14	21	15	3	2	12	21	28	10	16	27	8	14	40	11
Dependence	6	4	4	-	6	3	3	-	2	7	3	6	3	13	7
Suic.att./gest.	61	53	59	62	68	58	49	54	71	58	49	67	52	41	71
Unknow./Unwill.	+	-	4	-	-	-	-	-	-	-	-	-	+	-	-
Other	4	7	4	12	2	5	10	4	6	2	10	6	5	1	2
Unk./No resp.	16	15	15	24	21	25	21	13	11	20	14	14	26	5	11
Age (%) DAWN Grouping															
6-9	+	-	-	-	-	-	-	-	-	+	-	-	-	-	-
10-19	23	27	15	38	19	27	38	31	18	22	17	20	18	14	18
20-29	42	41	56	41	51	42	41	28	43	50	49	50	39	38	48
30-39	20	19	15	9	20	17	8	29	24	14	19	16	22	29	20
40-49	8	7	11	3	10	7	5	9	9	8	10	7	9	8	7
50 & Over	7	7	4	9	1	5	5	3	6	5	3	8	12	11	7
Unk./No resp.	+	-	-	-	-	1	3	-	-	+	2	-	-	-	-
Age (%) CODAP Grouping															
6-9	+	-	-	-	-	-	-	-	-	+	-	-	-	-	-
10-17	13	8	4	18	10	15	15	22	8	11	11	10	9	7	9
18-20	15	23	19	29	17	19	26	13	14	18	11	12	13	11	16
21-25	22	23	26	12	25	19	26	21	22	23	29	28	21	14	21
26-30	18	17	22	24	20	19	15	4	20	22	22	22	16	21	21
31-44	22	17	26	6	20	19	8	35	26	17	19	17	25	31	23
45 & Over	10	12	4	12	9	8	8	4	9	8	6	11	16	16	10
Unk./No resp.	+	-	-	-	-	1	3	-	-	+	2	-	-	-	-
Race (%)															
White	63	64	56	71	62	58	64	75	37	57	73	56	64	63	70
Black	20	24	33	15	21	25	28	16	5	34	25	18	19	18	2
Other	3	-	-	-	-	2	3	1	2	1	-	1	4	3	1
Unk./No resp.	14	12	11	15	17	16	5	7	57	8	2	26	12	15	26
Sex (%)															
Male	29	31	33	38	28	27	23	32	28	31	25	23	28	33	26
Female	71	69	67	62	70	72	77	68	72	69	75	77	72	67	74
Unk./No resp.	+	-	-	-	1	1	-	-	-	-	-	-	-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions

9**

Rank in TDS

12

Concomitance	N	%
Alone	4	44
In Comb.	5	56

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide				
Accid./Unexp.				
Unk./No resp.				

Age	N	%
6-9		
10-19		
20-29		
30-39		
40-49		
50 & Over		
Unk./No resp.		

Race	N	%
White		
Black		
Other		
Unk./No resp.		

Sex	N	%
Male		
Female		

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.13 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	2,842	42	162	38	31	52	122	39	37	132	42	106	145	351
Alone (%)	31	38	46	39	29	31	25	23	41	29	40	21	30	29
Rank in TDS/SMSA	11	10	11	7	8.5	11	8	9	7	8	10	8	8	9
Source (%)														
Legal RX	63	74	69	76	61	44	71	56	70	64	69	42	52	76
Forged RX	+	2	1	-	-	-	-	3	-	-	-	-	-	1
Stolen	3	2	13	3	-	2	5	5	8	5	-	2	10	2
Street buy	+	-	1	-	-	-	3	-	-	-	-	-	-	+
Over-the-counter	1	-	-	-	-	2	1	-	-	1	-	-	1	2
Gift	2	5	1	3	-	-	2	5	5	4	-	1	1	1
Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unk./No resp.	31	17	16	18	39	52	18	31	16	27	31	56	37	19
Motivation (%)														
Psychic effects	14	26	5	16	3	21	20	18	8	9	2	9	8	13
Dependence	6	7	19	-	-	4	10	5	-	7	5	5	6	4
Suic.att./gest.	61	55	67	76	68	40	52	59	70	59	76	67	79	68
Unknow./Unwill.	+	-	-	-	-	-	-	-	-	1	-	-	-	+
Other	4	5	2	5	-	4	3	-	3	11	5	5	4	2
Unk./No resp.	16	7	7	5	29	33	15	18	19	15	12	15	5	15
Age (%) DAWN Grouping														
6-9	+	-	-	-	-	2	-	-	-	-	-	-	-	-
10-19	23	21	32	24	16	25	25	18	22	20	14	25	31	22
20-29	42	36	38	50	45	40	34	46	51	41	40	38	41	42
30-39	20	26	18	21	29	13	24	18	22	18	24	25	18	20
40-49	8	12	7	5	3	10	7	10	3	10	10	5	8	10
50 & Over	7	5	5	-	6	8	10	5	-	10	12	8	2	6
Unk./No resp.	+	-	-	-	-	2	-	3	3	2	-	-	-	-
Age (%) CODAP Grouping														
6-9	+	-	-	-	-	2	-	-	-	-	-	-	-	-
10-17	13	10	20	13	10	19	19	18	16	9	7	8	22	13
18-20	15	14	17	16	10	12	10	10	19	12	7	23	12	12
21-25	22	17	19	29	23	21	21	21	30	21	19	16	21	26
26-30	18	24	18	24	23	13	12	26	8	19	24	18	18	17
31-44	22	26	17	16	29	23	25	10	24	25	31	25	21	23
45 & Over	10	10	9	3	6	8	12	13	-	12	12	9	6	10
Unk./No resp.	+	-	-	-	-	2	-	3	3	2	-	-	-	-
Race (%)														
White	63	52	72	71	52	56	84	69	57	55	55	60	37	80
Black	20	40	17	29	13	37	3	21	8	23	14	6	52	11
Other	3	-	6	-	3	-	9	-	35	8	12	7	-	1
Unk./No resp.	14	7	4	-	32	8	4	10	-	15	19	27	12	8
Sex (%)														
Male	29	26	35	29	10	37	25	38	24	36	48	29	12	29
Female	71	74	64	71	90	63	75	62	76	64	52	71	88	71
Unk./No resp.	+	-	1	-	-	-	-	-	-	-	-	-	-	+

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

Codeine is an alkaloid of opium. It has approximately one-eighth the analgesic effect of morphine and therefore is used for minor pain or for its antitussive action. Physical dependence on codeine is uncommon; when it does occur, the withdrawal symptoms are of a much less serious nature than those connected with morphine, heroin, or the barbiturates. Alcohol and the barbiturates can potentiate the effects of codeine.

TABLE 3.14 THERAPEUTIC CLASS - INHALANTS/SOLVENTS/AEROSOLS

Emergency Room Mentions - Demographics by SMSA in Column Percentages - January-December 1979

	Total DAWN System	Atlanta	Baltimore*	Boston	Buffalo	Chicago	Cleveland	Dallas	Denver	Detroit	Indianapolis	Kansas City	Los Angeles	Miami	Minneapolis
No. of Mentions	743	15**	12**	15**	14**	27	19**	15**	40	44	46	18**	35	63	40
Alone (%)	51	27	50	40	36	63	42	53	83	57	57	50	40	62	65
Rank in TDS/SMSA	12	12	12	12	12	12	12	12	12	12	11	12	12	12	12
Source (%)															
Legal RX	-					-			-	-	-		-	-	-
Forged RX	-					-			-	-	-		-	-	-
Stolen	2					-			-	-	-		-	-	3
Street buy	6					7			8	5	2		-	2	13
Over-the-counter	67					44			78	89	54		51	92	73
Gift	1					4			-	-	2		-	-	-
Other	5					4			-	7	-		9	-	3
Unk./No resp.	20					41			15	2	41		40	6	10
Motivation (%)															
Psychic effects	48					33			63	18	70		29	89	53
Dependence	14					-			53	52	4		-	6	13
Suic.att./gest.	27					33			15	23	11		40	5	28
Unknow./Unwill.	+					-			-	-	-		-	-	-
Other	2					4			-	2	2		3	-	3
Unk./No resp.	13					30			5	9	13		29	-	8
Age (%) DAWN Grouping															
6-9	+					-			-	-	-		-	-	-
10-19	40					48			38	27	63		26	38	25
20-29	42					44			55	59	33		29	56	60
30-39	9					4			5	9	-		29	6	5
40-49	4					4			-	2	-		11	-	5
50 & Over	4					-			3	2	4		3	-	5
Unk./No resp.	1					-			-	-	-		3	-	-
Age (%) CODAP Grouping															
6-9	+					-			-	-	-		-	-	-
10-17	25					41			23	11	39		9	24	18
18-20	22					15			23	23	28		26	21	35
21-25	25					19			28	34	20		14	35	28
26-30	13					19			20	20	9		20	14	8
31-44	9					4			5	9	-		23	6	8
45 & Over	5					4			3	2	4		6	-	5
Unk./No resp.	1					-			-	-	-		3	-	-
Race (%)															
White	62					56			30	59	96		54	52	48
Black	15					22			3	34	4		23	27	-
Other	12					11			40	-	-		3	2	5
Unk./No resp.	11					11			20	7	-		20	19	48
Sex (%)															
Male	73					67			55	75	78		74	75	80
Female	27					33			45	25	22		26	25	20
Unk./No resp.	-					-			-	-	-		-	-	-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

Medical Examiner Mentions - Demographics for Total DAWN System - January-December 1979

No. of Mentions	Concomitance	N	%
55	Alone	26	47
	In Comb.	29	53

Rank in TDS

10

Cause/Manner of Death	Drug-Induced Deaths N	Drug-Induced Deaths %	Drug-Related Deaths N	Drug-Related Deaths %
Suicide	9	16	7	13
Accid./Unexp.	23	42	13	24
Unk./No resp.	3	5	-	-

Age	N	%		N	%	Race	N	%	Sex	N	%
6-9	-	-	40-49	5	9	White	49	89	Male	39	71
10-19	13	24	50 & Over	9	16	Black	5	9	Female	16	29
20-29	21	38	Unk./No resp.	-	-	Other	1	2			
30-39	7	13				Unk./No resp.	-	-			

**Percentages for demographics not computed due to small numbers..

+Less than 0.5%

-Denotes zero (0) mentions

TABLE 3.14 - Continued

	Total DAWN System	New Orleans	New York	Norfolk	Oklahoma City	Philadelphia	Phoenix	St. Louis*	San Antonio	San Diego	San Francisco Co.	Seattle	Washington, D.C.	National Panel*
No. of Mentions	743	4**	50	-	10**	36	57	17**	9**	30	9**	29	14**	75
Alone (%)	51	25	48	-	40	47	56	41	22	27	22	59	14	53
Rank in TDS/SMSA	12	12	12	-	12	12	11	12	11	12	12	12	12	12
Source (%)														
Legal RX	-		-			-	-			-		-		-
Forged RX	-		-			-	-			-		-		-
Stolen	2		12			3	2			3		-		1
Street buy	6		12			3	5			13		-		5
Over-the-counter	67		68			67	81			53		97		57
Gift	1		-			-	4			-		-		-
Other	5		2			6	-			13		3		13
Unk./No resp.	20		6			22	11			17		-		23
Motivation (%)														
Psychic effects	48		44			50	81			43		55		27
Dependence	14		30			3	7			7		17		7
Suic.att./gest.	27		20			17	9			50		34		45
Unknow./Unwill.	+		-			-	-			-		-		-
Other	2		-			-	2			-		7		1
Unk./No resp.	13		6			33	5			3		-		23
Age (%) DAWN Grouping														
6-9	+		2			-	-			3		-		-
10-19	40		36			53	53			27		38		48
20-29	42		36			33	35			43		31		29
30-39	9		16			3	7			7		10		9
40-49	4		2			8	2			13		10		4
50 & Over	4		6			3	2			7		10		8
Unk./No resp.	1		2			-	2			-		-		1
Age (%) CODAP Grouping														
6-9	+		2			-	-			3		-		-
10-17	25		28			36	35			10		3		31
18-20	22		8			19	21			23		41		23
21-25	25		24			22	21			27		21		17
26-30	13		16			11	12			13		3		8
31-44	9		12			6	7			10		14		12
45 & Over	5		8			6	2			13		17		8
Unk./No resp.	1		2			-	2			-		-		1
Race (%)														
White	62		64			72	23			53		86		84
Black	15		20			17	5			13		-		11
Other	12		12			6	67			10		14		-
Unk./No resp.	11		4			6	5			23		-		5
Sex (%)														
Male	73		78			64	74			80		83		69
Female	27		22			36	26			20		17		31
Unk./No resp.	-		-			-	-			-		-		-

NOTE: Multiple mentions are possible for source and motivation.

*See Introduction

**Percentages for demographics not computed due to small numbers.

+Less than 0.5%

-Denotes zero (0) mentions

SUPPLEMENTARY INFORMATION

This DAWN category is composed of substances used primarily for non-therapeutic purposes. Included in this category are cleaning, polishing, painting and bonding materials, fuels, lubricants, room odorizers, leather preparations, waxes, coolants, and aerosol toiletries.

U.S. GOVERNMENT PRINTING OFFICE: 1980-328-585/6551

UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C. 20537

OFFICIAL BUSINESS

POSTAGE AND FEES PAID
U.S. DEPARTMENT OF JUSTICE
JUS-437

THIRD CLASS

U.S.MAIL



Project DAWN Cities
Annual Report - 1979

Atlanta
Baltimore
Boston
Buffalo
Chicago
Cleveland
Dallas
Denver
Detroit
Indianapolis
Kansas City
Los Angeles
Miami
Minneapolis
New Orleans
New York
Norfolk
Oklahoma City
Philadelphia
Phoenix
San Antonio
San Diego
San Francisco
Seattle
St. Louis
Washington, D.C.